(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 17 May 2001 (17.05.2001)

PCT

(10) International Publication Number WO 01/34629 A1

(51) International Patent Classification⁷: C07H 21/04, 21/02, C07K 5/00, 14/00, C12Q 1/68, C12N 1/21, 15/63, 15/85, 15/86

Redwing Road, Bethesda, MD 20817 (US). **BAKER**, **Kevin**, **P**. [GB/US]; 14006 Indian Run Drive, Darnestown, MD 20878 (US).

- (21) International Application Number: PCT/US00/30654
 - /30654 (7

(22) International Filing Date:

8 November 2000 (08.11.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/164,835 12 November 1999 (12.11.1999) US 60/221,142 27 July 2000 (27.07.2000) US

(71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). KOMATSOULIS, George, A. [US/US]; 9518 Garwood Steet, Silver Spring, MD 20901 (US). WEI, Ping [CN/US]; 19100 Baltimore Road, Brookeville, MD 20833 (US). FISCELLA, Michele [US/US]; 6308

- (74) Agents: HOOVER, Kenley, K. et al.; c/o Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 21 HUMAN SECRETED PROTEINS

(57) Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

21 Human Secreted Proteins

Field of the Invention

This invention relates to newly identified polynucleotides, polypeptides encoded by these polynucleotides, antibodies that bind these polypeptides, uses of such polynucleotides, polypeptides, and antibodies, and their production.

5

10

15

20

25

30

Background of the Invention

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoeitin. Thus, in light of

2

the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical diseases, disorders, and/or conditions by using secreted proteins or the genes that encode them.

Summary of the Invention

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting diseases, disorders, and/or conditions related to the polypeptides and polynucleotides, and therapeutic methods for treating such diseases, disorders, and/or conditions. The invention further relates to screening methods for identifying binding partners of the polypeptides.

Detailed Description

Definitions

5

10

15

20

25

30

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

3

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

5

10

15

20

25

30

In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As

4

shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

5

10

15

20

25

30

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 μg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of

10

15

20

25

30

ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

Many proteins (and translated DNA sequences) contain regions where the amino acid composition is highly biased toward a small subset of the available

7

residues. For example, membrane spanning domains and signal peptides (which are also membrane spanning) typically contain long stretches where Leucine (L), Valine (V), Alanine (A), and Isoleucine (I) predominate. Poly-Adenosine tracts (polyA) at the end of cDNAs appear in forward translations as poly-Lysine (poly-K) and poly-Phenylalanine (poly-F) when the reverse complement is translated. These regions are often referred to as "low complexity" regions.

5

10

15

20

25

30

Such regions can cause database similarity search programs such as BLAST to find high-scoring sequence matches that do not imply true homology. The problem is exacerbated by the fact that most weight matrices (used to score the alignments generated by BLAST) give a match between any of a group of hydrophobic amino acids (L,V and I) that are commonly found in certain low complexity regions almost as high a score as for exact matches.

In order to compensate for this, BLASTX.2 (version 2.0a5MP-WashU) employs two filters ("seg" and "xnu") which "mask" the low complexity regions in a particular sequence. These filters parse the sequence for such regions, and create a new sequence in which the amino acids in the low complexity region have been replaced with the character "X". This is then used as the input sequence (sometimes referred to herein as "Query" and/or "Q") to the BLASTX program. While this regime helps to ensure that high-scoring matches represent true homology, there is a negative consequence in that the BLASTX program uses the query sequence that has been masked by the filters to draw alignments.

Thus, a stretch of "X"s in an alignment shown in the following application does not necessarily indicate that either the underlying DNA sequence or the translated protein sequence is unknown or uncertain. Nor is the presence of such stretches meant to indicate that the sequence is identical or not identical to the sequence disclosed in the alignment of the present invention. Such stretches may simply indicate that the BLASTX program masked amino acids in that region due to the detection of a low complexity region, as defined above. In all cases, the reference sequence(s) (sometimes referred to herein as "Subject", "Sbjct", and/or "S") indicated in the specification, sequence table (Table 1), and/or the deposited clone is (are) the definitive embodiment(s) of the present invention, and should not be construed as

8

limiting the present invention to the partial sequence shown in an alignment, unless specifically noted otherwise herein.

Polynucleotides and Polypeptides of the Invention

5

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 1

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gb|AAD33892.1|AF142780_1 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "(AF142780) butyrophilin-like protein [Mus musculus]" A partial alignment demonstrating the observed homology is shown immediately below.

```
15
         >gb|AAD33892.1|AF142780_1 (AF142780) butyrophilin-like protein [Mus musculus]
                     >qb|AAD33892.1|AF142780 1 (AF142780) butyrophilin-like protein [Mus
                     musculus] >sp|AAD33892|AAD33892 Butyrophilin-like protein.
                     Length = 247
20
           Plus Strand HSPs:
          Score = 835 (293.9 bits), Expect = 1.5e-82, P = 1.5e-82
          Identities = 159/233 (68%), Positives = 183/233 (78%), Frame = +1
25
              313 HOIAALFTVTVPKELYIIEHGSNVTLECNFDTGSHVNLGAITASLOKVENDTSPHRERAT 492
                  H +AALFTVT PKE+Y ++ GS+V+LEC+FD
                                                     L I ASLOKVENDTS
         S:
              15 HPVAALFTVTAPKEVYTVDVGSSVSLECDFDRRECTELEGIRASLQKVENDTSLQSERAT 74
             493 LLEEQLPLGKASFHIPQVQVRDEGQYQCIIIYGVAWDYKYLTLKVKASYRKINTHILKVP 672
         0:
30
                  LLEEQLPLGKA FHIP VQVRD GQY+C++I G AWDYKYLT+KVKASY +I+T IL+VP
              75 LLEEQLPLGKALFHIPSVQVRDSGQYRCLVICGAAWDYKYLTVKVKASYMRIDTRILEVP 134
         S:
              673 ETDEVELTCQATGYPLAEVSWPNVSVPANTSHSRTPEGLYQVTSVLRLKPPPGRNFSCVF 852
         Q:
                   T EV+LTCQA GYPLAEVSW NVSVPANTSH RTPEGLYQVTSVLRLKP P RNFSC+F
35
             135 GTGEVQLTCQARGYPLAEVSWQNVSVPANTSHIRTPEGLYQVTSVLRLKPQPSRNFSCMF 194
         s:
         0:
              853 WNTHVRELTLASIDLQSQMEPRTHPTWLLHIFIPSCXXXXXXXXTVIALRKQL 1011
                  WN H++ELT A ID S+MEP+ TW LH+FIP+C
              195 WNAHMKELTSAIIDPLSRMEPKVPRTWPLHVFIPACTIALIFLAIVIIQRKRI 247
         S:
40
```

The segment of gb|AAD33892.1|AF142780_1 that is shown as "S" above is set out in the sequence listing as SEQ ID NO: Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein.

45 Assays for determining such activities are also known in the art, some of which have

5

10

15

20

25

been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

This gene is expressed primarily in the following tissues/cDNA libraries: Soares_pregnant_uterus_NbHPU and to a lesser extent in Primary Dendritic Cells, lib 1; Thymus; Human Adult Spleen; Aorta endothelial cells + TNF-a; Human T-cell lymphoma,re-excision; Primary Dendritic cells,frac 2 and Soares testis NHT.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune system diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based upon the tissue distribution and homology to butyrophilin, polynucleotides, translation products and antibodies corresponding to this gene may be useful in the diagnosis and/or treatment of a variety of disorders. Elevated expression in uterus suggests utility for the study diagnosis and/or treatment of reproductive disorders. The homology to butyrophilin suggests that polynucleotides, translation products and antibodies corresponding to this gene may be useful in dairy products, vaccines, and assays for susceptibility to multiple sclerosis. The tissue distribution indicates also an enrichment in hematopoietic/immune tissues.

Furthermore, this gene product shares homology to B7-H1, a novel member of the B7 family of T-cell costimulatory molecules. Thus, this gene product maybe useful in the treatment and/or diagnosis of immune disorders.

30

FEATURES OF PROTEIN ENCODED BY GENE NO: 2

Translation products corresponding to this gene share sequence homology with the murine Gremlin protein (See, e.g., Genbank Accession AAC40111), which is thought to play a role in the inhibition of Bone Morphogenic Proteins.

This gene is expressed primarily in the following tissues/cDNA libraries: Osteoblasts and to a lesser extent in Soares senescent fibroblasts NbHSF; Jia bone 10 marrow stroma; Human Osteoblasts II; Human Thymus Stromal Cells; Soares melanocyte 2NbHM; HSA 172 Cells; Human Osteoclastoma; Stromal cell TF274; Stratagene fibroblast (#937212); Human endometrial stromal cells-treated with progesterone; Human endometrial stromal cells-treated with estradiol; Human adult (K.Okubo); Human endometrial stromal cells; NCI CGAP Gas4; Human Gall Bladder; Colon Tumor; Human 8 Week Whole Embryo; Colon Tumor II; Human 15 Bone Marrow Stromal Fibroblast; HUMAN SCHWANOMA; Crohn's Disease; Pharvnx Carcinoma; Human Normal Cartilage Fraction IV; Human Pre-Differentiated Adipocytes; HSC172 cells; NCI CGAP Co12; human corpus colosum; NCI CGAP Co9; Synovial hypoxia-RSF subtracted; Human Stomach,re-excision; 20 Human Colon, re-excision; NCI CGAP Alv1; Gessler Wilms tumor; Monocyte activated, re-excision; 12 Week Old Early Stage Human, II; Human Pancreas Tumor, Reexcision; Synovial Fibroblasts (control); Bone Marrow Stromal Cell, untreated; NCI CGAP Co3; CHME Cell Line, untreated; Colon Carcinoma; NCI CGAP Co8; Human Placenta; Pancreas normal PCA4 No; Monocyte activated; Pancreas Tumor PCA4 Tu; Neutrophils IL-1 and LPS induced; H. Frontal cortex, epileptic, re-excision 25 and NCI CGAP Lu5.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the musculoskeletal system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of

5

10

15

20

25

30

disorders of the above tissues or cells, particularly of the musculoskeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., musculoskeletal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

11

The homology of translation products corresponding to this gene to the murine gremlin protein indicates that polynucleotides, translation products and antibodies corresponding to this gene may be useful for the inhibition of members of the TGF-beta family of growth factors. Elevated levels of expression of this gene product in osteoblasts and osteoclastoma tissue suggests that polynucleotides, translation products and antibodies corresponding to this gene may play a role in the survival, proliferation, and/or growth of osteoclasts. Therefore, it may be useful in influencing bone mass in such conditions as osteoporosis.

The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating /immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative

5

10

15

20

25

30

diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures.

12

The tissue distribution in immune tissue (e.g., neutrophils, bone marrow) indicates the protein product of this clone would be useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes suggests a usefulness for treatment of cancer (e.g. by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it would also be useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as hostversus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma.

Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The tissue distribution (e.g.,osteoblasts) suggests that the protein product of this clone is useful for the diagnosis and/or treatment of bone disorders. The tissue distribution in tumors of colon, pancreas, and pharynx origins suggests that the protein product of this clone is useful for the diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate

ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

PCT/US00/30654

5

10

15

20

25

30

WO 01/34629

FEATURES OF PROTEIN ENCODED BY GENE NO: 3

Translation products corresponding to this gene share sequence homology with the murine MPS-1 protein and rat MPG-1 protein (See Genbank Accession numbers AAA73957 and AAD38417, respectively). The MPS-1 protein is a macrophage specific protein having evolutionary conservation to the lytic family of perforin proteins. Based upon the homology, it is thought that translation products corresponding to this gene may function in a lytic capacity, causing cellular death.

This gene is expressed primarily in the following tissues/cDNA libraries: Human Bone Marrow, treated and to a lesser extent in Human rejected kidney; Human T-cell lymphoma, re-excision; Human Adult Small Intestine; Human Osteoblasts II; Ulcerative Colitis; Human Placenta; human tonsils; Hodgkin's Lymphoma II and Primary Dendritic Cells, lib 1.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

PCT/US00/30654

14

This gene is the human ortholog of mouse and rat Macrophage specific gene

1. The mouse gene was identified by differential cDNA analysis and showed
macrophage lineage and differentiation stage-specific expression with high level in
mature macrophages and moderate level in certain myelomonocytic cell lines.

The tissue distribution in human Bone Marrow and other hematopoietic cell types indicates the gene and its protein product is useful for the diagnosis and treatment of human immune system disorders, osteroblastoma, arthritis and other cancers. Translation products corresponding to this gene may function as a lytic protein involved in cellular death.

Alternatively, translation products corresponding to this gene may participate in immune function and immune surveillance. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15

10

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 4

This gene is expressed primarily in the following tissues/cDNA libraries: 20 Soares fetal liver spleen 1NFLS and to a lesser extent in NCI CGAP GCB1; Human Pituitary, subt IX; Soares NFL T GBC S1; Soares NhHMPu S1; Human Pituitary, subtracted; Soares adult brain N2b4HB55Y; Rejected Kidney, lib 4; H. Frontal cortex, epileptic, re-excision; Soares melanocyte 2NbHM; Human Cerebellum; Activated T-Cells, 12 hrs, subtracted; Human Colon, subtraction; Pancreatic Islet; NCI CGAP Ut4; Stratagene NT2 neuronal precursor 937230; NCI CGAP Kid6; 25 Stratagene pancreas (#937208); Stratagene HeLa cell s3 937216; Stratagene endothelial cell 937223; NCI CGAP Co3; Stratagene colon (#937204); Early Stage Human Brain; Human Fetal Kidney, Reexcision; Human Fetal Heart; human tonsils; NCI CGAP GC6; NCI CGAP Kid5; HUMAN B CELL LYMPHOMA; Soares 30 ovary tumor NbHOT; Hodgkin's Lymphoma II; Soares testis NHT; H.Leukocytes, normalized cot 50A3; PRMIX; Namalwa Cells; HL-60, RA 4h, Subtracted; NCI CGAP Pr8; NCI CGAP Pr9; Human Pituitary, re-excision; Human Fetal

25

30

PCT/US00/30654

Brain; stomach cancer (human); Human Colon; Human retina cDNA Tsp509Icleaved sublibrary; NCI_CGAP_Lip2; Human Fetal Spleen; Smooth muscle, control, re-excision; H. Epididiymus, caput & corpus; H. cerebellum, Enzyme subtracted; Human Lung; H. Epididiymus, cauda; Human Lung Cancer, re-excision; Healing groin wound - zero hr post-incision (control); Human Epididymus; STROMAL -5 OSTEOCLASTOMA; Synovial IL-1/TNF stimulated; Hepatocellular Tumor; pBMC stimulated w/poly I/C; Smooth muscle, IL1b induced; Stratagene schizo brain S11; Synovial hypoxia-RSF subtracted; NCI CGAP Co14; B-cells (unstimulated); LNCAP prostate cell line; Jurkat T-Cell, S phase; H. Lymph node breast Cancer; Human Adult Small Intestine; Breast, Normal: (4005522B2); Stratagene lung 10 carcinoma 937218; Human Prostate; B-Cells; Human Brain, Striatum; Monocyte activated, re-excision; Human Fetal Kidney; Human Uterine Cancer; NCI CGAP Gas4; Human Pancreas Tumor, Reexcision; Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma; Ovary, Cancer: (4004576 A8); Human Chondrosarcoma; Bone Marrow Stromal Cell, untreated; Human Thymus Stromal 15 Cells; Soares breast 2NbHBst; Human Adrenal Gland Tumor; Human Gall Bladder; Smooth muscle, serum induced, re-exc; Smooth muscle, serum treated; breast lymph node CDNA library; Human Placenta; H Macrophage (GM-CSF treated), re-excision; Normal colon; NCI CGAP GC4; Human Synovial Sarcoma; Pancreas normal PCA4 No; 12 Week Early Stage Human II, Reexcision; NCI CGAP Brn23; Monocyte 20 activated; Soares placenta 8to9weeks 2NbHP8to9W; Human Testes; Bone Marrow Cell Line (RS4,11); NCI CGAP_Lu5; Keratinocyte; Colon Normal III; Soares fetal heart NbHH19W and Primary Dendritic Cells, lib 1.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids

10

15

20

PCT/US00/30654

(e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

16

The observed tissue distribution suggests that this gene product may be useful in the diagnosis and/or treatment of a variety of disorders. Enriched expression in fetal liver and spleen suggests a possible role in hematopoiesis and in the survival, proliferation, differentiation, and/or activation of blood cell lineages. Thus, the gene product may be involved in immune system dysfunction, susceptibility to infection, autoimmunity, leukemia/lymphoma, inflammation, and immune modulation. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 5

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gb|AAC17217.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "| (AF016032) guanosine-diphosphatase like protein [Homo sapiens]" A partial alignment demonstrating the observed homology is shown immediately below.

```
25
         >gb|AAC17217.1| (AF016032) guanosine-diphosphatase like protein [Homo sapiens]
                     >sp|015092|015092 GUANOSINE-DIPHOSPHATASE LIKE PROTEIN (KIAA0392).
                     >dbj|BAA21575.1| (AB002390) KIAA0392 [Homo sapiens] {SUB 60-609}
                     Length = 609
30
           Plus Strand HSPs:
          Score = 829 (291.8 bits), Expect = 6.1e-82, P = 6.1e-82
         Identities = 168/283 (59%), Positives = 199/283 (70%), Frame = +3
35
              219 MARISFSYLCPASWYFTV-PTVSPF----LRQRVAXXXXXXXXXXXXXXXXXXDFRHWSA 380
        Q:
                 M RI S L PASW+F++ P P
                                              LRQ +
                1 MGRIGISCLFPASWHFSISPVGCPRILNTNLRQIMVISVLAAAAVSLLYFSVVIIRNKYG 60
         S:
             381 SLPRDROYERYLARVGELEATDTEDPNLNYGLXVDCGSSGSRIFXYFWPRHNGNPHDLLD 560
        Q:
40
                   L RD++++RYLARV ++EATDT +PN+NYG+ VDCGSSGSR+F Y WPRHNGNPHDLLD
               61 RLTRDKKFQRYLARVTDIEATDTNNPNVNYGIVVDCGSSGSRVFVYCWPRHNGNPHDLLD 120
        s:
```

15

20

25

30

35

PCT/US00/30654

561 IKOMRDRNSQPVVKKIKPGISAMADTPEHASDYLRPLLSFAAAHVPVKKHKETPLYILCT 740 I+QMRD+N +PVV KIKPGIS A +PE SDY+ PLL+FAA HVP KHKETPLYILCT 121 IROMRDKNRKPVVMKIKPGISEFATSPEKVSDYISPLLNFAAEHVPRAKHKETPLYILCT 180 s: 5 Q: 741 AGMRLLPERKQLAILADLVKDLPLEFDFLFSQSQAEVISGKQEGVYAWIGINFVLXRFDH 920 AGMR+LPE +Q AIL DL+ D+P+ FDFLFS S AEVISGKQEGVYAWIGINFVL RF+H S: 181 AGMRILPESQQKAILEDLLTDIPVHFDFLFSDSHAEVISGKQEGVYAWIGINFVLGRFEH 240 10 Q: 921 EDESDAEATQEL------AAGRRRTVGILDMGGAXXQIAYE 1025 ++ D EA E+ A R+RT GILDMGG S: 241 IEDDD-EAVVEVNIPGSESSEAIVRKRTAGILDMGGVSTQIAYE 283

The segment of gb|AAC17217.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO: . Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

17

This gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in Messangial cell, frac 1; Human Umbilical Vein Endothelial cells, frac B, re-excision; Adipocytes,re-excision; Fetal Heart, re-excision; Smooth muscle, IL1b induced; Human Osteosarcoma; human ovarian cancer; NCI_CGAP_CLL1; PC3 Prostate cell line; Soares melanocyte 2NbHM and Primary Dendritic Cells, lib 1.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

18

PCT/US00/30654

the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on its homology to apyrase, diphosphatase and CD39, which are thought to be involved in cell-cell interactions and aggregation, this protein may have similar roles in cell-cell interactions. Based on its expression in infant brain, the gene and its products may be involved in the formation of the correct neural interactions which are required for cognitive, learning and other higher neural functions such as memory. Thus this gene may be useful for the diagnosis and treatment of such disorders as well as other neurodegenerative disorders such as Alzheimer's, Parkinson's, ALS and multiple sclerosis. In addition the proteins may be useful in the treatment of nerve injuries including spinal cord injuries, where nerve regeneration would be advantageous. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15

20

25

30

10

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 6

Translation products corresponding to this gene share sequence homology with the human HER2 receptor protein (See, e.g., Genbank Accession AAA75493). This gene is expressed primarily in the following tissues/cDNA libraries: NCI_CGAP_Pr28 and to a lesser extent in NCI_CGAP_Pr23; Hodgkin's Lymphoma I; Healing groin wound - zero hr post-incision (control); Healing groin wound, 6.5 hours post incision; NCI_CGAP_Ut2; NCI_CGAP_Pr2; NCI_CGAP_Kid6; Soares adult brain N2b5HB55Y; Hodgkin's Lymphoma II; Soares_fetal_heart_NbHH19W and Soares infant brain 1NIB.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the immune system and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of

disorders of the above tissues or cells, particularly of the immune system and cancerous tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The homology to the human Her2 receptor, and the tissue distribution mainly in human prostate tumor and Hodgkin's Lymphoma I tissues, indicates the gene and its protein product is useful for the diagnosis and treatment of human prostate cancer, Hodgkin's lymphoma, and other immune system disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 7

15

20

25

30

10

5

Translation products corresponding to this gene share sequence homology with the human Steerin-1 protein (See, e.g., Genbank Accession AJ251973), and the extensin-like protein.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

MSDNAPASLESGSSSTPTNCSTSSAIPQPGAATKPWRSKSLSVKHSATVSMLS
VKPPGPEAPRPTPEAMKPAPNNQKSMLEKLKLFNSKGGSKAGEGPGSRDTSC
ERLETLPSFEESEELEAASRMLTTVGPASSSPKIALKGIAQRTFSRALTNKKSSL
KGNEKEKEKQQREKDKEKSKDLAKRASVTERLDLKEEPKEDPSGAAVPEMP
KKSSKIASFIPKGGKLNSAKKEPMAPSHSGIPKPGMKSMPGKSPSAPAPSKEG
ERSRSGKLSSGLPQQKPQLDGRHSSSSSSLASSEGKGPGGTTLNHSISSQTVSG
SVGTTQTTGSNTVSVQLPQPQQQYNHPNTATVAPFLYRSQTDTEGNXTXESS
STGVSVEPXHFPRLDSLLWKNSLGKILRLGGCGQ SNPHATMTQQGRRGREF
(SEQ ID NO: 146). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the

20

polynucleotide encoding these polypeptides) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the following tissues/cDNA libraries: Soares_pregnant_uterus_NbHPU and to a lesser extent in 7TM-PNMIX; Human Osteoblasts II; Human Fetal Kidney, Reexcision and Soares melanocyte 2NbHM.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: reproductive diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The homology to human Steerin-1 protein and to extensin-like protein as well as to Zn-finger transcription factor suggests it plays role in gene expression, regulation and development. The tissue distribution in human pregnant uterus and osteoblast indicates the gene and its protein product is useful for the diagnosis and treatment of female reproductive disorders and abnormal embryonic development. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30

5

10

15

20

25

5

10

15

20

25

30

This gene is expressed primarily in pooled Dendritic cells and Human Thymus Stromal Cells.

21

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in human dendritic and thymus stromal cells indicates the gene and its protein product is useful for the diagnosis and treatment of human immune system disorders. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

10

15

20

25

30

FEATURES OF PROTEIN ENCODED BY GENE NO: 9

The gene encoding the disclosed cDNA is thought to reside on chromosome 12. Accordingly, polynucleotides related to this invention have uses, such as, for example, as a marker in linkage analysis for chromosome 12.

This gene is expressed primarily in the following tissues/cDNA libraries:

Soares_fetal_heart_NbHH19W and to a lesser extent in Human Liver, normal; Early

Stage Human Brain; H. hypothalamus, frac A; Activated T-cells; Human Tonsils, Lib

2; human corpus colosum; Stratagene lung carcinoma 937218; Stratagene fetal spleen

(#937205); Human umbilical vein endothelial cells, IL-4 induced; Macrophage (GM-CSF treated); Stratagene liver (#937224); Bone marrow; Endothelial-induced; Human

Amygdala; Stratagene lung (#937210); Spleen, Chronic lymphocytic leukemia;

Human Bone Marrow, treated; Soares_NhHMPu_S1; Primary Dendritic Cells, lib 1

and Soares infant brain 1NIB.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: developmental and immune system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and developing systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, developing, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in human fetal tissues indicates the gene and its protein product are useful for the diagnosis and treatment of developmental disorders and adult immune disorders and cancers. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may

10

15

20

25

30

PCT/US00/30654

also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

23

FEATURES OF PROTEIN ENCODED BY GENE NO: 10

The gene encoding the disclosed cDNA is believed to reside on chromosome 19. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 19.

This gene is expressed primarily in T-cell helper and testis, and to a lesser extent ubiquitously.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the testis and the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the testis and the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., testis, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a

10

15

20

25

30

disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The observed tissue distribution suggests that this gene product may be useful in the diagnosis and/or treatment of a variety of disorders. Based upon the tissue distribution in T-cell helper this gene product may be useful for diagnosis and/or treatment of immune system dysfunctions, leukemias/lymphomas, susceptibility to infections, and circulatory disorders. Similarly, elevated expression in testis suggests a possible role in male fertility and a possible application of this gene product as a male contraceptive. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 11

5

10

15

20

25

30

This gene is expressed primarily in the following tissues/cDNA libraries: prostate, Dendritic cells, pooled; Soares_fetal_lung_NbHL19W and to a lesser extent in Human Pineal Gland; L428 and Activated T-Cell (12hs)/Thiouridine labelledEco.

25

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the immune system and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and cancerous tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in human prostate and hematopoietic cell lineage indicates the gene and its protein product is useful for the diagnosis and treatment of human prostate cancer and immune system disorders. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

10

15

20

25

30

FEATURES OF PROTEIN ENCODED BY GENE NO: 12

This gene is expressed primarily in the following tissues/cDNA libraries:

Human Whole Brain #2 - Oligo dT > 1.5Kb; Keratinocyte and to a lesser extent in

Bone Marrow Cell Line (RS4,11); T cell helper II; Testis 1; Human 8 Week Whole

Embryo, subtracted; Human retina cDNA Tsp509I-cleaved sublibrary; Stratagene
schizo brain S11; Human Umbilical Vein, Endo. remake; Human Stomach,reexcision; H. Lymph node breast Cancer; Human Infant Brain; Breast Cancer Cell line,
angiogenic; Human Activated T-Cells; T-Cell PHA 24 hrs; Stratagene hNT neuron
(#937233); Human Testes Tumor; Primary Dendritic cells,frac 2; Human Adult
Pulmonary,re-excision; Human 8 Week Whole Embryo;
Soares fetal lung NbHL19W and Primary Dendritic Cells, lib 1.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the neural and immune systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The observed tissue distribution suggests that this clone could be useful in the diagnosis and/or treatment of neurodevelopmental, neurodegenerative, hemopoietic and immune disorders and neoplasms. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune

27

responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 13

15

20

10

5

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

25

30

This gene is ubiquitously expressed with some enrichment in neural/sensory tissues, as well as in primary dendritic cells.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the neural and immune systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of

10

15

20

25

30

disorders of the above tissues or cells, particularly of the neural and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The observed tissue distribution suggests utility for the study diagnosis and/or treatment of a variety of diseases. The enriched expression in neural/sensory tissues indicates that this gene may be useful for the treatment, detection, and/or diagnosis of neurodegenerative disorders and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, learning disabilities. Alternatively, the expression in dendritic cells and the observed biological activity suggests utility for the study, diagnosis, and/or treatment of immune system diseases and/or disorders and infectious diseases. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 14

This gene is expressed primarily in cells of the immune/hematopoetic system, notably monocytes and dendritic cells as well as fetal liver and spleen which is known to have hematopoetic function.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on its expression in fetal liver and spleen which is known to have hematopoetic functions as well as expression in dendritic cells, this gene and its encoded polypeptides may be useful for the diagnosis and treatment of disorders associated with immune function such as over activity of the immune system as observed in autoimmunity syndromes including systemic lupus erythematosis (SLE) and rheumatoid arthritis or in the treatment of disorders associated with poor immune function such as specific immune cell cytopenias. The gene products may also be useful for the modulation of the immune response in organ transplantation, and allergies. The gene may be useful for the treatment of immune disorders or for the priming of immune based therapies against tumors. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30

FEATURES OF PROTEIN ENCODED BY GENE NO: 15

5

35

40

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gb|AAB57679.1| (all information available through the recited accession number is incorporated herein by reference in its entirety) which is described therein as "| transmembrane receptor UNC5H2 [Rattus norvegicus]" A partial alignment demonstrating the observed homology is shown immediately below.

```
10
         >gb|AAB57679.1| transmembrane receptor UNC5H2 [Rattus norvegicus]
                     >sp|008722|008722 TRANSMEMBRANE RECEPTOR UNC5H2.
                     Length = 945
           Plus Strand HSPs:
15
          Score = 638 (224.6 bits), Expect = 2.3e-61, P = 2.3e-61
          Identities = 122/130 (93%), Positives = 124/130 (95%), Frame = +3
                3 EGEGQIFQLHTTLAETPAGSLDTLCSAPGXTVTTQLGPYAFKIPLSIRQKICNSLDAPNS 182
20
                  EGEGQIFQLHTTLAETPAGSLD LCSAPG TTQLGPYAFKIPLSIRQKICNSLDAPNS
              816 EGEGQIFQLHTTLAETPAGSLDALCSAPGNAATTQLGPYAFKIPLSIRQKICNSLDAPNS 875
         S:
              183 RGNDWRMLAQKLSMDRYLNYFATKASPTGVILDLWEALQQDDGDLNSLASALEEMGKSEM 362
         Q:
                  RGNDWR+LAQKLSMDRYLNYFATKASPTGVILDLWEA QQDDGDLNSLASALEEMGKSEM
25
              876 RGNDWRLLAOKLSMDRYLNYFATKASPTGVILDLWEARQQDDGDLNSLASALEEMGKSEM 935
         S:
         Q:
              363 LVAVATDGDC 392
                  LVA+ TDGDC
              936 LVAMTTDGDC 945
30
```

The segment of gb|AAB57679.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO: Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

The translation product of this gene shares sequence homology with netrin receptors which are thought to be important in the developing nervous system. The netrins are a family of phylogenetically conserved guidance cues that can function as diffusible attractants and repellents for different classes of cells and axons. In

5

vertebrates, insects and nematodes, members of the DCC subfamily of the immunoglobulin superfamily have been implicated as receptors that are involved in migration towards netrin sources. Based on the sequence similarity of his human gene product to rat netrin receptor, the translation product of this clone is expected to share at least some biological activities with netrin receptor proteins. Such activities are known in the art, some of which are described elsewhere herein.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

EGEGQIFQLHTTLAETPAGSLDTLCSAPGXTVTTQLGPYAFKIPLSIRQKICNSL

DAPNSRGNDWRMLAQKLSMDRYLNYFATKASPTGVILDLWEALQQDDGDL

NSLASALEEMGKSEMLVAVATDGDC (SEQ ID NO: 152). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the following tissues/cDNA libraries: 20 normalized infant brain cDNA and to a lesser extent in Smooth muscle, serum treated; NCI CGAP Kid5; Soares multiple sclerosis 2NbHMSP; Soares ovary tumor NbHOT; Soares pregnant uterus NbHPU; H. Epididiymus, cauda; Smooth Muscle-HASTE normalized; Human Synovium; Gessler Wilms tumor; Human Chondrosarcoma; Human Thymus Stromal Cells; NCI CGAP Pan1; Fetal Heart; NCI CGAP GC4; Osteoblasts; Human Cerebellum; Soares NFL T GBC S1; 25 Soares NhHMPu S1; Soares infant brain 1NIB; Human Astrocyte; Sinus piniformis Tumour; Human OB MG63 treated (10 nM E2) fraction I; Barstead spleen HPLRB2; Normal Human Trabecular Bone Cells; Adipocytes, re-excision; Smooth Muscle Serum Treated, Norm; Smooth muscle-ILb induced; Human Normal Breast; 30 NCI CGAP AA1; Palate normal; Human adult (K.Okubo); H. Kidney Cortex, subtracted; Human Osteosarcoma; Prostate BPH; Spinal Cord, re-excision; Breast Cancer Cell line, angiogenic; 12 Week Old Early Stage Human, II; Human

Osteoblasts II; Human Pancreas Tumor; Stromal cell TF274; Human Pancreas Tumor, Reexcision; Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma; Hemangiopericytoma; Soares breast 2NbHBst; Human Adrenal Gland Tumor; Smooth muscle, serum induced,re-exc; Pancreas Islet Cell Tumor; Colon Normal II; Adipocytes; NCI_CGAP_Co8; Human Fetal Kidney, Reexcision; NCI_CGAP_Kid3; Human Bone Marrow, treated; Hodgkin's Lymphoma II; Keratinocyte; Soares fetal lung NbHL19W and Colon Tumor II.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the neural system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain and sequence homology to transmembrane receptor UNC5H2 [Rattus norvegicus] indicates the protein product of this clone would be useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism,

5

10

15

20

25

30

PCT/US00/30654

and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition,

33

homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 16

This gene is expressed primarily in the following tissues/cDNA libraries: Dendritic cells, pooled; human tonsils.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune system diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on its expression in tonsil and dendritic cells, this gene and its encoded polypeptides may be useful for the diagnosis and treatment of disorders associated with immune function such as those associated with over activity of the immune

10

15

20

25

30

34

PCT/US00/30654

system as observed in autoimmunity syndromes including systemic lupus erythematosis (SLE) and rheumatoid arthritis or in the treatment of disorders associated with poor immune function such as specific immune cell cytopenias. The gene products may also be useful for the modulation of the immune response in organ transplantation, and allergies.

FEATURES OF PROTEIN ENCODED BY GENE NO: 17

Preferred polypeptides of the invention comprise, or alternatively consist of, a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: 148. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the following tissues/cDNA libraries: KMH2; Human Adrenal Gland Tumor; Dendritic cells, pooled; Bone Marrow Cell Line (RS4,11).

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene

35

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on expression in bone marrow and dendritic cells this gene and its encoded gene products may be useful for the diagnosis and treatment of diseases of the immune system, including autoimmune syndromes such as systemic lupus erythematosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus as well as immune deficiency syndromes. The gene may also be used to regulate the immune response in such conditions as organ transplantation or allergies. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 18

15

10

5

This gene is expressed primarily in two distinct types of tissues- e.g., cells of immune/hematopoetic function and in testes as exemplified by the following tissues/cDNA libraries: Human Eosinophils; Human Testes, Reexcision; NCI CGAP Pr3; Early Stage Human Brain; Endothelial-induced; Activated T-20 cell(12h)/Thiouridine-re-excision; T cell helper II; Soares fetal heart NbHH19W; Primary Dendritic Cells, lib 1; HSC172 cells; H. Epididiymus, caput & corpus; Smooth Muscle- HASTE normalized; Amniotic Cells - Primary Culture; NCI CGAP Pr22; Soares pineal gland N3HPG; NCI CGAP Pr28; NCI_CGAP_CLL1; Resting T-Cell Library, II; Stratagene colon (#937204); Dendritic 25 cells, pooled; Soares pregnant uterus NbHPU; Soares NhHMPu S1; NCI CGAP Co1; Chromosome 7 HeLa cDNA Library; Atrium cDNA library Human heart; Chromosome 7 Fetal Brain cDNA Library; Human OB MG63 control fraction I; Cem cells cyclohexamide treated; Stomach cancer (human), re-excision; Human endometrial stromal cells-treated with estradiol; Smooth muscle, IL1b 30 induced; Synovial hypoxia-RSF subtracted; Human Whole Brain #2 - Oligo dT > 1.5Kb; HL-60, PMA 4H, re-excision; LNCAP prostate cell line; Synovial hypoxia; Jurkat T-cell G1 phase; Brain Frontal Cortex, re-excision; Stratagene neuroepithelium

(#937231); Human Umbilical Vein, Reexcision; Gessler Wilms tumor; HUMAN JURKAT MEMBRANE BOUND POLYSOMES; Human Fetal Dura Mater; Human Activated T-Cells; Human Hypothalmus, Schizophrenia; NCI_CGAP_Br2; Human Rhabdomyosarcoma; Human adult testis, large inserts; Pancreas Islet Cell Tumor; Colon Carcinoma; breast lymph node CDNA library; Adipocytes; CD34 depleted Buffy Coat (Cord Blood), re-excision; Human Microvascular Endothelial Cells, fract. A; Monocyte activated; HUMAN B CELL LYMPHOMA; Spleen, Chronic lymphocytic leukemia; Human Bone Marrow, treated; Human Testes; Soares_fetal_liver_spleen_1NFLS_S1 and Soares fetal liver spleen 1NFLS.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune system diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on its expression in various sources associated with immune function such as eosinophils, lymph node, T-cells, and dendritic cells this gene and its encoded polypeptides may be useful for the diagnosis and treatment of disorders associated with immune function such as those where over activity of the immune system is pathologic, as observed in autoimmunity syndromes including systemic lupus erythematosis (SLE) and rheumatoid arthritis or in the treatment of disorders associated with poor immune function such as specific immune cell cytopenias. The gene products may also be useful for the modulation of the immune response in organ transplantation, and allergies. Additionally, translation products corresponding to this

37

gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 19

10

15

20

25

30

This gene is expressed primarily in the following tissues/cDNA libraries: Human Fetal Brain; pBMC stimulated w/ poly I/C.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: neural system diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Due to its expression in the developing brain, this gene and its encoded polypeptides may be useful for the diagnosis and treatment of neurological disorders, including stroke, Alzheimer's disease, multiple sclerosis, ALS, and other disorders associated with loss of cognitive and learning functions. The protein may also be useful for treatment of spinal cord and other nerve injuries in which regeneration and regrowth on neural cells is required. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30

PCT/US00/30654

FEATURES OF PROTEIN ENCODED BY GENE NO: 20

38

This gene is expressed primarily in the following tissues/cDNA libraries: Soares pregnant uterus NbHPU and to a lesser extent in Human endometrial stromal cells-treated with progesterone; NCI CGAP Pr28; Human endometrial stromal cells; 5 Keratinocyte: Human Whole Brain #2 - Oligo dT > 1.5Kb; Soares NhHMPu S1; NCI CGAP GCB1; Human endometrial stromal cells-treated with estradiol; NCI CGAP Co10; NCI CGAP Ut2; NCI CGAP Gas4; NCI CGAP Pan1; NCI CGAP GC4; NCI CGAP GC6; Soares ovary tumor NbHOT; Bone Marrow Cell Line (RS4,11); Hodgkin's Lymphoma II; Human 8 Week Whole Embryo; 10 Soares fetal lung NbHL19W; T cell helper II; Soares NFL T GBC_S1; Healing Abdomen Wound, 15 days post incision; NCI CGAP Ov35; Testis 1; Human 8 Week Whole Embryo, subtracted; Human retina cDNA Tsp509I-cleaved sublibrary; NCI CGAP Ov23; Activated T-cells; H. Epididiymus, cauda; Stratagene schizo 15 brain S11; NCI CGAP Co9; Human Umbilical Vein, Endo. remake; Ovary, Cancer: (15799A1F) Poorly differentiated carcinoma; Human Stomach,re-excision; wilm's tumor; Human Manic Depression Tissue; H. Lymph node breast Cancer; Human Infant Brain; Breast Cancer Cell line, angiogenic; NCI CGAP Ut1; NCI CGAP Kid6; Human Fetal Dura Mater; Human Activated T-Cells; T-Cell PHA 24 hrs; NCI CGAP CLL1; Human Thymus Stromal Cells; CHME Cell Line, treated 20 5 hrs; Stratagene hNT neuron (#937233); Human T-Cell Lymphoma; Colon Carcinoma; Human Placenta; NCI CGAP Kid11; Human Testes Tumor; Primary Dendritic cells, frac 2; Pancreas normal PCA4 No; Human Adult Pulmonary, reexcision; Human Bone Marrow, treated; Soares parathyroid tumor NbHPA; Soares melanocyte 2NbHM; Colon Tumor II; Soares fetal heart NbHH19W and Primary 25 Dendritic Cells, lib 1.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the reproductive, immune, and hemapoietic systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell

type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive, immune, and hemapoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, immune, hemapoietic, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The observed tissue distribution suggests that this gene product may be useful for the diagnosis and/or treatment of diseases of the reproductive system, neoplasms and other proliferative disorders. Similarly, expression in hemapoietic cells may indicate roles in the proliferation, survival, differentiation, and/or activation of a variety of blood cell lineages, and implicate this gene product in immune system dysfunction, autoimmunity, leukemias/lymphomas, susceptibility to infections, and circulatory disorders. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 21

5

10

15

25

30

Preferred polypeptides of the invention comprise, or alternatively consist of, a polypeptide having the amino acid sequence: 157) set out in the sequence listing as SEQ ID NO: SEQ ID NO: and/or SEQ ID NO:156. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

5

10

15

20

25

30

Translation products corresponding to this gene share sequence homology with the human dermatan/chondroitin sulfate 2-sulfotransferase (See, e.g., Genbank Accession AB020316).

This gene is expressed primarily in the following tissues/cDNA libraries: STROMAL -OSTEOCLASTOMA; Dendritic cells, pooled; Smooth muscle,control; Nine Week Old Early Stage Human.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of musculoskeletal tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the musculoskeletal tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., musculoskeletal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating

41

infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Elevated levels of expression of this gene product in osteoclastoma suggests that it may play a role in the survival, proliferation, and/or growth of osteoclasts. Therefore, it may be useful in influencing bone mass in such conditions as osteoporosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5

10

Table 1

	Last	AA	Jo	ORF	283		23		93		184		77		84		716		61		11		99	
	First I		Sig Secreted	Portion C	20 2		19		70		25 1		2		2		18		16				7	
Last	AA	of	Sig	Pep]	19		18		19		24		1		1		17		15				1	
First Last	AA	Jo	Sig	Pep	1			٠	,		-		1		1		_				1			
AA	SEQ	А	NO:	Y	74		95		96		75		26		86		9/		66		100		101	
5° NT of	щ	AA of ID	Signal NO:	Pep	271		1003		261		170		2		1125		61		82		608		290	
	5° NT	Jo	Start	Codon	271				261		170						61		82					
3, NT	Jo	Clone	Seq.		2406		1613		982		3369		1063		1178		1690		190		1203		804	
5' NT 3' NT	Jo	Total Clone Clone	Seq.		1		1		-		1		533		1		1		1		1		1	
		Total	N	Seq.	2406		1675		786		3369		1063		1178		3258		200		1203		804	
Ľ	SEQ	А	NO:	X	11		32	-	33		12		34		35		13		36		37		38	
				Vector	pCMVSport	3.0	pCMVSport	3.0	pCMVSport	3.0	pCMVSport	2.0												
	ATCC	Deposit	No:Z and	Date	PTA-867	10/26/99																		
			cDNA	Clone ID	HDPPA04		HDPPA04		HDPPA04		HOHBY44		HOHBY44		HOHBY44		HOHBL42		HOHBL42		HOHBL42		HOHBL42	
			Gene	No.	1		1		-		2		2		2		3		3		3		3	

		Last	AA	of	ORF	617		505		191		288		33		83		19		29		83		39		63	
		First	AA of	Secreted	Portion	23		23		23		22		20		15		18		18		15		28		28	
	Last	AA		Sig		22		22		22		21		19		14		17		17		14		22		17	
	First Last	AA	Jo	Sig	Pep	1		-		_		_				1		П		-		1		1		1	
	AA	SEQ		NO:	Y	LL		102		103		28		104		62		105		106		101		08		108	
5' NT	Jo	First SEQ	AA of	Signal NO:	Pep	66		88		63		219		1711		691		175		116		673		369		396	
		5' NT	Jo	Start	Codon	66		88		63		219						175		116				369		396	
	5' NT 3' NT	Jo	Clone Clone	Seq.		3077		1602		1775		1082		2102		2070		1005		2988		2052		2055		219	
	5' NT	Jo	Clone	Seq.		1				209		64				20		_				2		1		1	
			Total	Z	Seq.	3077		1602		1789		1082		2102		2070		1005		2988		2052		2055		219	
	NT	SEQ		NO:	X	14		39		40		15		41		16		42		43		44		17		45	
					Vector	pCMVSport	3.0	pCMVSport	2.0	pCMVSport	2.0																
		ATCC	Deposit	No:Z and	Date	PTA-867	10/26/99	PTA-867	10/26/99																		
				cDNA	Clone ID	HRABV43		HRABV43		HRABV43		HDPRH52		HDPRH52	,	HDTEK44		HDTEK44		HDTEK44		HDTEK44		HOHBP82	-	HOHBP82	
				Gene	No.	4		4		4		5		5		9		9		9		9		7		7	

TALK
ATCC
Deposit
No:Z and
Date Vector
PTA-867 pCMVSport
10/26/99 2.0
PTA-867 pCMVSport
pCN
10/26/99 3.0
pCN
10/26/99 3.0
DC]
10/26/99 3.0
PTA-867 pCMVSport
10/26/99 3.0
PTA-867 pCMVSport
10/26/99 3.0
10/26/99 3.0
PTA-867 pCMVSport
10/26/99 3.0
PTA-867 pCMVSport
10/26/99 3.0
PTA-867 pCMVSport
10/26/99 3.0

5' NT		of 5'NT First SEQ AA AA First Last	of AA of	Sig Sig	Codon Pep Y Pep Pep	432 287 287 116 1 33 34 48		794 204 117 1 12		1019 528 118 1 1 2 129		6297 127 127 85 1 32 33 46		2042 117 117 119 1 26 27 46		5257 147 147 86 1 25 26 53		584 174 174 120 1 25 26 53		684 226 121 1 . 4		2070 2014 122 1 19		427 153 123 1 1 2 51		464 82 82 87 1 29 30 73
	5' NT 3' NT	Jo	Total Clone Clone	Seq. S	•	1		1 7		1 - 1		1 6		$1 \mid 2$		1 5.		1 5		1 6	_	1 2		1 4		$1 \mid 4$
			Total	NT		432		794		1019		6297		2042		5257		584		684		2070		427		464
	Z	SEQ		Ö.	×	53		54		22		22		99		23		25		58		69		09		24
					Vector	pCMVSport	3.0	pCMVSport	3.0	pCMVSport	3.0	pCMVSport	3.0	pCMVSport	3.0	pCMVSport	3.0	pCMVSport	3.0	pCMVSport	3.0	pCMVSport	3.0	pCMVSport	3.0	pCMVSport
		ATCC	Deposit	No:Z and	Date	PTA-867	10/26/99	PTA-867	10/26/99	PTA-867	10/26/99	PTA-867	10/26/99	PTA-867	10/26/99	PTA-867	10/26/99	PTA-867	10/26/99	PTA-867	10/26/99	PTA-867	10/26/99	PTA-867	10/26/99	PTA-867
				cDNA	Clone ID	HWBAR14		HWBAR14		HWBAR14		HDPPN86		HDPPN86		HDPIW06		HDPIW06		HDPIW06		HDPIW06		HDPIW06		HWBCH13
				Gene	No.	11		11		11		12		12		13		13		13		13		13		14

								_	5' NT					
				NT		5. NT 3. NT	3' NT		Jo	AA	First Last	Last		
		ATCC		SEQ		Jo	Jo	5' NT	First	SEQ	AA	AA	First	Last
		Deposit		Α	Total	Total Clone Clone	Clone	of	AA of		of	of	AA of	AA
Gene	cDNA	No:Z and		NO:	Z	Seq.	Sed.	Start	Signal NO:	SON.	Sig	Sig	Secreted	of
No.	_	Date	Vector	X	Seq.			Codon	Pep	Y	Pep	Pep	Portion	ORF
14	HWBCH13	798-AT4	pCMVSport	61	341	1	341		193	124	1			S
		10/26/99	$\hat{}3.0$											
14	HWBCH13	PTA-867	pCMVSport	62	804	-	804		535	125	1			10
		10/26/99	3.0										-	
14	HWBCH13	798-ATA	pCMVSport	63	1801	1	1081		772	126	1		2	57
. —		10/26/99	3.0											
15	06ГЭНОН	798-ATA	pCMVSport	25	1116	231	1116	307	307	88	1	56	30	- 08
		10/26/99	2.0				·							
15	нонсл90	PTA-867	pCMVSport	64	2211		1170		1275	127	1	1	2	164
		10/26/99	2.0				-						-	
16	HWBCM79	PTA-867	pCMVSport	76	1563	1	1563	381	381	68	_	76	27	36
		10/26/99	3.0											
17	HWBDM62	PTA-867	pCMVSport	27	1528	1	1528	101	101	96		17	18	40
		10/26/99	3.0											
17	HWBDM62	PTA-867	pCMVSport	65	1236		1236		387	128				7
		10/26/99	3.0											
17	HWBDM62	PTA-867	pCMVSport	99	<i>L6L</i>	1	197		309	129	1	17	18	22
		10/26/99	3.0											
17	HWBDM62	PTA-867	pCMVSport	<i>L</i> 9	534	_	534		179	130	1	-1	2	53
		10/26/99	3.0											
18	HWBCV72	PTA-867	pCMVSport	28	235		235	46	46	91	_	23	24	63
		10/26/99	3.0											

ATCC SEQ Of Of SINT SINT OF SINT SINT OF OF SINT OF OF SINT OF										5' NT					
ATCC SEQ of of s'NT Deposit Deposit Doposit Deposit Deposit Deposit Of of s'NT CDNA No.Z and No.Z and NO. NT Seq. Seq. Seq. Start Codon HWBCV72 PTA-867 pCMVSport 68 1096 1 1096 Codon HWBCV72 PTA-867 pCMVSport 69 1288 153 1288 Start HWBCV72 PTA-867 pCMVSport 70 3319 3125 3305 H HWTAL77 PTA-867 pCMVSport 70 3319 3125 3305 H HHEPG23 PTA-867 pCMVSport 71 372 41 372 41 HHEPG23 PTA-867 pCMVSport 72 337 23 337 124 HHEPG23 PTA-867 pCMVSport 72 337 23 337 124 10/26/99 3.0 3.0 3.0 1421 1415 1415					NT		5' NT	3, NT		Jo	AA	First Last	Last		
CDNA Deposit ID Total Clone Clone of Clone Clone of Clone Clone Date Vector NO: Saq. Seq. Seq. Start Clone ID Date Vector X Seq. Seq. Seq. Start HWBCV72 PTA-867 pCMVSport 68 1096 1 1096 Codon HWBCV72 PTA-867 pCMVSport 69 1288 153 1288 153 1288 HWBCV72 PTA-867 pCMVSport 70 3319 3125 3305 1 69 1 569 1 569 1 569 1 569 1 305 1 305 1 41 372 41 372 41 372 41 372 41 372 41			ATCC		SEQ		Jo	Jo	5' NT	First SEQ AA	SEQ	AA	AA	First	Last
cDNA No:Z and Clone ID Vector X X Seq. Seq. Seq.			Deposit		А	Total	Clone	Clone	Jo	AA of ID	Ω	Jo	Jo	AA of	AA
Clone ID Date Vector X Seq. Codon HWBCV72 PTA-867 pCMVSport 68 1096 1 1096 HWBCV72 PTA-867 pCMVSport 69 1288 153 1288 HWBCV72 PTA-867 pCMVSport 70 3319 3125 3305 HWBCV72 PTA-867 pCMVSport 29 569 1 569 HMTAL77 PTA-867 pCMVSport 71 372 41 372 HHEPG23 PTA-867 pCMVSport 30 2767 1 2767 421 HHEPG23 PTA-867 pCMVSport 72 337 23 337 124 HHEPG23 PTA-867 pCMVSport 73 1415 1 1415 HWBAR88 PTA-867 pCMVSport 73 1415 1 156 HWBAR88 PTA-867 pCMVSport 31 1051 1 156 HWBAR88 PTA-867	Je		No:Z and			NT	Seq.	Seq.		Signal			Sig	Secreted	Jo
HWBCV72 PTA-867 pCMVSport 68 1096 1 1096 HWBCV72 PTA-867 pCMVSport 69 1288 153 1288 HWBCV72 PTA-867 pCMVSport 70 3319 3125 3305 HWTAL77 PTA-867 pCMVSport 29 569 1 569 HMTAL77 PTA-867 pCMVSport 71 372 41 372 HHEPG23 PTA-867 pCMVSport 72 337 23 337 HHEPG23 PTA-867 pCMVSport 72 337 23 337 HHEPG23 PTA-867 pCMVSport 72 337 23 337 HHEPG23 PTA-867 pCMVSport 73 1415 1 1415 HWBAR88 PTA-867 pCMVSport 31 1051 1 1051 HWBAR88 PTA-867 pCMVSport 31 1051 1 1	No.		Date	Vector	X					Pep	Y	Pep	Pep	Portion	ORF
HWBCV72 PTA-867 pCMVSport 69 1288 153 1288 HWBCV72 PTA-867 pCMVSport 70 3319 3125 3305 HWBCV72 PTA-867 pCMVSport 70 3319 3125 3305 HMTAL77 PTA-867 pCMVSport 29 569 1 569 HMTAL77 PTA-867 pCMVSport 71 372 41 372 HHEPG23 PTA-867 pCMVSport 30 2767 1 2767 HHEPG23 PTA-867 pCMVSport 72 337 23 337 HHEPG23 PTA-867 pCMVSport 72 337 23 337 HHEPG23 PTA-867 pCMVSport 73 1415 1 1415 HWBAR88 PTA-867 pCMVSport 31 1051 1 1051	18	HWBCV72	PTA-867	pCMVSport	89	9601	-	1096		691	131	-			7
HWBCV72 PTA-867 pCMVSport 69 1288 153 1288 HWBCV72 PTA-867 pCMVSport 70 3319 3125 3305 HMTAL77 PTA-867 pCMVSport 29 569 1 569 HMTAL77 PTA-867 pCMVSport 71 372 41 372 HHEPG23 PTA-867 pCMVSport 30 2767 1 2767 HHEPG23 PTA-867 pCMVSport 72 337 23 337 HHEPG23 PTA-867 pCMVSport 72 337 23 337 HHEPG23 PTA-867 pCMVSport 72 337 23 337 HWBAR88 PTA-867 pCMVSport 73 1415 1 1415 HWBAR88 PTA-867 pCMVSport 31 1051 1 1051 HWBAR88 PTA-867 pCMVSport 31 1051 1 1052			10/26/99	3.0											
HWBCV72 PTA-867 pCMVSport 70 3319 3125 3305 HMTAL77 PTA-867 pCMVSport 29 569 1 569 HMTAL77 PTA-867 pCMVSport 71 372 41 372 HMTAL77 PTA-867 pCMVSport 71 372 41 372 HHEPG23 PTA-867 pCMVSport 3.0 2767 1 2767 HHEPG23 PTA-867 pCMVSport 72 337 23 337 HHEPG23 PTA-867 pCMVSport 73 1415 1 1415 HWBAR88 PTA-867 pCMVSport 3.0 3.0 10026/99 3.0 3.0 10026/99 3.0 10026/99 3.0 10026/99 3.0 10026/99 3.0 10026/99 3.0 1 10026/99 3.0 1 10026/99 3.0 1 <t< td=""><td>000</td><td>HWBCV72</td><td>PTA-867</td><td>pCMVSport</td><td>69</td><td>1288</td><td></td><td>1288</td><td></td><td>493</td><td>132</td><td>1</td><td></td><td></td><td>~</td></t<>	000	HWBCV72	PTA-867	pCMVSport	69	1288		1288		493	132	1			~
HWBCV72 PTA-867 pCMVSport 70 3319 3125 3305 HMTAL77 PTA-867 pCMVSport 29 569 1 569 HMTAL77 PTA-867 pCMVSport 71 372 41 372 HHEPG23 PTA-867 pCMVSport 3.0 3.0 1 2767 HHEPG23 PTA-867 pCMVSport 72 337 23 337 HHEPG23 PTA-867 pCMVSport 72 337 23 337 HHEPG23 PTA-867 pCMVSport 73 1415 1 1415 HWBAR88 PTA-867 pCMVSport 3.0 3.0 1026/99 3.0 HWBAR88 PTA-867 pCMVSport 31 1051 1 1415			10/26/99	3.0			·								
10/26/99 3.0 569 1 569 1 569 1 569 1 569 1 569 1 569 1 569 1 569 1 569 1 569 1 569 1 569 1 569 1 569 1 569 1 569 1 569 1 569 1 569 3.0 3	_∞	HWBCV72	PTA-867	pCMVSport	70		3125	3305		098	133	1	1	2	352
HMTAL77 PTA-867 pCMVSport 3.0 10,26/99 3.0 10,26/99 10,26/99 3.0 10,26/99			10/26/99	3.0											
HMTAL77 PTA-867 pCMVSport 71 372 41 372 1026/99 3.0 3.0 3.0 41 372 41 37	19	HMTAL77	PTA-867	pCMVSport	29	695	1	699		218	65	1	14	15	98
PTA-867 pCMVSport 71 372 41 372 10/26/99 3.0 2767 1			10/26/99	3.0											
HHEPG23 PTA-867 pCMVSport 30 2767 1 2	6	HMTAL77	PTA-867	pCMVSport	71	372	41	372		241	134	_			_
HHEPG23 PTA-867 pCMVSport 30 2767 1 2767 10/26/99 3.0 HHEPG23 PTA-867 pCMVSport 72 337 23 337 10/26/99 3.0 HWBAR88 PTA-867 pCMVSport 73 1415 1 1415 10/26/99 3.0 HWBAR88 PTA-867 pCMVSport 31 1051 1 1051			10/26/99	3.0											
HHEPG23 PTA-867 pCMVSport 72 337 23 337 10/26/99 3.0		HHEPG23	PTA-867	pCMVSport	30	2767	1	2767	421	421	93	-			70
HHEPG23 PTA-867 pCMVSport 72 337 23 337 10/26/99 3.0 HHEPG23 PTA-867 pCMVSport 73 1415 1 1415 1 1415 10/26/99 3.0 SOORVSport 73 1051 1 1051 1 1051			10/26/99	3.0											_
HHEPG23 PTA-867 pCMVSport 73 1415 1 1415 10/26/99 3.0 HWBAR88 PTA-867 pCMVSport 31 1051 1 1051 10/26/99 3.0	0	HHEPG23	PTA-867	pCMVSport	72	337	23	337	124	124	135				70
HHEPG23 PTA-867 pCMVSport 73 1415 1 1415 10/26/99 3.0 10/26/99 3.0 10/26/99 3.0			10/26/99	3.0											
HWBAR88 PTA-867 pCMVSport 31 1051 1 1051 10/26/99 3.0		HHEPG23	PTA-867	pCMVSport	73	1415	1	1415		886	136	1			Ξ
HWBAR88 PTA-867 pCMVSport 31 1051 1 1051 1 1051 3.0			10/26/99	3.0											
		HWBAR88	PTA-867	pCMVSport	31	1051	1	1051	156	156	94	_	18	19	75
			10/26/99	3.0											

5

10

15

20

25

30

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently

10

15

20

25

30

49

PCT/US00/30654

accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits.

Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed

5

10

herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

50

Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a deposited clone, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

Table 2 provides preferred epitopes contained in certain embodiments of the 15 invention and polynucleotide sequences that may be disclaimed according to certain embodiments of the invention. The first column refers to each "Gene No." described above in Table 1. The second column provides the sequence identifier, "NT SEQ ID NO:X", for polynucleotide sequences disclosed in Table 1. The third column provides the sequence identifier, "AA SEQ ID NO:Y", for polypeptide sequences disclosed in 20 Table 1. The fourth column provides a unique integer "ntA" where "ntA" is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X, and the fifth column provides a unique integer "ntB" where "ntB" is any integer between 15 and the final nucleotide of SEQ ID NO:X, where both ntA and ntB correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where ntB is greater 25 than or equal to a + 14. For each of the polynucleotides shown as SEQ ID NO:X, the uniquely defined integers can be substituted into the general formula of a-b, and used to describe polynucleotides which may be preferably excluded from the invention. Column 6 lists residues comprising predicted epitopes contained in the polypeptides encoded by each of the preferred ORFs (SEQ ID NO:Y). Identification of potential 30 immunogenic regions was performed according to the method of Jameson and Wolf ((1988) CABIOS, 4; 181-186); specifically, the Genetics Computer Group (GCG) implementation of this algorithm, embodied in the program PEPTIDESTRUCTURE

(Wisconsin Package v10.0, Genetics Computer Group (GCG), Madison, Wisc.). This method returns a measure of the probability that a given residue is found on the surface of the protein. Regions where the antigenic index score is greater than 0.9 over at least 6 amino acids are indicated in Table 2 as "Preferred Epitopes".

51

PCT/US00/30654

Polypeptides of the invention may possess one, two, three, four, five or more antigenic epitopes comprising residues described in Table 2. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly.

10

15

20

25

30

Table 3 summarizes the expression profile of polynucleotides corresponding to the clones disclosed in Table 1. The first column provides a unique clone identifier, "Clone ID", for a cDNA clone related to each contig sequence disclosed in Table 1. Column 2, "Library Codes" shows the expression profile of tissue and/or cell line libraries which express the polynucleotides of the invention. Each Library Code in column 2 represents a tissue/cell source identifier code corresponding to the Library Code and Library description provided in Table 5. Expression of these polynucleotides was not observed in the other tissues and/or cell libraries tested. One of skill in the art could routinely use this information to identify tissues which show a predominant expression pattern of the corresponding polynucleotide of the invention or to identify polynucleotides which show predominant and/or specific tissue expression.

Table 4, column 1, provides a nucleotide sequence identifier, "SEQ ID NO:X," that matches a nucleotide SEQ ID NO:X disclosed in Table 1, column 5. Table 4, column 2, provides the chromosomal location, "Cytologic Band or Chromosome," of polynucleotides corresponding to SEQ ID NO:X. Chromosomal location was determined by finding exact matches to EST and cDNA sequences contained in the NCBI (National Center for Biotechnology Information) UniGene database. Given a presumptive chromosomal location, disease locus association was determined by comparison with the Morbid Map, derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIMTM. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine

52

(Bethesda, MD) 2000. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/). If the putative chromosomal location of the Query overlapped with the chromosomal location of a Morbid Map entry, the OMIM reference identification number of the morbid map entry is provided in Table 4, column 3, labelled "OMIM ID." A key to the OMIM reference identification numbers is provided in Table 6.

5

10

15

20

Table 5 provides a key to the Library Code disclosed in Table 3. Column 1 provides the Library Code disclosed in Table 3, column 2. Column 2 provides a description of the tissue or cell source from which the corresponding library was derived. Library codes corresponding to diseased Tissues are indicated in column 3 with the word "disease".

Table 6 provides a key to the OMIM reference identification numbers disclosed in Table 4, column 3. OMIM reference identification numbers (Column 1) were derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine, (Bethesda, MD) 2000. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/). Column 2 provides diseases associated with the cytologic band disclosed in Table 4, column 2, as determined using the Morbid Map database.

Table 2

Gene #	NT SEQ ID NO: X	AA SEQ ID	nt A	nt B	Preferred Epitopes
1	11	NO: Y	1 - 2392	15 - 2406	Lys-61 to Arg-72
•	1 **	'	1 - 23/2	13 - 2400	Arg-95 to Tyr-100
			1 3		Ala-121 to Ile-126
					Asn-163 to Gly-172
					Lys-183 to Asn-189
	V 0				Ser-211 to His-218
					Leu-251 to Val-269.
1	32	95	1 - 1661	15 - 1675	Ser-16 to Lys-23.
1	33	96	1 - 772	15 - 786	Lys-61 to Arg-72.
2	12	75	1 - 3355	15 - 3369	Glu-23 to Gln-30
		'			Asn-42 to Gly-65
					Thr-84 to Lys-100
					Glu-105 to Ser-110
		İ			Arg-132 to Phe-138
					Pro-159 to Arg-172.
2	34	97	1 - 1049	15 - 1063	
2	35	98	1 - 1164	15 - 1178	Cys-25 to Asn-36.
3	13	76	1 - 3244	15 - 3258	
3	36	99	1 - 776	15 - 790	
3	37	100	1 - 1189	15 - 1203	
3	38	101	1 - 790	15 - 804	
4	14	77	1 - 3063	15 - 3077	Gln-200 to Lys-208
					Asn-273 to Glu-283
					Trp-319 to Thr-325
					Ala-340 to Pro-359
					Gln-365 to Pro-370
					Pro-395 to Ser-400
					Asn-541 to Thr-546
				•	Glu-563 to Ala-571
					Pro-574 to Ala-583
					Glu-590 to Asp-599
					Arg-604 to Glu-612.
4	39	102	1 - 1588	15 - 1602	Gln-200 to Lys-208
					Asn-273 to Glu-283
			1		Trp-319 to Thr-325
					Ala-340 to Pro-357.
4	40	103	1 - 1775	15 - 1789	
5	15	78	1 - 1068	15 - 1082	Leu-56 to Tyr-62
					Glu-73 to Asn-81.
5	41	104	1 - 2088	15 - 2102	
6	16	79	1 - 2056	15 - 2070	Arg-45 to Ser-54
	1	100	1	15 1005	Ser-78 to Ser-83.
6	42	105	1 - 991	15 - 1005	Leu-36 to Gly-41
			1		Lys-51 to Arg-56
	12	106	1 2074	15 2000	Arg-58 to Gly-66.
6	43	106	1 - 2974	15 - 2988	Leu-36 to Gly-41
			1		Lys-51 to Arg-56
6	44	107	1 - 2038	15 - 2052	Arg-58 to Gly-66. Arg-45 to Ser-54
U	***	107	1 - 2038	13 - 2032	Ser-78 to Ser-83.
7	17	80	1 - 2041	15 - 2055	Pro-20 to Gln-28.
	1/	T 90	1 - 2041	13 - 2033	110-20 to Gili-20.

7	45	108	1 - 603	15 - 617	
7	46	109	1 - 544	15 - 558	
7	47	110	1 - 1440	15 - 1454	Ala-45 to Arg-50.
8	18	81	1 - 815	15 - 829	
8	48	111	1 - 821	15 - 835	Pro-59 to Arg-67.
8	49	112	1 - 502	15 - 516	
9	19	82	1 - 1042	15 - 1056	
9	50	113	1 - 520	15 - 534	
9	51	114	1 - 489	15 - 503	
10	20	83	1 - 3129	15 - 3143	
10	52	115	1 - 593	15 - 607	
11	21	84	1 - 418	15 - 432	
11	53	116	1 - 780	15 - 794	Leu-2 to Leu-10.
11	54	117	1 - 1005	15 - 1019	Phe-13 to Ser-19
					Ser-96 to Pro-104.
12	22	85	1 - 6283	15 - 6297	
12	55	118	1 - 2028	15 - 2042	
13	23	86	1 - 5243	15 - 5257	Gln-30 to His-36.
13	56	119	1 - 570	15 - 584	Gln-30 to His-36.
13	57	120	1 - 670	15 - 684	
13	58	121	1 - 2056	15 - 2070	
13	59	122	1 - 413	15 - 427	Leu-24 to Arg-30
					Lys-42 to Ala-50.
14	24.	87	1 - 450	15 - 464	
14	60	123	1 - 327	15 - 341	
14	61	124	1 - 790	15 - 804	
14	62	125	1 - 1067	15 - 1081	Pro-34 to Gly-41.
15	25	88	1 - 1102	15 - 1116	Pro-10 to Arg-16.
15	63	126	1 - 2197	15 - 2211	
16	26	89	1 - 1549	15 - 1563	
17	27	90	1 - 1514	15 - 1528	
17	64	127	1 - 1222	15 - 1236	
17	65	128	1 - 783	15 - 797	
17	66	129	1 - 520	15 - 534	Arg-21 to Arg-34.
18	28	91	1 - 221	15 - 235	Glu-34 to Lys-40.
18	67	130	1 - 1082	15 - 1096	
18	68	131	1 - 1274	15 - 1288	
18	69	132	1 - 3305	15 - 3319	Ser-108 to Gly-131
					Ala-138 to Tyr-145
			[Lys-160 to Gly-165
					Ile-193 to Cys-200
			1		Pro-209 to Arg-215
					Thr-220 to Leu-229
			1		Ile-233 to Ile-253
					Leu-257 to Lys-263 Pro-273 to Pro-285
					Gly-345 to Phe-352.
19	29	92	1 - 555	15 - 569	G1y-343 to 1 He-332.
19	70	133	1 - 358	15 - 372	· · ·
20	30	93	1 - 2753	15 - 2767	
20	71	134	1 - 323	15 - 337	
20	72	135	1 - 1401	15 - 1415	
21	31	94	1 - 1037	15 - 1051	
<u> </u>	<u> </u>	<u> </u>	1	1 1001	

Table 3

Clone ID	Library Codes
HDPPA04	H0004 H0494 H0521 H0522 H0591 H0641 L1290 S0452 T0049
HOHBY44	H0013 H0014 H0031 H0171 H0327 H0489 H0544 H0545 H0551 H0597
	H0622 H0628 H0661 H0665 H0667 H0668 L1290 S0002 S0003 S0026
	S0053 S0126 S0192 S0212 S0222 S0250 S0276 S0336 S0350 S0360
	S0376 S0380 S0420 S0426 T0039 T0040
HOHBL42	H0031 H0036 H0251 H0264 H0306 H0309 H0361 H0402 H0427 H0445
	H0486 H0506 H0518 H0521 H0581 H0586 H0587 H0591 H0592 H0644
	H0656 H0657 H0677 H0690 L1290 S0116 S0152 S0250 S0358 S0374
	S0408
HRABV43	H0012 H0014 H0026 H0032 H0036 H0038 H0050 H0052 H0057 H0059
	H0085 H0135 H0150 H0156 H0178 H0213 H0224 H0231 H0251 H0255
	H0261 H0264 H0318 H0331 H0341 H0343 H0370 H0424 H0486 H0492
	H0494 H0518 H0519 H0521 H0549 H0550 H0551 H0553 H0555 H0587
	H0592 H0594 H0599 H0604 H0607 H0619 H0620 H0622 H0624 H0650
	H0656 H0658 H0662 H0672 H0673 H0677 H0687 L1290 S0002 S0007
	S0011 S0027 S0037 S0049 S0150 S0196 S0212 S0222 S0268 S0276
HDPRH52	S0278 S0358 S0374 S0378 S0390 S0426 S3014 T0042 H0252 H0328 H0433 H0521 H0645 L1290 S0037 S0152 S0208 S0342
HDPKH32	H0252 H0328 H0433 H0521 H0643 L1290 S0037 S0152 S0208 S0342
HDTEK44	H0485 H0486 H0586 H0592 H0683 H0687 L1290
HOHBP82	S0250
HWBAD01	H0551 H0580
HWABE12	H0327 H0412 H0435 H0445 H0488 H0510 H0521 H0539 H0581 H0638 H0657 L1290 S0007 S0010 S0046 S0116 S0144 S0330 S0358 S0376
	S0424 S6014 T0002
HHEPJ23	H0009 H0012 H0014 H0024 H0040 H0041 H0052 H0083 H0087 H0100
111101 123	H0123 H0125 H0131 H0135 H0136 H0156 H0215 H0252 H0256 H0257
	H0261 H0264 H0265 H0266 H0284 H0290 H0295 H0316 H0318 H0328
	H0402 H0412 H0415 H0424 H0445 H0484 H0486 H0494 H0520 H0529
	H0530 H0542 H0543 H0545 H0547 H0550 H0553 H0555 H0556 H0559
	H0560 H0580 H0581 H0586 H0592 H0593 H0618 H0620 H0650 H0652
	H0656 H0660 H0665 H0686 H0689 H0698 H0706 L1290 S0049 S0051
	S0110 S0144 S0150 S0182 S0210 S0222 S0278 S0358 S0360 S0376
	S0420
HWBAR14	H0012 H0265 H0560 H0561 H0580 H0593 H0665 H0687 H0693 H0694
	L1290_S0053_S6028_T0006
HDPPN86	H0013 H0056 H0090 H0341 H0423 H0494 H0521 H0522 H0542 H0543
	H0546 H0547 H0553 H0575 H0580 L1290 S0038 S0418 S6028 T0002
	T0010
HDPIW06	H0008 H0013 H0032 H0039 H0051 H0052 H0165 H0169 H0274 H0373
	H0427 H0431 H0445 H0509 H0520 H0521 H0547 H0553 H0575 H0587
	H0590 H0624 H0631 H0638 H0647 H0649 H0652 H0658 H0688 H0696
	L0022 L1290 S0007 S0015 S0026 S0028 S0031 S0036 S0038 S0040
	S0212 S0222 S0242 S0276 S0328 S0354 S0364 S0412 S0438 S0448
	S6024 S6028 T0060
HWBCH13	H0486 H0521 S0002
HOHCJ90	H0163 H0251 H0252 H0286 H0292 H0333 H0505 H0521 H0529 H0550
	H0551 H0555 H0619 H0620 H0622 H0633 H0658 L0022 S0026 S0027
	S0032 S0037 S0040 S0044 S0126 S0206 S0250 S0260 S0282 S0354
THUR CLAZO	S0360 S3012 S3014
HWBCM79	H0264 H0580
HWBDM62	H0156 H0341 H0560 H0580 L0022
HWBCV72	H0038 H0069 H0083 H0123 H0124 H0125 H0253 H0266 H0284 H0295

56

H0318 H0402 H0423 H0436 H0445 H0457 H0519 H0521 H0539 H0543
H0546 H0549 H0550 H0551 H0556 H0559 H0580 H0581 H0595 H0599
H0616 H0618 H0623 H0658 H0662 H0687 L0022 S0002 S0007 S0037
S0038 S0040 S0046 S0051 S0150 S0194 S0206 S0276 S0282 S0356
S0358 T0040 T0041
H0030 H0036 H0050 H0090 H0123 H0124 H0150 H0171 H0333 H0341
H0343 H0351 H0352 H0370 H0412 H0427 H0435 H0436 H0486 H0487
H0518 H0520 H0521 H0522 H0539 H0543 H0547 H0556 H0581 H0591
H0594 H0597 H0599 H0618 H0620 H0628 H0633 H0637 H0641 H0644
H0658 H0659 H0670 L0022 S0007 S0027 S0045 S0051 S0116 S0134
S0150 S0212 S0222 S0330 S0360 S0366 S0418 S0420 S0428 S3014
T0010 T0042 T0109
H0009 H0013 H0056 H0090 H0341 H0423 H0494 H0521 H0522 H0542
H0543 H0546 H0547 H0553 H0555 H0575 H0580 L0022 S0038 S0116
S0418 S6028 T0002 T0010
H0144 H0272 H0412 H0580 H0650 S0011 S0428

57

Table 4

SEQ ID NO: X	Cytologic Band or Chromosome:	OMIM Reference(s):
14	11q13	102200 106100 131100 133780 147050 153700 161015 164009 168461 180721 180840 191181 193235 209901 232600 259700 259770 600045 600319 600528 601884

Table 5

Library Code	Library Description	<u>Disease</u>
H0004	Human Adult Spleen	
H0008	Whole 6 Week Old Embryo	
H0009	Human Fetal Brain	
H0012	Human Fetal Kidney	
H0013	Human 8 Week Whole Embryo	
H0014	Human Gall Bladder	
H0024	Human Fetal Lung III	
H0026	Namalwa Cells	
H0030	Human Placenta	
H0031	Human Placenta	
H0032	Human Prostate	
H0036	Human Adult Small Intestine	
H0038	Human Testes	
H0039	Human Pancreas Tumor	disease
H0040	Human Testes Tumor	disease
H0041	Human Fetal Bone	
H0050	Human Fetal Heart	
H0051	Human Hippocampus	
H0052	Human Cerebellum	
H0056	Human Umbilical Vein, Endo. remake	
H0057	Human Fetal Spleen	
H0059	Human Uterine Cancer	disease
H0069	Human Activated T-Cells	
H0083	HUMAN JURKAT MEMBRANE BOUND POLYSOMES	
H0085	Human Colon	
H0087	Human Thymus	
H0090	Human T-Cell Lymphoma	disease
H0100	Human Whole Six Week Old Embryo	
H0123	Human Fetal Dura Mater	
H0124	Human Rhabdomyosarcoma	disease
H0125	Cem cells cyclohexamide treated	1 4.554.55
H0131	LNCAP + o.3nM R1881	
H0135	Human Synovial Sarcoma	
H0136	Supt Cells, cyclohexamide treated	
H0144	Nine Week Old Early Stage Human	
H0150	Human Epididymus	
H0156	Human Adrenal Gland Tumor	disease
H0163	Human Synovium	discuse
H0165	Human Prostate Cancer, Stage B2	disease
H0169	Human Prostate Cancer, Stage C fraction	disease
H0171	12 Week Old Early Stage Human, II	discuse
H0178	Human Fetal Brain	-
H0213	Human Pituitary, subtracted	
H0215	Raji cells, cyclohexamide treated, differentially expressed	-
H0224	Activated T-Cells, 12 hrs, subtracted	-
H0224	Human Colon, subtraction	-
H0251	Human Chondrosarcoma	disease
1 1 1 1 / / . 2	Transar Choraconia	
	Human Osteosarcoma	dicacco
H0252 H0253	Human Osteosarcoma Human adult testis, large inserts	disease

H0256	HL-60, unstimulated	
H0257	HL-60, PMA 4H	
H0261	H. cerebellum, Enzyme subtracted	
H0264	human tonsils	
H0265	Activated T-Cell (12hs)/Thiouridine labelledEco	
H0266	Human Microvascular Endothelial Cells, fract. A	
H0272	HUMAN TONSILS, FRACTION 2	
H0274	Human Adult Spleen, fractionII	
H0284	Human OB MG63 control fraction I	
H0286	Human OB MG63 treated (10 nM E2) fraction I	
H0290	Human OB HOS treated (1 nM E2) fraction I	
H0292	Human OB HOS treated (10 nM E2) fraction I	
H0295	Amniotic Cells - Primary Culture	
H0306	CD34 depleted Buffy Coat (Cord Blood)	
H0309	Human Chronic Synovitis	disease
H0316	HUMAN STOMACH	
H0318	HUMAN B CELL LYMPHOMA	disease
H0327	human corpus colosum	
H0328	human ovarian cancer	disease
H0331	Hepatocellular Tumor	disease
H0333	Hemangiopericytoma	disease
H0341	Bone Marrow Cell Line (RS4,11)	
H0343	stomach cancer (human)	disease
H0351	Glioblastoma	disease
H0352	wilm's tumor	disease
H0361	Human rejected kidney	disease
H0370	H. Lymph node breast Cancer	disease
H0373	Human Heart	
H0402	CD34 depleted Buffy Coat (Cord Blood), re-excision	·
H0412	Human umbilical vein endothelial cells, IL-4 induced	
H0415	H. Ovarian Tumor, II, OV5232	disease
H0423	T-Cell PHA 24 hrs	
H0424	Human Pituitary, subt IX	-
H0427	Human Adipose	<u> </u>
H0431	H. Kidney Medulla, re-excision	
H0433	Human Umbilical Vein Endothelial cells, frac B, re-excision	
H0435	Ovarian Tumor 10-3-95	
H0436	Resting T-Cell Library,II	
H0445	Spleen, Chronic lymphocytic leukemia	disease
H0457	Human Eosinophils	
H0484	Breast Cancer Cell line, angiogenic	
H0485	Hodgkin's Lymphoma I	disease
H0486	Hodgkin's Lymphoma II	disease
H0487	Human Tonsils, lib I	
H0488	Human Tonsils, Lib 2	
H0489	Crohn's Disease	disease
H0492	HL-60, RA 4h, Subtracted	
H0494	Keratinocyte	
H0505	Human Astrocyte	
H0506	Ulcerative Colitis	
H0509	Liver, Hepatoma	disease
H0510	Human Liver, normal	
H0518	pBMC stimulated w/ poly I/C	

770710		
H0519	NTERA2, control	
H0520	NTERA2 + retinoic acid, 14 days	
H0521	Primary Dendritic Cells, lib 1	
H0522	Primary Dendritic cells,frac 2	
H0529	Myoloid Progenitor Cell Line	
H0530	Human Dermal Endothelial Cells,untreated	
H0539	Pancreas Islet Cell Tumor	disease
H0542	T Cell helper I	
H0543	T cell helper II	
H0544	Human endometrial stromal cells	
H0545	Human endometrial stromal cells-treated with progesterone	
H0546	Human endometrial stromal cells-treated with estradiol	
H0547	NTERA2 teratocarcinoma cell line+retinoic acid (14 days)	
H0549	H. Epididiymus, caput & corpus	
H0550	H. Epididiymus, cauda	
H0551	Human Thymus Stromal Cells	<u> </u>
H0553	Human Placenta	
H0555	Rejected Kidney, lib 4	disease
H0556	Activated T-cell(12h)/Thiouridine-re-excision	3350050
H0559	HL-60, PMA 4H, re-excision	
H0560	KMH2	-
H0561	L428	
H0575	Human Adult Pulmonary,re-excision	
H0580	Dendritic cells, pooled	
H0581	Human Bone Marrow, treated	-
H0586	Healing groin wound, 6.5 hours post incision	disease
H0587	Healing groin wound, 7.5 hours post incision	
H0590	Human adult small intestine, re-excision	disease
H0591	Human T-cell lymphoma,re-excision	1:
H0592	Healing groin wound - zero hr post-incision (control)	disease
H0593	Olfactory epithelium, nasalcavity	disease
H0594	Human Lung Cancer,re-excision	1.
H0595	Stomach cancer (human),re-excision	disease
H0597		disease
H0599	Human Colon, re-excision Human Adult Heart,re-excision	
H0604		
	Human Pituitary, re-excision	
H0607	H.Leukocytes, normalized cot 50A3	ļ <u></u>
H0616	Human Testes, Reexcision	
H0618	Human Adult Testes, Large Inserts, Reexcision	
H0619	Fetal Heart	<u> </u>
H0620	Human Fetal Kidney, Reexcision	
H0622	Human Pancreas Tumor, Reexcision	disease
H0623	Human Umbilical Vein, Reexcision	
H0624	12 Week Early Stage Human II, Reexcision	
H0628	Human Pre-Differentiated Adipocytes	
H0631	Saos2, Dexamethosome Treated	
H0633	Lung Carcinoma A549 TNFalpha activated	disease
H0637	Dendritic Cells From CD34 Cells	
H0638	CD40 activated monocyte dendridic cells	
H0641	LPS activated derived dendritic cells	
H0644	Human Placenta (re-excision)	
H0645	Fetal Heart, re-excision	
H0647	Lung, Cancer (4005163 B7): Invasive, Poorly Diff.	disease
	Adenocarcinoma, Metastatic	

H0649	Lung, Normal: (4005313 B1)	
H0650	B-Cells	
H0652	Lung, Normal: (4005313 B1)	
H0656	B-cells (unstimulated)	
H0657	B-cells (stimulated)	
H0658	Ovary, Cancer (9809C332): Poorly differentiated	disease
	adenocarcinoma	
H0659	Ovary, Cancer (15395A1F): Grade II Papillary Carcinoma	disease
H0660	Ovary, Cancer: (15799A1F) Poorly differentiated carcinoma	disease
H0661	Breast, Cancer: (4004943 A5)	disease
H0662	Breast, Normal: (4005522B2)	
H0665	Stromal cells 3.88	
H0667	Stromal cells(HBM3.18)	
H0668	stromal cell clone 2.5	
H0670	Ovary, Cancer(4004650 A3): Well-Differentiated	
	Micropapillary Serous Carcinoma	
H0672	Ovary, Cancer: (4004576 A8)	
H0673	Human Prostate Cancer, Stage B2, re-excision	
H0677	TNFR degenerate oligo	
H0683	Ovarian cancer, Serous Papillary Adenocarcinoma	-
H0686	Adenocarcinoma of Ovary, Human Cell Line	
H0687	Human normal ovary(#9610G215)	
H0688	Human Ovarian Cancer(#9807G017)	T
H0689	Ovarian Cancer	
H0690	Ovarian Cancer, # 9702G001	
H0693	Normal Prostate #ODQ3958EN	
H0694	Prostate cancer (adenocarcinoma)	
H0696	Prostate Adenocarcinoma	
H0698	NK CellsYao20 IL2 treated for 48 hrs	
H0706	Human Adult Skeletal Muscle	
L0022	Stratagene schizo brain S11	
L1290	Human heart cDNA (YNakamura)	
S0002	Monocyte activated	
S0003	Human Osteoclastoma	disease
S0007	Early Stage Human Brain	discuse
S0010	Human Amygdala	
S0011	STROMAL -OSTEOCLASTOMA	disease
S0015	Kidney medulla	discase
S0026	Stromal cell TF274	
S0027	Smooth muscle, serum treated	-
S0028	Smooth muscle, control	-
S0031	Spinal cord	-
S0032	Smooth muscle-ILb induced	
S0036	Human Substantia Nigra	
S0037	Smooth muscle, IL1b induced	
S0037	Human Whole Brain #2 - Oligo dT > 1.5Kb	
S0040	Adipocytes	
S0040	Prostate BPH	diagram
S0045	Endothelial cells-control	disease
S0045	Endothelial-induced	
S0040 S0049	Human Brain, Striatum	
S0049 S0051	Human Hypothalmus, Schizophrenia	4:
S0053	Neutrophils IL-1 and LPS induced	disease
S0110	Brain Amygdala Depression	1:-
70110	L Diam Amyguala Depression	disease

00116		
S0116	Bone marrow	-
S0126	Osteoblasts	
S0134	Apoptotic T-cell	
S0144	Macrophage (GM-CSF treated)	
S0150	LNCAP prostate cell line	
S0152	PC3 Prostate cell line	
S0182	Human B Cell 8866	
S0192	Synovial Fibroblasts (control)	
S0194	Synovial hypoxia	
S0196	Synovial IL-1/TNF stimulated	
S0206	Smooth Muscle- HASTE normalized	
S0208	Messangial cell, frac 1	
S0210	Messangial cell, frac 2	
S0212	Bone Marrow Stromal Cell, untreated	
S0222	H. Frontal cortex,epileptic,re-excision	disease
S0242	Synovial Fibroblasts (II1/TNF), subt	
S0250	Human Osteoblasts II	disease
S0260	Spinal Cord, re-excision	
S0268	PRMIX	
S0276	Synovial hypoxia-RSF subtracted	
S0278	H Macrophage (GM-CSF treated), re-excision	
S0282	Brain Frontal Cortex, re-excision	
S0328	Palate carcinoma	disease
S0330	Palate normal	discase
S0336	Human Normal Cartilage Fraction IV	
S0342	Adipocytes,re-excision	
S0350	Pharynx Carcinoma	disease
S0354	Colon Normal II	uisease
S0354	Colon Carcinoma	4:
S0358	Colon Normal III	disease
S0358	Colon Tumor II	
S0364		disease
	Human Quadriceps	
S0366	Human Soleus	
S0374	Normal colon	
S0376	Colon Tumor	disease
S0378	Pancreas normal PCA4 No	
S0380	Pancreas Tumor PCA4 Tu	disease
S0390	Smooth muscle, control, re-excision	
S0408	Colon, normal	
S0412	Temporal cortex-Alzheizmer, subtracted	disease
S0418	CHME Cell Line,treated 5 hrs	
S0420	CHME Cell Line,untreated	
S0424	TF-1 Cell Line GM-CSF Treated	
S0426	Monocyte activated, re-excision	
S0428	Neutrophils control, re-excision	
S0438	Liver Normal Met5No	
S0448	Larynx Normal	
S0452	Thymus	
S3012	Smooth Muscle Serum Treated, Norm	
S3014	Smooth muscle, serum induced,re-exc	
S6014	H. hypothalamus, frac A	
S6024	Alzheimers, spongy change	disease
S6028	Human Manic Depression Tissue	disease

63

T0002	Activated T-cells
T0006	Human Pineal Gland
T0010	Human Infant Brain
T0039	HSA 172 Cells
T0040	HSC172 cells
T0041	Jurkat T-cell G1 phase
T0042	Jurkat T-Cell, S phase
T0049	Aorta endothelial cells + TNF-a
T0060	Human White Adipose
T0109	Human (HCC) cell line liver (mouse) metastasis, remake

Table 6

OMIM ID	OMIM Description
102200	Somatotrophinoma (2)
106100	Angioedema, hereditary (3)
131100	Carcinoid tumor of lung (3)
	Multiple endocrine neoplasia I (3)
	Prolactinoma, hyperparathyroidism, carcinoid syndrome (2)
133780	Vitreoretinopathy, exudative, familial (2)
147050	Atopy (2)
153700	Macular dystrophy, vitelliform type (3)
161015	Mitochondrial complex I deficiency, 252010 (1) (?)
164009	Leukemia, acute promyelocytic, NUMA/RARA type (3)
168461	Centrocytic lymphoma (2)
	Multiple myeloma, 254250 (2)
	Parathyroid adenomatosis 1 (2)
180721	Retinitis pigmentosa, digenic (3)
180840	Susceptibility to IDDM (1) (?)
191181	Cervical carcinoma (2)
193235	Vitreoretinopathy, neovascular inflammatory (2)
209901	Bardet-Biedl syndrome 1 (2)
232600	McArdle disease (3)
259700	Osteopetrosis, recessive (2)
259770	Osteoporosis-pseudoglioma syndrome (2)
600045	Xeroderma pigmentosum, group E, subtype 2 (1)
600319	Diabetes mellitus, insulin-dependent, 4 (2)
600528	CPT deficiency, hepatic, type I, 255120 (1)
601884	[High bone mass] (2)

5

10

15

20

25

30

PCT/US00/30654

65

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the secreted protein.

The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or a cDNA contained in ATCC deposit Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide encoded by the cDNA contained in ATCC deposit Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide sequence encoded by the cDNA contained in ATCC deposit Z are also encompassed by the invention.

Signal Sequences

The present invention also encompasses mature forms of the polypeptide having the polypeptide sequence of SEQ ID NO:Y and/or the polypeptide sequence encoded by the cDNA in a deposited clone. Polynucleotides encoding the mature forms (such as, for example, the polynucleotide sequence in SEQ ID NO:X and/or the

66

polynucleotide sequence contained in the cDNA of a deposited clone) are also encompassed by the invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal or secretary leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species of the protein. Further, it has long been known that cleavage specificity of a secreted protein is ultimately determined by the primary structure of the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide.

5

10

15

20

25

30

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, Virus Res. 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, Nucleic Acids Res. 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, supra.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty.

Accordingly, the present invention provides secreted polypeptides having a sequence

5

10

15

20

25

30

shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone, in a mammalian cell (e.g., COS cells, as desribed below). These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Polynucleotide and Polypeptide Variants

The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X, the complementary strand thereto, and/or the cDNA sequence contained in a deposited clone.

The present invention also encompasses variants of the polypeptide sequence disclosed in SEQ ID NO:Y and/or encoded by a deposited clone.

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence contained in a deposited cDNA clone or the

10

15

20

25

30

complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein).

68

PCT/US00/30654

Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

The present invention is also directed to polypeptides which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, for example, the polypeptide sequence shown in SEQ ID NO:Y, the polypeptide sequence encoded by the cDNA contained in a deposited clone, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein).

By a nucleic acid having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown inTable 1, the ORF (open reading frame), or any fragment specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the presence invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp.

5

10

15

20

25

30

App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

69

PCT/US00/30654

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the

5

10

15

20

25

30

70

PCT/US00/30654

deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, an amino acid sequences shown in Table 1 (SEQ ID NO:Y) or to the amino acid sequence encoded by cDNA contained in a deposited clone can be determined conventionally using known computer programs. A preferred method for determing the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window

5

10

15

20

25

30

71

PCT/US00/30654

Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or Cterminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for Nand C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not

5

10

15

20

25

30

matched/aligned with the query sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

72

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as E. coli).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over

73

3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

5

10

15

20

25

30

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

5

10

15

20

25

30

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used.

74

PCT/US00/30654

(Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification or (v) fusion of the polypeptide with another compound, such as albumin (including, but not limited to, recombinant albumin (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by reference in their entirety)). Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

75

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a peptide or polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

Polynucleotide and Polypeptide Fragments

5

10

15

20

25

30

The present invention is also directed to polynucleotide fragments of the polynucleotides of the invention.

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence which: is a portion of that contained in a deposited clone, or encoding the polypeptide encoded by the cDNA in a deposited clone; is a portion of that shown in SEQ ID NO:X or the complementary strand thereto, or is a portion of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:Y. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt,

76

and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in a deposited clone or the nucleotide sequence shown in SEQ ID NO:X. In this context "about" includes the particularly recited value, a value larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

5

10

15

20

25

30

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X, or the complementary strand thereto, or the cDNA contained in a deposited clone. In this context "about" includes the particularly recited ranges, and ranges larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40,

5

10

15

20

25

30

77

41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, and ranges or values larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotides encoding these domains are also contemplated.

Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

5

10

15

20

25

30

78

Preferably, the polynucleotide fragments of the invention encode a polypeptide which demonstrates a functional activity. By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) polypeptide of invention protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide of the invention for binding) to an antibody to the polypeptide of the invention], immunogenicity (ability to generate antibody which binds to a polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

The functional activity of polypeptides of the invention, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods.

For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the invention for binding to an antibody of the polypeptide of the invention, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

In another embodiment, where a ligand for a polypeptide of the invention identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel

5

10

15

20

25

30

79

PCT/US00/30654

chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky, E., et al., 1995, Microbiol. Rev. 59:94-123. In another embodiment, physiological correlates of binding of a polypeptide of the invention to its substrates (signal transduction) can be assayed.

In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the invention and fragments, variants derivatives and analogs thereof to elicit related biological activity related to that of the polypeptide of the invention (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope of the invention.

Epitopes and Antibodies

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID NO:Y, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. Z or encoded by a polynucleotide that hybridizes to the complement of the sequence of SEQ ID NO:X or contained in ATCC deposit No. Z under stringent hybridization conditions or lower stringency hybridization conditions as defined supra. The present invention further encompasses polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or lower stringency hybridization conditions defined supra.

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies

5

10

15

20

25

30

PCT/US00/30654

described infra. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross- reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985), further described in U.S. Patent No. 4,631,211).

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to

least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

5

10

15

20

25

30

an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very

81

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., supra; Wilson et al., supra, and Bittle et al., J. Gen. Virol., 66:2347-2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention comprising an immunogenic or antigenic epitope can be fused to other polypeptide sequences. For example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof), or albumin (including but not limited to recombinant

5

10

15

20

25

30

82

albumin (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by reference in their entirety)), resulting in chimeric polypeptides. Such fusion proteins may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., Nature, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion desulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., J. Biochem., 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, Proc. Natl. Acad. Sci. USA 88:8972-897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni2+ nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721;

5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference in its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

83

PCT/US00/30654

Antibodies

5

10

15

20

25

30

Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule. In preferred embodiments, the immunoglobulin

84

molecules of the invention are IgG1. In other preferred embodiments, the immunoglobulin molecules of the invention are IgG4.

5

10

15

20

25

30

Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')2, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, ship rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be

5

10

15

20

25

30

excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

85

Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or Kd less than 5 X 10^{-2} M, 10^{-2} M, 5 X 10^{-3} M, 10^{-3} M, 5 X 10^{-4} M, 10^{-4} M, $5 \times 10^{-5} M$, $10^{-5} M$, $5 \times 10^{-6} M$, $10^{-6} M$, $5 \times 10^{-7} M$, $10^{7} M$, $5 \times 10^{-8} M$, $10^{-8} M$, $5 \times 10^{-8} M$ 10^{-9} M, 10^{-9} M, 5 X 10^{-10} M, 10^{-10} M, 5 X 10^{-11} M, 10^{-11} M, 5 X 10^{-12} M, 10^{-12} M, 5 X 10^{-13} M, 10^{-13} M, 5 X 10^{-14} M, 10^{-14} M, 5 X 10^{-15} M, or 10^{-15} M.

The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the

5

10

15

20

25

30

86

epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferrably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No.

5

10

15

20

25

30

87

PCT/US00/30654

5,811,097; Deng et al., Blood 92(6):1981-1988 (1998); Chen et al., Cancer Res. 58(16):3668-3678 (1998); Harrop et al., J. Immunol. 161(4):1786-1794 (1998); Zhu et al., Cancer Res. 58(15):3209-3214 (1998); Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998); Pitard et al., J. Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241 (1997); Carlson et al., J. Biol. Chem. 272(17):11295-11301 (1997); Taryman et al., Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998);

Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998); Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties).

Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

The antibodies of the invention include derivatives that are modified, i.e, by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of

5

10

15

20

25

30

numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

88

PCT/US00/30654

The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of- interest can be produced by various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: Monoclonal Antibodies and T-Cell Hybridomas 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art and are discussed in detail in the Examples (e.g., Example 16). In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an

5

10

15

20

25

30

immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

89

PCT/US00/30654

Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')2 fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments). F(ab')2 fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage

5

10

15

20

25

30

gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

90

PCT/US00/30654

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')2 fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., BioTechniques 12(6):864-869 (1992); and Sawai et al., AJRI 34:26-34 (1995); and Better et al., Science 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., Methods in Enzymology 203:46-88 (1991); Shu et al., PNAS 90:7995-7999 (1993); and Skerra et al., Science 240:1038-1040 (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., (1989) J. Immunol.

5

10

15

20

25

30

91

PCT/US00/30654

Methods 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the nonhuman species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519.596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into

5

10

15

20

25

30

to that described above.

mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered nonfunctional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, Int. Rev. Immunol. 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., Bio/technology 12:899-903 (1988)).

Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotype antibodies that "mimic" polypeptides of the invention using

5

10

15

20

25

30

PCT/US00/30654

techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

93

Polynucleotides Encoding Antibodies

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., BioTechniques 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library

generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

Once the nucleotide sequence and corresponding amino acid sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well know in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino

5

10

15

20

30

acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

95

PCT/US00/30654

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423- 42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242:1038-1041 (1988)).

25 Methods of Producing Antibodies

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a

5

10

15

20

25

30

96

PCT/US00/30654

polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as

97

PCT/US00/30654

bacteria (e.g., E. coli, B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing 5 antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, 10 BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as Escherichia coli, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant 15 antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., Gene 45:101 (1986); Cockett et al., Bio/Technology 8:2 20 (1990)).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the E. coli expression vector pUR278 (Ruther et al., EMBO J. 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13:3101-3109 (1985); Van Heeke & Schuster, J. Biol. Chem. 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such

25

30

5

10

15

20

25

fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

98

PCT/US00/30654

In an insect system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein.

5

10

15

20

25

30

99

PCT/US00/30654

Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, Hela, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgprt- or aprt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt,

5

10

15

20

25

30

100

PCT/US00/30654

which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, 1993, TIB TECH 11(5):155-215); and hygro, which confers resistance to hygromycin (Santerre et al., Gene 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., J. Mol. Biol. 150:1 (1981), which are incorporated by reference herein in their entireties.

The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., Mol. Cell. Biol. 3:257 (1983)).

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler, Proc. Natl. Acad. Sci. USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

5

10

15

20

25

30

101

PCT/US00/30654

Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., supra, and PCT publication WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., PNAS 89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446-2452(1991), which are incorporated by reference in their entireties.

The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any

5

10

15

20

25

30

combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991); Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337-11341(1992) (said references incorporated by reference in their entireties).

102

As discussed, supra, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., Nature 331:84-86 (1988). The polypeptides of the present invention fused or conjugated to an antibody having disulfide- linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A 232,262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to

5

10

15

20

25

30

103

PCT/US00/30654

identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58 (1995); Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the "flag" tag.

The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin,

5

10

15

20

25

30

PCT/US00/30654

and aequorin; and examples of suitable radioactive material include 1251, 131I, 111In or 99Tc.

104

Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, 213Bi. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cisdichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, a-interferon, ß-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF-alpha, TNF-beta, AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al., Int. Immunol., 6*:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti- angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"),

5

10

15

20

25

30

granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev. 62:119-58 (1982).

Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

Immunophenotyping

The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present invention may be useful as a cell specific marker, or more specifically as a cellular marker that is differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific

5

10

15

20

25

30

epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison *et al.*, *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

Assays For Antibody Binding

The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A

5

10

15

20

25

30

107

and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or nonfat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., 32P or 125I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes

5

10

15

20

25

30

PCT/US00/30654

the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., 3H or 125I) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g., 3H or 125I) in the presence of increasing amounts of an unlabeled second antibody.

Therapeutic Uses

The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any

5

10

15

20

25

30

one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

109

PCT/US00/30654

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention,

110

including fragments thereof. Preferred binding affinities include those with a dissociation constant or Kd less than 5 X 10^{-2} M, 10^{-2} M, 5 X 10^{-3} M, 10^{-3} M, 5 X 10^{-4} M, 5 X 10^{-5} M, 10^{-5} M, 5 X 10^{-6} M, 10^{-6} M, 5 X 10^{-7} M, 10^{-7} M, 5 X 10^{-8} M, 10^{-8} M, 5 X 10^{-9} M, 10^{-9} M, 5 X 10^{-10} M, 10^{-10} M, 5 X 10^{-11} M, 10^{-11} M, 5 X 10^{-12} M, 10^{-12} M, 10^{-13} M, 10^{-13} M, 10^{-13} M, 10^{-14} M, 10^{-14} M, 10^{-15} M, and 10^{-15} M.

Gene Therapy

5

10

15

20

25

30

WO 01/34629

In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, TIBTECH 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990).

In a preferred aspect, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue- specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other

111

desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

5

10

Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be 15 accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; 20 Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target 25 cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT 30 Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination

(Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., Biotherapy 6:291-302 (1994), which describes the use of a retroviral vector to deliver the mdr1 gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., J. Clin. Invest. 93:644-651 (1994); Kiem et al., Blood 83:1467-1473 (1994); Salmons and Gunzberg, Human Gene Therapy 4:129-141 (1993); and Grossman and Wilson, Curr. Opin. in Genetics and Devel. 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, Current Opinion in Genetics and Development 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., Human Gene Therapy 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., Science 252:431-434 (1991); Rosenfeld et al., Cell 68:143- 155 (1992); Mastrangeli et al., J. Clin. Invest. 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., Gene Therapy 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., Proc. Soc. Exp. Biol. Med. 204:289-300 (1993); U.S. Patent No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

5

10

15

20

25

30

In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth. Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages,

5

10

15

25

30

114

PCT/US00/30654

neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.

20 Demonstration of Therapeutic or Prophylactic Activity

The compounds or pharmaceutical compositions of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

5

10

15

20

25

30

PCT/US00/30654

Therapeutic/Prophylactic Administration and Composition

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

115

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptormediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment;

116

this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

5

10

15

20

25

30

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid.)

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)). In another embodiment, polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., Macromol. Sci. Rev. Macromol. Chem. 23:61 (1983); see also Levy et al., Science 228:190 (1985); During et al., Ann. Neurol. 25:351 (1989); Howard et al., J.Neurosurg. 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)).

In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered in vivo to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by

117

use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (see e.g., Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

5

10

15

20

25

30

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of

5

10

15

20

25

30

the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

118

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compounds of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

5

10

15

20

25

30

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

119

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

Diagnosis and Imaging

Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect, diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

The invention provides a diagnostic assay for diagnosing a disorder, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level,

whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell. Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99Tc); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods

5

10

15

20

25

30

121

PCT/US00/30654

including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of 99mTc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by repeating the method for diagnosing the disease or disease, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with

a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patent using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI).

Kits

5

10

15

20

25

30

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may

123

also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by binding of the said reporter-labeled antibody.

5

10

15

20

25

30

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group.

Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface- bound

124

PCT/US00/30654

recombinant antigens, and a reporter-labeled anti-human antibody for detecting surface-bound anti-antigen antibody.

Fusion Proteins

5

10

15

20

25

30

WO 01/34629

Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any combination thereof, including both entire domains and portions thereof), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).)

5

10

15

20

25

30

Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).) Polynucleotides comprising or alternatively consisting of nucleic acids which encode these fusion proteins are also encompassed by the invention.

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

Vectors, Host Cells, and Protein Production

5

10

15

20

25

30

PCT/US00/30654

126

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells (e.g., Saccharomyces cerevisiae or Pichia pastoris (ATCC Accession No. 201178)); insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A,

5

10

15

20

25

30

127

PCT/US00/30654

pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ,pGAPZ, pGAPZalph, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-

128

mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

5

10

15

20

25

30

In one embodiment, the yeast Pichia pastoris is used to express the polypeptide of the present invention in a eukaryotic system. Pichia pastoris is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A main step in the methanol metabolization pathway is the oxidation of methanol to formaldehyde using O₂. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, Pichia pastoris must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O₂. Consequently, in a growth medium depending on methanol as a main carbon source, the promoter region of one of the two alcohol oxidase genes (AOX1) is highly active. In the presence of methanol, alcohol oxidase produced from the AOXI gene comprises up to approximately 30% of the total soluble protein in Pichia pastoris. See, Ellis, S.B., et al., Mol. Cell. Biol. 5:1111-21 (1985); Koutz, P.J, et al., Yeast 5:167-77 (1989); Tschopp, J.F., et al., Nucl. Acids Res. 15:3859-76 (1987). Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the AOXI regulatory sequence is expressed at exceptionally high levels in Pichia yeast grown in the presence of methanol.

In one example, the plasmid vector pPIC9K is used to express DNA encoding a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially as described in "*Pichia* Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a protein of the invention by virtue of the strong *AOX1* promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.

5

10

15

20

25

30

129

Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG as required.

In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination, resulting in the formation of a new transcription unit (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman & Co., N.Y., and Hunkapiller et al., *Nature*, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a

5

10

15

20

25

30

130

polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid, a-amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, b-alanine, fluoro-amino acids, designer amino acids such as b-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The invention encompasses polypeptides which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH₄; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, e.g., N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent NO: 4,179,337). The chemical moieties for

5

10

15

20

25

30

derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

131

PCT/US00/30654

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog). For example, the polyethylene glycol may have an average molecular weight of about 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, 95,000, or 100,000 kDa.

As noted above, the polyethylene glycol may have a branched structure. Branched polyethylene glycols are described, for example, in U.S. Patent No. 5,643,575; Morpurgo et al., Appl. Biochem. Biotechnol. 56:59-72 (1996); Vorobjev et al., Nucleosides Nucleotides 18:2745-2750 (1999); and Caliceti et al., Bioconjug. Chem. 10:638-646 (1999), the disclosures of each of which are incorporated herein by reference.

The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al., Exp. Hematol. 20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may

be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

As suggested above, polyethylene glycol may be attached to proteins via linkage to any of a number of amino acid residues. For example, polyethylene glycol can be linked to a proteins via covalent bonds to lysine, histidine, aspartic acid, glutamic acid, or cysteine residues. One or more reaction chemistries may be employed to attach polyethylene glycol to specific amino acid residues (e.g., lysine, histidine, aspartic acid, glutamic acid, or cysteine) of the protein or to more than one type of amino acid residue (e.g., lysine, histidine, aspartic acid, glutamic acid, cysteine and combinations thereof) of the protein.

One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

5

10

15

20

25

30

133

PCT/US00/30654

As indicated above, pegylation of the proteins of the invention may be accomplished by any number of means. For example, polyethylene glycol may be attached to the protein either directly or by an intervening linker. Linkerless systems for attaching polyethylene glycol to proteins are described in Delgado *et al.*, *Crit. Rev. Thera. Drug Carrier Sys. 9*:249-304 (1992); Francis *et al.*, *Intern. J. of Hematol.* 68:1-18 (1998); U.S. Patent No. 4,002,531; U.S. Patent No. 5,349,052; WO 95/06058; and WO 98/32466, the disclosures of each of which are incorporated herein by reference.

One system for attaching polyethylene glycol directly to amino acid residues of proteins without an intervening linker employs tresylated MPEG, which is produced by the modification of monmethoxy polyethylene glycol (MPEG) using tresylchloride (ClSO₂CH₂CF₃). Upon reaction of protein with tresylated MPEG, polyethylene glycol is directly attached to amine groups of the protein. Thus, the invention includes protein-polyethylene glycol conjugates produced by reacting proteins of the invention with a polyethylene glycol molecule having a 2,2,2-trifluoreothane sulphonyl group.

Polyethylene glycol can also be attached to proteins using a number of different intervening linkers. For example, U.S. Patent No. 5,612,460, the entire disclosure of which is incorporated herein by reference, discloses urethane linkers for connecting polyethylene glycol to proteins. Protein-polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein by a linker can also be produced by reaction of proteins with compounds such as MPEG-succinimidylsuccinate, MPEG activated with 1,1'-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG-p-nitrophenolcarbonate, and various MPEG-succinate derivatives. A number additional polyethylene glycol derivatives and reaction chemistries for attaching polyethylene glycol to proteins are described in WO 98/32466, the entire disclosure of which is incorporated herein by reference. Pegylated protein products produced using the reaction chemistries set out herein are included within the scope of the invention.

The number of polyethylene glycol moieties attached to each protein of the invention (*i.e.*, the degree of substitution) may also vary. For example, the pegylated proteins of the invention may be linked, on average, to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12,

15, 17, 20, or more polyethylene glycol molecules. Similarly, the average degree of substitution within ranges such as 1-3, 2-4, 3-5, 4-6, 5-7, 6-8, 7-9, 8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16, 15-17, 16-18, 17-19, or 18-20 polyethylene glycol moieties per protein molecule. Methods for determining the degree of substitution are discussed, for example, in Delgado *et al.*, *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992).

5

10

15

20

25

30

The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions (preferably, *Therapeutics*) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer, refers to a multimer containing only polypeptides corresponding to the amino acid sequence of SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone (including fragments, variants, splice variants, and fusion proteins, corresponding to these polypeptides as described herein). These homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (e.g., containing polypeptides having identical or different amino acid sequences) or a homotrimer (e.g., containing polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homoterramer.

As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (*i.e.*, polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional

5

10

15

20

25

30

embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

135

Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in the sequence listing, or contained in the polypeptide encoded by a deposited clone). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in an Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, oseteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627

5

10

15

20

25

30

136

PCT/US00/30654

(hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-Flag® antibody.

The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers

137

of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

5

10

15

20

25

30

Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hyrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into

138

PCT/US00/30654

liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Uses of the Polynucleotides

WO 01/34629

5

10

15

20

25

30

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, preselection by hybridization to construct chromosome specific-cDNA libraries and computer mapping techniques (See, e.g., Shuler, Trends Biotechnol 16:456-459 (1998) which is hereby incorporated by reference in its entirety)..

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see

Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

139

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes).

5

10

15

20

25

30

The polynucleotides of the present invention would likewise be useful for radiation hybrid mapping, HAPPY mapping, and long range restriction mapping. For a review of these techniques and others known in the art, see, e.g., Dear, "Genome Mapping: A Practical Approach," IRL Press at Oxford University Press, London (1997); Aydin, J. Mol. Med. 77:691-694 (1999); Hacia et al., Mol. Psychiatry 3:483-492 (1998); Herrick et al., Chromosome Res. 7:409-423 (1999); Hamilton et al., Methods Cell Biol. 62:265-280 (2000); and/or Ott, J. Hered. 90:68-70 (1999) each of which is hereby incorporated by reference in its entirety.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library).) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

140

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

5

10

15

20

25

30

Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the present invention in cells or body fluid from an individual and comparing the measured gene expression level with a standard level of polynucleotide expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder.

In still another embodiment, the invention includes a kit for analyzing samples for the presence of proliferative and/or cancerous polynucleotides derived from a test subject. In a general embodiment, the kit includes at least one polynucleotide probe containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the present invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the present invention, where each probe has one strand containing a 31'mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a disorder, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the present invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

By "measuring the expression level of polynucleotide of the present invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the present invention or the level of the mRNA encoding the polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or

5

10

15

20

25

30

141

estimated and compared to a standard polypeptide level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder. As will be appreciated in the art, once a standard polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains the polypeptide of the present invention or mRNA. As indicated, biological samples include body fluids (such as semen, lymph, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and other tissue sources found to express the polypeptide of the present invention. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

The method(s) provided above may preferrably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides are attached to a solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with polynucleotides of the present invention attached may be used to identify polymorphisms between the polynucleotide sequences, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e. their location, as well as, their existence) would be beneficial in identifying disease loci for many disorders, including cancerous diseases and conditions. Such a method is described in US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

The present invention encompasses polynucleotides of the present invention that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine,

5

10

15

20

25

30

142

thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, Science 254, 1497 (1991); and M. Egholm, O. Buchardt, L.Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, Nature 365, 666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point (T.sub.m) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Pathological cell proliferative diseases, disorders, and/or conditions are often associated with inappropriate activation of proto-oncogenes. (Gelmann, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in Neoplastic Diseases of the Blood, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)). Neoplasias are now believed to result from the qualitative alteration of a normal

5

10

15

20

cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Gelmann et al., supra) It is likely that mutated or altered expression of specific genes is involved in the pathogenesis of some leukemias, among other tissues and cell types. (Gelmann et al., supra) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Gelmann et al., supra)

143

PCT/US00/30654

For example, c-myc expression is highly amplified in the non-lymphocytic leukemia cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580) However, it has been shown that exposure of HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness would not be limited to treatment of proliferative diseases, disorders, and/or conditions of hematopoietic cells and tissues, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991);

"Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRCPress, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456

5

10

15

20

25

30

144

PCT/US00/30654

(1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat or prevent disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

5

10

15

20

25

30

PCT/US00/30654

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or surfactant,urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression

5

10

15

20

25

30

146

PCT/US00/30654

in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell. Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99mTc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, 131I, 112In, 99mTc), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of 99mTc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

5

10

15

20

25

30

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Moreover, polypeptides of the present invention can be used to treat, prevent, and/or diagnose disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor supressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune response to proliferative cells or tissues).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat, prevent, and/or diagnose disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also

be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

148

PCT/US00/30654

5

10

15

20

25

30

Gene Therapy Methods

Another aspect of the present invention is to gene therapy methods for treatingor preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a polypeptide of the present invention. This method requires a polynucleotide which codes for a polypeptide of the invention that operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a polynucleotide of the invention *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, see Belldegrun et al., J. Natl. Cancer Inst., 85:207-216 (1993); Ferrantini et al., Cancer Research, 53:107-1112 (1993); Ferrantini et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura et al., Cancer Research 50: 5102-5106 (1990); Santodonato, et al., Human Gene Therapy 7:1-10 (1996); Santodonato, et al., Gene Therapy 4:1246-1255 (1997); and Zhang, et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver,

149

and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

5

10

15

20

25

30

In one embodiment, the polynucleotide of the invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs of the invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving the expression of polynucleotide sequence of the invention. Suitable promoters include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoAI promoter; human globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotides of the invention.

Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA

150

sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

5

10

15

20

25

30

The polynucleotide construct of the invention can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. In vivo muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked *nucleic* acid sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

5

10

15

20

25

30

151

PCT/US00/30654

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

In certain embodiments, the polynucleotide constructs of the invention are complexed in a liposome preparation. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA, 84:7413-7416 (1987), which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA, 86:6077-6081 (1989), which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem., 265:10189-10192 (1990), which is herein incorporated by reference), in functional form.

Cationic liposomes are readily available. For example, N[1-2,3-dioleyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA, 84:7413-7416 (1987), which is herein incorporated by reference). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication NO: WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., Felgner et al., Proc.

152

Natl. Acad. Sci. USA, 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphoshatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

5

10

15

20

25

30

For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred. The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., Methods of Immunology, 101:512-527 (1983), which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass tube and subsequently hydrating with a solution of the material to be encapsulated. SUVs are prepared by extended sonication of MLVs to produce a homogeneous population of unilamellar liposomes. The material to be entrapped is added to a

153

suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes 5 to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods include Ca²⁺-EDTA chelation (Papahadiopoulos et al., Biochim, Biophys, Acta, 394:483 (1975); Wilson et al., Cell, 17:77 (1979)); ether injection (Deamer et al., 10 Biochim. Biophys. Acta, 443:629 (1976); Ostro et al., Biochem. Biophys. Res. Commun., 76:836 (1977); Fraley et al., Proc. Natl. Acad. Sci. USA, 76:3348 (1979)); detergent dialysis (Enoch et al., Proc. Natl. Acad. Sci. USA, 76:145 (1979)); and reverse-phase evaporation (REV) (Fraley et al., J. Biol. Chem., 255:10431 (1980); Szoka et al., Proc. Natl. Acad. Sci. USA, 75:145 (1978); Schaefer-Ridder et al., 15 Science, 215:166 (1982)), which are herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent NO: 5,676,954 (which is herein incorporated by reference) reports
on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding polypeptides of the invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis

30

5

10

15

20

25

30

virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy, 1:5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO₄ precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding polypeptides of the invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express polypeptides of the invention.

In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with polynucleotides of the invention contained in an adenovirus vector. Adenovirus can be manipulated such that it encodes and expresses polypeptides of the invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for many years with an excellent safety profile (Schwartzet al., Am. Rev. Respir. Dis., 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld et al., Science, 252:431-434 (1991); Rosenfeld et al., Cell, 68:143-155 (1992)). Furthermore, extensive studies to attempt to establish adenovirus as a causative agent in human cancer were uniformly negative (Green et al. Proc. Natl. Acad. Sci. USA, 76:6606 (1979)).

Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel., 3:499-503 (1993);

5

10

15

20

25

30

Rosenfeld et al., Cell, 68:143-155 (1992); Engelhardt et al., Human Genet. Ther., 4:759-769 (1993); Yang et al., Nature Genet., 7:362-369 (1994); Wilson et al., Nature, 365:691-692 (1993); and U.S. Patent NO: 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and constitutively express Ela and Elb, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

155

PCT/US00/30654

Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, Curr. Topics in Microbiol. Immunol., 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct containing polynucleotides of the invention is inserted into the AAV vector using standard cloning methods, such as those found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including

5

10

15

20

25

30

156

PCT/US00/30654

lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention.

These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express the desired gene product.

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding the polypeptide sequence of interest) via homologous recombination (see, e.g., U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5' end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

5

10

15

20

25

30

157

The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can be delivered by any method, included direct needle injection, intravenous injection, topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

The polynucleotides encoding polypeptides of the present invention may be administered along with other polynucleotides encoding other angiongenic proteins. Angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2 (VEGF-C), VEGF-3 (VEGF-B), epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

Preferably, the polynucleotide encoding a polypeptide of the invention contains a secretory signal sequence that facilitates secretion of the protein. Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid

5

10

15

20

25

30

158

(tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the rat livers. (Kaneda et al., Science, 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries.

Administration of a composition locally within the area of arteries refers to injecting the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue inside the wound.

Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a particular site.

Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad. Sci. USA, 189:11277-11281 (1992), which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

159

Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian. Therapeutic compositions of the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly

Biological Activities

The polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

20

25

30

5

10

15

Immune Activity

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of the immune system, by, for example, activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer and some autoimmune diseases, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of

5

10

15

20

25

30

160

the present invention can be used as a marker or detector of a particular immune system disease or disorder.

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein diseases, disorders, and/or conditions (e.g., agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, polynucleotides or polypeptides, and/or agonists or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies), blood platelet diseases, disorders, and/or conditions (e.g., thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment or prevention of heart attacks (infarction), strokes, or scarring.

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing autoimmune disorders. Many autoimmune disorders result from inappropriate

5

10

15

20

25

30

161

PCT/US00/30654

recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of polynucleotides and polypeptides of the invention that can inhibit an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Autoimmune diseases or disorders that may be treated, prevented, and/or diagnosed by polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, one or more of the following: autoimmune hemolytic anemia, autoimmune neonatal thrombocytopenia, idiopathic autoimmunocytopenia, hemolytic anemia, thrombocytopenia purpura, antiphospholipid syndrome, dermatitis, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, glomerulonephritis (e.g., IgA nephropathy), Multiple Sclerosis, Neuritis, **Uveitis** Ophthalmia, Polyendocrinopathies, Purpura (e.g., Henloch-Scoenlein purpura), Reiter's Disease, Stiff-Man Syndrome, Autoimmune Pulmonary Inflammation, Autism, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye, autoimmune thyroiditis, hypothyroidism (i.e., Hashimoto's thyroiditis, systemic lupus erhythematosus, Goodpasture's syndrome, Pemphigus, Receptor autoimmunities such as, for example, (a) Graves' Disease, (b) Myasthenia Gravis, and (c) insulin resistance, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, rheumatoid arthritis, schleroderma with anti-collagen antibodies, mixed connective tissue disease, polymyositis/dermatomyositis, pernicious anemia, idiopathic Addison's disease, infertility, glomerulonephritis such as primary glomerulonephritis and IgA nephropathy, bullous pemphigoid, Sjogren's syndrome, diabetes millitus, and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis), chronic active hepatitis, primary biliary cirrhosis, other endocrine gland failure, vitiligo, vasculitis, post-MI, cardiotomy syndrome, urticaria, atopic dermatitis, asthma, inflammatory myopathies, and other inflammatory, granulamatous, degenerative, and atrophic disorders.

Additional autoimmune disorders (that are probable) that may be treated, prevented, and/or diagnosed with the compositions of the invention include, but are

5

10

15

20

25

30

not limited to, rheumatoid arthritis (often characterized, e.g., by immune complexes in joints), scleroderma with anti-collagen antibodies (often characterized, e.g., by nucleolar and other nuclear antibodies), mixed connective tissue disease (often characterized, e.g., by antibodies to extractable nuclear antigens (e.g., ribonucleoprotein)), polymyositis (often characterized, e.g., by nonhistone ANA), pernicious anemia (often characterized, e.g., by antiparietal cell, microsomes, and intrinsic factor antibodies), idiopathic Addison's disease (often characterized, e.g., by humoral and cell-mediated adrenal cytotoxicity, infertility (often characterized, e.g., by antispermatozoal antibodies), glomerulonephritis (often characterized, e.g., by glomerular basement membrane antibodies or immune complexes), bullous pemphigoid (often characterized, e.g., by IgG and complement in basement membrane), Sjogren's syndrome (often characterized, e.g., by multiple tissue antibodies, and/or a specific nonhistone ANA (SS-B)), diabetes millitus (often characterized, e.g., by cell-mediated and humoral islet cell antibodies), and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis) (often characterized, e.g., by beta-adrenergic receptor antibodies).

Additional autoimmune disorders (that are possible) that may be treated, prevented, and/or diagnosed with the compositions of the invention include, but are not limited to, chronic active hepatitis (often characterized, e.g., by smooth muscle antibodies), primary biliary cirrhosis (often characterized, e.g., by mitchondrial antibodies), other endocrine gland failure (often characterized, e.g., by specific tissue antibodies in some cases), vitiligo (often characterized, e.g., by melanocyte antibodies), vasculitis (often characterized, e.g., by Ig and complement in vessel walls and/or low serum complement), post-MI (often characterized, e.g., by myocardial antibodies), cardiotomy syndrome (often characterized, e.g., by IgG and IgM antibodies to IgE), atopic dermatitis (often characterized, e.g., by IgG and IgM antibodies to IgE), asthma (often characterized, e.g., by IgG and IgM antibodies to IgE), and many other inflammatory, granulamatous, degenerative, and atrophic disorders.

In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated,

5

30

prevented, and/or diagnosed using for example, antagonists or agonists, polypeptides or polynucleotides, or antibodies of the present invention.

163

In a preferred embodiment polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used as an agent to boost immunoresponsiveness among B cell and/or T cell immunodeficient individuals.

B cell immunodeficiencies that may be ameliorated or treated by administering the polypeptides or polynucleotides of the invention, and/or agonists thereof, include, but are not limited to, severe combined immunodeficiency (SCID)-X linked, SCID-autosomal, adenosine deaminase deficiency (ADA deficiency), X-10 linked agammaglobulinemia (XLA), Bruton's disease, congenital agammaglobulinemia, X-linked infantile agammaglobulinemia, acquired agammaglobulinemia, adult onset agammaglobulinemia, late-onset agammaglobulinemia, dysgammaglobulinemia, hypogammaglobulinemia, transient hypogammaglobulinemia of infancy, unspecified hypogammaglobulinemia, agammaglobulinemia, common variable immunodeficiency (CVI) (acquired), 15 Wiskott-Aldrich Syndrome (WAS), X-linked immunodeficiency with hyper IgM, non X-linked immunodeficiency with hyper IgM, selective IgA deficiency, IgG subclass deficiency (with or without IgA deficiency), antibody deficiency with normal or elevated Igs, immunodeficiency with thymoma, Ig heavy chain deletions, kappa 20 chain deficiency, B cell lymphoproliferative disorder (BLPD), selective IgM immunodeficiency, recessive agammaglobulinemia (Swiss type), reticular dysgenesis, neonatal neutropenia, severe congenital leukopenia, thymic alymophoplasia-aplasia or dysplasia with immunodeficiency, ataxia-telangiectasia, short limbed dwarfism, X-linked lymphoproliferative syndrome (XLP), Nezelof 25 syndrome-combined immunodeficiency with Igs, purine nucleoside phosphorylase deficiency (PNP), MHC Class II deficiency (Bare Lymphocyte Syndrome) and severe combined immunodeficiency.

T cell deficiencies that may be ameliorated or treated by administering the polypeptides or polynucleotides of the invention, and/or agonists thereof include, but are not limited to, for example, DiGeorge anomaly, thymic hypoplasia, third and fourth pharyngeal pouch syndrome, 22q11.2 deletion, chronic mucocutaneous candidiasis, natural killer cell deficiency (NK), idiopathic CD4+ T-lymphocytopenia,

5

10

15

20

25

30

164

PCT/US00/30654

immunodeficiency with predominant T cell defect (unspecified), and unspecified immunodeficiency of cell mediated immunity. In specific embodiments, DiGeorge anomaly or conditions associated with DiGeorge anomaly are ameliorated or treated by, for example, administering the polypeptides or polynucleotides of the invention, or antagonists or agonists thereof.

Other immunodeficiencies that may be ameliorated or treated by administering polypeptides or polynucleotides of the invention, and/or agonists thereof, include, but are not limited to, severe combined immunodeficiency (SCID; e.g., X-linked SCID, autosomal SCID, and adenosine deaminase deficiency), ataxia-telangiectasia, Wiskott-Aldrich syndrome, short-limber dwarfism, X-linked lymphoproliferative syndrome (XLP), Nezelof syndrome (e.g., purine nucleoside phosphorylase deficiency), MHC Class II deficiency. In specific embodiments, ataxia-telangiectasia or conditions associated with ataxia-telangiectasia are ameliorated or treated by administering the polypeptides or polynucleotides of the invention, and/or agonists thereof.

In a specific preferred embodiment, rheumatoid arthritis is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment, systemic lupus erythemosus is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment, idiopathic thrombocytopenia purpura is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment IgA nephropathy is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, and/or diagnosed using antibodies against the protein of the invention.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, and/or diagnosed using polypeptides, antibodies, or polynucleotides of the invention, and/or

5

10

15

20

25

30

165

agonists or antagonists thereof. Moreover, these molecules can be used to treat, prevent, and/or diagnose anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

Moreover, inflammatory conditions may also be treated, diagnosed, and/or prevented with polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. Such inflammatory conditions include, but are not limited to, for example, respiratory disorders (such as, e.g., asthma and allergy); gastrointestinal disorders (such as, e.g., inflammatory bowel disease); cancers (such as, e.g., gastric, ovarian, lung, bladder, liver, and breast); CNS disorders (such as, e.g., multiple sclerosis, blood-brain barrier permeability, ischemic brain injury and/or stroke, traumatic brain injury, neurodegenerative disorders (such as, e.g., Parkinson's disease and Alzheimer's disease), AIDS-related dementia, and prion disease); cardiovascular disorders (such as, e.g., atherosclerosis, myocarditis, cardiovascular disease, and cardiopulmonary bypass complications); as well as many additional diseases, conditions, and disorders that are characterized by inflammation (such as, e.g., chronic hepatitis (B and C), rheumatoid arthritis, gout, trauma, septic shock, pancreatitis, sarcoidosis, dermatitis, renal ischemia-reperfusion injury, Grave's disease, systemic lupus erythematosis, diabetes mellitus (i.e., type 1 diabetes), and allogenic transplant rejection).

In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to treat, diagnose, and/or prevent transplantation rejections, graft-versus-host disease, autoimmune and inflammatory diseases (e.g., immune complex-induced vasculitis, glomerulonephritis, hemolytic anemia, myasthenia gravis, type II collagen-induced arthritis, experimental allergic and hyperacute xenograft rejection, rheumatoid arthritis, and systemic lupus erythematosus (SLE). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. Polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

5

10

15

20

25

30

166

Similarly, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also be used to modulate and/or diagnose inflammation. For example, since polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists of the invention may inhibit the activation, proliferation and/or differentiation of cells involved in an inflammatory response, these molecules can be used to treat, diagnose, or prognose, inflammatory conditions, both chronic and acute conditions, including, but not limited to, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, and resulting from over production of cytokines (e.g., TNF or IL-1.).

Polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the invention can be used to treat, detect, and/or prevent infectious agents. For example, by increasing the immune response, particularly increasing the proliferation activation and/or differentiation of B and/or T cells, infectious diseases may be treated, detected, and/or prevented. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also directly inhibit the infectious agent (refer to section of application listing infectious agents, etc), without necessarily eliciting an immune response.

Additional preferred embodiments of the invention include, but are not limited to, the use of polypeptides, antibodies, polynucleotides and/or agonists or antagonists in the following applications:

Administration to an animal (e.g., mouse, rat, rabbit, hamster, guinea pig, pigs, micro-pig, chicken, camel, goat, horse, cow, sheep, dog, cat, non-human primate, and human, most preferably human) to boost the immune system to produce increased quantities of one or more antibodies (e.g., IgG, IgA, IgM, and IgE), to induce higher affinity antibody production (e.g., IgG, IgA, IgM, and IgE), and/or to increase an immune response.

5

10

15

20

25

30

167

PCT/US00/30654

Administration to an animal (including, but not limited to, those listed above, and also including transgenic animals) incapable of producing functional endogenous antibody molecules or having an otherwise compromised endogenous immune system, but which is capable of producing human immunoglobulin molecules by means of a reconstituted or partially reconstituted immune system from another animal (see, e.g., published PCT Application Nos. WO98/24893, WO/9634096, WO/9633735, and WO/9110741.

A vaccine adjuvant that enhances immune responsiveness to specific antigen.

An adjuvant to enhance tumor-specific immune responses.

An adjuvant to enhance anti-viral immune responses. Anti-viral immune responses that may be enhanced using the compositions of the invention as an adjuvant, include virus and virus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: AIDS, meningitis, Dengue, EBV, and hepatitis (e.g., hepatitis B). In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: HIV/AIDS, Respiratory syncytial virus, Dengue, Rotavirus, Japanese B encephalitis, Influenza A and B, Parainfluenza, Measles, Cytomegalovirus, Rabies, Junin, Chikungunya, Rift Valley fever, Herpes simplex, and yellow fever.

An adjuvant to enhance anti-bacterial or anti-fungal immune responses. Anti-bacterial or anti-fungal immune responses that may be enhanced using the compositions of the invention as an adjuvant, include bacteria or fungus and bacteria or fungus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: tetanus, Diphtheria, botulism, and meningitis type B. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: Vibrio cholerae, Mycobacterium leprae, Salmonella typhi, Salmonella paratyphi, Meisseria meningitidis,

10

15

20

25

30

Streptococcus pneumoniae, Group B streptococcus, Shigella spp., Enterotoxigenic Escherichia coli, Enterohemorrhagic E. coli, Borrelia burgdorferi, and Plasmodium (malaria).

An adjuvant to enhance anti-parasitic immune responses. Anti-parasitic immune responses that may be enhanced using the compositions of the invention as an adjuvant, include parasite and parasite associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a parasite. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to Plasmodium (malaria).

As a stimulator of B cell responsiveness to pathogens.

As an activator of T cells.

As an agent that elevates the immune status of an individual prior to their receipt of immunosuppressive therapies.

As an agent to induce higher affinity antibodies.

As an agent to increase serum immunoglobulin concentrations.

As an agent to accelerate recovery of immunocompromised individuals.

As an agent to boost immunoresponsiveness among aged populations.

As an immune system enhancer prior to, during, or after bone marrow transplant and/or other transplants (e.g., allogeneic or xenogeneic organ transplantation). With respect to transplantation, compositions of the invention may be administered prior to, concomitant with, and/or after transplantation. In a specific embodiment, compositions of the invention are administered after transplantation, prior to the beginning of recovery of T-cell populations. In another specific embodiment, compositions of the invention are first administered after transplantation after the beginning of recovery of T cell populations, but prior to full recovery of B cell populations.

As an agent to boost immunoresponsiveness among individuals having an acquired loss of B cell function. Conditions resulting in an acquired loss of B cell function that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are

10

15

20

25

not limited to, HIV Infection, AIDS, bone marrow transplant, and B cell chronic lymphocytic leukemia (CLL).

As an agent to boost immunoresponsiveness among individuals having a temporary immune deficiency. Conditions resulting in a temporary immune deficiency that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, recovery from viral infections (e.g., influenza), conditions associated with malnutrition, recovery from infectious mononucleosis, or conditions associated with stress, recovery from measles, recovery from blood transfusion, recovery from surgery.

As a regulator of antigen presentation by monocytes, dendritic cells, and/or B-cells. In one embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention enhance antigen presentation or antagonizes antigen presentation in vitro or in vivo. Moreover, in related embodiments, said enhancement or antagonization of antigen presentation may be useful as an anti-tumor treatment or to modulate the immune system.

As an agent to direct an individuals immune system towards development of a humoral response (i.e. TH2) as opposed to a TH1 cellular response.

As a means to induce tumor proliferation and thus make it more susceptible to anti-neoplastic agents. For example, multiple myeloma is a slowly dividing disease and is thus refractory to virtually all anti-neoplastic regimens. If these cells were forced to proliferate more rapidly their susceptibility profile would likely change.

As a stimulator of B cell production in pathologies such as AIDS, chronic lymphocyte disorder and/or Common Variable Immunodificiency.

As a therapy for generation and/or regeneration of lymphoid tissues following surgery, trauma or genetic defect.

As a gene-based therapy for genetically inherited disorders resulting in immuno-incompetence such as observed among SCID patients.

As an antigen for the generation of antibodies to inhibit or enhance immune mediated responses against polypeptides of the invention.

As a means of activating T cells.

10

15

20

25

30

As a means of activating monocytes/macrophages to defend against parasitic diseases that effect monocytes such as Leshmania.

As pretreatment of bone marrow samples prior to transplant. Such treatment would increase B cell representation and thus accelerate recover.

As a means of regulating secreted cytokines that are elicited by polypeptides of the invention.

Additionally, polypeptides or polynucleotides of the invention, and/or agonists thereof, may be used to treat or prevent IgE-mediated allergic reactions. Such allergic reactions include, but are not limited to, asthma, rhinitis, and eczema.

All of the above described applications as they may apply to veterinary medicine.

Antagonists of the invention include, for example, binding and/or inhibitory antibodies, antisense nucleic acids, or ribozymes. These would be expected to reverse many of the activities of the ligand described above as well as find clinical or practical application as:

A means of blocking various aspects of immune responses to foreign agents or self. Examples include autoimmune disorders such as lupus, and arthritis, as well as immunoresponsiveness to skin allergies, inflammation, bowel disease, injury and pathogens.

A therapy for preventing the B cell proliferation and Ig secretion associated with autoimmune diseases such as idiopathic thrombocytopenic purpura, systemic lupus erythramatosus and MS.

An inhibitor of B and/or T cell migration in endothelial cells. This activity disrupts tissue architecture or cognate responses and is useful, for example in disrupting immune responses, and blocking sepsis.

An inhibitor of graft versus host disease or transplant rejection.

A therapy for B cell and/or T cell malignancies such as ALL, Hodgkins disease, non-Hodgkins lymphoma, Chronic lymphocyte leukemia, plasmacytomas, multiple myeloma, Burkitt's lymphoma, and EBV-transformed diseases.

A therapy for chronic hypergammaglobulinemeia evident in such diseases as monoclonalgammopathy of undetermined significance (MGUS), Waldenstrom's disease, related idiopathic monoclonalgammopathies, and plasmacytomas.

5

10

15

20

25

30

171

PCT/US00/30654

A therapy for decreasing cellular proliferation of Large B-cell Lymphomas.

A means of decreasing the involvement of B cells and Ig associated with Chronic Myelogenous Leukemia.

An immunosuppressive agent(s).

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate IgE concentrations in vitro or in vivo.

In another embodiment, administration of polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the invention, may be used to treat or prevent IgE-mediated allergic reactions including, but not limited to, asthma, rhinitis, and eczema.

The agonists and antagonists may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as described herein.

The agonists or antagonists may be employed for instance to inhibit polypeptide chemotaxis and activation of macrophages and their precursors, and of neutrophils, basophils, B lymphocytes and some T-cell subsets, e.g., activated and CD8 cytotoxic T cells and natural killer cells, in certain auto-immune and chronic inflammatory and infective diseases. Examples of autoimmune diseases are described herein and include multiple sclerosis, and insulin-dependent diabetes. The antagonists or agonists may also be employed to treat infectious diseases including silicosis, sarcoidosis, idiopathic pulmonary fibrosis by, for example, preventing the recruitment and activation of mononuclear phagocytes. They may also be employed to treat idiopathic hyper-eosinophilic syndrome by, for example, preventing eosinophil production and migration. The antagonists or agonists or may also be employed for treating atherosclerosis, for example, by preventing monocyte infiltration in the artery wall.

Antibodies against polypeptides of the invention may be employed to treat ARDS.

Agonists and/or antagonists of the invention also have uses in stimulating wound and tissue repair, stimulating angiogenesis, stimulating the repair of vascular or lymphatic diseases or disorders. Additionally, agonists and antagonists of the invention may be used to stimulate the regeneration of mucosal surfaces.

5

10

15

20

25

30

172

In a specific embodiment, polynucleotides or polypeptides, and/or agonists thereof are used to treat or prevent a disorder characterized by primary or acquired immunodeficiency, deficient serum immunoglobulin production, recurrent infections, and/or immune system dysfunction. Moreover, polynucleotides or polypeptides, and/or agonists thereof may be used to treat or prevent infections of the joints, bones, skin, and/or parotid glands, blood-borne infections (e.g., sepsis, meningitis, septic arthritis, and/or osteomyelitis), autoimmune diseases (e.g., those disclosed herein), inflammatory disorders, and malignancies, and/or any disease or disorder or condition associated with these infections, diseases, disorders and/or malignancies) including, but not limited to, CVID, other primary immune deficiencies, HIV disease, CLL, recurrent bronchitis, sinusitis, otitis media, conjunctivitis, pneumonia, hepatitis, meningitis, herpes zoster (e.g., severe herpes zoster), and/or pneumocystis carnii.

In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention are used to treat, and/or diagnose an individual having common variable immunodeficiency disease ("CVID"; also known as "acquired agammaglobulinemia" and "acquired hypogammaglobulinemia") or a subset of this disease.

In a specific embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to treat, diagnose, and/or prevent (1) cancers or neoplasms and (2) autoimmune cell or tissue-related cancers or neoplasms. In a preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat, diagnose, and/or prevent acute myelogeneous leukemia. In a further preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat, diagnose, and/or prevent, chronic myelogeneous leukemia, multiple myeloma, non-Hodgkins lymphoma, and/or Hodgkins disease.

In another specific embodiment, polynucleotides or polypeptides, and/or agonists or antagonists of the invention may be used to treat, diagnose, prognose, and/or prevent selective IgA deficiency, myeloperoxidase deficiency, C2 deficiency, ataxia-telangiectasia, DiGeorge anomaly, common variable immunodeficiency (CVI),

5

10

15

20

25

30

X-linked agammaglobulinemia, severe combined immunodeficiency (SCID), chronic granulomatous disease (CGD), and Wiskott-Aldrich syndrome.

173

Examples of autoimmune disorders that can be treated or detected are described above and also include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.

In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prognosed, prevented, and/or diagnosed using antibodies against the polypeptide of the invention.

As an agent to boost immunoresponsiveness among B cell immunodeficient individuals, such as, for example, an individual who has undergone a partial or complete splenectomy.

Additionally, polynucleotides, polypeptides, and/or antagonists of the invention may affect apoptosis, and therefore, would be useful in treating a number of diseases associated with increased cell survival or the inhibition of apoptosis. For example, diseases associated with increased cell survival or the inhibition of apoptosis that could be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related

174

glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, polynucleotides, polypeptides, and/or antagonists of the invention are used to inhibit growth, progression, and/or metastisis of cancers, in particular those listed above.

5

10

15

20

25

30

Additional diseases or conditions associated with increased cell survival that could be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, chordoma, angiosarcoma, endotheliosarcoma, osteogenic sarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, glioma, astrocytoma, medulloblastoma, carcinoma, epithelial craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and

5

10

15

20

25

30

brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Hyperproliferative diseases and/or disorders that could be detected and/or treated by polynucleotides, polypeptides, and/or antagonists of the invention, include, but are not limited to neoplasms located in the: liver, abdomen, bone, breast, digestive system, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention. Examples of such hyperproliferative disorders include, but are not limited to:

hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstron's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

Hyperproliferative Disorders

A polynucleotides or polypeptides, or agonists or antagonists of the invention can be used to treat, prevent, and/or diagnose hyperproliferative diseases, disorders, and/or conditions, including neoplasms. A polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

10

15

20

25

30

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative diseases, disorders, and/or conditions can be treated, prevented, and/or diagnosed. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating, preventing, and/or diagnosing hyperproliferative diseases, disorders, and/or conditions, such as a chemotherapeutic agent.

Examples of hyperproliferative diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative diseases, disorders, and/or conditions can also be treated, prevented, and/or diagnosed by a polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative diseases, disorders, and/or conditions include, but are not limited to:

hypergammaglobulinemia, lymphoproliferative diseases, disorders, and/or conditions, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstron's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

Thus, the present invention provides a method for treating or preventing cell proliferative diseases, disorders, and/or conditions by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

Another embodiment of the present invention provides a method of treating or preventing cell-proliferative diseases, disorders, and/or conditions in individuals

comprising administration of one or more active gene copies of the present invention

to an abnormally proliferating cell or cells. In a preferred embodiment,

177

polynucleotides of the present invention is a DNA construct comprising a

recombinant expression vector effective in expressing a DNA sequence encoding said

polynucleotides. In another preferred embodiment of the present invention, the DNA

construct encoding the poynucleotides of the present invention is inserted into cells to

be treated utilizing a retrovirus, or more preferrably an adenoviral vector (See G J.

Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference).

In a most preferred embodiment, the viral vector is defective and will not transform

non-proliferating cells, only proliferating cells. Moreover, in a preferred

embodiment, the polynucleotides of the present invention inserted into proliferating

cells either alone, or in combination with or fused to other polynucleotides, can then

be modulated via an external stimulus (i.e. magnetic, specific small molecule,

chemical, or drug administration, etc.), which acts upon the promoter upstream of said

polynucleotides to induce expression of the encoded protein product. As such the

beneficial therapeutic affect of the present invention may be expressly modulated (i.e.

to increase, decrease, or inhibit expression of the present invention) based upon said

external stimulus.

5

10

15

20

25

30

Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes" is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature

5

10

15

20

25

30

320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

178

PCT/US00/30654

The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

5

10

15

20

25

30

The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating, preventing, and/or diagnosing one or more of the described diseases, disorders, and/or conditions. Methods for producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

179

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

In particular, the antibodies, fragments and derivatives of the present invention are useful for treating, preventing, and/or diagnosing a subject having or developing cell proliferative and/or differentiation diseases, disorders, and/or conditions as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of diseases, disorders, and/or conditions related to polynucleotides or polypeptides, including fragements thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragements thereof. Preferred binding affinities include those

5

10

15

20

25

30

PCT/US00/30654

with a dissociation constant or Kd less than 5X10⁻⁶M, 10⁻⁶M, 5X10⁻⁷M, 10⁻⁷M, 5X10⁻⁸M, 10⁻⁸M, 5X10⁻⁹M, 10⁻⁹M, 5X10⁻¹⁰M, 10⁻¹⁰M, 5X10⁻¹¹M, 10⁻¹¹M, 5X10⁻¹²M, 10⁻¹²M, 5X10⁻¹³M, 10⁻¹³M, 5X10⁻¹⁴M, 10⁻¹⁴M, 5X10⁻¹⁵M, and 10⁻¹⁵M.

180

Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference). Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al., Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a deathdomain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference). Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuviants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React; 20(1):3-15 (1998), which are all hereby incorporated by reference).

5

10

15

20

25

30

Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such thereapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodes associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodes of the invention may be associated with with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

Cardiovascular Disorders

Polynucleotides or polypeptides, or agonists or antagonists of the invention may be used to treat, prevent, and/or diagnose cardiovascular diseases, disorders, and/or conditions, including peripheral artery disease, such as limb ischemia.

Cardiovascular diseases, disorders, and/or conditions include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus

5

10

15

20

25

30

182

arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilogy of Fallot, ventricular heart septal defects.

Cardiovascular diseases, disorders, and/or conditions also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaimtype pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

Heart valve disease include aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

5

10

15

20

25

30

PCT/US00/30654

183

Myocardial diseases include alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

Myocardial ischemias include coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms, angiodysplasia, angiomatosis, bacillary angiomatosis, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular diseases, disorders, and/or conditions, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, atacia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

Cerebrovascular diseases, disorders, and/or conditions include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural

184

WO 01/34629

5

10

15

20

25

30

PCT/US00/30654

hematoma, subaraxhnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromoboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

Ischemia includes cerebral ischemia, ischemic colitis, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

Polynucleotides or polypeptides, or agonists or antagonists of the invention, are especially effective for the treatment of critical limb ischemia and coronary disease.

Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppositorial solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides of the invention may be administered as part of a *Therapeutic*, described in more detail below. Methods of delivering polynucleotides of the invention are described in more detail herein.

Anti-Angiogenesis Activity

The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell 56*:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound

5

10

15

20

25

30

185

healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of eye diseases, disorders, and/or conditions, and psoriasis. See, e.g., reviews by Moses et al., Biotech. 9:630-634 (1991); Folkman et al., N. Engl. J. Med., 333:1757-1763 (1995); Auerbach et al., J. Microvasc. Res. 29:401-411 (1985); Folkman, Advances in Cancer Research, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, Am. J. Opthalmol. 94:715-743 (1982); and Folkman et al., Science 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, Science 235:442-447 (1987).

The present invention provides for treatment of diseases, disorders, and/or conditions associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman et al., Medicine, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating, preventing, and/or diagnosing an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treator prevent a cancer or tumor. Cancers which may be treated, prevented, and/or diagnosed with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors,

5

10

15

20

25

30

including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non- small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat or prevent cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

186

Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating, preventing, and/or diagnosing other diseases, disorders, and/or conditions, besides cancers, which involve angiogenesis. These diseases, disorders, and/or conditions include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic artheroscleric plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uvietis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided for treating, preventing, and/or diagnosing hypertrophic scars and keloids, comprising

5

10

15

20

25

30

the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

187

Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating, preventing, and/or diagnosing neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

Moreover, Ocular diseases, disorders, and/or conditions associated with neovascularization which can be treated, prevented, and/or diagnosed with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman et al., Am. J. Ophthal. 85:704-710 (1978) and Gartner et al., Surv. Ophthal. 22:291-312 (1978).

Thus, within one aspect of the present invention methods are provided for treating or preventing neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of

diseases, disorders, and/or conditions can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic comea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-

5

10

15

20

25

30

3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

189

Within another aspect of the present invention, methods are provided for treating or preventing neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat or prevent early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating or preventing proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for treating or preventing retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreous injection and/or via intraocular implants.

Additionally, diseases, disorders, and/or conditions which can be treated, prevented, and/or diagnosed with the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome,

5

10

15

20

25

30

190

PCT/US00/30654

pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

Moreover, diseases, disorders, and/or conditions and/or states, which can be treated, prevented, and/or diagnosed with the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uvietis, delayed wound healing, endometriosis, vascluogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (Rochele minalia quintosa), ulcers (Helicobacter pylori), Bartonellosis and bacillary angiomatosis.

In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized

5

10

15

20

25

30

191

PCT/US00/30654

to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti- angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive

5

10

15

20

25

30

192

PCT/US00/30654

Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP-PG) (the function of this compound may be enhanced by the presence

of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolmidazole; and metalloproteinase inhibitors such as BB94.

Diseases at the Cellular Level

Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides and/or antagonists or agonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, the polynucleotides or polypeptides, and/or

5

10

15

20

25

30

agonists or antagonists of the invention are used to inhibit growth, progression, and/or metasis of cancers, in particular those listed above.

194

Additional diseases or conditions associated with increased cell survival that could be treated, prevented or diagnosed by the polynucleotides or polypeptides, or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder epithelial carcinoma, astrocytoma, medulloblastoma, carcinoma. glioma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative diseases, disorders, and/or conditions (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis,

5

10

15

20

25

30

195

PCT/US00/30654

Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Wound Healing and Epithelial Cell Proliferation

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds. Polynucleotides or polypeptides, as well as agonists or antagonists of the invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eve tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associted with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote dermal reestablishment subsequent to dermal loss

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are a non-exhaustive list of grafts that polynucleotides or polypeptides, agonists or antagonists of the invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepdermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft,

5

10

15

20

25

30

epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omenpal graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, can be used to promote skin strength and to improve the appearance of aged skin.

196

PCT/US00/30654

It is believed that the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intesting, and large intestine. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may have a cytoprotective effect on the small intestine mucosa. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. The polynucleotides or polypeptides, and/or

5

10

15

20

25

30

197

PCT/US00/30654

agonists or antagonists of the invention, could also be used to treat gastric and doudenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflamamatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large intestine, respectively. Thus, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat diseases associate with the under expression of the polynucleotides of the invention.

Moreover, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to prevent and heal damage to the lungs due to various pathological states. A growth factor such as the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and brochiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of aveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated, prevented, and/or diagnosed using the polynucleotides or polypeptides, and/or agonists or antagonists of the invention. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary displasia, in premature infants.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could stimulate the proliferation and differentiation of hepatocytes and,

198

thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetraholoride and other hepatotoxins known in the art).

In addition, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

15 Neurological Diseases

WO 01/34629

5

10

20

25

30

Nervous system diseases, disorders, and/or conditions, which can be treated, prevented, and/or diagnosed with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases, disorders, and/or conditions which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated, prevented, and/or diagnosed in a patient (including human and non-human mammalian patients) according to the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3) malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is

.

WO 01/34629

5

10

15

20

25

30

199

PCT/US00/30654

destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6) lesions associated with nutritional diseases, disorders, and/or conditions, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

In a preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral hypoxia. In one aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral ischemia. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral infarction. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose or prevent neural cell injury associated with a stroke. In a further aspect of this embodiment, the polypeptides, polynucleotides, or agonists

5

10

15

20

25

30

200

PCT/US00/30654

or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with a heart attack.

The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture; (2) increased sprouting of neurons in culture or in vivo; (3) increased production of a neuron-associated molecule in culture or in vivo, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction in vivo. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, the method set forth in Arakawa et al. (J. Neurosci. 10:3507-3515 (1990)); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk et al. (Exp. Neurol. 70:65-82 (1980)) or Brown et al. (Ann. Rev. Neurosci. 4:17-42 (1981)); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron diseases, disorders, and/or conditions that may be treated, prevented, and/or diagnosed according to the invention include, but are not limited to, diseases, disorders, and/or conditions such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as diseases, disorders, and/or conditions that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-

5

10

15

20

25

30

201

Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

Further, polypeptides or polynucleotides of the invention may play a role in neuronal survival; synapse formation; conductance; neural differentiation, etc. Thus, compositions of the invention (including polynucleotides, polypeptides, and agonists or antagonists) may be used to diagnose and/or treat or prevent diseases or disorders associated with these roles, including, but not limited to, learning and/or cognition disorders. The compositions of the invention may also be useful in the treatment or prevention of neurodegenerative disease states and/or behavioural disorders. Such neurodegenerative disease states and/or behavioral disorders include, but are not limited to, Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, compositions of the invention may also play a role in the treatment, prevention and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders.

Additionally, polypeptides, polynucleotides and/or agonists or antagonists of the invention, may be useful in protecting neural cells from diseases, damage, disorders, or injury, associated with cerebrovascular disorders including, but not limited to, carotid artery diseases (e.g., carotid artery thrombosis, carotid stenosis, or Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis (e.g., carotid artery thrombosis, sinus thrombosis, or Wallenberg's Syndrome), cerebral hemorrhage (e.g., epidural or subdural hematoma, or subarachnoid hemorrhage), cerebral infarction, cerebral ischemia (e.g., transient cerebral ischemia, Subclavian Steal Syndrome, or vertebrobasilar insufficiency), vascular dementia (e.g., multi-infarct), leukomalacia, periventricular, and vascular headache (e.g., cluster headache or migraines).

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to

5

10

15

20

25

30

stimulate neurological cell proliferation and/or differentiation. Therefore, polynucleotides, polypeptides, agonists and/or antagonists of the invention may be used to treat and/or detect neurologic diseases. Moreover, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used as a marker or detector of a particular nervous system disease or disorder.

202

Examples of neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include brain diseases, such as metabolic brain diseases which includes phenylketonuria such as maternal phenylketonuria, pyruvate carboxylase deficiency, pyruvate dehydrogenase complex deficiency, Wernicke's Encephalopathy, brain edema, brain neoplasms such as cerebellar neoplasms which include infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms, supratentorial neoplasms, canavan disease, cerebellar diseases such as cerebellar ataxia which include spinocerebellar degeneration such as ataxia telangiectasia, cerebellar dyssynergia, Friederich's Ataxia, Machado-Joseph Disease, olivopontocerebellar atrophy, cerebellar neoplasms such as infratentorial neoplasms, diffuse cerebral sclerosis such as encephalitis periaxialis, globoid cell leukodystrophy leukodystrophy, metachromatic and subacute sclerosing panencephalitis.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include cerebrovascular disorders (such as carotid artery diseases which include carotid artery thrombosis, carotid stenosis and Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis such as carotid artery thrombosis, sinus thrombosis and Wallenberg's Syndrome, cerebral hemorrhage such as epidural hematoma, subdural hematoma and subarachnoid hemorrhage, cerebral infarction, cerebral ischemia such as transient cerebral ischemia, Subclavian Steal Syndrome and vertebrobasilar insufficiency, vascular dementia such as multi-infarct dementia, periventricular leukomalacia, vascular headache such as cluster headache and migraine.

5

10

15

20

25

30

203

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include dementia such as AIDS Dementia Complex, presenile dementia such as Alzheimer's Disease and Creutzfeldt-Jakob Syndrome, senile dementia such as Alzheimer's Disease and progressive supranuclear palsy, vascular dementia such as multi-infarct dementia, encephalitis which include encephalitis periaxialis, viral encephalitis such as epidemic encephalitis, Japanese Encephalitis, St. Louis Encephalitis, tick-borne encephalitis and West Nile Fever, acute disseminated encephalomyelitis, meningoencephalitis such as uveomeningoencephalitic syndrome, Postencephalitic Parkinson Disease and subacute sclerosing panencephalitis, encephalomalacia such as periventricular leukomalacia, epilepsy such as generalized epilepsy which includes infantile spasms, absence epilepsy, myoclonic epilepsy which includes MERRF Syndrome, tonic-clonic epilepsy, partial epilepsy such as complex partial epilepsy, frontal lobe epilepsy and temporal lobe epilepsy, post-traumatic epilepsy, status epilepticus such as Epilepsia Partialis Continua, and Hallervorden-Spatz Syndrome.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hydrocephalus such as Dandy-Walker Syndrome and normal pressure hydrocephalus, hypothalamic diseases such as hypothalamic neoplasms, cerebral malaria, narcolepsy which includes cataplexy, bulbar poliomyelitis, cerebri pseudotumor, Rett Syndrome, Reye's Syndrome, thalamic diseases, cerebral toxoplasmosis, intracranial tuberculoma and Zellweger Syndrome, central nervous system infections such as AIDS Dementia Complex, Brain Abscess, subdural empyema, encephalomyelitis such as Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis, Necrotizing Hemorrhagic Encephalomyelitis, Visna, and cerebral malaria.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include meningitis such as arachnoiditis, aseptic meningitis such as viral meningitis which includes lymphocytic choriomeningitis, Bacterial meningitis which includes Haemophilus Meningitis, Listeria Meningitis, Meningococcal Meningitis such as

204

Waterhouse-Friderichsen Syndrome, Pneumococcal Meningtitis and meningeal tuberculosis, fungal meningitis such as Cryptococcal Meningtitis, subdural effusion, meningoencephalitis such as uvemeningoencephalitic syndrome, myelitis such as transverse myelitis, neurosyphilis such as tabes dorsalis, poliomyelitis which includes bulbar poliomyelitis and postpoliomyelitis syndrome, prion diseases (such as Creutzfeldt-Jakob Syndrome, Bovine Spongiform Encephalopathy, Gerstmann-Straussler Syndrome, Kuru, Scrapie), and cerebral toxoplasmosis.

5

10

15

20

25

30

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include central nervous system neoplasms such as brain neoplasms that include cerebellar neoplasms such as infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms and supratentorial neoplasms, meningeal neoplasms, spinal cord neoplasms which include epidural neoplasms, demyelinating diseases such as Canavan Diseases, diffuse cerebral sceloris which includes adrenoleukodystrophy, encephalitis periaxialis, globoid cell leukodystrophy, diffuse cerebral sclerosis such as metachromatic leukodystrophy, allergic encephalomyelitis, necrotizing hemorrhagic encephalomyelitis, progressive multifocal leukoencephalopathy, multiple sclerosis, central pontine myelinolysis, transverse myelitis, neuromyelitis optica, Scrapie, Swayback, Chronic Fatigue Syndrome, Visna, High Pressure Nervous Syndrome, Meningism, spinal cord diseases such as amyotonia congenita, amyotrophic lateral sclerosis, spinal muscular atrophy such as Werdnig-Hoffmann Disease, spinal cord compression, spinal cord neoplasms such as epidural neoplasms, syringomyelia, Tabes Dorsalis, Stiff-Man Syndrome, mental retardation such as Angelman Syndrome, Cri-du-Chat Syndrome, De Lange's Syndrome, Down Syndrome, Gangliosidoses such as gangliosidoses G(M1), Sandhoff Disease, Tay-Sachs Disease, Hartnup Disease, homocystinuria, Laurence-Moon-Biedl Syndrome, Lesch-Nyhan Syndrome, Maple Syrup Urine Disease, mucolipidosis such as fucosidosis, neuronal ceroid-lipofuscinosis, oculocerebrorenal syndrome, phenylketonuria such as maternal phenylketonuria, Prader-Willi Syndrome, Rett Syndrome, Rubinstein-Taybi Syndrome, Tuberous Sclerosis, WAGR Syndrome, nervous system abnormalities such as holoprosencephaly, neural tube defects such as anencephaly which includes hydrangencephaly, Arnold-Chairi Deformity,

205

encephalocele, meningocele, meningomyelocele, spinal dysraphism such as spina bifida cystica and spina bifida occulta.

5

10

15

20

25

30

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hereditary motor and sensory neuropathies which include Charcot-Marie Disease, Hereditary optic atrophy, Refsum's Disease, hereditary spastic paraplegia, Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies such as Congenital Analgesia and Familial Dysautonomia, Neurologic manifestations (such as agnosia that include Gerstmann's Syndrome, Amnesia such as retrograde amnesia, apraxia, neurogenic bladder, cataplexy, communicative disorders such as hearing disorders that includes deafness, partial hearing loss, loudness recruitment and tinnitus, language disorders such as aphasia which include agraphia, anomia, broca aphasia, and Wernicke Aphasia, Dyslexia such as Acquired Dyslexia, language development disorders, speech disorders such as aphasia which includes anomia, broca aphasia and Wernicke Aphasia, articulation disorders, communicative disorders such as speech disorders which include dysarthria, echolalia, mutism and stuttering, voice disorders such as aphonia and hoarseness, decerebrate state, delirium, fasciculation, hallucinations, meningism, movement disorders such as angelman syndrome, ataxia, athetosis, chorea, dystonia, hypokinesia, muscle hypotonia, myoclonus, tic, torticollis and tremor, muscle hypertonia such as muscle rigidity such as stiff-man syndrome, muscle spasticity, paralysis such as facial paralysis which includes Herpes Zoster Oticus, Gastroparesis, Hemiplegia, ophthalmoplegia such as diplopia, Duane's Syndrome, Horner's Syndrome, Chronic progressive external ophthalmoplegia such as Kearns Syndrome, Bulbar Paralysis, Tropical Spastic Paraparesis, Paraplegia such as Brown-Sequard Syndrome, quadriplegia, respiratory paralysis and vocal cord paralysis, paresis, phantom limb, taste disorders such as ageusia and dysgeusia, vision disorders such as amblyopia, blindness, color vision defects, diplopia, hemianopsia, scotoma and subnormal vision, sleep disorders such as hypersomnia which includes Kleine-Levin Syndrome, insomnia, and somnambulism, spasm such as trismus, unconsciousness such as coma, persistent vegetative state and syncope and vertigo, neuromuscular diseases such as amyotonia congenita, amyotrophic lateral sclerosis, Lambert-Eaton Myasthenic Syndrome, motor neuron

5

10

15

20

25

30

PCT/US00/30654

disease, muscular atrophy such as spinal muscular atrophy, Charcot-Marie Disease and Werdnig-Hoffmann Disease, Postpoliomyelitis Syndrome, Muscular Dystrophy, Myasthenia Gravis, Myotonia Atrophica, Myotonia Confenita, Nemaline Myopathy, Familial Periodic Paralysis, Multiplex Paramyloclonus, Tropical Spastic Paraparesis and Stiff-Man Syndrome, peripheral nervous system diseases such as acrodynia, amyloid neuropathies, autonomic nervous system diseases such as Adie's Syndrome, Barre-Lieou Syndrome, Familial Dysautonomia, Horner's Syndrome, Reflex Sympathetic Dystrophy and Shy-Drager Syndrome, Cranial Nerve Diseases such as Acoustic Nerve Diseases such as Acoustic Neuroma which includes Neurofibromatosis 2, Facial Nerve Diseases such as Facial Neuralgia, Melkersson-Rosenthal Syndrome, ocular motility disorders which includes amblyopia, nystagmus, oculomotor nerve paralysis, ophthalmoplegia such as Duane's Syndrome, Horner's Syndrome, Chronic Progressive External Ophthalmoplegia which includes Kearns Syndrome, Strabismus such as Esotropia and Exotropia, Oculomotor Nerve Paralysis, Optic Nerve Diseases such as Optic Atrophy which includes Hereditary Optic Atrophy, Optic Disk Drusen, Optic Neuritis such as Neuromyelitis Optica, Papilledema, Trigeminal Neuralgia, Vocal Cord Paralysis, Demyelinating Diseases such as Neuromyelitis Optica and Swayback, and Diabetic neuropathies such as diabetic foot.

206

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include nerve compression syndromes such as carpal tunnel syndrome, tarsal tunnel syndrome, thoracic outlet syndrome such as cervical rib syndrome, ulnar nerve compression syndrome, neuralgia such as causalgia, cervico-brachial neuralgia, facial neuralgia and trigeminal neuralgia, neuritis such as experimental allergic neuritis, optic neuritis, polyneuritis, polyradiculoneuritis and radiculities such as polyradiculitis, hereditary motor and sensory neuropathies such as Charcot-Marie Disease, Hereditary Optic Atrophy, Refsum's Disease, Hereditary Spastic Paraplegia and Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies which include Congenital Analgesia and Familial Dysautonomia, POEMS Syndrome, Sciatica, Gustatory Sweating and Tetany).

207

PCT/US00/30654

Infectious Disease

5

10

15

20

25

30

A polypeptide or polynucleotide and/or agonist or antagonist of the present invention can be used to treat, prevent, and/or diagnose infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated, prevented, and/or diagnosed. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polypeptide or polynucleotide and/or agonist or antagonist of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiollitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or

5

PCT/US00/30654

208

diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose AIDS.

Similarly, bacterial or fungal agents that can cause disease or symptoms and 10 that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Cryptococcus neoformans, Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia 15 (e.g., Borrelia burgdorferi), Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, E. coli (e.g., Enterotoxigenic E. coli and Enterohemorrhagic E. coli), Enterobacteriaceae (Klebsiella, Salmonella (e.g., Salmonella typhi, and Salmonella paratyphi), Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, 20 Mycobacterium leprae, Vibrio cholerae, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Menigococcal), Meisseria meningitidis, Pasteurellacea Infections (e.g., Actinobacillus, Heamophilus (e.g., Heamophilus influenza type B), Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, Shigella spp., Staphylococcal, Meningiococcal, Pneumococcal and Streptococcal (e.g., 25 Streptococcus pneumoniae and Group B Streptococcus). These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, 30 prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as

Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease,

Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea,

5

10

15

20

25

30

209

PCT/US00/30654

meningitis (e.g., mengitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific

to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: tetanus, Diptheria, botulism, and/or meningitis type B.

Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis,

Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., Plasmodium virax, Plasmodium falciparium, Plasmodium malariae and Plasmodium ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used totreat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.

Preferably, treatment or prevention using a polypeptide or polynucleotide and/or agonist or antagonist of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

210

PCT/US00/30654

Regeneration

5

10

15

20

25

30

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteocarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide and/or agonist or antagonist of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated, prevented, and/or diagnosed include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide and/or agonist or antagonist of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated, prevented, and/or diagnosed using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic diseases, disorders, and/or conditions (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stoke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-

211

Drager syndrome), could all be treated, prevented, and/or diagnosed using the polynucleotide or polypeptide and/or agonist or antagonist of the present invention.

Chemotaxis

5

10

15

20

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may have chemotaxis activity. A chemotaxic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase chemotaxic activity of particular cells. These chemotactic molecules can then be used to treat, prevent, and/or diagnose inflammation, infection, hyperproliferative diseases, disorders, and/or conditions, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotaxic molecules can be used to treat, prevent, and/or diagnose wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat, prevent, and/or diagnose wounds.

It is also contemplated that a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may inhibit chemotactic activity. These molecules could also be used totreat, prevent, and/or diagnose diseases, disorders, and/or conditions. Thus, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention could be used as an inhibitor of chemotaxis.

25

30

Binding Activity

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

5

10

15

20

25

30

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

Additionally, the receptor to which a polypeptide of the invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein

5

10

15

20

25

30

213

polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and retransfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of polypeptides of the invention thereby effectively generating agonists and antagonists of polypeptides of the invention. See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, S. Trends Biotechnol. 16(2):76-82 (1998); Hansson, L. O., et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. Biotechniques 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides of the invention may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired polynucleotide

5

10

15

20

25

30

214

sequence of the invention molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides of the invention may be alterred by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptides of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glialderived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the polypeptides of the invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and 3[H] thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the uptake of 3[H] thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of

5

10

15

20

25

30

3[H] thymidine. Both agonist and antagonist compounds may be identified by this procedure.

215

PCT/US00/30654

In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat, prevent, and/or diagnose disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues. Therefore, the invention includes a method of identifying compounds which bind to the polypeptides of the invention comprising the steps of: (a) incubating a candidate binding compound with the polypeptide; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with the polypeptide, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Also, one could identify molecules bind a polypeptide of the invention experimentally by using the beta-pleated sheet regions contained in the polypeptide sequence of the protein. Accordingly, specific embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, the amino acid sequence of each beta pleated sheet regions in a disclosed polypeptide sequence. Additional embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of,

PCT/US00/30654

any combination or all of contained in the polypeptide sequences of the invention. Additional preferred embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, the amino acid sequence of each of the beta pleated sheet regions in one of the polypeptide sequences of the invention. Additional embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, any combination or all of the beta pleated sheet regions in one of the polypeptide sequences of the invention.

216

Targeted Delivery

5

10

15

20

25

30

In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes

5

10

15

20

25

30

PCT/US00/30654

known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNAse, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

217

Drug Screening

Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the

5

10

15

20

25

30

218

present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

Polypeptides of the Invention Binding Peptides and Other Molecules

The invention also encompasses screening methods for identifying polypeptides and nonpolypeptides that bind polypeptides of the invention, and the polypeptide of the invention binding molecules identified thereby. These binding molecules are useful, for example, as agonists and antagonists of the polypeptides of the invention. Such agonists and antagonists can be used, in accordance with the invention, in the therapeutic embodiments described in detail, below.

This method comprises the steps of:

5

10

15

20

25

30

a. contacting a polypeptide of the invention with a plurality of molecules; and b. identifying a molecule that binds the polypeptide of the invention.

219

PCT/US00/30654

The step of contacting the polypeptide of the invention with the plurality of molecules may be effected in a number of ways. For example, one may contemplate immobilizing the polypeptide of the invention on a solid support and bringing a solution of the plurality of molecules in contact with the immobilized polypeptide of the invention. Such a procedure would be akin to an affinity chromatographic process, with the affinity matrix being comprised of the immobilized polypeptide of the invention. The molecules having a selective affinity for the polypeptide of the invention can then be purified by affinity selection. The nature of the solid support, process for attachment of the polypeptide of the invention to the solid support, solvent, and conditions of the affinity isolation or selection are largely conventional and well known to those of ordinary skill in the art.

Alternatively, one may also separate a plurality of polypeptides into substantially separate fractions comprising a subset of or individual polypeptides. For instance, one can separate the plurality of polypeptides by gel electrophoresis, column chromatography, or like method known to those of ordinary skill for the separation of polypeptides. The individual polypeptides can also be produced by a transformed host cell in such a way as to be expressed on or about its outer surface (e.g., a recombinant phage). Individual isolates can then be "probed" by the polypeptide of the invention, optionally in the presence of an inducer should one be required for expression, to determine if any selective affinity interaction takes place between the polypeptide of the invention and the individual clone. Prior to contacting the polypeptide of the invention with each fraction comprising individual polypeptides, the polypeptides could first be transferred to a solid support for additional convenience. Such a solid support may simply be a piece of filter membrane, such as one made of nitrocellulose or nylon. In this manner, positive clones could be identified from a collection of transformed host cells of an expression library, which harbor a DNA construct encoding a polypeptide having a selective affinity for a polypeptide of the invention. Furthermore, the amino acid sequence of the polypeptide having a selective affinity for the polypeptide of the invention can be determined directly by conventional means or the coding sequence of the DNA encoding the polypeptide can frequently be

5

10

15

20

25

30

determined more conveniently. The primary sequence can then be deduced from the corresponding DNA sequence. If the amino acid sequence is to be determined from the polypeptide itself, one may use microsequencing techniques. The sequencing technique may include mass spectroscopy.

In certain situations, it may be desirable to wash away any unbound polypeptide of the invention, or alterntatively, unbound polypeptides, from a mixture of the polypeptide of the invention and the plurality of polypeptides prior to attempting to determine or to detect the presence of a selective affinity interaction. Such a wash step may be particularly desirable when the polypeptide of the invention or the plurality of polypeptides is bound to a solid support.

The plurality of molecules provided according to this method may be provided by way of diversity libraries, such as random or combinatorial peptide or nonpeptide libraries which can be screened for molecules that specifically bind to a polypeptide of the invention. Many libraries are known in the art that can be used, e.g., chemically synthesized libraries, recombinant (e.g., phage display libraries), and in vitro translation-based libraries. Examples of chemically synthesized libraries are described in Fodor et al., 1991, Science 251:767-773; Houghten et al., 1991, Nature 354:84-86; Lam et al., 1991, Nature 354:82-84; Medynski, 1994, Bio/Technology 12:709-710; Gallop et al., 1994, J. Medicinal Chemistry 37(9):1233-1251; Ohlmeyer et al., 1993, Proc. Natl. Acad. Sci. USA 90:10922-10926; Erb et al., 1994, Proc. Natl. Acad. Sci. USA 91:11422-11426; Houghten et al., 1992, Biotechniques 13:412; Jayawickreme et al., 1994, Proc. Natl. Acad. Sci. USA 91:1614-1618; Salmon et al., 1993, Proc. Natl. Acad. Sci. USA 90:11708-11712; PCT Publication No. WO 93/20242; and Brenner and Lerner, 1992, Proc. Natl. Acad. Sci. USA 89:5381-5383.

Examples of phage display libraries are described in Scott and Smith, 1990, Science 249:386-390; Devlin et al., 1990, Science, 249:404-406; Christian, R. B., et al., 1992, J. Mol. Biol. 227:711-718); Lenstra, 1992, J. Immunol. Meth. 152:149-157; Kay et al., 1993, Gene 128:59-65; and PCT Publication No. WO 94/18318 dated Aug. 18, 1994.

In vitro translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated Apr. 18, 1991; and Mattheakis et al., 1994, Proc. Natl. Acad. Sci. USA 91:9022-9026.

5

10

15

20

25

30

By way of examples of nonpeptide libraries, a benzodiazepine library (see e.g., Bunin et al., 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712) can be adapted for use. Peptoid libraries (Simon et al., 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371) can also be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).

221

PCT/US00/30654

The variety of non-peptide libraries that are useful in the present invention is great. For example, Ecker and Crooke, 1995, Bio/Technology 13:351-360 list benzodiazepines, hydantoins, piperazinediones, biphenyls, sugar analogs, beta-mercaptoketones, arylacetic acids, acylpiperidines, benzopyrans, cubanes, xanthines, aminimides, and oxazolones as among the chemical species that form the basis of various libraries.

Non-peptide libraries can be classified broadly into two types: decorated monomers and oligomers. Decorated monomer libraries employ a relatively simple scaffold structure upon which a variety functional groups is added. Often the scaffold will be a molecule with a known useful pharmacological activity. For example, the scaffold might be the benzodiazepine structure.

Non-peptide oligomer libraries utilize a large number of monomers that are assembled together in ways that create new shapes that depend on the order of the monomers. Among the monomer units that have been used are carbamates, pyrrolinones, and morpholinos. Peptoids, peptide-like oligomers in which the side chain is attached to the alpha amino group rather than the alpha carbon, form the basis of another version of non-peptide oligomer libraries. The first non-peptide oligomer libraries utilized a single type of monomer and thus contained a repeating backbone. Recent libraries have utilized more than one monomer, giving the libraries added flexibility.

Screening the libraries can be accomplished by any of a variety of commonly known methods. See, e.g., the following references, which disclose screening of peptide libraries: Parmley and Smith, 1989, Adv. Exp. Med. Biol. 251:215-218; Scott and Smith, 1990, Science 249:386-390; Fowlkes et al., 1992; BioTechniques 13:422-427; Oldenburg et al., 1992, Proc. Natl. Acad. Sci. USA 89:5393-5397; Yu et al.,

5

10

15

20

25

30

1994, Cell 76:933-945; Staudt et al., 1988, Science 241:577-580; Bock et al., 1992, Nature 355:564-566; Tuerk et al., 1992, Proc. Natl. Acad. Sci. USA 89:6988-6992; Ellington et al., 1992, Nature 355:850-852; U.S. Pat. No. 5,096,815, U.S. Pat. No. 5,223,409, and U.S. Pat. No. 5,198,346, all to Ladner et al.; Rebar and Pabo, 1993, Science 263:671-673; and CT Publication No. WO 94/18318.

In a specific embodiment, screening to identify a molecule that binds a polypeptide of the invention can be carried out by contacting the library members with a polypeptide of the invention immobilized on a solid phase and harvesting those library members that bind to the polypeptide of the invention. Examples of such screening methods, termed "panning" techniques are described by way of example in Parmley and Smith, 1988, Gene 73:305-318; Fowlkes et al., 1992, BioTechniques 13:422-427; PCT Publication No. WO 94/18318; and in references cited herein.

In another embodiment, the two-hybrid system for selecting interacting proteins in yeast (Fields and Song, 1989, Nature 340:245-246; Chien et al., 1991, Proc. Natl. Acad. Sci. USA 88:9578-9582) can be used to identify molecules that specifically bind to a polypeptide of the invention.

Where the polypeptide of the invention binding molecule is a polypeptide, the polypeptide can be conveniently selected from any peptide library, including random peptide libraries, combinatorial peptide libraries, or biased peptide libraries. The term "biased" is used herein to mean that the method of generating the library is manipulated so as to restrict one or more parameters that govern the diversity of the resulting collection of molecules, in this case peptides.

Thus, a truly random peptide library would generate a collection of peptides in which the probability of finding a particular amino acid at a given position of the peptide is the same for all 20 amino acids. A bias can be introduced into the library, however, by specifying, for example, that a lysine occur every fifth amino acid or that positions 4, 8, and 9 of a decapeptide library be fixed to include only arginine. Clearly, many types of biases can be contemplated, and the present invention is not restricted to any particular bias. Furthermore, the present invention contemplates specific types of peptide libraries, such as phage displayed peptide libraries and those that utilize a DNA construct comprising a lambda phage vector with a DNA insert.

As mentioned above, in the case of a polypeptide of the invention binding

223

molecule that is a polypeptide, the polypeptide may have about 6 to less than about 60 amino acid residues, preferably about 6 to about 10 amino acid residues, and most preferably, about 6 to about 22 amino acids. In another embodiment, a polypeptide of the invention binding polypeptide has in the range of 15-100 amino acids, or 20-50 amino acids.

The selected polypeptide of the invention binding polypeptide can be obtained by chemical synthesis or recombinant expression.

Antisense And Ribozyme (Antagonists)

5

10

15

20

25

30

In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained a deposited clone. In one embodiment, antisense sequence is generated internally by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, Neurochem., 56:560 (1991). Oligodeoxynucleotides as Anitsense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., Nucleic Acids Research, 6:3073 (1979); Cooney et al., Science, 241:456 (1988); and Dervan et al., Science, 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide. A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoR1 site on the 5 end and a HindIII site on the 3 end. Next, the pair of oligonucleotides is

224

heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl2, 10MM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoR1/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the mature polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

5

10

15

20

25

30

In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid of the invention. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding a polypeptide of the invention, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, Nature, 29:304-310 (1981), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., Cell, 22:787-797 (1980), the herpes thymidine promoter (Wagner et al., Proc. Natl. Acad. Sci. U.S.A., 78:1441-1445 (1981), the regulatory sequences of the metallothionein gene (Brinster et al., Nature, 296:39-42 (1982)), etc.

The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of interest. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA,

5

10

15

20

25

30

forming a stable duplex; in the case of double stranded antisense nucleic acids of the invention, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA sequence of the invention it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

225

PCT/US00/30654

Oligonucleotides that are complementary to the 5' end of the message, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., Nature, 372:333-335 (1994). Thus, oligonucleotides complementary to either the 5' - or 3' non-translated, non-coding regions of a polynucleotide sequence of the invention could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5'-, 3'- or coding region of mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556 (1989); Lemaitre et al., Proc. Natl. Acad. Sci., 84:648-652 (1987); PCT Publication

5

25

30

NO: WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication NO: WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., BioTechniques, 6:958-976 (1988)) or intercalating agents. (See, e.g., Zon, Pharm. Res., 5:539-549 (1988)). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 10 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 15 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 20 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidate, a phosphoramidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded

227

hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., Nucl. Acids Res., 15:6625-6641 (1987)). The oligonucleotide is a 2-0-methylribonucleotide (Inoue et al., Nucl. Acids Res., 15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215:327-330 (1987)).

5

10

15

20

25

30

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (Nucl. Acids Res., 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A., 85:7448-7451 (1988)), etc.

While antisense nucleotides complementary to the coding region sequence of the invention could be used, those complementary to the transcribed untranslated region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science, 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs corresponding to the polynucleotides of the invention, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature, 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within each nucleotide sequence disclosed in the sequence listing. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA corresponding to the polynucleotides of the invention; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

5

10

15

20

25

30

As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the polynucleotides of the invention in vivo. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

228

PCT/US00/30654

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirous in cases such as restenosis after balloon angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

The antagonist/agonist may also be employed to treat, prevent, and/or diagnose the diseases described herein.

Thus, the invention provides a method of treating or preventing diseases, disorders, and/or conditions, including but not limited to the diseases, disorders, and/or conditions listed throughout this application, associated with overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

PCT/US00/30654

invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention

229

Other Activities

5

10

15

20

25

30

WO 01/34629

The polypeptide of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating revascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. These polypeptide may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

The polypeptide may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

The polypeptide of the present invention may also be employed stimulate neuronal growth and to treat, prevent, and/or diagnose neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. The polypeptide of the invention may have the ability to stimulate chondrocyte growth, therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

The polypeptide of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

The polypeptide of the invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, the polypeptides of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

The polypeptide of the invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues.

The polypeptide of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, polypeptides or polynucleotides and/or agonist or antagonists of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, caricadic rhythms, depression (including depressive diseases, disorders, and/or conditions), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

Other Preferred Embodiments

5

10

15

20

25

30

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of

5

10

15

20

25

30

231

PCT/US00/30654

the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5′ Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3′ Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5′ Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3′ Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization

5

10

15

20

25

30

232

conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table

5

10

15

20

25

30

233

1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a

234

nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

5

10

15

20

25

30

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

5

10

15

20

25

30

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

235

PCT/US00/30654

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

5

10

15

20

25

30

PCT/US00/30654

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

237

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

5

10

15

20

25

30

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence

5

10

15

20

25

30

PCT/US00/30654

selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone

238

Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number

shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

5

10

15

20

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

In specific embodiments of the invention, for each "Contig ID" listed in the fourth column of Table 7, preferably excluded are one or more polynucleotides comprising, or alternatively consisting of, a nucleotide sequence referenced in the fifth column of Table 7 and described by the general formula of a-b, whereas a and b are uniquely determined for the corresponding SEQ ID NO:X referred to in column 3 of Table 7. Further specific embodiments are directed to polynucleotide sequences excluding one, two, three, four, or more of the specific polynucleotide sequences referred to in the fifth column of Table 7. In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

TABLE 7

Gene No.	cDNA Clone ID	NT SEQ	Contig ID	Public Accession Numbers
	·	ID NO:		
1	HDPPA04	11	904765	A1990290, A1798762, AA044757,
				AW105205, AW197379, AA039608, AA247117, AA303575, AA036918,
				AA247128, AI214428, AW449368, AA044631, AI762460, and AF142780.
1	HDPPA04	32	905419	AI990290, AI798762, AA044757, AW105205, AW197379, AA039608,

				AA303575, AA036918, AA247117, AI214428,
1				AW449368, AA247128, AA044631,
				AI762460, AI432644, AI431337, AI623302,
				AI432662, AI431248, AI431328, AI432649,
				AI431254, AI431243, AI432665, AI431347,
				AI432653, AI431230, AI432654, AI431354,
				AI432655, AI431310, AI431312, AI431330,
-				AW081103, AI432651, AI432647, AI432677,
				AI432661, AI432675, AI492519, AI431241,
				AI432658, AI431357, AI432676, AI431351,
				AI432673, AI431345, AI431353, AW128900,
				AI432672, AI432674, AI431346, AI431255,
				AI431340, AW128846, AI432664, AI432650,
1				AI791349, AI431307, AI431316, AW128897,
				AI492520, AI431751, AI492509, AI432643,
				AI432657, AI492510, AI432666, AW129223,
				AI431247, AI431308, AW128884, Y17793,
1				and AF064854.
1	HDPPA04	33	905418	AA247128 and AA247117.
2	НОНВУ44	12	873264	AI037867, AW368603, AW151676,
~		17	0,520,	AW383192, AI753734, AI754387,
1		ĺ		AW044602, AW383224, AI041650,
				AW383194, AI750595, AW383164,
1				AI884505, W52686, AW069006, AI750594,
ĺ				AA600082, AW078795, AI753050, AI802788,
				AW190902, AI750578, AI041803, AI621183,
		Ì		AI750577, AW383125, AA599801,
				AW087935, N31127, W51909, AI087351,
		l		AA071381, W47324, W48619, AA670070,
				W48852, N35377, AI752124, AI090390,
				W42791, W47325, N28395, N28453,
				AI085102, AI678451, AA545734, W42884,
	†			AA373348, AI302125, AI910477, H80042,
1]	1		AA071138, AA669811, AW361415,
1	į			AW069430, AA788723, AW069485,
ļ	1			AI940729, AI754608, AA376403, AA373673,
1	}			H99469, AA373544, AI888605, AA373014,
				AI940705, AA373975, N27040, C01826,
			1	AA373298, AA112124, AA084001, AI940795,
				AA372833, AW005943, AW239511,
		1		AI521673, AW138508, AI932934, AA373557,
1				AA344024, W25447, AI537571, C01953,
1	ļ			AI476777, AF110137, Y10019, AB032372,
1				AF045800, AF108189, and AF045801.
2	HOHDVAA	34	872262	AW069165, AI968107, AW069264,
4	НОНВҮ44	34	873263	1 ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
1				AI754660, AA912445, AI754594, N21113,
1	İ			AA703927, AA543066, AW130486,
1				AI814434, AI924946, AW069841,
1	!			AW173667, AI753523, AI753558, AA789056,
				AI753482, AW068940, AI022286, AI753593,
1				AI753469, AA669866, AI753255, AW008360,
				AI949111, AW069588, AI754028, AI679005,
1				AI677772, AI754354, AI589279, AI888455,
1				AI752878, AI753002, AA836970, N20040,
1				W19275, AI968546, AA788723, AW016646,
1				AI440410, AI752123, AI801326, AI610424,
1				AI753621, AI446171, AI753087, AI453455,
L	L	L	<u> </u>	1

				AA599863, AI802571, AI537325, AA669978,
1	1			AI811571, AI753506, AI309543, AA670062,
				A1623845, A1075634, AA729459, H80043,
				AI921732, AA329219, AA577421, AA668620,
				C01795, AI919521, AA600003, AA653400,
				AI445339, AI802573, AW130343, AA373014,
				C01953, AA600104, AI090390, AI302125,
				AI087351, AW069006, AI754608, AA071381,
				W51909, W47325, W42791, AW069430,
				AI085102, AW005943, AA670070,
				AW069485, AA600082, AI753734, AI041803,
				AW138508, AI932934, AI754387, AI750577,
				AI750594, and AF110137.
2	НОНВҮ44	35	785886	AW082079, N35762, N42296, AI081481,
				AW009605, AI949111, W19275, AW130343,
				AA600104, AI445339, AA653400, AA600003,
				AA577421, AI919521, AI075634, AA729459,
1				AI623845, AI309543, AI811571, AI537325,
				AI802571, AA599863, AI453455, AI446171,
				AI610424, AI753087, AI440410, AI753621,
				A1801326, N20040, A1679005, A1589279,
				AI677772, AI752878, AI754354, AI754028,
				AW069588, AW008360, AI753255,
				AA669866, AI753506, AI753593, AW068940,
				AA009800, A1733500, A1733593, AW008940, A1753482, A1753558, A1753523, AW173667,
				AW069841, AI924946, AI814434,
				AW130486, AA543066, AA703927,
			j	AI754594, AI754660, AW069264, N21113,
				AI968107, AW069165, AA912445,
				AA668620, AA836970, AA669978, AI968546,
				AI888455, AI753469, AA789056, AW016646,
				AI022286, C01795, and AF110137.
3	HOHBL42	13	1020664	H95505 and L20314.
3	HOHBL42	36	863123	H95505.
3	HOHBL42	38	834714	L20314.
4	HRABV43	14	1024909	AA740749, AA844682, AA977690,
İ				AA864844, AI801095, AI206056, AA488673,
				AA815296, AI742443, AI932302, AA180508,
				AI833279, AI859081, AA157888, AA179837,
				AW192608, AA532678, AA479341,
				AA946767, AA804256, AA401011, AI982686,
				AI096855, AA187599, N69435, AI342048,
ŀ				AI745007, AI831165, AA088238, W22883,
				R92180, AA769339, AI377067, AI143620,
				AW075726, AA620478, H81204, AA479449,
				H97641, AA973113, AA400972, AI082108,
				AA808322, T79180, AA326358, AA856779,
				AA157576, AW204418, AA907790,
				AA493191, H81203, AA455438, AA486056,
				AW206126, AA969911, AI364159, AI475423,
				H43700, R00938, AA720606, T77234,
				AW135686, R92284, AI672889, AI656432,
				R70152, H41249, T85995, AA984380,
				R86741, AA088288, R02180, T98954,
- 50				R71371, AI915388, AI383063, R85065,
				T77448, T79264, T80896, T32391, T10419,
i .	l	I	Ī	R05703, AI270644, AA506839, AI290031,

				AI459837, AA894596, AA974600, T99869,
				T90967, R05702, AA312338, AA582695,
				R87108, R08118, T98910, AA335307,
				AA187391, N84682, T80825, R08119,
				R00566, R00671, N46204, AA362528,
				AI696531, AI652607, AA342282, AW237396,
				AA593124, W03260, T77927, H90040,
				T97899, AA341243, AA748184, W60591,
				AI695823, AA502058, AI040466, AA768593,
				AI147277, AI674501, AA211074, AA453417,
				AA723863, AI673001, AW008534, AI590725,
				C00030, AI919118, AA476751, AA782496,
				AI360894, AI308970, AI356725, AI800701,
l				AI281134, AI027052, AW162438, AI421854,
				AI521004, AA834980, AI885897, H93566,
				AA975309, AI339377, AW149528,
				AA227152, AI580862, AW162508,
				AW149834, N27209, AA199737, AA873471,
				AW000752, AI862036, AI061193, AI348286,
				AW073221, AI049653, T32729, N69257,
				AW117999, AI371126, AI190452, AA046621,
				AI816144, AA069829, H54017, AA223575,
				AA593953, AW134905, W48701, AA533599,
				AA815362, AI355030, AI807069, AI346194,
				AI272101, AW183008, AA587783,
				AA703690, AA134981, AW103418,
				AI589847, AA401916, AA652228, T70319,
				AA054221, AW195167, AI676031,
				AA001439, R67338, R67057, AA577283,
				T57926, AI434272, W51922, W51921,
				R83286, AI688408, AA205942, AA557254,
				AI189237, R80210, and U39400.
4	HRABV43	39	883826	AA740749, T77234, T85995, T79264,
				N84682, AA157576, and AA768593.
4	HRABV43	40	902457	AA844682, AA977690, AA864844,
				AA488673, AA815296, AI206056, AI801095,
				AI932302, AI742443, AA180508, AI833279,
				AI859081, AA157888, AA179837,
				AW192608, AA532678, AA479341,
				AA946767, AI982686, AA401011, AI831165,
				AI096855, AA187599, N69435, AI342048,
				AI745007, W22883, AA088238, R92180,
1				AA804256, AI377067, AI143620, AA769339,
				H81204, AA620478, AA479449, H97641,
				AA973113, AA400972, AW075726,
				AA808322, AI082108, T79180, AA326358,
				AA856779, AA493191, H81203, AA907790,
				AA455438, AW204418, AA486056,
				AA969911, AI364159, AI475423, H43700,
				AW206126, R00938, AA720606, R92284,
				AI672889, AA157576, R70152, AI656432,
				H41249, AA984380, R86741, AW135686,
				AA088288, R02180, T98954, R71371,
				AI915388, R85065, T77448, T80896, T32391,
				R05703, T10419, AI383063, AA506839,
				AI290031, AI459837, AA894596, AI270644,
				T99869, AA974600, R05702, T90967,
L	L			277007, 1110771000, 1007702, 170707,

				AA582695, AA312338, R87108, R08118,
				T98910, AA335307, AA187391, R08119,
				T80825, R00566, R00671, N46204,
				AA362528, AI696531, AI652607, AA342282,
				AW237396, AA593124, W03260, T77927,
				H90040, T97899, AA748184, AA341243,
				W60591, AI695823, AA502058, AI040466,
				A1147277, A1674501, AA211074, AA453417,
				AA723863, AI673001, AW008534, AI590725,
				C00030, AA476751, AA782496, AI360894,
				AI308970, AI356725, AI800701, AI281134,
				AI027052, AW162438, AI421854, AI521004,
				AI919118, AA834980, H93566, AI885897,
				AA975309, AI339377, AW149528, AI580862,
				AA227152, AW162508, AW149834, N27209,
				AA199737, AA873471, AW000752,
				AI862036, AI061193, AI348286, AW073221,
				AI049653, T32729, N69257, AW117999,
				AI371126, AI190452, AA046621, AI816144,
				AA069829, H54017, AA223575, AA593953,
				AW134905, W48701, AA533599, AA815362,
				AI355030, AI272101, AI346194, AW183008,
				AA587783, AA703690, AA134981, AI589847,
1				AW103418, AA401916, AI807069,
				AA652228, T70319, AA054221, AW195167,
				AI676031, AA001439, R67338, W51922,
ŀ		İ		W51921, R67057, AA577283, T57926,
				AI434272, R83286, AI688408, AA205942,
				AA557254, AI189237, R80210, and U39400.
5	HDPRH52	15	906430	AW297778, AA704347, AI693619, and
				AL133353.
5	HDPRH52	41	905416	AA316209, N35618, AA121285, AI394711,
				R19007, R44077, AI687282, and AL133353.
6	HDTEK44	16	1025421	AW263031, AI825947, AI674408, AI949058,
				AI686114, AW236450, AI131456, AI921750,
				AI499386, AI744116, H17702, AA968971,
				AI202380, AI612728, AW151821, AA612626,
				AI568798, AI678940, AI868979, and
-				AW084407.
6	HDTEK44	42	890972	AW392275, H20592, AA658220, AI583172,
		'-		AA888002, H20504, AW392670, AL119457,
				AL119497, AW363220, AW384394, U46351,
				AL119443, U46347, U46346, Z99396,
			1	AW372827, AL119319, U46349, AL119444,
				U46350, AL119324, AL119484, AL119363,
				AL119391, AL119335, AL042965, AL119355,
				U46341, AL119483, AL119341, AL119439,
				AL119396, AL119511, AL119522, AL119418,
				AL119464, AB026436, AR054110, A81671,
				AR069079, AR060234, and AR066494.
6	HDTEK44	43	904770	AW263031, AI825947, AI949058, AI686114,
"	IIDI EK44	43	304//0	AW263031, Al823947, Al949038, Al680114, Al674408, AW236450, Al131456, Al921750,
				A1499386, A1744116, H17702, AW392275,
				AA968971, AI202380, H20592, AI612728,
				AW151821, AA612626, AA658220,
				AI583172, AA888002, AI568798, AI678940, AI868979, H20504, and AW084407.
				TATOUGY / Y. FIZUSUA. AND A WUNAAU /.

	TIDTER 44	14	002424	AMIGC2021 A1025047 A1040050 A1606111
6	HDTEK44	44	902431	AW263031, AI825947, AI949058, AI686114, AI674408, AW236450, AI131456, AI499386, AI921750, AI744116, H17702, AA968971, AI202380, AI612728, AW151821, AA612626, AI568798, AI678940, AI868979, and AW084407.
7	НОНВР82	17	906794	AI739417, N44813, and A91748.
7	НОНВР82	45	906796	A91748.
7	НОНВР82	46	906795	A1269759, W44508, M79074, AI218914, AA969620, W44507, AA905017, and A91748.
7	HOHBP82	47	902318	AA150056, W44507, AA152178, AA037745, AA039255, AA247807, AA247955, AI218914, AI269759, W44508, AA969620, and A91748.
8	HWBAD01	49	610491	R17760, AC004231, Z77249, AC005632, AC004000, AC005189, AC005755, AL022067, AC005041, AC007298, AC004832, Z93241, U95742, AC007216, AC002306, AC006057, AC007371, AC005752, Z95152, and AL031295.
9	HWABE12	19	815536	AA524063, AI751102, AA978352, AI800962, AI125904, AI148136, AW021017, AI817327, AI090472, AA864640, AA910568, AA129538, AI347257, AA994194, AA055492, AA055493, AI186179, T59947, AI127212, AW367523, T71365, AW276864, W78183, W58529, AI183851, T50338, AW367579, H17402, AA171811, T51546, AA194069, AA352426, AW376869, AW377057, AW377030, AW117263, AW377059, AA399164, AI541412, AW339825, AA411205, AA194185, AA452074, AA311049, T71528, AI420299, AW367570, AI770095, AI126814, and AI751103.
9	HWABE12	50	815537	AI420299, AI126814, AI185173, AI125904, AI800962, AI148136, W58417, AA994194, AA978352, T50338, AA055493, T51546, AI817327, AI090472, AA910568, AI186179, AI127212, T71365, W58529, AI347257, AI183851, AA524063, AA194069, AA864640, AI751102, AA352426, H17402, T59947, AA830076, AA451878, W72641, AA744611, AA855081, AW117263, AI081422, AA399164, AA224273, AW339825, AA411205, AA171696, AI123489, AW021017, AA744609, AA279075, AI160983, AA744606, W78183, AA677361, AA055492, AW276864, AA136501, AA745601, AI142596, AW193618, AI055938, AW367523, AA129538, W77930, AW367579, AW241440, AW241497, AA452074, AI699697, AI698785, AA860754, F04664, F03954, AA487085, AA364006, AA009855, AA364988, AA296614, T39853, AA366269, T39843, AC002040, AC002468, AC005873, Z93241, AC005828, AC000120, Z98884,

		•		AC004106, AC005350, and AC005479.
9	HWABE12	51	694670	W72641, AI126814, AI185173, W58417,
´	111111111111111111111111111111111111111	"	051070	AI420299, AA744611, AI081422, AA830076,
				AA855081, AA171696, AA451878, W77930,
				AA224273, AI123489, AA744609, AA677361,
				AI160983, AA744606, AA279075, AA136501,
				AA745601, AI142596, AI055938, AW193618,
				AW241440, AW241497, AI698785,
				AI699697, AA860754, N95156, AI653333,
				AI933953, AI201780, D19771, W70320,
				AA887563, AI368873, AA127570, AI982547,
				AA364006, AA856842, AC002352,
				AC002040, AC020663, AC005350,
}				AF053356, AC004678, AC005231,
				AC005412, AC011311, U47924, AC004686,
}				AC004893, AF030453, AC000120, AL096701,
				AC005088, AC004966, AC005399,
				AC005512, AC002468, AL031729,
				AL117344, AL008726, AP000313, Z98884,
				AL022336, AC007731, D87022, AC005500,
				AP000553, AP000226, AC005873, AP000087,
				AP000050, AF001550, AP000117, AC005057,
				AC002385, AC004106, AC004851,
				AC005952, AF196971, AP000194, AC005944,
				AP000555, AL035465, AP000691, and
				AC003684.
10	HHEPJ23	20	1043435	T50625, R09009, R20490, R45313, R45313,
				H18236, H20422, H41102, H46766, R87981,
				R88024, R88944, H50900, N30260, N41983,
				N74323, N91758, W05230, W05562, W23596,
				W24176, W31111, W67681, W67680,
				AA034395, AA034396, AA044434,
				AA044605, AA161369, AA593612,
				AA595237, AA602781, AA632450,
				AA576151, AA566019, AA744132,
				AA808389, AA864841, AA877754,
				AA948357, AA706278, AA844058, AA844324, AA994658, AI027455, AI051083,
				AI041576, AI083966, AI268158, AI345057,
				AI347726, AI363264, AI199583, AI199634,
				AI564878, AI419579, AI571744, AI424352,
				AI126459, AI191262, AI199798, AI208380,
				AI312683, AI332581, AI760697, AI798543,
				AI817558, AI830412, AI871292, AI970628,
				AW003596, AW006710, AW083202,
				AW191061, and AW470476.
10	ННЕРЈ23	52	879858	AI126459, AI815708, R47401, AW392670,
				AI138849, AL119443, AA463298,
				AW384394, AW363220, U46349, AL119341,
				AW372827, U46351, AL119497, AL119319,
				AL119457, AL119324, U46341, Z99396,
				AL119444, AL119396, AL119355, AL119484,
				AL119363, AL119391, AL119483, U46350,
				U46347, U46346, AL134902, AL119418,
				AL119335, AL119439, AL119522, AL134525,
				AL119496, AL119401, AL134518, AL119399,
t	i l	l :		AL037205, U46345, AL134538, AL134536,

				AL042450, AL042614, AL042970, AL042965,
,				AL042975, AL042544, AL043019, AL042984,
				AL042542, AL042995, AL043029, AL042551,
				AL043003, AL119464, AL119488, AB026436,
				AR054110, A81671, AR066494, AR060234,
				and AR069079.
11	HWBAR14	53	845408	AF109303 and AI911903.
11	HWBAR14	54	873239	AA364356.
11	HWBAR14	55	762339	AA631143, AI703348, AA579486, AI969820,
				AA640153, AA225106, AI587483, AA631024,
				AI468280, AI911903, AI696721, N95796,
				AA492342, AI472447, W24907, AA652651,
				AA552457, AA579735, AA570251,
				AA652452, AA579320, AI984307, AA579319,
				AI432644, AI623302, AI431307, AI431316,
		[AI431238, AI432666, AI431328, AI432657,
				AI431318, AI431347, AI432661, AI432653,
				AI431231, AI431230, AI431257, AI432654,
				AI432655, AI431310, AI431312, AW081103,
				AI432650, AI432677, AI431350, AI431323, AI431354, AI791349, AL045494, AI431353,
				AI431334, AI791349, AL043494, AI431333, AI431235, AI431247, AI431321, AI431315,
				AI431233, AI431247, AI431321, AI431313, AI431246, AI492519, AI432643, AI432675,
				A1431240, A1432519, A1432043, A1432073, A1431337, A1432651, A1432647, AW129223,
				AI431337, AI432031, AI432047, AW 129223, AI432674, AI431330, AI431308, AI431243,
				AL042729, AI431248, AI431314, AL042931,
				AI492510, AI432649, AI432672, AI432665,
				AI432659, Y17793, and AF019249.
12	HDPPN86	22	1037893	AI821271, AI313180, W22478, AI002815,
				AA680243, AL037632, AI076616,
				AW406162, AI732120, AA484962, AI110760,
				AI313166, AA381195, AI364780, AA722372,
				AL044000, AL041706, AL040921, AI817516,
				AI565581, AI284640, AI963600, AI608771,
				AL048626, AW440545, AI204304,
				AW317075, AA836811, AW088224,
				AA634072, AI350211, AW193265, AI133164,
				AL046409, AA491814, N94311, AI431303,
				AI963720, AW276817, AI613280, AA601355,
				AW080939, AA599480, AI924251,
				AA469451, F36273, AI289067, AL119691,
				AI061334, AL045053, AI471481, AI305766,
		}		AL138265, AI679294, AA205915, AI754955,
				AW265385, AW419262, AL046205,
				AW276827, AI345654, AW327868,
				AI334443, AW269488, AW276435, AI270117, AI085719, AI890348, AI281881,
				AW193432, AL138455, AI341664, AI110688,
				AW 193432, AL 138433, Al 341604, Al 110088, Al 1149478, AW 245747, Al 754658, Al 375710,
				A1149476, AW243747, A1734036, A1373710, AA587604, A1688846, AW406755,
				AW438643, AA581903, AI619997,
				AW407578, AA682912, AW029038,
}				A1053623, A1801600, A1610159, AW023672,
				AI307608, AA610491, AA491284,
				AW303196, AW274349, AI679871,
	1			AA613345, AW021583, AW103758,
				AI792287, AA652764, AI537506, AW301350,
	L			

247

AI053672, AA526787, AL041690, AL037683, AI355206, AI281697, AI358571, AW407632, AW088202, AL042853, AW004911, AI110770, AW265170, AI379719, AA502104, AW102811, AI192631, AI761471, AW088846, AI799642, AI679782, AA743907, AI754253, AA649642, AW073470, AI805363, AI696962, AL118991, AI469172, AA713815, AW339568, AI344844, AI887483, AL044940, AI064864, AW162049, AA284179, AI590958, AI929531, AI469968, AA714453, AI262909, AI298710, AI801482, AI754336, AL048925, AA490183, AI339850, AI434695, AI471543, AI921476, AI254316, AA720702, AI962050, AI340453, AI017024, AA806796, AW148792, AW265009, AA938105, AW338086, AA631507, AW265393, C75026, AI590689, AA513141, AI635818, AI358229, AI357551, AI434706, AA394271, W79504, AI246796, AI951863, AW022379, AW410400, AI049634, AW408717, AA654771, AI457397, AI918421, AI567674, AI561060, AI561255, AI919265, AI866856, AI053790, AI888752, AI669453, AA669840, AI499938, AL137737, AC005280, AC004263, AC005484, AF088219, AC004134, AC005288, AC005911, U47924, AC004859, AL035587, AL022724, AP000359, AC005324, AC005257, AC003009, AC005011, AL049759, AE000658, AC005670, AC007204, AC006251, AL139054, AC004821, AC003006, AC004678, AL117351, AC000118, U85195, Z93023, AC006211, AF196779, AL049776, AL133448, AC004675, AC005771, AC005234, AC000075, AC005488, AC004997, AC004876, AC005844, AL023575, AP000553, AC004596, AL031597, AB023049, AL121658, AC006064, AC005664, AF001549, AL121603, AC007052, AC007011, U95742, AL035422, AC004686, AF196971, AL132642, AC004638, AC007227, AC005585, AC003007, AC002314, AC005632, AP000302, AL078477, AL022328, AC003070, AC007298, AC003085, AC005696, AC005839, AD000092, AC005682, AP000513, Z98200, AC005668, AL096791, AC002470, AC005755, Z99129, AL035683, AC006128, AC008039, AC004019, AC008079, AC005330, AL031255, U78027, AC003111, AC004975, AC005377, AC005520, AC005081, AP000474, AL034420, AC006487, AP000555, AC007666, AC006468, AC006480, AC005399, AC006132, AC006312, AL035450, AC006130, AL133500, U91326, AL021939, AL035458, AL109985, Z82901, AC002549, Z85986,

				AC004841, AC005231, AC005900,
				AC008101, AL020995, AP000114, AP000046,
				AF010238, AP000351, AL132992, AC005200,
				AC007207, AP000512, AC005071,
-				AC005608, AP000298, Z95114, AL031073,
				AC005821, AL035659, AC006449,
				AC005778, D87009, AC006137, AC003957,
				AL136295, AJ003147, AC005562, AC007308,
				AL132987, AC004894, AL078593,
				AC006277, AR036572, U91328, AC002402,
				AL121653, AJ010598, AL024507, AJ010770,
				AC004257, AC009516, AC005971,
				AL035400, AC005808, AF095725, AC009247,
				AC007216, AF123462, AF039907, AC005701,
				AC007216, AF123402, AF039907, AC003701, AC005846, AL034582, AF002223, AC005695,
				AL023284, AL117344, Z99716, AC005747,
				AC000026, AL022400, AL031295,
				AC004858, U63721, AC002316, AC006285,
				AC005242, AP000049, AL121591, AL049643,
				AC005785, AC005261, AC000066,
	1			AC003982, AC007842, AL023879,
				AC004253, AC002477, AL133238, Z83820,
				AC006014, AC002542, AL035425, AP000090,
				AP000044, AC005412, AC005177, AL049829,
				AL049779, AC007919, AC002059,
				AC005740, AC002350, AP000311, AL022721,
				Z83826, AF111169, AL021578, AC006511,
				AC007536, AP000556, AC006538, AP000558,
	1			Z98051, AC004887, AC005041, AC004752,
				AC004797, AC007043, AC004690,
	İ			AL033392, AC002395, AC005089,
				AC007785, AC007151, AC005531,
				AL009181, AC005913, AC004862,
				AC005996, AL021878, AC005304,
				AL008726, AC005754, AC007688,
				AL050332, L48038, AC004682, AL117352,
				AC006530, AC002468, AC005005,
				AC005250, AC005666, and AC004985.
12	HDPPN86	56	895711	AI313180, W22478, AI002815, AA484962,
12	IIDFFNoo] 30	093/11	AA381195, AA634072, AA350454,
			}	AA332295, AA360806, AI033197, AI821271,
12	IID DIIIIO C		1010053	AA663922, AA769467, and AL137737.
13	HDPIW06	23	1018873	T71144, T81645, AA812058, AA604645,
				AA302937, N38979, AI915081, AL043351,
				AA610588, AI524453, AI280535, AA557945,
				AI984168, AA309156, AW272815,
				AA579276, AA703818, AA761606,
				AA761714, AW020150, AI453155,
				AA659324, R93341, AL044489, AA479751,
				AA368616, AI097051, AA347232, AA904275,
		ļ		AI797998, AI754064, AI521525, AI697239,
				H94269, AW272606, AI697242, AA877992,
				AI926102, AA847504, AA608729, AA664163,
				AA523293, T05604, AA367672, AI267320,
				N54538, AI573009, AF134726, AL034417,
				AP000503, AC007386, AF129756, AJ133269,
				AF196779, AB029025, Z95116, AL022316,
			·	

AL023807, Z83820, AP000152, AC002990, AP000555, AL049749, AC005224, Z95114, AP000356, AC004903, AC005506, AC004903, AC005066, AC00666, AC006106, AC004903, AC00566, AC006666, AC006664, AC004383, AC004079, AC004983, AL008729, AC002544, M63796, AC016830, AC004961, AC007066, AC007151, AL023656, AC008018, AL02721, AC005088, AC008018, AL02721, AC005088, AC008018, AL02721, AC005088, AC008018, AL02721, AC005088, AC008464, AP000049, AC004816, AC00723, AC004684, AP000311, AC004682, AC004584, AP000311, AC006482, AC004584, AP000311, AC007685, AC1031577, AC007685, AC016027, AC003108, AC002558, AC003682, AL023755, AL008718, AL021393, AL035667, AC00408 AF109907, AC005014, AB023048, AL04977 AC002301, AC007666, AC0022549, AC002300, AF111168, AC004585, AL034429, AF053356, AP000045, AL035412, AC004501, AL03566, AL0334429, AC005230, AF11168, AC004585, AL034429, AC005230, AF11168, AC004585, AL034429, AC005230, AC007684, AL031666, AL133163, AP000696, AC00306, AC00737 AC00052, AC006711, AC007216, AC005562, AC007784, Z95326, AL049745, AC004678, AC004678, AC004671, AC007216, AC005562, AC007784, Z95326, AL049745, AC004678, AC004678, AC004678, AC004678, AC003503, AC004678, AC003504, AC003504, AC003504, AC003504, AC003504, AC003504, AC003504, AC003504, AC003504, AC003504, AC003504, AC005243, AL031613, AC004678, AC004678, AC004678, AC004678, AC004678, AC004678, AC004678, AC004678, AC004678, AC004678, AC004678, AC005509, AC0035091, AC004686, AC005519, AC00327, AL033091, Z93017, AC004686, AC005519, AC003332, AL031846, AC00242, AL033504, U91322, AP000013, AC004586, AC005519, AC003332, AL031846, AC00242, AC007687, AL033097, AC003524, AL030927, AL033091, Z93017, AC003482, AP000017, AC00366, AL133064, AC003332, AL031846, AC003332, AL031846, AC003332, AL031846, AC003332, AL031846, AC003434, AL030931, AC003434, AL117694, AF16592, AL033306, AL122023, AC00997, AC003151, AL133246, AP00099, AC004311, AL133246, AP047825, AC003535, AC003529, AL034371, US2112, AP000511, AL008723, Z33826, AL022396, AC007919, AC003111, AL008723, Z33826, AL022396, AC007919,		
AP000555, AL049749, AC005224, Z95114, AP000356, AC002106, AC004963, AC005049, AP000353, AC005015, AC005096, AC006064, AC004383, AC006409, AC004079, AC004979, AC004983, AL008729, AC002544, M63796, AC016830, AC004491, AC007066, AC007151, AL023656, AC008018, AL022721, AC005088, AC006449, AJ003147, AF030453, AC004962 U91318, AC004593, 299716, AL050318, AP000049, AC004816, AC007263, AC004584, AP000311, AC006482, AC004584, AP000311, AC006482, AC004584, AP000311, AC006482, AC004584, AP000311, AC006482, AC002558, AC003658, AC016027, AC003108, AC002558, AC003658, AC036582, AL023375, AL008718, AL021393, AL033667, AC00408 AF109907, AC005014, AB023048, AL04977 AC002301, AC007666, AC002549, AC002300, AF11168, AC004685, AL094979, AC002301, AC007666, AC002549, AC002301, AC004581, AL03453, AL033663, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC007373 AC000528, AC006784, AL031666, AL133163, AP000696, AC003006, AC007374, AC0005562, AC006784, AC035476, AC004678, AC004678, AC006977, AC008111, AF111169, AL049835, AC004677, AC008111, AF111169, AL049835, AC004677, AC008111, AF111169, AL049835, AC004677, AC008111, AF111169, AL049835, AC004677, AC008111, AF111169, AL049835, AC004677, AC008111, AF111169, AL049835, AC004677, AC008111, AC007684, AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004677, AC009154, AP000657, AC00412, AL039627, AL039627, AL039672, AL0396		AL022098, AC005369, AP000010, AC005081,
AP000356, AC002106, AC004963, AC005015, AC005049, AP000353, AC005015, AC005696, AC006064, AC004383, AC004079, AC004983, AL008729, AC002544, M63796, AC016830, AC004491, AC007066, AC007151, AL023656, AC008018, AL022721, AC005088, AC006449, AC006449, AC006449, AC006469, AC007151, AL023656, AC008018, AL022721, AC005088, AC004646, AC007263, AC004664, AC007263, AC004682, AC004584, AP000031, AC006482, AC004216, AC007226, AL031577, AC007685, AC016027, AC003108, AC002558, AC016027, AC003108, AC002558, AC006362, AL023575, AL008718, AL023193, AL035667, AC00408, AF109907, AC005014, AB023048, AL04977 AC002301, AC007666, AC002549, AC002300, AF111168, AC004685, AL00918 AL022320, AF005230, Z84480, AL121658, AL034429, AF053356, AP000045, AL03561, AC005821, AL049553, AL035683, AC004510, AC007684, AL031666, AL133163, AP000696, AC00306, AC00737 AC000052, AC006071, AC007216, AC00566, AC002560, AC00306, AC00737 AC000652, AC006671, AC007216, AC00566, AC003576, AC003576, AC003576, AC003577, AC00386, AC003577, AC00386, AC00336, AC00337, AC00386, AL139054, AC00337, AC00336, AC00337, AC003486, AC00333, AC00346, AC00334, AL117694, AF16592 AL133396, AL12023, AC005976, AC00335, AC005529, AL033371, US2112, AP000511, AL008723, AC00346, AC00731, AC003523, AC003579, AC003579,		· · · · · · · · · · · · · · · · · · ·
AC005049, AP000353, AC005015, AC005696, AC006064, AC004383, AC004079, AC004983, AL008729, AC002544, M63796, AC016830, AC004491, AC007066, AC007151, AL023656, AC008018, AL022721, AC005088, AC006449, AJ003147, AF030453, AC004962 U91318, AC004593, 299716, AL050318, AP000049, AC004816, AC007263, AC004584, AP000311, AC006482, AC004584, AP000311, AC006482, AC004584, AP000311, AC006482, AC004585, AC016027, AC003108, AC002558, AC003682, AL031577, AC007685, AC016027, AC003108, AC002558, AC003682, AL033575, AL008718, AL021393, AL035667, AC00408 AF109907, AC005014, AB023048, AL04977 AC002301, AC007504, AC003148, AC002300, AF111168, AC004685, AL09178 AC002301, AC007504, AL031666, AL133163, AP000596, AC003006, AC00737 AC0005521, AL049553, AL033683, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC000522, AC006071, AC007216, AC005562, AC007784, Z95326, AL049745, AC004568, AC007701, Z93242, AP000269, U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC0030033, AC004582, AC006783, AC006714, AC007216, AC005562, AC007784, AP000085, AC00412 AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004758, AC004582, AC006741, AC00727, AL035091, Z93017, AC004821, AC005519, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005532, AL031846, AC0025519, AC006733, AC004278, AC004882, AP000067, AL030997, AC00255 U95742, AP00053, AC015833, Z95115, AC005882, AP000067, AL030997, AC00255 U95742, AP000553, AC015853, Z95115, AC00596, AC005534, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005519, AC007586, AL139054, AC007631, AL133246, AF047825, AC00535 AC005519, AL034371, U52112, AP000511, AL13396, AL122023, AC005702, AB001523, AC005514, AC004099, AC004311, AC005523, AL031846, AC005751, AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL0222396, AC007919,	,	· · · · · · · · · · · · · · · · · · ·
AC005696, AC006464, AC004383, AC004079, AC004979, AC004979, AC004983, AL008729, AC002544, M63796, AC016330, AC004491, AC007066, AC007151, AL023656, AC080818, AL022721, AC005088, AC006449, A1003147, AF630453, AC004967 U91318, AC004593, Z99716, AL050318, AP000049, AC004816, AC007263, AC004584, AP000311, AC006482, AC004584, AP000311, AC006482, AC004584, AP000311, AC006482, AC002558, AC03682, AL023575, AL088718, AL021393, AL033667, AC00408 AF109907, AC005144, AB023048, AL04977 AC002301, AC007666, AC002549, AC002300, AF111168, AC004685, AL0918 AL022320, AC005280, Z84480, AL121658, AL034429, AC003356, AC005281, AL049553, AL035683, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC000528, AC006784, AD03568, AC004586, AL0494745, AC004678, AC0070694, AC005269, U91321, AC004056, AP000697, AC008101, AF111169, AL049853, AC003233, AC004410, AC007564, AP000697, AC008101, AF111169, AL049853, AC003234, AC004586, AC003035, AC004408, AC003035, AC004408, AC003035, AC004408, AC003035, AC004408, AC003035, AC004408, AC003035, AC004408, AC003035, AC004408, AC003035, AC004421, AL035071, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC00479, AL035091, Z93017, AC004821, AC003511, AC004758, AC00479, AL035091, AC00351, AC004821, AC003511, AC003	,	
AC004079, AC004983, AL008729, AC002544, M63796, AC016830, AC004491, AC007066, AC007151, AL023656, AC008018, AL022721, AC005088, AC006449, AJ003147, AF030453, AC004966 U91318, AC004593, Z99716, AL050318, AP000049, AC004816, AC007263, AC004384, AP000311, AC006482, AC004216, AC007226, AL031577, AC007685, AC016027, AC003108, AC002558, AC003682, AL023575, AL008718, AL021393, AL035667, AC00408 AF109907, AC005014, AB023048, AL04977 AC002301, AC007666, AC002549, AC002300, AF111168, AC004685, AL04977 AC002301, AC007666, AC002549, AC002300, AF111168, AC004685, AL031666, AL133163, AP000696, AC003006, AL03168, AL003429, AF053356, AP000045, AL03541; AC005821, AL049553, AL035683, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC000052, AC006071, AC007216, AC005562, AC007784, Z95326, AL049745, AC004678, AC007021, Z93242, AP000269, U91321, AC004056, AC0003005, AC00671, AF111169, AL049835, AC002476, Z83732, AC004678, AC007021, Z93242, AP000269, U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC00476, AP000885, AC00412, AL033504, U91322, AP000085, AC00412, AL033504, U91322, AP000085, AC00412, AL033504, U91322, AP000085, AC00412, AL033504, U91322, AP0000721, AC03171, AC004821, AC007546, AP000897, AC008101, AF11169, AL049835, AC006471, AC003101, AC004821, AC007546, AP000985, AC00412, AL033504, U91322, AP0000071, AC004886, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035072, Z82184, AL080243, AL109827, AL035081, Z93017, AC004821, AC005610, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP0000505, AC015853, Z95115, AC005479, AL021154, AC003101, AL035071, AC005606, AC004975, AC005482, AP000067, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122033, AC005702, AB001523, AC005914, AC004099, AC004131, Z970544, AC007686, AL139054, AC007051, AL133246, AF047825, AC005511, AL008723, Z83826, AL1022396, AC007919,	,	
AC002544, M63796, AC016830, AC004491, AC007066, AC007151, AL023656, AC008018, AL022721, AC005088, AC006449, AJ003147, AF030453, AC004962, U91318, AC004593, Z99716, AL050318, AP000049, AC004816, AC007263, AC004584, AP000311, AC006482, AC004216, AC007226, AL031577, AC007685, AC016027, AC003108, AC002558, AC003682, AL023575, AL008718, AL021393, AL035667, AC00408 AF109907, AC005014, AB023048, AL04977 AC002301, AC007666, AC002549, AC002300, AF111168, AC004685, AL00918 AL022320, AC005280, Z84480, AL121658, AL034429, AF053356, AP000045, AL035412 AC005821, AL049653, AL035663, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC000520, AC006711, AC007216, AC005562, AC006784, Z95326, AL049745, AC004678, AC007212, Z93224, AP00269, U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003355, AC006285, AC006450, AC005243, AL031504, U91322, AP000103, AC004228, AL0313120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL03120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL03120, Y14768, AC0004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL0304243, AL109827, AL035072, Z82184, AL03120, Y14768, AC0004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL038243, AL109827, AL0335071, AC004826, AC005360, AC004975, AC006482, AP000067, AL033097, AC00228, AL031311, AC006479, AL021154, AC03111, AC064679, AC005479, AC005482, AP000013, AC006428, AC005363, AC006482, AP000113, AC005469, AC005497, AC002428, AL033396, AL122023, AC005702, AB001523, AC005914, AC006499, AC006511, AL133246, AF047825, AC005514, AC005512, AL033386, AL122023, AC006702, AB001523, AC005529, AL034371, U52112, AP000511, AL005723, AC005828, AC007514, AL133286, AL1022359, AC000511, AL005723, AC005825, AC005529, AL034371, U52112, AP000511, AL005723, AC005828, AC007519, AC000511, AL005723, AC005826, AC00751919, AC005828, AC0077919, AC004528, AC0077919, AC006523, AC0077919, AC006523, AC0077919, AC006523, AC0077919, AC006523, AC0077919, AC006523, AC0077919, AC0065	,	AC005696, AC006064, AC004383,
AC007066, AC007151, AL023656, AC008018, AL002721, AC005088, AC006449, AJ003147, AF030453, AC004961 L91318, AC004593, Z99716, AL050318, AP000499, AC004816, AC007263, AC004584, AP000311, AC006482, AC004216, AC007226, AL031577, AC007685, AC016027, AC003108, AC002558, AC003682, AL023575, AL008718, AL021393, AL035667, AC00408 AF109907, AC005014, AB023048, AL04977 AC002301, AC007666, AC002549, AC002300, AF111168, AC004685, AL00918 AL022302, AC005280, Z84480, AL121658, AL034429, AF033356, AP000045, AL03541: AC005821, AL049553, AL035683, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC000052, AC006071, AC007216, AC005626, AC007384, Z95326, AL049745, AC004678, AC004678, AC004676, AC005676, AS3732, AC004303, AC0044319, AC007466, AP000697, AC008101, AF111169, AL049835, AC004476, Z83732, AC007308, AC004408, AC003035, AC006285, AC006786, AC005476, AC005483, AL031120, Y14768, AC004671, AC004228, AL031120, Y14768, AC004671, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC00727, AL035091, Z93017, AC004821, AC005479, AL031111, AC006479, AL021134, AC003101, AL035071, AC005060, AC004975, AC006479, AL021134, AC003101, AL035071, AC005060, AC004975, AC005474, AL035091, AC007544, AC005479, AL031111, AC006479, AL021134, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL033997, AC00252 U9732, AC005763, U9732, AC005702, AB001523, AC005332, AL031846, AC00424, AC005637, AC002394, AL117694, AF16592 AL133396, AL122023, AC00699, AC00499, AC004131, Z97054, AC007606, AC000591, AC0005425, AC005529, AL0313140, AC005646, AC005519, AC007520, AR001523, AC005499, AC004131, Z97054, AC000699, AC0004131, Z97054, AC000699, AC0004131, Z97054, AC000699, AC000511, AL005823, AC005529, AL034371, U52112, AP000511, AL005823, AC005529, AL034371, U52112, AP000511, AL005823, AC005234, AC007051, AL133246, AF047825, AC005529, AL034371, U52112, AP000511, AL005823, AC005529, AL034371, U52112, AP000511, AL005823, AC005238, AC005529, AL034371, U52112, AP000511, AL005823, AC005238, AC005529, AL034371, U52112, A		AC004079, AC004983, AL008729,
AC008018, AL022721, AC005088, AC006449, AJ003147, AF030453, AC004962 U91318, AC004593, Z99716, AL050318, AP000049, AC004816, AC007263, AC004216, AC007226, AL031577, AC004216, AC007226, AL031577, AC007685, AC016027, AC003108, AC002558, AC016027, AC003108, AC002558, AC003682, AL023575, AL008718, AL021393, AL035667, AC00408 AF109907, AC005014, AB023048, AL04977 AC002301, AC007666, AC002549, AC002300, AF111168, AC004685, AL09918 AL022320, AC005280, Z84480, AL121658, AL034429, AF053356, AP000045, AL035412 AC005821, AL049553, AL035683, AC0044510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC00052, AC006071, AC007216, AC005526, AC007784, AP000269, U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003035, AC006285, AC006480, AC005243, AL0303504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004228, AL031120, Y14768, AC004671, AC004228, AL0313304, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC003101, AL035071, AC005606, AC003111, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U5742, AP000505, AC01853, Z95115, AC006996, AC006536, U80017, AL07863, AP000113, AC005323, AC005702, AB001523, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005324, AC00586, AL139054, AC007537, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005529, AL034371, U52112, AP000511, AC006431, AP000413, AC005529, AC006536, AC005529, AC005529, AC005323, AC005529, AC005529, AC005529, AC005310, AC005511, AC005529, AC006536, AC005529, AC006536, AC005529, AC006536, AC005529, AC006536, AC005529, AC006536, AC0055096, AC006536, AC0055096, AC006536, AC0055096, AC006536, AC0055096, AC006536, AC0055096, AC006536, AC0055096, AC006536, AC0055096, AC006536, AC0055096, AC006536, AC0055096, AC006536, AC0055096, AC006536, AC0055096, AC006536, AC0055096, AC006536, AC0055096, AC006536, AC0055096, AC006511, AC0055096, AC006511, AC0056096, AC006511, AC0056096, AC006511, AC0056096, AC006511, AC00		AC002544, M63796, AC016830, AC004491,
AC006449, AJ003147, AF030453, AC004966 U91318, AC004593, Z99716, AL050318, AP000049, AC004816, AC007263, AC004584, AP000311, AC006482, AC004216, AC007226, AL031577, AC007685, AC016027, AC003108, AC002558, AC016027, AC003108, AC002558, AC003682, AL023575, AL008718, AL021393, AL035667, AC00408 AF109907, AC005014, AB023048, AL04977 AC002301, AC007666, AC002549, AC002300, AF111168, AC004685, AL00918, AL023220, AC005280, Z84480, AL121658, AL034429, AF053356, AP000045, AL035413 AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC000052, AC006071, AC007216, AC005562, AC007784, Z95326, AL049745, AC004518, AC007484, AL031666, AL133163, AP000696, AC003006, AC00737 AC000052, AC006071, AC007216, AC005562, AC007784, Z95326, AL049745, AC004678, AC007414, Z95326, AL049745, AC004678, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC006458, AC004408, AC003035, AC006285, AC004408, AC003035, AC006285, AC006450, AC005243, AL033104, Y14768, AC004671, AC004686, AC005519, AC007227, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005606, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015833, Z95115, AC005482, AP0000067, AL031846, AC00242 AL033504, U91322, AP000167, AL078463, AP000113, AC005329, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC0047825, AC005514, AC007527, AL033966, AC006478, AC005519, AC007527, AL033966, AC006516, AC005511, AC005629, AL034371, U52112, AP000511, AL008723, Z83826, AL02396, AC007511, AL008723, Z83826, AL02396, AC007511, AL008723, Z83826, AL02396, AC007511, AL008723, Z83826, AL02396, AC007919,		AC007066, AC007151, AL023656,
U91318, AC004593, 299716, AL050318, AP0000049, AC004816, AC007263, AC004584, AP000311, AC006482, AC004584, AP000311, AC006482, AC004585, AC016027, AC003108, AC0072558, AC016027, AC003108, AC0072558, AC016027, AC003108, AC002558, AC016027, AC003108, AC002558, AC016027, AC003104, AL04977, AC002301, AC007666, AC002549, AC002301, AC007666, AC002549, AC002300, AF111168, AC004685, AL0918, AL02320, AC005280, Z8480, AL121658, AL034429, AP053356, AP000045, AL035415, AC005821, AL049553, AL035683, AC0044510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737, AC000052, AC006071, AC007216, AC007684, AC007684, AC004678, AC007684, AC007687, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003055, AC006285, AC006285, AC006450, AC003243, AL030931, AC007546, AP000065, AC00412, AL033504, U91322, AP000103, AC00428, AL031120, Y14768, AC004671, AC004686, AC005243, AL080243, AL109827, AL035072, Z82184, AL03120, Y14768, AC004671, AC004686, AC0052519, AC007227, AL035072, Z82184, AL03204, AL109827, AL035071, C904286, AC005482, AP000067, AL033111, AC006479, AL021154, AC003101, AL035071, AC005406, AC004975, AC008821, AC006332, AL0331311, AC006479, AL021154, AC003101, AL035071, AC005682, AP000067, AL033111, AC006479, AL031013, AC005332, AL031846, AC00255 U95742, AP000505, AC015853, Z95115, AC005882, AP000013, AC007534, AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC00570		AC008018, AL022721, AC005088,
AP00049, AC004816, AC007263, AC004216, AC007226, AL031577, AC004216, AC007226, AL031577, AC007685, AC016027, AC003108, AC002558, AC016027, AC003108, AC002558, AC016027, AC003108, AF109907, AC005014, AB023048, AL04977 AC002300, AF111168, AC0004685, AL00918 AL022320, AC005280, Z84480, AL121658, AL034429, AF053356, AP000045, AL035412 AC0083821, AL049553, AL035663, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC000052, AC006071, AC007216, AC005562, AC007784, Z95326, AL049745, AC004678, AC007021, Z93242, AP00069, UJ321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003035, AC006285, AC006450, AC003243, AL009031, AC007546, AP000697, AC008101, AF11120, Y14768, AC004671, AC004286, AL031120, Y14768, AC004671, AC004286, AC005519, AC007227, AL035072, Z82184, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC006479, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC008482, AP000067, AL030997, AC00255 U95742, AP000503, AC015853, Z95115, AC005482, AP000067, AL031846, AC00254 AL033396, AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC0007511,		AC006449, AJ003147, AF030453, AC004962,
AC004584, AP000311, AC006482, AC004216, AC007226, AL031577, AC007685, AC016027, AC003108, AC002558, AC016027, AC003108, AC002558, AC003682, AL023575, AL008718, AL021393, AL035667, AC00408, AF109907, AC005014, AB023048, AL04977, AC002301, AC007666, AC002549, AC002300, AF111168, AC004685, AL09974, AC002300, AF111168, AC004685, AL035412, AC005280, Z84480, AL121658, AL034429, AF053356, AP000045, AL035412, AC005821, AL035453, AL035643, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737, AC00522, AC006071, AC007216, AC005562, AC007784, Z95326, AL049745, AC004678, AC004678, AC0030067, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003035, AC004278, AC006285, AC006450, AC005243, AL030931, AC004408, AC003035, AC006285, AC006450, AC005243, AL0313120, Y14768, AC004671, AC004686, AC03519, AC005412, AL035071, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005660, AC004975, AC005482, AP000067, AL039997, AC00255 U95742, AP000505, AC018833, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005322, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005768, AL139054, AC005412, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005686, AL139054, AC007511, AL133246, AF047825, AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC000511, AC004512, AL000511, AL008723, Z83826, AL022396, AC000511, AC004512, AL000511, AL008723, Z83826, AL022396, AC000511, AL008723, Z83826, AL022396		U91318, AC004593, Z99716, AL050318,
AC004216, AC007226, AL031577, AC007685, AC016027, AC003108, AC002558, AC016027, AC003108, AC002558, AC003682, AL023575, AL008718, AL021393, AL035667, AC00408 AF109907, AC005014, AB023048, AL04977 AC002301, AC007666, AC002549, AC002300, AF111168, AC004685, AL00918 AL022320, AC005280, Z84480, AL121658, AL034429, AF053356, AP000045, AL035412 AC005821, AL049553, AL035683, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC000052, AC006071, AC007216, AC005562, AC007784, Z95326, AL049745, AC004678, AC007021, Z93242, AP000269, U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003035, AC006285, AC006450, AC005243, AL009031, AC007546, AP000085, AC00412 AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005606, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005329, AL0131846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC005559, AL003523, AC006586, AL139054, AC007051, AL133246, AF047825, AC005559, AL003532, AL022396, AC0005711, AL003511, AL008723, Z83826, AL022396, AC000511, AL008723, Z83826, AL022396, AC000511,		AP000049, AC004816, AC007263,
AC007685, AC016027, AC003108, AC002558, AC003682, AL023575, AL008718, AL021393, AL035667, AC00408 AF109907, AC005014, AB023048, AL04977 AC002301, AC007666, AC002549, AC0023200, AF111168, AC004685, AL0918 AL022320, AC005280, Z84480, AL121658, AL034429, AF053356, AP000045, AL035412 AC005821, AL049553, AL035683, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC000052, AC006071, AC007216, AC005562, AC007784, 295326, AL049745, AC004678, AC007784, 295326, AL049745, AC004678, AC007021, Z93242, AP000269, U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003243, AL009031, AC007546, AP000085, AC00412 AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005606, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005322, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC005559, AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC000511,		AC004584, AP000311, AC006482,
AC002558, AC003682, AL023575, AL008718, AL021393, AL035667, AC00408 AF109907, AC005014, AB023048, AL04977 AC002301, AC007666, AC002549, AC002300, AF111168, AC004685, AL00918 AL022320, AC005280, Z84480, AL121658, AL034429, AF053356, AP000045, AL03541: AC005821, AL049553, AL035683, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC000052, AC006071, AC007216, AC005562, AC007784, Z95326, AL049745, AC004678, AC00741, Z93242, AP000269, U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003035, AC006285, AC006746, AP000085, AC00412 AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC00532, AL031846, AC00242 AC007637, AC000532, AL031846, AC00242 AC007637, AC000532, AL031846, AC00242 AC007637, AC0003394, AL117694, AF16592 AL133396, AL122023, AC005970, AB001523, AC0005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC0075519, AL133246, AF047825, AC000511, AL008723, Z83826, AL022396, AC007919,		AC004216, AC007226, AL031577,
AL008718, AL021393, AL035667, AC00408 AF109907, AC005014, AB023048, AL04977 AC002301, AC007666, AC002549, AC002300, AF111168, AC004685, AL0918 AL022320, AC005280, Z84480, AL121658, AL034429, AF053336, AP000045, AL03541: AC005821, AL049553, AL035683, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC000052, AC00671, AC007216, AC005562, AC007784, Z95326, AL049745, AC004678, AC007021, Z93242, AP000269, U91321, AC004656, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003035, AC006285, AC006450, AC005243, AL009031, AC007546, AP000085, AC00412 AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005482, AP000067, AL030997, AC002428, AL0313396, AL1020234, AL117694, AF16592 AL133396, AL122023, AC006709, AC004131, Z97054, AC005706, AL139054, AC007051, AL133246, AF047825, AC005353, AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AC007685, AC016027, AC003108,
AL008718, AL021393, AL035667, AC00408 AF109907, AC005014, AB023048, AL04977 AC002301, AC007666, AC002549, AC002300, AF111168, AC004685, AL0918 AL022320, AC005280, Z84480, AL121658, AL034429, AF053336, AP000045, AL03541: AC005821, AL049553, AL035683, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC000052, AC00671, AC007216, AC005562, AC007784, Z95326, AL049745, AC004678, AC007021, Z93242, AP000269, U91321, AC004656, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003035, AC006285, AC006450, AC005243, AL009031, AC007546, AP000085, AC00412 AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005482, AP000067, AL030997, AC002428, AL0313396, AL1020234, AL117694, AF16592 AL133396, AL122023, AC006709, AC004131, Z97054, AC005706, AL139054, AC007051, AL133246, AF047825, AC005353, AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		
AF109907, AC005014, AB023048, AL04977 AC002301, AC007666, AC002549, AC002300, AF111168, AC004685, AL00918 AL022320, AC005280, Z84480, AL121658, AL034429, AF053356, AP000045, AL035413 AC005821, AL049553, AL035683, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC000052, AC006071, AC007216, AC005562, AC007784, Z95326, AL049745, AC004678, AC007021, Z93242, AP000269, U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC0030335, AC006285, AC006450, AC005243, AL009031, AC007546, AP000085, AC00412 AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC000499, AC004131, Z97054, AC007686, AL139054, AC007651, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AL008718, AL021393, AL035667, AC004084,
AC002301, AC007666, AC002549, AC002300, AF111168, AC004685, AL00918 AL022320, AC005280, Z84480, AL121658, AL034429, AF053356, AP000045, AL03541: AC005821, AL049553, AL035683, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC000052, AC006071, AC007216, AC005562, AC007784, Z95326, AL049745, AC004678, AC007021, Z93242, AP000269, U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003035, AC006285, AC006450, AC005243, AL009031, AC007546, AP000085, AC00412 AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF07825, AC00535 AC007529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AF109907, AC005014, AB023048, AL049776,
AC002300, AF111168, AC004685, AL00918 AL022320, AC005280, Z84480, AL121658, AL034429, AF053356, AP000045, AL03541. AC005821, AL049553, AL035683, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC000052, AC006071, AC007216, AC005562, AC0007784, Z95326, AL049745, AC004678, AC007021, Z93242, AP000269, U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003035, AC006285, AC006450, AC005243, AL003504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL0335091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC00596, AC006536, U80017, AL078463, AP000113, AC005482, AP00067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF07825, AC00555 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC0079119,		
AL022320, AC005280, Z84480, AL121658, AL034429, AF053356, AP000045, AL03541: AC005821, AL049553, AL035683, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC000052, AC006071, AC007216, AC005562, AC007784, Z95326, AL049745, AC004678, AC00721, Z93242, AP000269, U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003035, AC006285, AC006450, AC005243, AL009031, AC007546, AP000085, AC00412, AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005067, AL030997, AC00255 U95742, AP000067, AL030997, AC00255 U95742, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006336, U80017, AL078463, AP00113, AC005332, AL031846, AC00242 AC07637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC004099, AC004131, Z97054, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC0055529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AC002300, AF111168, AC004685, AL009181,
AL034429, AF053356, AP000045, AL035413 AC005821, AL049553, AL035683, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC000052, AC006071, AC007216, AC005562, AC007784, Z95326, AL049745, AC004678, AC007021, Z93242, AP000269, U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003035, AC006285, AC006450, AC005243, AL009031, AC007546, AP000085, AC004128, AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP00113, AC005394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC0055529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		
AC005821, AL049553, AL035683, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC00737 AC000052, AC006071, AC007216, AC005562, AC006714, Z95326, AL049745, AC004678, AC007021, Z93242, AP000269, U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003035, AC006285, AC006450, AC005243, AL009031, AC007546, AP000085, AC00412 AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005482, AP00013, AC0075332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC0075051, AL133246, AF047825, AC005355 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AL034429, AF053356, AP000045, AL035413,
AL133163, AP000696, AC003006, AC00737 AC000052, AC006071, AC007216, AC005562, AC0007784, Z95326, AL049745, AC004678, AC007021, Z93242, AP000269, U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003035, AC006285, AC006450, AC005243, AL009031, AC007546, AP000085, AC00412 AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC005511, AL008723, Z83826, AL022396, AC007919,		
AC000052, AC006071, AC007216, AC005562, AC007784, Z95326, AL049745, AC004678, AC007021, Z93242, AP000269, U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003035, AC006285, AC006450, AC005243, AL009031, AC007546, AP000085, AC00412 AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005482, AP000673, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC0075529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AC004510, AC007684, AL031666,
AC005562, AC007784, Z95326, AL049745, AC004678, AC004678, AC007021, Z93242, AP000269, U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC006408, AC003035, AC006285, AC006450, AC005243, AL009031, AC007546, AP000085, AC00412 AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AL133163, AP000696, AC003006, AC007371,
AC004678, AC007021, Z93242, AP000269, U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003035, AC006285, AC006450, AC005243, AL009031, AC007546, AP000085, AC00412 AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005482, AP00013, AC005496, AC005497, AL031311, AC006379, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AC000052, AC006071, AC007216,
U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003035, AC006285, AC006450, AC005243, AL009031, AC007546, AP000085, AC00412 AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC005511, AL008723, Z83826, AL022396, AC007919,		AC005562, AC007784, Z95326, AL049745,
AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003035, AC006285, AC006450, AC005243, AL009031, AC007546, AP000085, AC00412 AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP00113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AC004678, AC007021, Z93242, AP000269,
AC007308, AC004408, AC003035, AC006285, AC006450, AC005243, AL009031, AC007546, AP000085, AC00412 AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		U91321, AC004056, AP000697, AC008101,
AC006285, AC006450, AC005243, AL009031, AC007546, AP000085, AC00412 AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AF111169, AL049835, AC002476, Z83732,
AL009031, AC007546, AP000085, AC00412 AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AC007308, AC004408, AC003035,
AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AC006285, AC006450, AC005243,
AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AL009031, AC007546, AP000085, AC004129,
AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AL033504, U91322, AP000103, AC004228,
AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC005355 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AL031120, Y14768, AC004671, AC004686,
AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AC005519, AC007227, AL035072, Z82184,
AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AL080243, AL109827, AL035091, Z93017,
AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AC004821, AC005412, AL031311,
AC005482, AP000067, AL030997, AC00255 U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AC006479, AL021154, AC003101,
U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AL035071, AC005060, AC004975,
AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AC005482, AP000067, AL030997, AC002553,
AP000113, AC005332, AL031846, AC00242 AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		
AC007637, AC002394, AL117694, AF16592 AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		
AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		
AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AC007637, AC002394, AL117694, AF165926,
AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		AL133396, AL122023, AC005702,
AC007051, AL133246, AF047825, AC00535 AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		
AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919,		
AL008723, Z83826, AL022396, AC007919,		AC007051, AL133246, AF047825, AC005358,
		AC004019, AL022238, AC005722,
AC004217, AC004832, AC000026,		AC004217, AC004832, AC000026,
AL031230, AC004882, AC003684,		
AC005899, AC012384, AL049843, Z97876,		· · · · · · · · · · · · · · · · · · ·
AC004858, AC007436, AL133382,		AC004858, AC007436, AL133382,

ĺ				AC007917, AF196969, AC007172, D88268,
				AC006537, AC007707, AC002326,
1				AC005102, AC002039, Z99943, AL049697,
				Z98036, AC005288, Z98941, AC007324,
				AC004854, AC006961, AP000068, U80460,
				AL109865, AC003982, AL050348,
				AC003071, AC002492, AC006211,
				AL008582, AF088219, AP000300, AL031602,
				AL031393, AC009263, AC008055, and
1				AL008710.
13	HDPIW06	58	902388	AB029025.
13	HDPIW06	60	531470	T71144, AW182499, AA678404, AC005081,
13	HDP1W00	60	331470	, and the second
[AL078638, AF030453, AC005088, AL022721,
				AC005488, AC005486, AC005482,
				AC005015, AC005339, AF053356, AL096791,
•				Z98036, AC002120, AC006101, AC003078,
				AC007663, AC006549, AC007488,
				AC004985, U73634, AL035413, AC002132,
1				AC002288, L78833, AL034429, AC003065,
				AF134726, AL031577, AC006312, AL122023,
ţ				AC005033, AF121781, AL022320, AC002996,
1				AL135745, AC006208, AC005183,
				AC004228, AC004130, AC004253,
				AL022336, AC000025, AF001548, AC005822,
				AC005527, AL031677, AC007993,
1				AL009181, AC002477, AL021391,
		:		AC006544, AC008119, AL034554, AF129756,
1				AC005531, AC005899, AC004453,
1				AC004841, AC005529, AC004983,
1				AC000026, AC002551, AC004129,
1				AC002452, AC005011, AC003109,
				AB004907, AC007386, AL049776,
				AC003969, AL009183, and AC006487.
	THUD CITES	- 62	015535	
14	HWBCH13	63	815535	AI056866, W90205, W90079, Z80900,
l i				AC003964, AC006197, AL121877,
				AC003009, and AC007312.
15	НОНСЈ90	25	890046	AW372170, AA604346, AW068358,
				AA738473, AA913567, AA665740, AI799350,
1				AI382075, AI142471, AW071731, AI818200,
1				N92765, AW054966, AI869237, AI690475,
				AW135129, AA846091, AA678907,
				AA233833, AA934769, AA233799, T18597,
				Z33559, AI557262, Z32887, D59751,
				AI535660, AI557864, AI525316, AI541205,
				AI525500, AI525556, AI541356, C14210,
				D59436, AI540903, AI526078, AI541365,
				AI535639, AI536138, AI557084, D50992,
				R29657, AI557533, AI557809, AI541034,
				AI557852, AI557731, AI557317, AI541075,
				A1557602, D59458, AA585325, A1557264,
				A1557155, D57491, A1525302, A1525856,
				AI541346, AI557082, AI557808, AI546829,
				R45895, AI541321, AI540974, C15406,
				AA585098, AI525852, C15069, AA585101,
				C14228, Z32822, AI536150, D53161,
				AI526169, AI557810, AI547196, D61185,
. '				AI557238, AI546971, R28892, AI526112,

D51433, D54850, AI541517, Z28355, AI525168, AI526016, AI526118, AI541353, AI557718, R28967, AA585430, AA385439, AI536070, D60765, D60844, AI557740, D54897, AI557041, AI546831, AI541013, R28735, R29445, AI557094, AI525656, AI526140, AA585155, AI541450, AI54162, AI526140, AA585155, AI541450, AI54162, AI526147, AI541364, AI557039, AI547250, AI239433, AI525568, AA585378, AI541535, R28965, AI526002, AI541422, AA585329, C16294, C16315, AI526024, AI547189, AI526146, AI541383, AI5577312, Z33585, AA170832, AI526191, Z36724, AI557758, AI557727, AI547137, AI546999, AI525114, H65400, AA585356, AI546875, AI557758, AI557727, AI547137, AI546999, AI525114, H65400, AA585339, AI547039, AI541027, AI557734, D30843, AI541307, AI541374, AI541515, AI557807, D61254, D53447, C16292, C15120, C15762, D52835, AI541510, R28895, AI547140, AA585389, AI525757, AI547140, AA585389, AI525575, AI547140, AA585389, AI525757, AI547140, AA585389, AI525757, AI547140, AA585389, AI525757, AI547158, C16300, AI557787, AI525653, AI546945, AI525431, AI546891, AI525878, AI526117, AI541402, AI546996, AI541423, D7824, AI525320, AI547138, AI557841, AI557543, AI557785, AI541516, AI524890, AI526176, AI525661, AA585434, AI526626, AA585453, AI546855, AI293466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y099181, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82844, A62300, AF213384, X82786, U45328, AF135243, A85395, A708072, U49592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82846, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466.					
AIS25168, AIS26016, AIS26138, AIS41353, AIS57718, R28967, AA585430, AA585439, AIS36070, D60765, D60844, AI557740, D54897, AIS57041, AIS46831, AIS41013, R28735, R29445, AIS57048, AIS25066, AIS26140, AA585155, AIS41450, AI541692, AI526187, AIS41336, AIS57039, AI547250, AI239433, AI525568, AA585378, AI541535, R28965, AIS26205, AI541422, AA585329, C16294, C16315, AI526024, AI547189, AI526164, AI541383, AI557312, Z33585, AA170832, AI526191, Z36724, AI557758, AI557727, AIS47137, AI546999, AI525114, H65400, AA585356, AI546875, AI557279, AI526109, AI540928, AI557763, AI557258, D55233, AI525339, AI547039, AI541027, AI557734, J030843, AI541307, AI541374, AI541515, AI557807, D61254, D53447, C16292, C15120, C15762, D52835, AI541510, R28895, AI547140, AA585389, AI525757, AI547202, AI525076, AI541362, D53472, AI547158, C16300, AI557787, AI525633, AI546945, AI525431, AI546891, AI525673, AI547158, C16300, AI557787, AI525673, AI557734, AI5577585, AI541516, AI526878, AI526177, AI541402, AI546996, AI541423, D78224, AI525320, AI547138, AI557241, AI557543, AI557785, AI541516, AI524890, AI526176, AI525661, AA585434, AI526026, AA58453, AI546855, AI239466, AI524891, AI540967, AI524904, U87306, Z30183, A6298, AR050070, A82595, A82593, AF060672, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A83395, A70672, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AJ760912, AI817827, AI144009, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AD985778, R38024,					D51433, D54850, AI541517, Z28355,
AIS57718, R28967, AAS85430, AAS85439, AIS67070, D60765, D60844, AI557740, D54897, AIS57041, AI546831, AI541013, R28735, R29445, AI557408, AI525656, AI526140, AA585155, AI541450, AI541492, AI526187, AI541336, AI557039, AI547250, AI239433, AI525568, AA585378, AI541123, AA585329, C16294, C16315, AI541824, AA585329, C16294, C16315, AI541824, AA585329, C16294, C16315, AI547024, AI557758, AI557024, AI557734, AI546999, AI525114, H65400, AA583536, AI546875, AI557727, AI547137, AI546999, AI525114, H65400, AA583536, AI546875, AI557279, AI526109, AI540209, AI54027, AI557734, D30843, AI541307, AI541374, AI541515, AI557887, D61254, D53447, C16292, C15120, C15762, D52835, AI5414104, AI541515, AI557887, D61254, D53447, C16292, C15120, C15762, D52835, AI5414104, AI541515, AI55734, AI547202, AI557787, AI547202, AI557787, AI547202, AI557787, AI547202, AI557578, AI547202, AI557587, AI557587, AI547202, AI557587,					
AI536070, D60765, D60844, AI557740, D54897, AI557041, AI546831, AI541013, R28735, R29445, AI557041, AI546831, AI541013, R28735, R29445, AI557048, AI525656, AI526140, AA585155, AI541490, AI526187, AI54136, AI557039, AI547250, AI526187, AI54136, AI557039, AI547250, AI239433, AI525568, AA585378, AI541535, R28965, AI526025, AI541422, AA585329, C16294, C16315, AI526024, AI547189, AI526146, AI541383, AI557312, Z33585, AA170832, AI526191, Z36724, AI557758, AI557727, AI547137, AI546999, AI557758, AI557727, AI547137, AI546999, AI557758, AI557727, AI526109, AI549028, AI557763, AI557258, D55233, AI526339, AI547039, AI541027, AI547154, AI547513, AI54739, AI547039, AI547027, AI547134, AI541515, AI557807, D61254, D53447, C16292, C15120, C15762, D52835, AI541510, R28895, AI547140, AA585389, AI525757, AI547202, AI525076, AI541362, D53472, AI547158, C16300, AI557787, AI525653, AI546945, AI525431, AI546891, AI525878, AI5471402, AI547158, C16300, AI557787, AI525653, AI546945, AI525320, AI547138, AI557241, AI557543, AI557543, AI557543, AI557685, AI546896, AI524891, AI54067, AI522661, AA585434, AI526026, AA585453, AI546855, AI239466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X28284, A62300, AF213384, X82786, U45328, AF1352431, AS34433, AI65641, AI318050, AI471973, Z44946, AR295252, F07655, AI370426, R724466, N57522, AA897641, AJ985778, R38024, AA2955252, F07655, AI370426, R724466, N57522, AA897641, AJ985778, R38024, AA2955252, F07655, AI370426, R724466, N57522, AA897641, AJ985778, R38024,					
D54897, AI557041, AI546831, AI541013, R28735, R29445, AI557408, AI5265656, AI526140, AA585155, AI541450, AI541492, AI526187, AI541336, AI557039, AI547250, AI239433, AI525568, AA585378, AI541535, R28965, AI526020, AI54122, AA585329, C16294, C16315, AI526024, AI547189, AI526146, AI541383, AI557312, Z33385, AA170832, AI526191, Z36724, AI557758, AI557727, AI547137, AI546999, AI525114, H65400, AA585356, AI546875, AI557279, AI526109, AI540928, AI557763, AI557279, AI526109, AI540928, AI557763, AI557279, AI557734, D30843, AI541307, AI541374, AI541515, AI557807, D61254, D53447, C16292, C15120, C15762, D52835, AI541510, R28895, AI55776, AI547140, AA585389, AI525757, AI547202, AI525076, AI541362, D53472, AI547158, C16300, AI557787, AI525653, AI546945, AI525320, AI541402, AI54696, AI541423, D78224, AI525320, AI541402, AI54696, AI541423, D78224, AI525320, AI547138, AI557241, AI557543, AI557785, AI541516, AI524890, AI526176, AI525661, AA58544, AI526026, AA585453, AI546967, AI524904, U87306, Z30183, A62098, AR030870, A82593, AR5006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF155243, AB5395, A70872, A70869, A85476, AB005666, AR037157, L36917, AI54400967, AI157828, AF153243, A85395, A70872, A70869, A85476, AB005666, AR037157, L369133, AI156641, AI318050, AI471973, Z44946, AA295525, F07655, AI370426, R72446, N57522, AA897641, AJ985778, R38024, AA2390578, AI34046, RA295525, F07655, AI370426, R72446, N57522, AA897641, AJ985778, R38024, AA2905525, P07655, AI370426, R72446, N57522, AA897641, AJ985778, R38024,					1
R28735, R29445, AI557408, AI525656, AI526140, AA585155, AI541450, AI541492, AI526187, AI541336, AI557039, AI547250, AI239433, AI525568, AA585378, AI541535, R28965, AI526205, AI541422, AA585329, CI6294, CI6315, AI526205, AI541422, AA585329, CI6294, CI6315, AI526205, AI547189, AI526146, AI541383, AI557312, Z33585, AA170832, AI526191, Z36724, AI557758, AI557727, AI547137, AI546999, AI557758, AI557727, AI547137, AI546999, AI557259, AI526109, AI540928, AI557763, AI557229, AI526109, AI540928, AI557763, AI557229, AI526109, AI540928, AI557763, AI541027, AI557734, D30843, AI541307, AI541027, AI557734, D30843, AI541307, AI541374, AI541515, AI557807, D61254, D53447, CI6292, C15120, C15762, D52835, AI541510, R28895, AI547140, AA585389, AI6257577, AI547202, AI525076, AI541362, D53472, AI547158, C16300, AI557787, AI525653, AI546945, AI5225431, AI546891, AI525878, AI526117, AI541402, AI546996, AI541423, D78224, AI525320, AI547138, AI557241, AI557543, AI557788, AI541516, AI524890, AI526176, AI525661, AA585434, AI526026, AA585453, AI546855, AI239466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, Al144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, Al3344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AJ988778, R38024,					
AI526140, AA585155, AI541450, AI541492, AI526187, AI54136, AI57039, AI547250, AI239433, AI525568, AA585378, AI541535, R28965, AI5526024, AI547189, AI526146, AI5414383, AI55732, Z35885, AA170832, AI526191, Z36724, AI557758, AI557727, AI547137, AI546999, AI525114, H65400, AA583536, AI54687, AI557727, AI547137, AI546999, AI525114, H65400, AA583536, AI54687, AI557729, AI526109, AI540928, AI557763, AI557258, D55233, AI525339, AI547039, AI541027, AI557734, D30843, AI541307, AI541374, AI541515, AI557807, D61254, D53447, C16292, C15120, C15762, D52835, AI641510, R28895, AI547140, AA585389, AI541510, R28895, AI547140, AA585389, AI541510, R28895, AI547140, AA585389, AI545631, AI546996, AI547140, AI547202, AI525076, AI547138, AI557541, AI5575543, AI557785, AI547138, AI557541, AI5575543, AI5578543, AI546996, AI5471423, D78224, AI525320, AI547138, AI557241, AI557543, AI557641, AI54706, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466.					
AI526187, AI541336, AI557039, AI547250, AI239433, AI525568, AA585378, AI541535, R28965, AI526020, AI541422, AA585329, C16294, C16315, AI526024, AI547189, AI526146, AI541383, AI557312, Z33585, AA170832, AI526191, Z36724, AI557758, AI557727, AI547137, AI546999, AI525114, H65400, AA585336, AI546875, AI557279, AI526109, AI540928, AI557763, AI557258, D55233, AI525339, AI547039, AI541027, AI557734, D30843, AI541307, AI541374, AI541515, AI557807, D61254, D52347, C16292, C15120, C15762, D52835, AI541510, R28895, AI547140, AA585389, AI525757, AI547202, AI522076, AI541362, D53472, AI547158, C16300, AI557787, AI525653, AI546945, AI525431, AI546891, AI525878, AI526117, AI541402, AI546996, AI541423, D78224, AI525320, AI547138, AI557241, AI557543, AI557785, AI541516, AI524890, AI526176, AI525661, AA585434, AI526026, AA585453, AI546855, AI239466, AI524891, AI540967, AI524904, U87306, Z30183, A6298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, N57522, AA897641, AIJ985778, R38024,					
AJ239433, AJ525568, AAS85378, AI541535, R28965, AI526205, AI541422, AA585329, C16294, C16315, AJ526024, AI547189, AJ526146, AJ547137, AJ54909, AJ525114, H65400, AA585356, AI546875, AI557727, AJ547137, AJ54909, AJ525114, H65400, AA585356, AI546875, AJ557279, AJ526109, AJ540928, AJ557763, AJ557258, D55233, AJ525339, AJ547039, AJ541027, AJ557734, D30843, AJ541307, AJ541027, AJ557734, D30843, AJ541307, AJ541374, AJ541515, AJ557807, D61254, D53447, C16292, C15120, C15762, D52835, AJ541510, R28895, AJ547140, AA585389, AJ525757, AJ547202, AJ525076, AJ541362, D53472, AJ547158, C16300, AJ557787, AJ525653, AJ547158, C16300, AJ557787, AJ547202, AJ525076, AJ541362, D53472, AJ547158, C16300, AJ557787, AJ525653, AJ547543, AJ525673, AJ547583, AJ546891, AJ525878, AJ526117, AJ541402, AJ5575743, AJ557434, AJ557434, AJ557434, AJ557434, AJ557434, AJ557434, AJ557434, AJ557434, AJ557434, AJ557434, AJ557434, AJ557434, AJ557434, AJ54708, AJ54708, AJ54708, AJ54708, AJ526176, AJ524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR052871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AJ760912, AJ817827, AJ144009, AA127855, AJ819433, AJ815208, AJ683865, AA127885, AW197055, AW300678, AJ344433, AJ765641, AJ318050, AJ471973, Z44946, A2952522, F07655, AJ370426, R72446, N57522, AA897641, AJ3985778, R38024,					
R28965, AI526205, AI541422, AA585329, C16294, C16315, AI526024, AI547189, AI526146, AI541383, AI557312, Z33585, AA170832, AI526191, Z36724, AI557758, AI557727, AI547137, AI546999, AI525114, H65400, AA585356, AI546875, AI557279, AI526109, AI540928, AI55763, AI557279, AI526109, AI540928, AI557763, AI557258, D55233, AI525339, AI547039, AI541027, AI557734, D30843, AI541307, AI541374, AI541515, AI557807, D61254, D53447, C16292, C15120, C15762, D52835, AI541510, R28895, AI547140, AA585389, AI525757, AI547202, AI525076, AI541362, D534472, AI547108, C16300, AI557787, AI525653, AI546945, AI525431, AI546891, AI525878, AI546945, AI525320, AI547138, AI557241, AI557543, AI55738, AI546896, AI541423, D78224, AI525320, AI547138, AI557241, AI557543, AI557785, AI541516, AI524890, AI526176, AI5255661, AA585434, AI526026, AA585453, AI546855, AJ239466, AI524891, AI540967, AI524904, UR7306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A83395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI765641, AI318050, AI471973, Z44946, AA295525, F07655, AJ370426, R72446, N57522, AA897641, AJ985778, R38024,					
C16294, C16315, AI526024, AI547189, AI526146, AI541383, AI557312, Z35885, AA170832, AI526191, Z36724, AI557758, AI557727, AI547137, AI546999, AI525114, H65400, AA585356, AI546875, AI557279, AI526109, AI540928, AI557763, AI557258, D55233, AI525339, AI547039, AI541027, AI557734, D30843, AI541307, AI541027, AI557734, D30843, AI541307, AI541374, AI541515, AI557807, D61254, D52835, AI541510, R28895, AI547140, AA585389, AI525757, AI547202, AI525076, AI541362, D53472, AI547158, C16300, AI557787, AI525653, AI546945, AI525431, AI546891, AI525878, AI526117, AI541402, AI546996, AI541423, D78224, AI525320, AI547138, AI557241, AI557543, AI557785, AI541516, AI524890, AI526176, AI525661, AA585434, AI526026, AA585453, AI546855, AI239466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI4711973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AJ985778, R38024,					
AI526146, AI541383, AI557312, Z33585,					1 ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
AA170832, AI526191, Z36724, AI557758, AI557727, AI547137, AI546999, AI525114, H65400, AA585356, AI546875, AI557279, AI526109, AI540928, AI557763, AI557258, D55233, AI525339, AI547039, AI541027, AI557734, D30843, AI541307, AI541374, AI541515, AI557807, D61254, D53447, C16292, C15120, C15762, D52835, AI541510, R28895, AI547140, AA585389, AI525757, AI547202, AI525076, AI541362, D53472, AI547158, C16300, AI557787, AI525653, AI546945, AI525431, AI546891, AI525878, AI526117, AI541402, AI546996, AI541423, D78224, AI525320, AI547138, AI557241, AI557543, AI5575785, AI541516, AI524890, AI526176, AI525661, AA585434, AI526026, AA585453, AI546855, AI239466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
AI557727, AI547137, AI546999, AI525114, H65400, AA585356, AI546875, AI557279, AI526109, AI540928, AI557763, AI557258, D55233, AI525339, AI547039, AI541027, AI557734, D30843, AI541307, AI541374, AI541515, AI557807, D61254, D53447, C16292, C15120, C15762, D52835, AI541510, R28895, AI547140, AA585389, AI525757, AI547202, AI525076, AI541362, D53472, AI547202, AI525076, AI541362, D53472, AI547158, C16300, AI557787, AI525653, AI546945, AI525431, AI546891, AI525878, AI526117, AI541402, AI546996, AI541423, D78224, AI525320, AI547138, AI557241, AI557543, AI557785, AI541516, AI524890, AI526176, AI525361, AA585434, AI526026, AA585453, AI546855, AI239466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR62871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
H65400, AA585356, AI546875, AI557279, AI526109, AI540928, AI557763, AI557258, D55233, AI526339, AI547039, AI541027, AI557734, D30843, AI541307, AI541374, AI541515, AI557807, D61254, D53447, C16292, C15120, C15762, D52835, AI541510, R28895, AI547140, AA585389, AI525757, AI547202, AI525076, AI541362, D53472, AI547158, C16300, AI557787, AI525653, AI546945, AI525431, AI546891, AI525878, AI526117, AI541402, AI546996, AI54123, D78224, AI525320, AI547138, AI557241, AI557543, AI557785, AI541516, AI524890, AI526176, AI525661, AA585434, AI526026, AA585453, AI546855, AJ239466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
AI526109, AI540928, AI557763, AI557258, D55233, AI525339, AI547039, AI541027, AI557734, D30843, AI541307, AI541374, AI541515, AI557807, D61254, D53447, C16292, C15120, C15762, D52835, AI541510, R28895, AI547140, AA585389, AI525757, AI547202, AI525076, AI541362, D53472, AI547158, C16300, AI557787, AI525673, AI546945, AI525431, AI546891, AI525878, AI526117, AI541402, AI546996, AI541423, D78224, AI525320, AI547138, AI557241, AI557543, AI557643, AI557643, AI557643, AI557643, AI557643, AI557643, AI557643, AI526176, AI525616, AA585434, AI526026, AA585453, AI546855, AJ239466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, A295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
D55233, AI525339, AI547039, AI541027, AI557734, D30843, AI541307, AI541374, AI541515, AI557807, D61254, D53447, C16292, C15120, C15762, D52835, AI541510, R28895, AI547140, AA585389, AI525757, AI547202, AI525076, AI541362, D53472, AI547158, C16300, AI557787, AI525653, AI546945, AI525431, AI546891, AI525878, AI526117, AI541402, AI546996, AI541423, D78224, AI525320, AI547138, AI557241, AI557543, AI557785, AI541516, AI524890, AI526176, AI525661, AA585434, AI526026, AA585453, AI546855, AI239466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
AI557734, D30843, AI541307, AI541374, AI541515, AI557807, D61254, D53447, C16292, C15120, C15762, D52835, AI541510, R28895, AI547140, AA585389, AI525757, AI547202, AI525076, AI541362, D53472, AI547158, C16300, AI557787, AI525653, AI546945, AI525431, AI546891, AI525878, AI526117, AI541402, AI546996, AI541423, D78224, AI525320, AI547138, AI557241, AI557543, AI557785, AI541516, AI524890, AI526176, AI525661, AA585434, AI526026, AA585453, AI546855, AJ239466, AI524891, AI540967, AI524904, U87306, Z30183, A60298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
AI541515, AI557807, D61254, D53447, C16292, C15120, C15762, D52835, AI541510, R28895, AI547140, AA585389, AI525757, AI547202, AI525076, AI541362, D53472, AI547158, C16300, AI557787, AI525653, AI546945, AI525431, AI546891, AI525878, AI526117, AI541402, AI546996, AI541423, D78224, AI525320, AI547138, AI557241, AI557543, AI557785, AI541516, AI524890, AI526176, AI52561, AA585434, AI526026, AA585453, AI546855, AJ239466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, P70655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
C16292, C15120, C15762, D52835, A1541510, R28895, A1547140, AA585389, A1525757, A1547202, A1525076, A1541362, D53472, A1547158, C16300, A1557787, A1525653, A1546945, A1525431, A1546891, A1525878, A1526117, A1541402, A1546996, A1541423, D78224, A1525320, A1547138, A1557241, A1557543, A1557785, A1541516, A1524890, A1526176, A1523661, AA585434, A1526026, AA585453, A1546855, AJ239466, A1524891, A1540967, A1524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 A1760912, A1817827, A1144009, AA127855, AI819433, AI815208, A1683865, AA127885, AW197055, AW300678, A1344433, A1765641, A1318050, A1471973, Z44946, AA295252, P707655, Al370426, R72446, N57522, AA897641, A1985778, R38024,]				
R28895, AI547140, AA585389, AI525757, AI547202, AI525076, AI541362, D53472, AI547158, C16300, AI557787, AI525653, AI546945, AI525431, AI546891, AI525878, AI526117, AI541402, AI546996, AI541423, D78224, AI525320, AI547138, AI557241, AI557543, AI557785, AI541516, AI524890, AI526176, AI525661, AA585434, AI526026, AA585453, AI546855, AJ239466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
AI547202, AI525076, AI541362, D53472, AI547158, C16300, AI557787, AI525653, AI546945, AI525431, AI546891, AI525878, AI526117, AI541402, AI546996, AI541423, D78224, AI525320, AI547138, AI557241, AI557543, AI557785, AI541516, AI524890, AI526176, AI525661, AA585434, AI526026, AA585453, AI546855, AJ239466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI69912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
AI547158, C16300, AI557787, AI525653, AI546945, AI525431, AI546891, AI525878, AI526117, AI541402, AI546996, AI541423, D78224, AI525320, AI547138, AI557241, AI557543, AI557785, AI541516, AI524890, AI526176, AI525661, AA585434, AI526026, AA585453, AI546855, AJ239466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,	1				· · · · · · · · · · · · · · · · · · ·
AI546945, AI525431, AI546891, AI525878, AI526117, AI541402, AI546996, AI541423, D78224, AI525320, AI547138, AI557241, AI557543, AI557785, AI541516, AI524890, AI526176, AI525661, AA585434, AI526026, AA585453, AI546855, AJ239466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,	1				
AI526117, AI541402, AI546996, AI541423, D78224, AI525320, AI547138, AI557241, AI557543, AI557785, AI541516, AI524890, AI526176, AI525661, AA585434, AI526026, AA585453, AI546855, AJ239466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
D78224, AI525320, AI547138, AI557241, AI557543, AI557785, AI541516, AI524890, AI526176, AI525661, AA585434, AI526026, AA585453, AI546855, AJ239466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
A1557543, A1557785, AI541516, AI524890, A1526176, AI525661, AA585434, AI526026, AA585453, AI546855, AJ239466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
AI526176, AI525661, AA585434, AI526026, AA585453, AI546855, AJ239466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
AA585453, AI546855, AJ239466, AI524891, AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,			1		
AI540967, AI524904, U87306, Z30183, A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
A62298, AR050070, A82595, A82593, AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,	1		1		
AF006072, U94592, Y09813, AR031358, AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
AR017826, AR031365, AR062871, A25909, AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
AR038855, X82834, A62300, AF213384, X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
X82786, U45328, AF135243, A85395, A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
A70872, A70869, A85476, AB005666, AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
AR037157, L36913, AJ131952, U87250, and AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
AR025466. 15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
15 HOHCJ90 64 862934 AI760912, AI817827, AI144009, AA127855, AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,			[
AI819433, AI815208, AI683865, AA127885, AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
AW197055, AW300678, AI344433, AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,	15	НОНСЈ90	64	862934	
AI765641, AI318050, AI471973, Z44946, AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
AA295252, F07655, AI370426, R72446, N57522, AA897641, AI985778, R38024,					
N57522, AA897641, AI985778, R38024,					
					1
I I I AA873508 AA426097. AA852480. H61346.					1
					AA873508, AA426097, AA852480, H61346,
AA953288, C02345, Z40698, F05244, T78309,					
D60961, AI250054, H62373, AA330282,			[
AA911800, AI249948, AI674798, AI141688,]		
AI962233, AI222384, N55399, F01499,					
F03905, N47672, AW050435, and AL049370.					
16 HWBCM79 26 839427 AL042756, AL133668, AW303196,	16	HWBCM79	26	839427	
AW301350, AI345550, AL046746, AL045709,					
AI445914, AW271904, AW274349,					
AI364180, AI590458, AA457249, AL079734,					
AI590499, AI272052, AA714690, F23327,	1				
AA176917, AA664521, AW019964, F17700,					
AL134330, AI061313, AA837715, AI521049,					AA176917, AA664521, AW019964, F17700,

		AL042853, AA608520, AI635819, AA115725,
		AA665330, AI973173, AI285615, AI783911,
		AI084012, F26719, F31654, AI872227,
		AL120976, AA191418, AI753365, AA535937,
		AL048616, F29541, AW074060, AW075132,
		AL119838, AA077776, AL119405,
		AA744001, AA630517, AA879053,
		AW419389, AW193493, AA516207,
	<u> </u>	AI561116, AI049986, AW090028, N85991,
		N83375, AA834821, AA745356, AW271917,
		AL050318, AF029308, U66061, U89335,
		AC009516, AC000353, AC007242,
		AC005696, AC002430, AC007993,
		AC007384, AC002070, AL022312,
		AC007358, AL034429, AC004032,
		AC003025, AC007011, AC008372,
		AC005231, AC005972, AC005358,
		AC007707, Z99716, AF139813, AL034420,
		AL109613, U91318, AC005105, AL031733,
		AC007486, AL031737, Z98949, AC007385,
		AL022721, AL049829, AC005678, AF061032,
		AC005920, AC003104, AC005081,
		AC004966, AC006449, AC002492,
		AL035398, AP000557, AC002425, AL020995,
		AC010202, AC006530, Z86090, AL050309,
		AC005015, AC004383, AC002115,
		AL031985, AL031228, AL035703, AC007225,
	1 1	AF196779, AF117829, AL049709, AC004984,
		AL031662, AC004828, AL034424,
		AC004687, AL109984, Z82194, AL031685,
		AC004913, AL023803, AL021154,
		AC002394, AC004003, AC004477,
		AC003957, AC007880, AC006111,
	[]	
		AC005356, AC004552, AC006063,
		AC006013, AC004812, AC000111,
		AC005412, Z92545, AC004228, AC019014,
	,	AC002544, AL122020, AC002477, Z98941,
		U78027, AC005261, AC004230, AC006017,
		AC011625, AC002554, M89651, U91321,
		AC005355, AL021977, AF134726, AL022316,
		AC006112, AC005552, AC007686,
		AL133485, AC005781, AL122023,
		AC003663, AL035422, AL031782,
		AC007363, AL035072, AP000014, AL031729,
		AL096763, AL035251, AL049569, AC007151,
		AC006285, AC005829, AC005189,
		AL136295, AC007161, AC007263, Z83844,
		AC006241, AL080317, AC005224,
		AL132857, AL031734, AF111168, AC005146,
		AF001549, AC003015, AL022400, AL132712,
		AC006071, AF095901, AP000558, AP000345,
		Z99755, AC007298, AC002352, AC005703,
		AC002302, AC006509, AC004859,
		AF129756, AL049759, Z97876, AF111169,
1		AL035458, AP000128, AP000206, AC006948,
		AC005191, AL035455, U91326, AC002553,
		AP000043, AP000518, AC005722, AF107885,
L		

				AC006120, AL121825, AC002476, U95743,
				AF001550, AL031279, AC005753, AF047825,
				AC003982, AC004887, Z83840, AC005242,
				AC004955, U95739, AL109623, Z99916,
				AC003992, AC003692, AC002316,
1				AC005014, AC006965, AC006116,
				AF181897, AC004526, AP000247, AC000039,
				AL033530, AL035681, AC004883, AL050312,
				AP000248, AL008635, AC007193, Z70289,
				AL031054, AC004814, AC006571, Z93020,
				AL034548, AL022327, AC016025, AP000208,
				AP000130, AC007649, AC002303, AL035683,
				AP000130, AC007049, AC002303, AL033083, AP000245, AC007096, AL031674, AC018769,
				AC007688, AC006023, Z98750, AC016831,
				AC005069, AC002289, AC005284,
1				
				AC002558, AC005567, AL021328,
1				AC004865, AC003969, U91319, Y14768, AC006059, AF053356, AL035086, AC009946,
				1
1				AC005070, AL049692, AC007073,
				AC005670, AC005921, AC002331, and
17	IIIVDDMACC	27	006770	AC004821.
17	HWBDM62	27	906779	AI284640, AW303196, AW301350,
				AL046409, AA680243, AI963720, AL138265,
				AW274349, AI270117, AI281881, AW265385, AA587604, AW419262,
				AW 203383, AA387004, AW 419202, AI732120, AL044940, AI133164, AA526787,
	·			AI732120, AL044940, AI133104, AA320787, AI431303, AI754658, AI754955, AI761097,
			ļ	AW193265, AW276827, AL037683,
Ī	•			AI350211, AI679782, AL138455, AI341548,
1				AA490183, AI801591, AI298710, AW439558,
				AL042753, AI345654, AW088846, AL134972,
				AI110770, AL079645, AI473943, AI434695,
1				A1471481, A1610159, AW021583,
		į		AW072587, AA126051, AA126035,
				AL120687, AI919265, AA587256,
			İ	AW270270, AW162049, AI929531,
				AI564185, AW438643, AL119391, AI733755,
				AA977743, F36273, AI619997, AA584195,
				AL040921, AI567674, AA470969, R17793,
				AW304584, AW088202, AW073470,
				AI289067, AI368745, AL040130, AI345681,
				AI345675, AA713815, AL038785, AI718446,
				AA621858, AW338086, AL119691,
				AI962050, AI061334, AI732764, AW406755,
				AI312309, AI471487, AI379719, AI110760,
				AA469451, AA488746, AI339850, AI688846,
				AI148277, AA682912, AW167372,
				AW088616, AI192631, AI457397, AI537955,
				AI814735, AW407578, AI559705, AL048925,
				AA649642, AL044858, AW193432,
		1		AW302013, AI653886, AA074130, AI623898,
				AW103758, AI798473, AW340844,
				AA491814, AI859742, AA719292, AI365988,
		1		AI375710, AI340453, AW162489, AA584581,
				AW166815, AI358229, AA719805,
	1			AW406447, AI281697, AA523843,
				AA502155, AW157005, AA482711,
	1			, , , , , , , , , , , , , , , , , , , ,

WO 01/34629

AW327868, AI358343, AI568678, AI745325, AI254615, AA584201, AL135405, AI871722, AW148792, AA581903, AI291268, AI267818, AI291124, AI144055, AW274346, AI286356, AA179944, AA446657, AA178953, AA192740, W79504, AI570261, AW410400, AI064864, AI368256, AI499938, AI303008, AA483771, AI674873, N29941, AI355224, AI951889, AA758934, AA652764, AI287485, AL041412, AI499503, AI110688, AA657835, AI143242, AI587583, AW023672, AA579063, AA177061, C06303, AI028510, AI635274, AW339568, AI587565, AA521323, F29989, AA629992, AP000330, AP000125, AP000057, AP000172, Z98742, AC007043, AC009069, AC003692, AP000365, AP000501, U66059, AF001550, Z98749, AC005839, AL022163, AC007226, AC005632, AC004263, AF015156, AC005815, U18398, AL050341, AC005019, AL132992, U18399, U18391, AC006057, AC006292, AC002477. AC016025, AC016830, U18395, AL022721, L44140, AF015149, AL050320, X55926, AC005755, U18394, AC005245, X54181, 151997, AL031280, AL121603, AL049757, AL049869, AF029308, AL049829, AC002492, AC005393, X54180, AC007541, AC005694, AF196969, U63630, AF015151, AC002045, AC005018, AL031650, AC006128, U95742, AC004992, AC004987, AC005562, D83989, Z73965, AC004593, AD000092, AC009516, AC006285, AF077058, AC007382, AC005250, S43650, AC004982, Z49816, AC005939, AC002377, AP000244, AC007227, AL008710, AP000204, AP000126, AB003151, AC004033, AC004948, AC004765, AL031003, AC004797, AC007319, Z98046, Z81314, AL080242, AP000156, AC006960, AL031311, AC008372, AL078644, AC006501, AL049544, X54176, AC005387, AC002430, AC006251, AC006130, AC004993, AL031767, Z84487, AC006208, AC007384, AL034351, AC004650, AC006205, AC004814, AC005360, AL021808, AC004024, AF015147, AC004019, AL133355, U18387, AC003957, AL008735, AC005529, AL008718, AC008064, AP000014, AL049748, AC005324, AL096712, AC006277, AP000431, Y18000, AC003048, X60459, AC002565, AC007666, AC006045, AL023575, AP000044, AP000112, AL034384, AC004963, AC005251, AC005777, AC005912, Z97200, AC006017, AC008079, AC005666, U12584, AC004381, AC002310, Z86061, AC000052, Z75744, AL031283, AL022328, AC006050, AC005331, AC006048, AC000353, Z93930,

PCT/US00/30654

				AC005190, AC010077, AL035455,
1				AL133485, AC004940, X54178, AL035451,
				AC005740, AC007216, AC007875,
				AL031319, D84394, AL132799, AL035681,
				AC003982, AC005154, U07563, AP000297,
				AL021453, AL133494, AL133399, AC004638,
				AF015148, AL035072, AL031709, AP000504,
				AC004890, AC008009, AL031281,
				AC005209, AC008101, AC005284,
				AL096776, AC004825, AL034343, X55927,
				X55925, AC003003, AC000114, X55923,
				AL035683, Y10196, AL031848, AL024498,
				AL008728, AF129756, AL031257, AC007676,
				U91323, AL022322, AP000338, AC005998,
				AC002984, AC007228, AC008173,
				AP000495, AL022400, X88791, AL031053,
				U67231, AC005156, AC006153, AC004686,
1				AL034417, AL031054, D87675, X55924,
				AC006071, AC005914, AC006480,
				AL035422, AL133246, AC005859, AL033392,
1				AP000216, U57006, AL049760, AC005089,
				AC005091, Z93241, AC006511, U57009,
				AC006213, AC004887, and AC005808.
17	HWBDM62	65	902316	AP000330, AP000125, AP000057, and
17	I II W BBINIOZ	05	702310	AP000172.
17	HWBDM62	66	895690	AI761097, AP000172, AP000057, AP000125,
17	11 W BBINIO2		023020	and AP000330.
17	HWBDM62	67	734124	AI431347, AW081103, AW128900,
1 '	11 W DDW102	07	754124	AC002544, X99832, AC002425, and Y17793.
18	HWBCV72	28	882920	AC006518.
18	HWBCV72	68	905783	AW266498, AL037695, and AC006518.
18	HWBCV72	69	905767	Z33596, AI284640, AA610491, AI344844,
10	IIWBCV/2	09	903707	AI200051, AA720702, AI471481, AA630030,
				AA771811, T07451, AA525824, AA670468,
}				AA554319, AA494099, N62433, AA908422,
				AA813902, AI049940, N26685, AI801591,
				AA346454, AA348017, AW272925, H15679,
				R43331, AI669453, AC006518, D83989,
				X75335, AC005839, AF042090, AF077058,
				X55922, AC006539, AC003047, AC005887,
	}			AL031904, AL009181, AC006211, AF064863,
				AC006057, AC005531, AC007630,
				AC005736, AC006261, U67827, AP000567,
	1			AC005750, AC000201, G07627, AI 000307, AC005519, AC007227, AC004463, U95742,
1	,			AC005516, AC005227, AC004403, 693742, AC005516, AC005520, AC002379,
				AC003316, AC003326, AC002379, AL023879, Z32774, AC007216, AC005785,
	1			AC005373, AC005082, AC006277,
	1			AC003375, AC003082, AC000277, AL049776, AF196779, AP000088, AC003962,
	1			AC005081, AC005037, AL021546,
	[AL133371, AC004966, AL031848,
				AC002091, AC006241, AC007043,
				AC002091, AC000241, AC007043, AC002059, AC004534, AL034371,
				AC002039, AC004334, AL034371, AL022326, M89651, AC004485, AC006312,
				AL109984, AC004019, AC012380,
				AC006600, AC006538, AP000114,
	1			AC008000, AC000338, AP000114, AC008033, AL132712, AC005180,
				AC008033, AL132712, AC003180, AC009330, AC002369, AL021939,
1	I	I		ACOUPED, ACOUPED , ALUETYES,

	. <u>.</u>	· · · · · · · · · · · · · · · · · · ·		
				AC004812, AP000303, AC005523, Z98304, AL031281, AL049869, AF165926, AC004990,
				U07000, AC002509, AP001137, AC005411,
				AC004884, AF045555, AC000052,
				AC006051, AC008079, AC005011,
				AC004184, AC004858, AL135744, AP000046,
			0.604.55	and AC003104.
18	HWBCV72	70	869177	AA206019, AA650210, AI018503, AI380539,
				AI223829, AI934781, AA311371, AA430231,
				AI978828, AI916761, AA654703, AW139620,
				W55873, AA659588, AI752482, AI093053,
				AW207120, AA659723, AW204025, H92450,
	·			AA654949, R05745, AW075995, AA644273,
				AI418805, AA627128, H92449, D61582,
				AA375163, AA994023, AI201537,
				AW293550, AA077918, AA102222,
1				AA045668, AA010326, AA376452,
				AL135481, AA077049, AI739469, AI051657,
				AI870944, W56301, AI383697, AI383695,
				AA598926, AA317114, AA586345,
				AW058408, AA077082, AA102223,
1				AI091799, AA045669, T51787, AW361959,
				AA214166, W27535, AW370222, AA209520,
	<u> </u>	ļ		and D16938.
19	HMTAL77	29	855227	AW248271, AA351119, and AL137682.
19	HMTAL77	71	855226	AA351119, T75083, AA338164, AW248271,
				AA356283, AA829052, AA873659,
		<u> </u>	1001511	AF114124, and AL137682.
20	HHEPG23	30	1034541	AA732566, AI432371, AI394417, AI313180,
				AI367073, AI821271, W22478, AI521279,
				AI025957, AA612859, AW062389,
				AA485239, AI002815, AW183741,
				AW081769, AA769467, AI868573, AI076616,
				AL037632, AA680243, AA722372, AI732120,
				AW406162, AL040921, AA484962,
				AI110760, AI313166, AI364780, AL041706,
				AL044000, AI817516, AI924251, AI284640,
				A1963600, AW407632, AA634072, AI565581,
				A1608771, AL048626, AA836811,
				AW440545, AW088224, AW245747, AI204304, AW317075, AI350211, AI305766,
				AI133164, AW193265, AL138265, AL046409, N94311, AW276817, AA491814, AL045053,
				AI431303, AI963720, AI334443, AA601355,
				A1613280, A1679294, A1110688, AW080939,
				A1613280, A1679294, A1110088, AW080939, AA599480, AL042853, AL044940, F36273,
				AA359480, AL042833, AL044940, F30273, AA350454, AL119691, AA469451, AI289067,
				AA330434, AL119091, AA409431, A1289007, AA610491, AW303196, AA604333,
				AX010491, AW303196, AA004333, AI061334, AA205915, AI754955, AA353281,
				A1001334, AA203913, A1734933, AA333281, A1471481, AL042420, AW301350,
				AW265385, AW419262, AW276827,
				A1679871, A1345654, AW327868,
				AW406755, AW269488, AW276435,
				A1270117, A1064864, A1085719, A1890348,
				AL046205, Al281881, AW193432, AL138455, AI341664, AA587604, AL044858, AI754658,
	J	.1		AI375710, AI688846, AW029038,

AW438643, AI149478, AA581903, AI619997, AW407578, AA682912, AW023672, AI801600, AI792287, AA526787, AI307608, AW265170, AA652764, AW102811, AI471603, AA491284, AI888752, AW274349, AA743907, AA613345, AW021583, AA502104, AA665330, AI610159, AA468022, AL037683, AA482711, AW088202, AI110770, AI499503, AI537506, AW103758, AI053672, AL041690, AA846935, AI355206, AI799642, AI679782, AI281697, AI358571, AW004911, AA284179, N24538, AI379719, AA649642, AI192631, AA713815, AI761471, AI887483, AW088846, AW248847, AI249997, AA470969, AW162049, AI754253, AI929531, AW073470, AI805363, AI305547, AI696962, AI469172, AI754336, AW339568, AI344844, AI339850, AI471543, AI962050, AI590958, AI469968, AA714453, AL079645, AI262909, AW304584, AW062724, AI801482, AL048925, AA490183, AA938105, AW265393, AI434695, AI921476, AI254316, AA720702, AI340453, AI017024, AL137737, AC005280, AC004263, AC005911, AC005484, AC005288, AL035587, AF088219, AC004134, U47924, AC004859, AP000359, AL022724, AC005257, AE000658, AL117351, AL139054, AC005324, AC005844, AC005670, AC003009, AC000118, AL049776, AC006211, AL023575, AC005585, Z93023, U85195, AC004821, AC005234, AL121603, AC007227, AC005682, AC007204, AL035422, AC005488, AC004997, AC006251, AC005696, AP000553, AC004675, AF196779, AC003007, AL031597, AC002314, AC000075, AL121658, AC005632, AC005839, AC006965, AF001549, AL133448, Z99129, AP000513, AC004638, AC003085, AC004854, AC004876, AL022721, AB023049, AL034420, AC008101, AL049759, AC004686, AL021939, U78027, AC008079, AC002470, AP000302, Z98200, AC005231, AC007216, AL132642, AL132992, U95742, AL035450, AL022328, AL078477, AD000092, AC006312, AC005011, AC007011, AL080243, AC004841, AC009247, AC004678, AC006128, AC005664, AC007052, AC005081, AC003006, AP000512, AF196971. AC007207, AJ010598, Z82901, AC004257, AC008039, AC003957, AP000351, AC006449, AJ003147, AC006064, AC006137, AC006480, AC006130, AC004894, AC005377, AC005755, AC004019, AL023284, Z85986, AL035458, AP000049, AC004975, AL024507, AC005005.

				AC005200, AC005520, AF010238,
				AC002402, AC005900, AL133500,
				AC003982, AL096791, AC009516, D87009,
	:			AP000555, AP000114, AP000046, AC002549,
				AL035683, U91326, AP000311, AC004858,
				AL035400, AC003070, Z98051, AL136295,
:				AC006277, AL034582, AC005771,
				AL031255, AC002477, AL117344,
				AC005913, AL031650, AC007043,
				AC005747, AP000556, AL050332, AP000090,
				AC007785, AC006468, AC005089,
				AC000066, AL031073, AF123462, AC004690,
				Z97195, AC004253, AL050318, AC006001,
				AC007308, AJ010770, AC005177, AL035425,
				AC006111, AL049779, AC005041,
				AL109985, AC005399, AC007676,
i i				AC007298, AC005608, AC007666,
				AC005193, AC004985, AL008726,
				AL132987, AC004596, AC002301,
				AL132987, AC004390, AC002301, AL121653, AL035659, AF111169, AC002120,
				AC006132, AC005778, AP000298,
				AC005330, AC007919, AC004862,
				AL008725, AP000158, Z95114, Z83826,
ļ				
				AL023494, AC006017, AC005531,
				AC005071, AP000349, AC006285, AL021878,
				AF095725, AC007387, AC004797,
				AC005859, AC005291, U66059, AP000558,
				AC006511, AC006960, AL049845,
				AC008018, AC005668, L48038, AC006487,
				AC005695, AC007064, AC002468,
٠.				AC005242, AL021578, AL022400, AL117352,
				AL050341, AC006538, AL022323, AF109907,
				AC002347, AC003111, AP000044, Z83820,
			:	AL109758, AC005218, AC004990,
				AC000026, AC007536, AC005019,
				AC005785, AL023879, AL020995, AL121591,
1				AF039907, Z94056, AL009181, AC005996,
				AL031320, AL035398, Z99716, and
				AL133238.
20	HHEPG23	72	884590	AI821271.
20	HHEPG23	73	902169	AA732566, AI432371, AI394417, AI367073,
				AI521279, AI025957, AA612859, AW062389,
				AA485239, AW183741, AW081769,
				AA769467, AI868573, AA353281, N24538,
				AI313180, AW206261, AA484962,
				AA381195, AA829326, T29199, AA362689,
				AA362688, AA362690, AA360806, AI033197,
	*			AF019049, I66487, A94048, A94061,
				AR035224, AR067734, I07209, I09252,
				109251, 107249, AR068508, 109270, 109268,
				109269, AR068510, AR068509, A63954,
				A49701, A29109, A32111, I66495, AR068550,
				A23373, AR068551, I66494, E01324, I08638,
				A94046, A94054, I09267, I58322, I58323,
				I66498, I66497, I66496, I66486, A27169,
1				A27170, A39929, A83151, AR038307,
				AI002815, AL044652, AL137737, A49045, AF019049, I66487, A94048, A94061, AR035224, AR067734, I07209, I09252, I09251, I07249, AR068508, I09270, I09268, I09269, AR068510, AR068509, A63954, A49701, A29109, A32111, I66495, AR068550 A23373, AR068551, I66494, E01324, I08638, A94046, A94054, I09267, I58322, I58323, I66498, I66497, I66496, I66486, A27169,

259

				AR038321, I91969, AR067731, AR067732, I12325, M68882, AR051537, AR051524, AR051528, AR051547, Y17793, and A42964.
21	HWBAR88	31	836469	AA334103, AI654920, AW418882, AI949038, AI093540, AA703125, AI076049, AI356640, AI359681, AI160128, AI422536, and AB020316.

260

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

5

10

15

30

Examples

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	Vector Used to Construct Library	Corresponding Deposited
	Plasmid	
·	Lambda Zap	pBluescript (pBS)
20	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSport 2.0	pCMVSport 2.0
25	pCMVSport 3.0	pCMVSport 3.0
	pCR [®] 2.1	pCR®2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey

5

25

30

Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

261

10 Vectors pSport1, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, 15 NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., 20 Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

5

10

15

20

25

30

262

PCT/US00/30654

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ³²P-γ-ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 ul of reaction mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl₂, 0.01% (w/v) gelatin, 20 uM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

5

10

15

20

25

30

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

264

Example 3: Tissue Distribution of Polypeptide

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P³² using the rediprimeTM DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100TM column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHybTM hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70 degree C overnight, and the films developed according to standard procedures.

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions: 30 seconds,95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C. This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

30

5

10

15

Example 5: Bacterial Expression of a Polypeptide

5

10

15

20

25

30

265

PCT/US00/30654

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with

5

10

15

20

25

30

266

high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM immidazole. Immidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains:

1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (lacIq). The origin of replication (oriC) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

5

10

15

20

25

30

PCT/US00/30654

267

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 6: Purification of a Polypeptide from an Inclusion Body

The following alternative method can be used to purify a polypeptide expressed in *E coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10 degree C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10 degree C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfuidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 um membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive

10

15

20

25

30

Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A₂₈₀ monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 ug of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral

5

10

15

20

25

30

sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

269

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

5

10

15

20

25

30

270

PCT/US00/30654

Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0 ug of a commercially available linearized baculovirus DNA ("BaculoGoldTM baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug of BaculoGoldTM virus DNA and 5 ug of the plasmid are mixed in a sterile well of a microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27 degrees C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 uCi of ³⁵S-methionine and 5 uCi ³⁵S-cysteine (available from Amersham) are added.

5

10

15

20

25

30

271

PCT/US00/30654

The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSport 2.0, and pCMVSport 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of

10

15

20

25

30

interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No.209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector

273

are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five µg of the expression plasmid pC6 a pC4 is cotransfected with 0.5 ug of the plasmid pSVneo using lipofectin (Felgner et al., supra). The plasmid pSV2neo contains a dominant selectable marker, the neo gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of metothrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 uM, 2 uM, 5 uM, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 uM. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

20

25

30

5

10

15

Example 9: Protein Fusions

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused

5

10

15

25

30

274

PCT/US00/30654

protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

20 Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAAACTCACACATGCCCACCGTGC
CCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAAA
CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGT
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA
CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT
GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA
ACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCGAGAAC
CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG
GTCAGCCTGACCTGCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT
CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTG

10

15

20

25

30

275

GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG GTAAATGAGTGCGACGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

5 Example 10: Production of an Antibody from a Polypeptide

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56 degrees C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

5

10

15

276

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')2 and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

"humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

Example 11: Production Of Secreted Protein For High-Throughput Screening

30 Assays

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described herein.

10

15

20

25

30

277

PCT/US00/30654

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2 x 10⁵ cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degrees C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl2 (anhyd); 0.00130

30

 $mg/L CuSO_4-5H_2O$; 0.050 $mg/L of Fe(NO_3)_3-9H_2O$; 0.417 $mg/L of FeSO_4-7H_2O$; 311.80 mg/L of Kcl; 28.64 mg/L of MgCl₂; 48.84 mg/L of MgSO₄; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO₃; 62.50 mg/L of NaH₂PO₄-H₂O; 71.02 mg/L of Na₂HPO4; .4320 mg/L of ZnSO₄-7H₂O; .002 mg/L of Arachidonic Acid; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic 5 Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H₂0; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-10 2HCL-H₂0; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H₂0; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalainine; 40.0 15 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tryrosine-2Na-2H₂0; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 20 0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin 25 complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person

279

B adds 1.5ml appropriate media to each well. Incubate at 37 degrees C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

Example 12: Construction of GAS Reporter Construct

5

10

15

20

25

30

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferonsensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

280

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

5

10

15

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

281

<u>Ligand</u>	tyk2	<u>JAKs</u> <u>Jak1</u>	<u>Jak2</u>	Jak3	<u>STATS</u>	GAS(elements) or ISRE
IFN family IFN-a/B IFN-g II-10	+	+ + ?	- + ?	- -	1,2,3 1 1,3	ISRE GAS (IRF1>Lys6>IFP)
gp130 family IL-6 (Pleiotrophic) Il-11(Pleiotrophic) OnM(Pleiotrophic) LIF(Pleiotrophic) CNTF(Pleiotrophic) G-CSF(Pleiotrophic) IL-12(Pleiotrophic)	+ ? ? ? -/+ ?	+ + + + +	+ ? + + + ?	? ? ? ? ?	1,3 1,3 1,3 1,3 1,3 1,3	GAS (IRF1>Lys6>IFP)
g-C family IL-2 (lymphocytes) IL-4 (lymph/myeloid) IL-7 (lymphocytes) IL-9 (lymphocytes) IL-13 (lymphocyte) IL-15	-)- - - - ?	+ + + + +	- - - ? ?	+ + + + ? +	1,3,5 6 5 5 6 5	GAS GAS (IRF1 = IFP >>Ly6)(IgH) GAS GAS GAS GAS GAS
gp140 family IL-3 (myeloid) IL-5 (myeloid) GM-CSF (myeloid)	- - -	- - -	+ + +	- - -	5 5 5	GAS (IRF1>IFP>>Ly6) GAS GAS
Growth hormone fam GH PRL EPO	ily ? ? ?	- +/- -	+ + +	- - -	5 1,3,5 5	GAS(B-CAS>IRF1=IFP>>Ly6)
Receptor Tyrosine Ki EGF PDGF CSF-1	nases ? ? ?	+++++	+ + +	- - -	1,3 1,3 1,3	GAS (IRF1) GAS (not IRF1)

10

15

30

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAATGATTTCCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAA TGATTTCCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCG CCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCT CCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCC TCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTTGGAGGCCT
25 AGGCTTTTGCAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

5

10

15

20

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, Il-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

Example 13: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway.

The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

5

10

15

20

25

30

284

PCT/US00/30654

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml genticin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells (10⁷ per transfection), and resuspend in OPTI-MEM to a final concentration of 10⁷ cells/ml. Then add 1ml of 1 x 10⁷ cells in OPTI-MEM to T25 flask and incubate at 37 degrees C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Genticin, and 1% Pen-Strep. These cells are treated with supernatants containing polypeptides of the invention and/or induced polypeptides of the invention as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100; 000 cells per well).

10

15

20

25

30

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20 degrees C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4 degrees C and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as, stable transfected cells, which would be apparent to those of skill in the art.

Example 14: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity by determining whether polypeptides of the invention proliferates and/or differentiates myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2x10e⁷ U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

10

15

25

30

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM Na₂HPO₄.7H₂O, 1 mM MgCl₂, and 675 uM CaCl₂. Incubate at 37 degrees C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degrees C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

These cells are tested by harvesting $1x10^8$ cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of $5x10^5$ cells/ml. Plate 200 ul cells per well in the 96-well plate (or $1x10^5$ cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37 degrees C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

20 Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP

reporter, activation of PC12 cells can be assessed.

10

15

20

25

30

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

- 5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)
- 5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heatinactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count

15

20

25

30

288

PCT/US00/30654

the cell number and add more low serum medium to reach final cell density as $5x10^5$ cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to $1x10^5$ cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

10 Example 16: High-Throughput Screening Assay for T-cell Activity

NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF-KB would be useful in treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence

5

10

15

PCT/US00/30654

complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

289

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene) Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGACTTTCCCGGGGACTTTCCGGGGACTTTCC
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC
ATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA
CTAATTTTTTTATTTATTCAGAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTA
TTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAA
GCTT:3' (SEQ ID NO:10)

20

25

30

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the

GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described

5

10

15

20

290

PCT/US00/30654

in Example 13. As a positive control, exogenous TNF alpha (0.1,1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 17: Assay for SEAP Activity

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

Reaction Duties 1 of Maiation.			
# of plates	Rxn buffer diluent (ml)	CSPD (ml)	
10	60	3	
11	65	3.25	
12	70	3.5	
13	75	3.75	
14	80	4	
15	85	4.25	
16	90	4.5	
17	95	4.75	
18	100	5	
19	105	5.25	
20	110	5.5	
21	115	5.75	
22	120	6	
23	125	6.25	
24	130	6.5	

25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

10

15

Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for

10

15

20

30

20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to $2-5\times10^6$ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1×10^6 cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca⁺⁺ concentration.

25 Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is

293

unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

5

10

15

20

25

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford,MA), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford,MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of

Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium.

Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in

10

15

20

25

30

Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na3VO4, 2 mM Na4P2O7 and a cocktail of protease inhibitors (# 1836170) obtained from Boeheringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4 degrees C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degrees C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg₂₊ (5mM ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30 degrees C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mm EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degrees C for 20

min. This allows the streptavadin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phospotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degrees C for one hour. Wash the well as above.

5

10

15

20

25

30

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity

As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degrees C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and

5

10

20

25

30

cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

15 Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95 degrees C for 30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United

297

States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Manheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

5

10

15

20

25

30

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in

5

10

15

20

25

30

298

PCT/US00/30654

Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

Example 23: Formulation

The invention also provides methods of treatment and/or prevention diseases, disorders, and/or conditions (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

10

15

20

25

30

299

PCT/US00/30654

As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about 1ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Therapeutics can be are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), bucally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), bucally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or mirocapsules), suitable hydrophobic materials

10

15

20

25

30

(for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., Id.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988).

Sustained-release Therapeutics also include liposomally entrapped Therapeutics of the invention (see generally, Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci.(USA) 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal Therapeutic.

In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see* Langer, *supra*; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.

5

10

15

20

25

30

301

PCT/US00/30654

For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum immunoglobulins; albumin, gelatin, or hydrophilic polymers such polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized

formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

5

10

15

20

25

30

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG, and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diptheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate

administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, other members of the TNF family, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

5

10

15

20

25

30

In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6 (International Publication No. WO 98/30694), OPG, and neutrokine-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-IBB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

5

10

15

20

25

30

PCT/US00/30654

In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors. Nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ EPIVIR™ (lamivudine/3TC), (stavudine/d4T). and **COMBIVIR™** (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delayirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

304

In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but not limited TRIMETHOPRIM-SULFAMETHOXAZOLE™, are to, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™. ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™. GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, NEUPOGEN™ LEUCOVORIN™. (filgrastim/G-CSF), and LEUKINE[™] (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In

5

10

15

20

25

30

305

PCT/US00/30654

another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic Mycobacterium avium complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTINTM, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic Mycobacterium tuberculosis infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic Toxoplasma gondii infection. In another specific embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin,

5

10

15

20

25

30

306

PCT/US00/30654

erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamthoxazole, and vancomycin.

Conventional nonspecific immunosuppressive agents, that may be administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells.

In specific embodiments, Therapeutics of the invention are administered in combination with immunosuppressants. Immunosuppressants preparations that may be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONETM (OKT3), SANDIMMUNETM/NEORALTM/SANGDYATM (cyclosporin), PROGRAFTM (tacrolimus), CELLCEPTTM (mycophenolate), Azathioprine, glucorticosteroids, and RAPAMUNETM (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, and GAMIMUNE™. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

In an additional embodiment, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-

5

10

15

20

25

30

.

PCT/US00/30654

acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

307

In another embodiment, compostions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin. bleomycin, daunorubicin. dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephalen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and etoposide).

In a specific embodiment, Therapeutics of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another embodiment, Therapeutics of the invention are administered in combination with Rituximab. In a further embodiment, Therapeutics of the invention are administered with Rituxmab and CHOP, or Rituxmab and any combination of the components of CHOP.

In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered

with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

5

10

15

20

25

30

In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PIGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PIGF-2), as disclosed in Hauser et al., Gorwth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by reference herein.

In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, LEUKINETM (SARGRAMOSTIMTM) and NEUPOGENTM (FILGRASTIMTM).

In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but

10

15

20

25

30

are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

Example 24: Method of Treating Decreased Levels of the Polypeptide

The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

Example 25: Method of Treating Increased Levels of the Polypeptide

The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of

PCT/US00/30654

decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer. For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

Example 26: Method of Treatment Using Gene Therapy-Ex Vivo

5

10

15

20

25

30

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is

10

15

20

30

maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

25 Example 27: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention

Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935

5

10

15

20

25

30

(1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

312

Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of endogenous polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol precipitation.

In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the polynucleotide in the cell. Expression may be detected by immunological staining, or any other method known in the art.

5

10

15

20

25

30

following resuspension.

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining cells are subjected to centrifugation. The supernatant is aspirated and the pellet is

313

cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na₂ HPO₄, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains approximately 3X10⁶ cells/ml. Electroporation should be performed immediately

Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3'end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3'end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5'end and a HindIII site at the 3'end. The CMV promoter and the fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least 120 μg/ml. 0.5 ml of the cell suspension (containing approximately 1.5.X10⁶ cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960 μF and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

10

15

20

25

30

Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

Example 28: Method of Treatment Using Gene Therapy - In Vivo

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata et al., Cardiovasc. Res. 35(3):470-479 (1997); Chao et al., Pharmacol. Res. 35(6):517-522 (1997); Wolff, Neuromuscul. Disord. 7(5):314-318 (1997); Schwartz et al., Gene Ther. 3(5):405-411 (1996); Tsurumi et al., Circulation 94(12):3281-3290 (1996) (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or

5

10

15

20

25

30

315

precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. In vivo muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg

5

10

15

20

25

30

body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be

316

PCT/US00/30654

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

delivered to arteries during angioplasty by the catheter used in the procedure.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper

317

dosages and other treatment parameters in humans and other animals using naked DNA.

Example 29: Transgenic Animals.

5

10

15

20

25

30

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (i.e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e.g., Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pleuripotent stem cells and transferring the stem cells back into the blastocyst; and spermmediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

5

10

15

20

25

30

318

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, i.e., mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, e.g., head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding

strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

319

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

Example 30: Knock-Out Animals.

5

10

15

20

25

30

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (E.g., see Smithies et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention in vivo. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e.g., see Thomas &

5

10

15

20

25

30

PCT/US00/30654

Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

320

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient in vivo. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered in vitro using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, <u>e.g.</u>, genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For

15

20

25

30

example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

10 Example 31: Production of an Antibody

a) Hybridoma Technology

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing polypeptide(s) of the invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide(s) of the invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

Monoclonal antibodies specific for polypeptide(s) of the invention are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with polypeptide(s) of the invention, or, more preferably, with a secreted polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 μg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line

10

15

20

25

30

(SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide(s) of the invention.

Alternatively, additional antibodies capable of binding polypeptide(s) of the invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the polypeptide(s) of the invention protein-specific antibody can be blocked by polypeptide(s) of the invention. Such antibodies comprise anti-idiotypic antibodies to the polypeptide(s) of the invention protein-specific antibody and are used to immunize an animal to induce formation of further polypeptide(s) of the invention protein-specific antibodies.

For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

b) Isolation Of Antibody Fragments Directed polypeptide(s) of the invention From A Library Of scFvs

Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide(s) of the

5

10

15

20

25

30

323

PCT/US00/30654

invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library. A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 109 E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 μg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to innoculate 50 ml of 2xTY-AMP-GLU, 2 x 108 TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 μg/ml ampicillin and 50 ug/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 μg ampicillin/ml and 25 μg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 μm filter (Minisart NML; Sartorius) to give a final concentration of approximately 1013 transducing units/ml (ampicillin-resistant clones).

Panning of the Library. Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either $100 \,\mu\text{g/ml}$ or $10 \,\mu\text{g/ml}$ of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 1013 TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to

PCT/US00/30654

stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders. Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

Example 32: Assays Detecting Stimulation or Inhibition of B cell Proliferation and **Differentiation**

25

30

5

10

15

20

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can,

5

10

15

20

25

30

325

in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

PCT/US00/30654

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Purified polypeptides of the invention, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the polypeptides of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed Staphylococcus aureus Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added 10⁵ B-cells suspended in culture medium (RPMI 1640 containing 10% FBS, 5 X 10⁻⁵M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and 10⁻⁵ dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse (1uCi/well) with 3H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

<u>In Vivo Assay-</u> BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of a polypeptide of the invention, or truncated forms thereof. Mice

5

10

15

20

25

30

receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with polypeptides of the invention identify the results of the activity of the polypeptides on spleen cells, such as the diffusion of periarterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

Flow cytometric analyses of the spleens from mice treated with polypeptide is used to indicate whether the polypeptide specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and polypeptide-treated mice.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

Example 33: T Cell Proliferation Assay

Proliferation assay for Resting PBLs.

A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of ³H-thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100 microliters per well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 C (1 microgram/ml in .05M bicarbonate buffer, pH 9.5), then wash three times with PBS. PBMC are isolated by F/H gradient centrifugation from human periphera blood and added to quadruplicate wells (5 x 10⁴/well) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of TNF Delta and/or TNF Epsilon protein (total volume 200 microliters). Relevant protein buffer and medium alone are controls.

5

PCT/US00/30654

After 48 hr. culture at 37 °C, plates are spun for 2 min. at 1000 rpm and 100 microliters of supernatant is removed and stored -20 °C for measurement of IL-2 (or other cytokines) if effect of proliferation is observed. Wells are supplemented with 100 microliters of medium containing 0 microcuries of ³H-thymidine and cultured at 37 °C for 18-24 hr. Wells are harvested and incorporation of ³H-thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of TNF Delta and/or TNF Epsilon proteins.

327

Alternatively, a proliferation assay on resting PBL (peripheral blood lymphocytes) is measured by the up-take of ³H-thymidine. The assay is performed as 10 follows. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% (Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the 15 plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non-adherent cells are collected, washed and used in the proliferation assay. The assay is performed in a 96 well plate using 2 x10⁴ cells/well in a final volume of 200 microliters. The supernatants (e.g., CHO or 293T 20 supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector (negative control), IL-2 (*), IFNγ, TNFα, IL-10 and TR2. In addition to the control supernatants, recombinant human IL-2 (R & D Systems, Minneapolois, MN) 25 at a final concentration of 100ng/ml is also used. After 24 hours of culture, each well is pulsed with 1uCi of ³H-thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of ³H-thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

30 (*) The amount of the control cytokines IL-2, IFNγ, TNFα and IL-10 produced in each transfection varies between 300pg to 5ng/ml.

Costimulation assay.

WO 01/34629

5

10

15

20

25

30

A costimulation assay on resting PBL (peripheral blood lymphocytes) is performed in the presence of immobilized antibodies to CD3 and CD28. The use of antibodies specific for the invariant regions of CD3 mimic the induction of T cell activation that would occur through stimulation of the T cell receptor by an antigen. Cross-linking of the TCR (first signal) in the absence of a costimulatory signal (second signal) causes very low induction of proliferation and will eventually result in a state of "anergy", which is characterized by the absence of growth and inability to produce cytokines. The addition of a costimulatory signal such as an antibody to CD28, which mimics the action of the costimulatory molecule. B7-1 expressed on activated APCs, results in enhancement of T cell responses including cell survival and production of IL-2. Therefore this type of assay allows to detect both positive and negative effects caused by addition of supernatants expressing the proteins of interest on T cell proliferation.

The assay is performed as follows. Ninety-six well plates are coated with 100ng/ml anti-CD3 and 5ug/ml anti-CD28 (Pharmingen, San Diego, CA) in a final volume of 100ul and incubated overnight at 4C. Plates are washed twice with PBS before use. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% FCS(Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non adherent cells are collected, washed and used in the proliferation assay. The assay is performed in a 96 well plate using 2 x 10⁴ cells/well in a final volume of 200ul. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector only (negative control), IL-2, IFNγ, TNFα, IL-10 and TR2. In addition to the control supernatants recombinant human IL-2 (R & D Systems, Minneapolis, MN) at a final concentration of 10ng/ml is also used. After 24 hours of culture, each well is

329

pulsed with 1uCi of ³H-thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of ³H-thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

5 Costimulation assay: IFN γ and IL-2 ELISA

The assay is performed as follows. Twenty-four well plates are coated with either 300ng/ml or 600ng/ml anti-CD3 and 5ug/ml anti-CD28 (Pharmingen, San Diego, CA) in a final volume of 500ul and incubated overnight at 4C. Plates are washed twice with PBS before use. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, 10 Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% FCS(Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non adherent cells are collected, washed and used in 15 the costimulation assay. The assay is performed in the pre-coated twenty-four well plate using 1 x 10⁵ cells/well in a final volume of 900ul. The supernatants (293T) supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 300ul are added to 600ul of 10% FCS/RPMI containing the cells. Control 20 supernatants are used at the same final dilution and express the following proteins: vector only(negative control), IL-2, IFNy, IL-12 and IL-18. In addition to the control supernatants recombinant human IL-2 (all cytokines were purchased from R & D Systems, Minneapolis, MN) at a final concentration of 10ng/ml, IL-12 at a final concentration of 1ng/ml and IL-18 at a final concentration of 50ng/ml are also used. Controls and unknown samples are tested in duplicate. Supernatant samples (250ul) 25 are collected 2 days and 5 days after the beginning of the assay. ELISAs to test for IFNγ and IL-2 secretion are performed using kits purchased from R & D Systems, (Minneapolis, MN). Results are expressed as an average of duplicate samples plus or minus standard error.

30

5

10

15

20

25

30

A proliferation assay on preactivated-resting T cells is performed on cells that are previously activated with the lectin phytohemagglutinin (PHA). Lectins are polymeric plant proteins that can bind to residues on T cell surface glycoproteins including the TCR and act as polyclonal activators. PBLs treated with PHA and then cultured in the presence of low doses of IL-2 resemble effector T cells. These cells are generally more sensitive to further activation induced by growth factors such as IL-2. This is due to the expression of high affinity IL-2 receptors that allows this population to respond to amounts of IL-2 that are 100 fold lower than what would have an effect on a naïve T cell. Therefore the use of this type of cells might enable to detect the effect of very low doses of an unknown growth factor, that would not be sufficient to induce proliferation on resting (naïve) T cells.

330

The assay is performed as follows. PBMC are isolated by F/H gradient centrifugation from human peripheral blood, and are cultured in 10% FCS(Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD) in the presence of 2ug/ml PHA (Sigma, Saint Louis, MO) for three days. The cells are then washed in PBS and cultured in 10% FCS/RPMI in the presence of 5ng/ml of human recombinant IL-2 (R & D Systems, Minneapolis, MN) for 3 days. The cells are washed and rested in starvation medium (1%FCS/RPMI) for 16 hours prior to the beginning of the proliferation assay. An aliquot of the cells is analyzed by FACS to determine the percentage of T cells (CD3 positive cells) present; this usually ranges between 93-97% depending on the donor. The assay is performed in a 96 well plate using 2 x10⁴ cells/well in a final volume of 200ul. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of in10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector (negative control), IL-2, IFNγ, TNFα, IL-10 and TR2. In addition to the control supernatants recombinant human IL-2 at a final concentration of 10ng/ml is also used. After 24 hours of culture, each well is pulsed with 1uCi of ³Hthymidine(Nen, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of ³H-thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

331

The studies described in this example test activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

5

10

15

20

Example 34: Effect of Polypeptides of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells

Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF-α, causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FCγRII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

25

30

Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Thl helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to measure the IL-12 release as follows. Dendritic cells (10⁶/ml) are treated with increasing concentrations of polypeptides of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell

cultures are then collected and analyzed for IL-12 content using commercial ELISA kit (e..g, R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or activator of monocytes. Polypeptides, agonists, or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

30

5

10

15

20

25

Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results

from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of 2 x 10⁶/ml in PBS containing PI at a final concentration of 5 µg/ml, and then incubated at room temperature for 5 minutes before FACScan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of $5x10^5$ cells/ml with increasing concentrations of the a polypeptide of the invention and under the same conditions, but in the absence of the polypeptide. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of a polypeptide of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e..g, R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

Oxidative burst. Purified monocytes are plated in 96-w plate at 2-1x10⁵ cell/well. Increasing concentrations of polypeptides of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20 µl 1N NaOH per well. The absorbance is read at 610

334

nm. To calculate the amount of H_2O_2 produced by the macrophages, a standard curve of a H_2O_2 solution of known molarity is performed for each experiment.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polypeptides, polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 35: Biological Effects of Polypeptides of the Invention

Astrocyte and Neuronal Assays.

5

10

15

20

25

30

Recombinant polypeptides of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate a polypeptide of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA 83*:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of a polypeptide of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

5

10

15

20

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE2 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or polypeptides of the invention with or without IL-1α for 24 hours. The supernatants are collected and assayed for PGE₂ by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without polypeptides of the invention IL-1 α for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or polypeptides of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with polypeptides of the invention.

Parkinson Models.

25 The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP⁺) and released.

5

10

15

20

25

30

Subsequently, MPP⁺ is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP⁺ is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotidamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

336

It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

Based on the data with FGF-2, polypeptides of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential effect of a polypeptide of the invention is first examined in vitro in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm² on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days in vitro and are processed for tyrosine hydroxylase, a specific marker for dopminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if a polypeptide of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the polypeptide may be involved in Parkinson's Disease.

337

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

5

10

15

20

25

30

Example 36: The Effect of Polypeptides of the Invention on the Growth of Vascular Endothelial Cells

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at 2-5x10⁴ cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnique, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. A polypeptide having the amino acid sequence of SEQ ID NO:Y, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that the polypeptide of the invention may proliferate vascular endothelial cells.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 37: Stimulatory Effect of Polypeptides of the Invention on the Proliferation of Vascular Endothelial Cells

For evaluation of mitogenic activity of growth factors, the colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) was performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000 cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight. After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF₁₆₅ or a

polypeptide of the invention in 0.5% FBS) with or without Heparin (8 U/ml) are added to wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is subtracted, and seven wells are performed in parallel for each condition. See, Leak *et al.* In Vitro Cell. Dev. Biol. 30A:512-518 (1994).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 38: Inhibition of PDGF-induced Vascular Smooth Muscle Cell Proliferation Stimulatory Effect

10

15

20

25

30

HAoSMC proliferation can be measured, for example, by BrdUrd incorporation. Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with 10% calf serum and 6 mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4 degrees C for 2 h after being exposed to denaturing solution and then incubated with the streptavidin-peroxidase and diaminobenzidine. After counterstaining with hematoxylin, the cells are mounted for microscopic examination, and the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for individual cells by the concomitant use of bright field illumination and dark field-UV fluorescent illumination. See, Hayashida et al., J. Biol. Chem. 6:271(36):21985-21992 (1996).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 39: Stimulation of Endothelial Migration

5

10

15

20

25

30

This example will be used to explore the possibility that a polypeptide of the invention may stimulate lymphatic endothelial cell migration.

Endothelial cell migration assays are performed using a 48 well microchemotaxis chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., et al., J. Immunological Methods 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8 um (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours at room temperature and dried under sterile air. Test substances are diluted to appropriate concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25 ul of the final dilution is placed in the lower chamber of the modified Boyden apparatus. Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter between lower and upper chamber, 2.5 x 10⁵ cells suspended in 50 ul M199 containing 1% FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at 37°C in a humidified chamber with 5% CO2 to allow cell migration. After the incubation period, the filter is removed and the upper side of the filter with the non-migrated cells is scraped with a rubber policeman. The filters are fixed with methanol and stained with a Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by counting cells of three random high-power fields (40x) in each well, and all groups are performed in quadruplicate.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 40: Stimulation of Nitric Oxide Production by Endothelial Cells

Nitric oxide released by the vascular endothelium is believed to be a mediator of vascular endothelium relaxation. Thus, activity of a polypeptide of the invention can be

5

10

15

20

25

30

assayed by determining nitric oxide production by endothelial cells in response to the polypeptide.

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various levels of a positive control (such as VEGF-1) and the polypeptide of the invention. Nitric oxide in the medium is determined by use of the Griess reagent to measure total nitrite after reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of the polypeptide of the invention on nitric oxide release is examined on HUVEC.

Briefly, NO release from cultured HUVEC monolayer is measured with a NO-specific polarographic electrode connected to a NO meter (Iso-NO, World Precision Instruments Inc.) (1049). Calibration of the NO elements is performed according to the following equation:

$$2 \text{ KNO}_2 + 2 \text{ KI} + 2 \text{ H}_2 \text{SO}_4 6 2 \text{ NO} + \text{I}_2 + 2 \text{ H}_2 \text{O} + 2 \text{ K}_2 \text{SO}_4$$

The standard calibration curve is obtained by adding graded concentrations of KNO₂ (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing KI and H₂SO₄. The specificity of the Iso-NO electrode to NO is previously determined by measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then bathed in 5 ml of filtered Krebs-Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) To maintain the temperature at 37°C. The NO sensor probe is inserted vertically into the wells, keeping the tip of the electrode 2 mm under the surface of the solution, before addition of the different conditions. S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of released NO is expressed as picomoles per 1x10⁶ endothelial cells. All values reported are means of four to six measurements in each group (number of cell culture wells). See, Leak et al. Biochem. and Biophys. Res. Comm. 217:96-105 (1995).

The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 41: Effect of Polypepides of the Invention on Cord Formation in Angiogenesis

Another step in angiogenesis is cord formation, marked by differentiation of endothelial cells. This bioassay measures the ability of microvascular endothelial cells to form capillary-like structures (hollow structures) when cultured *in vitro*.

CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the *in vitro* angiogenesis assay, the wells of a 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium (200 ml/well) for 30 min. at 37°C. CADMEC are seeded onto the coated wells at 7,500 cells/well and cultured overnight in Growth Medium. The Growth Medium is then replaced with 300 mg Cell Applications' Chord Formation Medium containing control buffer or a polypeptide of the invention (0.1 to 100 ng/ml) and the cells are cultured for an additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the Boeckeler VIA-170 video image analyzer. All assays are done in triplicate.

Commercial (R&D) VEGF (50 ng/ml) is used as a positive control. b-esteradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also utilized as a control.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

25

30

5

10

15

20

Example 42: Angiogenic Effect on Chick Chorioallantoic Membrane

Chick chorioallantoic membrane (CAM) is a well-established system to examine angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The ability of polypeptides of the invention to stimulate angiogenesis in CAM can be examined.

5

10

15

20

25

30

Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese qual (*Coturnix coturnix*) are incubated at 37.8°C and 80% humidity. Differentiated CAM of 16-day-old chick and 13-day-old qual embryos is studied with the following methods.

On Day 4 of development, a window is made into the egg shell of chick eggs. The embryos are checked for normal development and the eggs sealed with cellotape. They are further incubated until Day 13. Thermanox coverslips (Nunc, Naperville, IL) are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in distilled water and about 3.3 mg/ 5 ml are pipetted on the disks. After air-drying, the inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope [Wild M8] and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 43: Angiogenesis Assay Using a Matrigel Implant in Mouse

In vivo angiogenesis assay of a polypeptide of the invention measures the ability of an existing capillary network to form new vessels in an implanted capsule of murine extracellular matrix material (Matrigel). The protein is mixed with the liquid Matrigel at 4 degree C and the mixture is then injected subcutaneously in mice where it solidifies. After 7 days, the solid "plug" of Matrigel is removed and examined for the presence of new blood vessels. Matrigel is purchased from Becton Dickinson Labware/Collaborative Biomedical Products.

When thawed at 4 degree C the Matrigel material is a liquid. The Matrigel is mixed with a polypeptide of the invention at 150 ng/ml at 4 degrees C and drawn into cold 3 ml syringes. Female C57Bl/6 mice approximately 8 weeks old are injected with the mixture of Matrigel and experimental protein at 2 sites at the midventral aspect of the abdomen (0.5 ml/site). After 7 days, the mice are sacrificed by cervical dislocation, the

343

Matrigel plugs are removed and cleaned (i.e., all clinging membranes and fibrous tissue is removed). Replicate whole plugs are fixed in neutral buffered 10% formaldehyde, embedded in paraffin and used to produce sections for histological examination after staining with Masson's Trichrome. Cross sections from 3 different regions of each plug are processed. Selected sections are stained for the presence of vWF. The positive control for this assay is bovine basic FGF (150 ng/ml). Matrigel alone is used to determine basal levels of angiogenesis.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 44: Rescue of Ischemia in Rabbit Lower Limb Model

5

10

15

20

25

30

To study the in vivo effects of polynucleotides and polypeptides of the invention on ischemia, a rabbit hindlimb ischemia model is created by surgical removal of one femoral arteries as described previously (Takeshita et al., Am J. Pathol 147:1649-1660 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb is dependent upon collateral vessels originating from the internal iliac artery (Takeshitaet al. Am J. Pathol 147:1649-1660 (1995)). An interval of 10 days is allowed for postoperative recovery of rabbits and development of endogenous collateral vessels. At 10 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked expression plasmid containing a polynucleotide of the invention by arterial gene transfer technology using a hydrogel-coated balloon catheter as described (Riessen et al. Hum Gene Ther. 4:749-758 (1993); Leclerc et al. J. Clin. Invest. 90: 936-944 (1992)). When a polypeptide of the invention is used in the treatment, a single bolus of 500 mg polypeptide of the invention or control is delivered into the internal iliac artery of the ischemic limb over a period of 1 min. through an infusion catheter. On day 30, various parameters are measured in these rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow

PCT/US00/30654

during undilated condition and Max FL: the blood flow during fully dilated condition (also an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number m the rabbit thigh; (d) Capillary density - The number of collateral capillaries determined in light microscopic sections taken from hindlimbs.

The studies described in this example tested activity of polynucleotides and polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the agonists, and/or antagonists of the invention.

Example 45: Effect of Polypeptides of the Invention on Vasodilation

Since dilation of vascular endothelium is important in reducing blood pressure, the ability of polypeptides of the invention to affect the blood pressure in spontaneously hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900 mg/kg) of the polypeptides of the invention are administered to 13-14 week old spontaneously hypertensive rats (SHR). Data are expressed as the mean +/- SEM. Statistical analysis are performed with a paired t-test and statistical significance is defined as p<0.05 vs. the response to buffer alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

25

30

5

10

15

20

Example 46: Rat Ischemic Skin Flap Model

The evaluation parameters include skin blood flow, skin temperature, and factor VIII immunohistochemistry or endothelial alkaline phosphatase reaction. Expression of polypeptides of the invention, during the skin ischemia, is studied using in situ hybridization.

The study in this model is divided into three parts as follows:

345

a) Ischemic skin

WO 01/34629

5

10

15

20

25

30

- b) Ischemic skin wounds
- c) Normal wounds

The experimental protocol includes:

- a) Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).
 - b) An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).
 - c) Topical treatment with a polypeptide of the invention of the excisional wounds (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.
- d) Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 47: Peripheral Arterial Disease Model

Angiogenic therapy using a polypeptide of the invention is a novel therapeutic strategy to obtain restoration of blood flow around the ischemia in case of peripheral arterial diseases. The experimental protocol includes:

- a) One side of the femoral artery is ligated to create ischemic muscle of the hindlimb, the other side of hindlimb serves as a control.
- b) a polypeptide of the invention, in a dosage range of 20 mg 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3 weeks.
 - c) The ischemic muscle tissue is collected after ligation of the femoral artery at 1, 2, and 3 weeks for the analysis of expression of a polypeptide of the invention and histology. Biopsy is also performed on the other side of normal muscle of the contralateral hindlimb.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to

test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 48: Ischemic Myocardial Disease Model

5

15

20

25

30

A polypeptide of the invention is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after coronary artery occlusion. Alteration of expression of the polypeptide is investigated in situ. The experimental protocol includes:

- a) The heart is exposed through a left-side thoracotomy in the rat. Immediately, the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.
 - b) a polypeptide of the invention, in a dosage range of 20 mg 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4 weeks.
 - c) Thirty days after the surgery, the heart is removed and cross-sectioned for morphometric and in situ analyzes.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 49: Rat Corneal Wound Healing Model

This animal model shows the effect of a polypeptide of the invention on neovascularization. The experimental protocol includes:

- a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.
- b) Inserting a spatula below the lip of the incision facing the outer corner of the eye.
 - c) Making a pocket (its base is 1-1.5 mm form the edge of the eye).
- d) Positioning a pellet, containing 50ng- 5ug of a polypeptide of the invention, within the pocket.

347

e) Treatment with a polypeptide of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 50: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models

10

15

5

A. Diabetic db+/db+ Mouse Model.

To demonstrate that a polypeptide of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. et al., J. Surg. Res. 52:389 (1992); Greenhalgh, D.G. et al., Am. J. Pathol. 136:1235 (1990)).

The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal 20 heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman et al. Proc. Natl. Acad. Sci. USA 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel et al., J. Immunol. 120:1375 25 4 (1978); Debray-Sachs, M. et al., Clin. Exp. Immunol. 51(1):1-7 (1983); Leiter et al., Am. J. of Pathol. 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. et al., Exp. Neurol. 83(2):221-232 (1984); Robertson et al., Diabetes 29(1):60-67 (1980); Giacomelli et al., 30 Lab Invest. 40(4):460-473 (1979); Coleman, D.L., Diabetes 31 (Suppl):1-6 (1982)). These

5

10

15

20

25

30

.

PCT/US00/30654

homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol. 120*:1375-1377 (1978)).

348

The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, et al., Am. J. of Pathol. 136:1235-1246 (1990)).

Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med. 172*:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

A polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

5

10

15

20

25

30

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

[Open area on day 8] - [Open area on day 1] / [Open area on day 1]

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by treatment with a polypeptide of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, reepithelialization and epidermal maturity (Greenhalgh, D.G. et al., Am. J. Pathol. 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer can serve as a positive tissue control and human brain tissue can be used as a negative tissue control. Each specimen includes a section with omission of the primary

5

10

15

20

25

30

350

antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

B. Steroid Impaired Rat Model

The inhibition of wound healing by steroids has been well documented in various in vitro and in vivo systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahlet al., J. Immunol. 115: 476-481 (1975); Werb et al., J. Exp. Med. 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert et al., An. Intern. Med. 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck et al., Growth Factors. 5: 295-304 (1991); Haynes et al., J. Clin. Invest. 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes et al., J. Clin. Invest. 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck et al., Growth Factors. 5: 295-304 (1991); Haynes et al., J. Clin. Invest. 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce et al., Proc. Natl. Acad. Sci. USA 86: 2229-2233 (1989)).

To demonstrate that a polypeptide of the invention can accelerate the healing process, the effects of multiple topical applications of the polypeptide on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad*

5

10

15

20

25

30

351

PCT/US00/30654

libitum. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment. Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

The polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8).

PCT/US00/30654

The wound area on day 1 is 64mm², the corresponding size of the dermal punch.

Calculations are made using the following formula:

[Open area on day 8] - [Open area on day 1] / [Open area on day 1]

5

10

15

25

30

WO 01/34629

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with a polypeptide of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

352

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

20 Example 51: Lymphadema Animal Model

or The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of a polypeptide of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing.

5

10

15

20

25

30

353

Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated suture ligated.

Using a microscope, muscles in back of the leg (near the semitendinosis and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

5

10

15

20

25

30

Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca2+ comparison.

Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 52: Suppression of TNF alpha-induced adhesion molecule expression by a Polypeptide of the Invention

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and

5

10

15

20

25

30

extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Tumor necrosis factor alpha (TNF-a), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

The potential of a polypeptide of the invention to mediate a suppression of TNF-a induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF-a treated ECs when co-stimulated with a member of the FGF family of proteins.

To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO₂. HUVECs are seeded in 96-well plates at concentrations of 1 x 10⁴ cells/well in EGM

HUVECs are seeded in 96-well plates at concentrations of 1 x 10⁴ cells/well in EGM medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90 ul of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 ul volumes). Plates are incubated at 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100 μ l of 0.1% paraformaldehyde-PBS(with Ca++ and Mg++) is added to each well. Plates are held at 4°C for 30 min.

Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10 μ l of diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 μ g/ml (1:10 dilution

PCT/US00/30654

of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

Then add 20 µl of diluted ExtrAvidin-Alkaline Phosphotase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml 5 of glycine buffer (pH 10.4). 100 ul of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphotase in glycine buffer: 1:5,000 (10^{0}) > $10^{-0.5}$ > 10^{-1} > $10^{-1.5}$. 5 ul of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 µl of pNNP reagent must then be added to each of 10 the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50 μl of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-15 conjugate in each sample.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 53: Assay for the Stimulation of Bone Marrow CD34+ Cell Proliferation

20

25

30

This assay is based on the ability of human CD34+ to proliferate in the presence of hematopoietic growth factors and evaluates the ability of isolated polypeptides expressed in mammalian cells to stimulate proliferation of CD34+ cells.

It has been previously shown that most mature precursors will respond to only a single signal. More immature precursors require at least two signals to respond. Therefore, to test the effect of polypeptides on hematopoietic activity of a wide range of progenitor cells, the assay contains a given polypeptide in the presence or absence of other hematopoietic growth factors. Isolated cells are cultured for 5 days in the presence of Stem Cell Factor (SCF) in combination with tested sample. SCF alone

has a very limited effect on the proliferation of bone marrow (BM) cells, acting in such conditions only as a "survival" factor. However, combined with any factor exhibiting stimulatory effect on these cells (e.g., IL-3), SCF will cause a synergistic effect. Therefore, if the tested polypeptide has a stimulatory effect on a hematopoietic progenitors, such activity can be easily detected. Since normal BM cells have a low level of cycling cells, it is likely that any inhibitory effect of a given polypeptide, or agonists or antagonists thereof, might not be detected. Accordingly, assays for an inhibitory effect on progenitors is preferably tested in cells that are first subjected to *in vitro* stimulation with SCF+IL+3, and then contacted with the compound that is being evaluated for inhibition of such induced proliferation.

Briefly, CD34+ cells are isolated using methods known in the art. The cells are thawed and resuspended in medium (QBSF 60 serum-free medium with 1% L-glutamine (500ml) Quality Biological, Inc., Gaithersburg, MD Cat# 160-204-101). After several gentle centrifugation steps at 200 x g, cells are allowed to rest for one hour. The cell count is adjusted to 2.5 x 10^5 cells/ml. During this time, $100 \,\mu l$ of sterile water is added to the peripheral wells of a 96-well plate. The cytokines that can be tested with a given polypeptide in this assay is rhSCF (R&D Systems, Minneapolis, MN, Cat# 255-SC) at 50 ng/ml alone and in combination with rhSCF and rhIL-3 (R&D Systems, Minneapolis, MN, Cat# 203-ML) at 30 ng/ml. After one hour, $10 \,\mu l$ of prepared cytokines, $50 \,\mu l$ SID (supernatants at 1:2 dilution = $50 \,\mu l$) and $20 \,\mu l$ of diluted cells are added to the media which is already present in the wells to allow for a final total volume of $100 \,\mu l$. The plates are then placed in a 37° C/5% CO₂ incubator for five days.

Eighteen hours before the assay is harvested, 0.5 μ Ci/well of [3H] Thymidine is added in a 10 μ l volume to each well to determine the proliferation rate. The experiment is terminated by harvesting the cells from each 96-well plate to a filtermat using the Tomtec Harvester 96. After harvesting, the filtermats are dried, trimmed and placed into OmniFilter assemblies consisting of one OmniFilter plate and one OmniFilter Tray. 60 μ l Microscint is added to each well and the plate sealed with TopSeal-A press-on sealing film A bar code 15 sticker is affixed to the first plate for counting. The sealed plates is then loaded and the level of radioactivity determined

5

10

15

20

25

30

358

PCT/US00/30654

via the Packard Top Count and the printed data collected for analysis. The level of radioactivity reflects the amount of cell proliferation.

The studies described in this example test the activity of a given polypeptide to stimulate bone marrow CD34+ cell proliferation. One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof. As a nonlimiting example, potential antagonists tested in this assay would be expected to inhibit cell proliferation in the presence of cytokines and/or to increase the inhibition of cell proliferation in the presence of cytokines and a given polypeptide. In contrast, potential agonists tested in this assay would be expected to enhance cell proliferation and/or to decrease the inhibition of cell proliferation in the presence of cytokines and a given polypeptide.

The ability of a gene to stimulate the proliferation of bone marrow CD34+ cells indicates that polynucleotides and polypeptides corresponding to the gene are useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein.

Example 54: Assay for Extracellular Matrix Enhanced Cell Response (EMECR)

The objective of the Extracellular Matrix Enhanced Cell Response (EMECR) assay is to identify gene products (e.g., isolated polypeptides) that act on the hematopoietic stem cells in the context of the extracellular matrix (ECM) induced signal.

Cells respond to the regulatory factors in the context of signal(s) received from the surrounding microenvironment. For example, fibroblasts, and endothelial and epithelial stem cells fail to replicate in the absence of signals from the ECM. Hematopoietic stem cells can undergo self-renewal in the bone marrow, but not in *in vitro* suspension culture. The ability of stem cells to undergo self-renewal *in vitro* is dependent upon their interaction with the stromal cells and the ECM protein fibronectin (fn). Adhesion of cells to fn is mediated by the α_5 . β_1 and α_4 . β_1 integrin receptors, which are expressed by human and mouse hematopoietic stem cells. The factor(s) which integrate with the ECM environment and responsible for stimulating

359

stem cell self-renewal has not yet been identified. Discovery of such factors should be of great interest in gene therapy and bone marrow transplant applications

5

10

15

20

25

30

Briefly, polystyrene, non tissue culture treated, 96-well plates are coated with fn fragment at a coating concentration of $0.2~\mu g/~cm^2$. Mouse bone marrow cells are plated (1,000 cells/well) in 0.2~ml of serum-free medium. Cells cultured in the presence of IL-3 (5~ng/ml) + SCF (50~ng/ml) would serve as the positive control, conditions under which little self-renewal but pronounced differentiation of the stem cells is to be expected. Gene products are tested with appropriate negative controls in the presence and absence of SCF(5.0~ng/ml), where test factor supernates represent 10% of the total assay volume. The plated cells are then allowed to grow by incubating in a low oxygen environment ($5\%~CO_2$, $7\%~O_2$, and $88\%~N_2$) tissue culture incubator for 7 days. The number of proliferating cells within the wells is then quantitated by measuring thymidine incorporation into cellular DNA. Verification of the positive hits in the assay will require phenotypic characterization of the cells, which can be accomplished by scaling up of the culture system and using appropriate antibody reagents against cell surface antigens and FACScan.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

If a particular gene product is found to be a stimulator of hematopoietic progenitors, polynucleotides and polypeptides corresponding to the gene may be useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein. The gene product may also be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Additionally, the polynucleotides and/or polypeptides of the gene of interest and/or agonists and/or antagonists thereof, may also be employed to inhibit the proliferation and differentiation of hematopoietic cells and therefore may be employed to protect bone marrow stem cells from chemotherapeutic agents during chemotherapy. This antiproliferative effect may allow administration of higher doses

360

of chemotherapeutic agents and, therefore, more effective chemotherapeutic treatment.

Moreover, polynucleotides and polypeptides corresponding to the gene of interest may also be useful for the treatment and diagnosis of hematopoietic related disorders such as, for example, anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

10

15

20

25

30

5

Example 55: Human Dermal Fibroblast and Aortic Smooth Muscle Cell Proliferation

The polypeptide of interest is added to cultures of normal human dermal fibroblasts (NHDF) and human aortic smooth muscle cells (AoSMC) and two coassays are performed with each sample. The first assay examines the effect of the polypeptide of interest on the proliferation of normal human dermal fibroblasts (NHDF) or aortic smooth muscle cells (AoSMC). Aberrant growth of fibroblasts or smooth muscle cells is a part of several pathological processes, including fibrosis, and restenosis. The second assay examines IL6 production by both NHDF and SMC. IL6 production is an indication of functional activation. Activated cells will have increased production of a number of cytokines and other factors, which can result in a proinflammatory or immunomodulatory outcome. Assays are run with and without co-TNFa stimulation, in order to check for costimulatory or inhibitory activity.

Briefly, on day 1, 96-well black plates are set up with 1000 cells/well (NHDF) or 2000 cells/well (AoSMC) in 100 μl culture media. NHDF culture media contains: Clonetics FB basal media, 1mg/ml hFGF, 5mg/ml insulin, 50mg/ml gentamycin, 2%FBS, while AoSMC culture media contains Clonetics SM basal media, 0.5 μg/ml hEGF, 5mg/ml insulin, 1μg/ml hFGF, 50mg/ml gentamycin, 50 μg/ml Amphotericin B, 5%FBS. After incubation @ 37°C for at least 4-5 hours culture media is aspirated and replaced with growth arrest media. Growth arrest media for NHDF contains

fibroblast basal media, 50mg/ml gentamycin, 2% FBS, while growth arrest media for

WO 01/34629

5

10

15

20

25

30

AoSMC contains SM basal media, 50mg/ml gentamycin, 50μg/ml Amphotericin B, 0.4% FBS. Incubate at 37C until day 2.

On day 2, serial dilutions and templates of the polypeptide of interest are designed which should always include media controls and known-protein controls. For both stimulation and inhibition experiments, proteins are diluted in growth arrest media. For inhibition experiments, TNFa is added to a final concentration of 2ng/ml (NHDF) or 5ng/ml (AoSMC). Then add 1/3 vol media containing controls or supernatants and incubate at 37C/5% CO₂ until day 5.

Transfer 60µl from each well to another labeled 96-well plate, cover with a plate-sealer, and store at 4C until Day 6 (for IL6 ELISA). To the remaining 100 µl in the cell culture plate, aseptically add Alamar Blue in an amount equal to 10% of the culture volume (10µl). Return plates to incubator for 3 to 4 hours. Then measure fluorescence with excitation at 530nm and emission at 590nm using the CytoFluor. This yields the growth stimulation/inhibition data.

On day 5, the IL6 ELISA is performed by coating a 96 well plate with 50-100 ul/well of Anti-Human IL6 Monoclonal antibody diluted in PBS, pH 7.4, incubate ON at room temperature.

On day 6, empty the plates into the sink and blot on paper towels. Prepare Assay Buffer containing PBS with 4% BSA. Block the plates with 200 µl/well of Pierce Super Block blocking buffer in PBS for 1-2 hr and then wash plates with wash buffer (PBS, 0.05% Tween-20). Blot plates on paper towels. Then add 50 µl/well of diluted Anti-Human IL-6 Monoclonal, Biotin-labeled antibody at 0.50 mg/ml. Make dilutions of IL-6 stock in media (30, 10, 3, 1, 0.3, 0 ng/ml). Add duplicate samples to top row of plate. Cover the plates and incubate for 2 hours at RT on shaker.

Wash plates with wash buffer and blot on paper towels. Dilute EU-labeled Streptavidin 1:1000 in Assay buffer, and add 100 μ l/well. Cover the plate and incubate 1 h at RT. Wash plates with wash buffer. Blot on paper towels.

Add 100 µl/well of Enhancement Solution. Shake for 5 minutes. Read the plate on the Wallac DELFIA Fluorometer. Readings from triplicate samples in each assay were tabulated and averaged.

A positive result in this assay suggests AoSMC cell proliferation and that the gene product of interest may be involved in dermal fibroblast proliferation and/or

5

10

15

20

25

30

362

smooth muscle cell proliferation. A positive result also suggests many potential uses of polypeptides, polynucleotides, agonists and/or antagonists of the gene/gene product of interest. For example, inflammation and immune responses, wound healing, and angiogenesis, as detailed throughout this specification. Particularly, polypeptides of the gene product and polynucleotides of the gene may be used in wound healing and dermal regeneration, as well as the promotion of vasculargenesis, both of the blood vessels and lymphatics. The growth of vessels can be used in the treatment of, for example, cardiovascular diseases. Additionally, antagonists of polypeptides of the gene product and polynucleotides of the gene may be useful in treating diseases, disorders, and/or conditions which involve angiogenesis by acting as an anti-vascular (e.g., anti-angiogenesis). These diseases, disorders, and/or conditions are known in the art and/or are described herein, such as, for example, malignancies, solid tumors, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; artheroscleric plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uvietis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis. Moreover, antagonists of polypeptides of the gene product and polynucleotides of the gene may be useful in treating antihyperproliferative diseases and/or anti-inflammatory known in the art and/or described herein.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

10

15

20

25

30

363

Example 56: Cellular Adhesion Molecule (CAM) Expression on Endothelial Cells

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Briefly, endothelial cells (e.g., Human Umbilical Vein Endothelial cells (HUVECs)) are grown in a standard 96 well plate to confluence, growth medium is removed from the cells and replaced with 100 µl of 199 Medium (10% fetal bovine serum (FBS)). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 µl volumes). Plates are then incubated at 37°C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100 µl of 0.1% paraformaldehyde-PBS(with Ca++ and Mg++) is added to each well. Plates are held at 4°C for 30 min. Fixative is removed from the wells and wells are washed 1X with PBS(+Ca,Mg) + 0.5% BSA and drained. 10 µl of diluted primary antibody is added to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 µg/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed three times with PBS(+Ca,Mg) + 0.5% BSA. 20 µl of diluted ExtrAvidin-Alkaline Phosphotase (1:5,000 dilution, refered to herein as the working dilution) are added to each well and incubated at 37°C for 30 min. Wells are washed three times with PBS(+Ca,Mg)+0.5% BSA. Dissolve 1 tablet of p-Nitrophenol Phosphate pNPP per 5 ml of glycine buffer (pH 10.4). 100 µl of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of

PCT/US00/30654

the ExtrAvidin-Alkaline Phosphotase in glycine buffer: $1:5,000 \ (10^0) > 10^{-0.5} > 10^{-1} > 10^{-1.5}$. 5 µl of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 µl of pNNP reagent is then added to each of the standard wells. The plate is incubated at 37°C for 4h. A volume of 50 µl of 3M NaOH is added to all wells. The plate is read on a plate reader at 405 nm using the background subtraction option on blank wells filled with glycine buffer only. Additionally, the template is set up to indicate the concentration of APconjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

364

10

15

20

25

30

5

WO 01/34629

Example 57: Alamar Blue Endothelial Cells Proliferation Assay

This assay may be used to quantitatively determine protein mediated inhibition of bFGF-induced proliferation of Bovine Lymphatic Endothelial Cells (LECs), Bovine Aortic Endothelial Cells (BAECs) or Human Microvascular Uterine Myometrial Cells (UTMECs). This assay incorporates a fluorometric growth indicator based on detection of metabolic activity. A standard Alamar Blue Proliferation Assay is prepared in EGM-2MV with 10 ng/ml of bFGF added as a source of endothelial cell stimulation. This assay may be used with a variety of endothelial cells with slight changes in growth medium and cell concentration. Dilutions of the protein batches to be tested are diluted as appropriate. Serum-free medium (GIBCO SFM) without bFGF is used as a non-stimulated control and Angiostatin or TSP-1 are included as a known inhibitory controls.

Briefly, LEC, BAECs or UTMECs are seeded in growth media at a density of 5000 to 2000 cells/well in a 96 well plate and placed at 37-C overnight. After the overnight incubation of the cells, the growth media is removed and replaced with GIBCO EC-SFM. The cells are treated with the appropriate dilutions of the protein of interest or control protein sample(s) (prepared in SFM) in triplicate wells with additional bFGF to a concentration of 10 ng/ml. Once the cells have been treated with the samples, the plate(s) is/are placed back in the 37° C incubator for three days. After three days 10 ml of stock alamar blue (Biosource Cat# DAL1100) is added to each well and the plate(s) is/are placed back in the 37°C incubator for four hours. The

10

20

25

30

plate(s) are then read at 530nm excitation and 590nm emission using the CytoFluor fluorescence reader. Direct output is recorded in relative fluorescence units.

Alamar blue is an oxidation-reduction indicator that both fluoresces and changes color in response to chemical reduction of growth medium resulting from cell growth. As cells grow in culture, innate metabolic activity results in a chemical reduction of the immediate surrounding environment. Reduction related to growth causes the indicator to change from oxidized (non-fluorescent blue) form to reduced (fluorescent red) form. i.e. stimulated proliferation will produce a stronger signal and inhibited proliferation will produce a weaker signal and the total signal is proportional to the total number of cells as well as their metabolic activity. The background level of activity is observed with the starvation medium alone. This is compared to the output observed from the positive control samples (bFGF in growth medium) and protein dilutions.

15 Example 58: Detection of Inhibition of a Mixed Lymphocyte Reaction

This assay can be used to detect and evaluate inhibition of a Mixed Lymphocyte Reaction (MLR) by gene products (e.g., isolated polypeptides). Inhibition of a MLR may be due to a direct effect on cell proliferation and viability, modulation of costimulatory molecules on interacting cells, modulation of adhesiveness between lymphocytes and accessory cells, or modulation of cytokine production by accessory cells. Multiple cells may be targeted by these polypeptides since the peripheral blood mononuclear fraction used in this assay includes T, B and natural killer lymphocytes, as well as monocytes and dendritic cells.

Polypeptides of interest found to inhibit the MLR may find application in diseases associated with lymphocyte and monocyte activation or proliferation. These include, but are not limited to, diseases such as asthma, arthritis, diabetes, inflammatory skin conditions, psoriasis, eczema, systemic lupus erythematosus, multiple sclerosis, glomerulonephritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, arteriosclerosis, cirrhosis, graft vs. host disease, host vs. graft disease, hepatitis, leukemia and lymphoma.

Briefly, PBMCs from human donors are purified by density gradient centrifugation using Lymphocyte Separation Medium (LSM[®], density 1.0770 g/ml,

WO 01/34629

5

10

15

20

25

30

366

PCT/US00/30654

Organon Teknika Corporation, West Chester, PA). PBMCs from two donors are adjusted to 2 x 10^6 cells/ml in RPMI-1640 (Life Technologies, Grand Island, NY) supplemented with 10% FCS and 2 mM glutamine. PBMCs from a third donor is adjusted to 2 x 10^5 cells/ml. Fifty microliters of PBMCs from each donor is added to wells of a 96-well round bottom microtiter plate. Dilutions of test materials (50 μ l) is added in triplicate to microtiter wells. Test samples (of the protein of interest) are added for final dilution of 1:4; rhuIL-2 (R&D Systems, Minneapolis, MN, catalog number 202-IL) is added to a final concentration of 1 μ g/ml; anti-CD4 mAb (R&D Systems, clone 34930.11, catalog number MAB379) is added to a final concentration of 10μ g/ml. Cells are cultured for 7-8 days at 37°C in 5% CO₂, and 1μ C of [3 H] thymidine is added to wells for the last 16 hrs of culture. Cells are harvested and thymidine incorporation determined using a Packard TopCount. Data is expressed as the mean and standard deviation of triplicate determinations.

Samples of the protein of interest are screened in separate experiments and compared to the negative control treatment, anti-CD4 mAb, which inhibits proliferation of lymphocytes and the positive control treatment, IL-2 (either as recombinant material or supernatant), which enhances proliferation of lymphocytes.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties. Additionally, the contents of U.S. Provisional Applications Nos. 60/164,835 and 60/221,142 are all hereby incorporated by reference in their entirety.

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13 bis)

A. The indications made below relate to the microorganism refer	red to in the description
on page, line	N/A .
B. IDENTIFICATIONOFDEPOSIT	Further deposits are identified on an additional sheet
Name of depositary institution American Type Culture Colle	ection
Address of depositary institution (including postal code and coun 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit	Accession Number
26 October 1999	PTA-867
C. ADDITIONAL INDICATIONS (leave blank if not applicab	le) This information is continued on an additional sheet
Europe In respect to those designations in which a European F microorganism will be made available until the publicat or until the date on which application has been refused the issue of such a sample to an expert nominated by the sa	Patent is sought a sample of the deposited ion of the mention of the grant of the European patent or withdrawn or is deemed to be withdrawn, only by the person requesting the sample (Rule 28 (4) EPC). Continued on the Attached Pages 2 & 3
E. SEPARATE FURNISHING OF INDICATIONS (leave to	
The indications listed below will be submitted to the Internation Number of Deposit")	nal Bureau later (specify the general nature of the indications e.g., "Accession
For receiving Office use only	For International Bureau use only
This sheet was received with the international application	This sheet was received by the International Bureau on:
Authorized officer	Authorized officer

ATCC Deposit No. PTA-867 Page No. 2

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

ATCC Deposit No.: PTA-867

Page No. 3

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

PCT/US00/30654

370

What Is Claimed Is:

WO 01/34629

5

10

15

- 1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;
 - (f) a polynucleotide which is a variant of SEQ ID NO:X;
 - (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
- (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
- 25 (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

371

- 2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.
- The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
- 4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
- 15 5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
- 6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
 - 7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

25

- 8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
 - 9. A recombinant host cell produced by the method of claim 8.

30

10. The recombinant host cell of claim 9 comprising vector sequences.

- 11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
- (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;
 - (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
- (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (g) a variant of SEQ ID NO:Y;

5

15

- (h) an allelic variant of SEQ ID NO:Y; or
- (i) a species homologue of the SEQ ID NO:Y.
- 12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.
- 13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.
- 25 14. A recombinant host cell that expresses the isolated polypeptide of claim 11.
 - 15. A method of making an isolated polypeptide comprising:
- (a) culturing the recombinant host cell of claim 14 under conditions such thatsaid polypeptide is expressed; and
 - (b) recovering said polypeptide.

WO 01/34629

PCT/US00/30654

373

- 16. The polypeptide produced by claim 15.
- 17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.
 - 18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
- (a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and
 - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.
- 19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
 - (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and
 - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20

- 20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:
 - (a) contacting the polypeptide of claim 11 with a binding partner; and
- (b) determining whether the binding partner effects an activity of thepolypeptide.
 - 21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.
- 22. A method of identifying an activity in a biological assay, wherein the 30 method comprises:
 - (a) expressing SEQ ID NO:X in a cell;
 - (b) isolating the supernatant;

374

- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

<110> Human Genome Sciences, Inc.

```
<120> 21 Human Secreted Proteins
<130> PS711PCT
<140> Unassigned
<141> 2000-11-08
<150> 60/164.835
<151> 1999-11-12
<150> 60/221,142
<151> 2000-07-27
<160> 157
<170> PatentIn Ver. 2.0
<210> 1
<211> 733
<212> DNA
<213> Homo sapiens
<400> 1
gggatccgga gcccaaatct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg
                                                                       60
aattcqaqqq tqcaccqtca qtcttcctct tccccccaaa acccaaqqac accctcatqa
                                                                       120
tctcccggac tcctgaggtc acatgcgtgg tggtggacgt aagccacgaa gaccctgagg
                                                                       180
tcaagttcaa ctggtacgtg gacggcqtqq aggtgcataa tgccaagaca aagccgcgqq
                                                                       240
aggageagta caacaqeacq taccqtqtqq teaqcqtect caccqtectq caccaqqact
                                                                       300
ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca acccccatcg
agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc
                                                                       420
catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct
                                                                       480
atccaagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac aactacaaga
                                                                       540
ccacgectee egtgetggae teegaegget cettetteet etacageaag etcacegtgg
                                                                       600
acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggctctgc
                                                                       660
acaaccacta cacgcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc
                                                                       720
qactctaqaq qat
                                                                       733
<210> 2
<211> 5
<212> PRT
<213> Homo sapiens
<220>
<221> Site
<222> (3)
<223> Xaa equals any of the twenty naturally ocurring L-amino acids
<400> 2
Trp Ser Xaa Trp Ser
1
<210> 3
<211> 86
```

2

<212> DNA <213> Homo	sapiens					
	atttccccga ctgccatctc	aatctagatt aattag	tccccgaaat	gatttccccg	aaatgatttc	60 86
<210> 4 <211> 27 <212> DNA <213> Homo	sapiens					
<400> 4 gcggcaagct	ttttgcaaag	cctaggc				27
<210> 5 <211> 271 <212> DNA <213> Homo	sapiens					
aaatatctgc gcccctaact ttatgcagag	catctcaatt ccgcccagtt gccgaggccg	tagatttece agtcagcaac cegcceatte ceteggeete gcaaaaaget	catagteceg teegececat tgagetatte	cccctaactc ggctgactaa	cgcccatccc tttttttat	
<210> 6 <211> 32 <212> DNA <213> Homo	sapiens					
<400> 6 gcgctcgagg	gatgacagcg	atagaacccc	aa			32
<210> 7 <211> 31 <212> DNA <213> Homo	sapiens					
<400> 7 gcgaagcttc	gcgactcccc	ggatccgcct	С			31
<210> 8 <211> 12 <212> DNA <213> Homo	sapiens					
<400> 8 ggggactttc	cc					12

<210> 9

<211> 73 <212> DNA <213> Homo sapiens <400> 9 gcggcctcga ggggactttc ccatctcaat tag	ccggggactt	tccggggact	ttccgggact	ttccatcctg	60 73
<210> 10 <211> 256 <212> DNA <213> Homo sapiens					
<pre><400> 10 ctcgaggga ctttcccggg caattagtca gcaaccatag cagttccgcc cattctccgc ggccgcctcg gcctctgagc cttttgcaaa aagctt</pre>	tecegeceet eccatggetg	aactccgccc actaattttt	atcccgcccc tttatttatg	taactccgcc cagaggccga	60 120 180 240 256
<210> 11 <211> 2406 <212> DNA <213> Homo sapiens					
<400> 11 ccacgcgtcc ggaatgaaca					60
gtgctttttt gttacccatc					120
ctgcatgttg attgttttgt					180
aatctaacac aaacagcaac					240
tgtggcaagt cctcatatca					300
gaattgcagc ttcaccagat					360
ataatagagc atggcagcaa					420
aaccttggag caataacagc					480
gaaagagcca ctttgctgga					540
caagtccaag tgagggacga					600 660
gactacaagt acctgactct		_			720
ctaaaggttc cagaaacaga gcagaagtat cctggccaaa					780
gaaggeetet accaggteac					840
agctgtgtgt tctggaatac					900
agtcagatgg aacccaggac					960
atcattgctt tcattttcat					1020
ctgtattctt caaaagacac					1080
agtgctgtga atctgaacct	gtggtcttgg	gagccagggt	gacctgatat	gacatctaaa	1140
gaagcttctg gactctgaac	aagaattcgg	tggcctgcag	agcttgccat	ttgcactttt	1200
caaatgcctt tggatgaccc					1260
ctggccatga aacttgcccc					1320
gcaagcacta ctgcacttta					1380
caggateett ettgetgeea					1440
agtgatttcc aaaagcagag					1500
aatagagtta ttttttatct					1560 1620
gageteacag acagggette					1620
tggaatcttg atagcataat aagtgcacaa attgtggagt					1740
catttgtttt aacctgtaat					1800
J J	5590	33-33		3	

tttcctttaa	aaattattgg	tttcttttta	tttatttta	ccttagaaat	caattatata	1860
	tatttgatat					1920
	aagccccaaa		_			1.980
						2040
_	tgcctcagtt	_	_	_		
	gcactatgga					2100
	tacagtaaca					2160
	cattagctga					2220
	ggtgggccta					2280
	tgtgaaattg					2340
tgtaaatcag	agaatgcctt	taaagaataa	aactcaattg	ttattcttca	aaaaaaaaa	2400
aaaaaa						2406
<210> 12						
<211> 3369						
<212> DNA						
<213> Homo	sapiens					
	_					
<400> 12						
	ccgcgtcgga	ccttccqcqq	accoggcgac	ccaqtqcacq	accaccacat	60
	cccgctgacc					120
	tcgaaagcgc					180
	gtgggagccc					240
	gggtcccaag					300
	cagtcgccc					360
						420
	atgcccgggg					480
	tacctgaagc					
	tgcaacagtc					540
	cccaggcaca					600
	aaattcacta					660
	aagagagtca					720
	tccaggtgca					780
	ccagattctt					840
	gagcctgctt					900
	gacaccagag					960
	tttaatgggg					1020
	gtggtctggt					1080
tcctttcgga	atgaatgttc	atggaagagg	ctcctctgag	ggcaagagac	ctgttttagt	1140
gctgcattcg	acatggaaaa	gtccttttaa	cctgtgcttg	catcctcctt	tectectect	1200
cctcacaatc	catctcttct	taagttgaya	gtgactatgt	cagtctaatc	tcttgtttgc	1260
carggttcct	aaattaattc	acttaaccat	gatgcaaatg	tttttcattt	tgtgaagacc	1320
	tgggagaggc					1380
ggagggtgga	gggtgaggcc	aaatcaggtc	cagcaaaagt	cagtagggac	attgcagaag	1440
cttgaaaggc	caataccaga	acacaggctg	atgcttctga	gaaagtcttt	tcctagtatt	1500
taacagaacc	caagtgaaca	gaggagaaat	gagattgcca	gaaagtgatt	aactttggcc	1560
gttgcaatct	gctcaaacct	aacaccaaac	tgaaaacata	aatactgacc	actcctatgt	1620
tcggacccaa	gcaagttagc	taaaccaaac	caactcctct	gctttgtccc	tcaggtggaa	1680
	gtttagaact					1740
	aatacctttc					1800
_	gcttctgaga		_	_		1860
	gtagtctaag	-				1920
	ctttttgttt					1980
	ataaagggaa	_				2040
	gggatatgac	-				2100
	agcatagcat					2160
	gtaactattc					2220
	tggctactta					2280
	ggatttggtt					2340
	2240003300			Jaggereare		2310

5

cctgaatact ctttttgcct gaaaacaaac actgcagact cccttgcaac tcgagaagct ctaacaacta acaggagcc gtctgattt caaactttta aaacacatact tcaacattct ccaacataca agaattttga gggtggagaa atgacattca gccacaagaa tgcaattcg taggagctg taccacct aacttcactg cctcaacact aacttcactg	tgagattcag gtttttattt atttcaaggc aactcactac ttgtatacac agcacagagt gaagaaaagg gaaccagcaa ttaayggaga ttgcacataa	ttgccgatca cgtttttgtt gggagatatt tgatgattct tgtatgaccc ggatttaatt gaaagaagct acactgaatt tgacttaagt gtgcagattt	aggetetgge ttgatecagt ttaaacacec caegetagge caececaaat aageacacaa gaaaatgtaa tetettgttg tggeageagt ggeteaagta	attcagagaa gctctcccat aaaatgttgg gaatttgtcc ctttgtattg atgctaaggc aaccacacca ttttaactct aatcttcttt aagagaattt	2400 2460 2520 2580 2640 2700 2760 2820 2880 2940 3000 3060
gccaaagagg gaaatatctg gtgtgtcttc caactttcat gatgatgtaa tgatatattt gtggtcttga tcatacctat cactttgtgc ttggcattaa tgcgcgatc	tgaaaatgcc tttcattatt taaaataatg	atatctatac atagtagaat ccaaacacca	catattttat atttttatgg aatatgaatt	tcgagtcact caagatattt ttatgatgta	3120 3180 3240 3300 3360 3369
<210> 13 <211> 3258 <212> DNA <213> Homo sapiens					
<400> 13 gcggccgcgt cgacgctggc	cactatataa	aactaatasa	taactaaaac	tatetaaace	60
atgaacaact tcagggccac					120
aagccttcgg gagagatgga					180
cctgtcctgg aagtcctacc					240
cgagttatgg aattgactta					300
cctgatgaaa tcttcaccat					360
ctggaatcct gggcaaatta					420
cttttttcca aagtcaatgg	caagttttcc	actgagttcc	agaggatgaa	gaccctccaa	480
gtgaaggacc aagctataac					540
atcaacccaa ctttagagct					600
cgtctagaga acaaccagac					660
tatggcaccc acgtcaccac					720
ctcagggcct ccttcctcca					780
ggacttgcct ttcaaaacac gtcctcacca agagctacct					840 900
gttccttttt acccaggcat					960
gtggccatcg accgctctgg					1020
gacttgccag gccccctggt					1080
tattatacat tcaacaccta					1140
caggccaaca cggatgatgg	ctcctgcgag	gggaaaatga	ccaacttctc	tttcggtggg	1200
gtttatcagg aatgcactca	gctctcaggg	aatagggatg	tcctcctctg	ccaaaagttg	1260
gagcagaaga atccactcac	tggtgatttc	tcctgcccct	ctggctactc	cccggtgcac	1320
ctgttatccc agatccacga					1380
ctcctcgtct tctgcaagac					1440
agggcttttt ggtgtgtggc					1500
ggcctcttca gcagcaagag					1560 1620
tactttccac tgagactctt ggaagcaggt ttgcggtccc					1620
gtagatcctg ctatatccag					1740
ttcagccagc acccagccct					1800
gggctcttca caggagggtc					1860
ctcatgagtc aggctgccac					1920
	~	2 0	2 3		

tggattaaag	actcccagac	ccaccagtgg	aggctgggag	aaccgataga	gctgcggagg	1980
			ggtctgtcag			2040
			gttatcacct			2100
			gaggaaaggc			2160
			caggggcaga			2220
			tcattgctga			2280
			atattcgtga			2340
						2400
			ggttgggatt			2460
			ataggaagca			
			aaaaatagcg			2520
			tttgcagttg			2580
			tttattttga			2640
			gaaaagacac			2700
tttttaactt	tgagggctct	atgttgacag	actgttatct	cctctgggtg	acctcaaaca	2760
tctgaaaaga	aagatgttgc	ctgtgccaat	tccacttttt	ccagctgccc	cttgatgaac	2820
actcccttat	accagaccac	tcttggactt	ctgactggtg	tcatcaagtc	ctcagaaaat	2880
			ggatgatttg			2940
			taagtactac			3000
			gaacacacac			3060
			tacctttcct			3120
			cacataccac			3180
			ttatatgaac			3240
acacacacgc		cgccccccg	ccacacgaac	acacacacac	acacacac	3258
acacacacge	acggccga					3230
<210> 14						
<211> 3077						
<212> DNA						
<213> Homo	sapiens					
<400> 14						
ccacgcgtcc			ggggcagccg			60
ccacgcgtcc gctcgcggcg	ctgggttcct	ggtctccggg	ccagggcaat	gttccgcacg	gcagtgatga	120
ccacgcgtcc gctcgcggcg tggcggccag	ctgggttcct cctggcgctg	ggtctccggg accggggctg	ccagggcaat tggtggctca	gttccgcacg cgcctactac	gcagtgatga ctcaaacacc	120 180
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc	ctgggttcct cctggcgctg cactgtggtg	ggtctccggg accggggctg tacctgacca	ccagggcaat tggtggctca agtccagccc	gttccgcacg cgcctactac cagcatggca	gcagtgatga ctcaaacacc gtcctgtaca	120 180 240
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc	ctgggttcct cctggcgctg cactgtggtg	ggtctccggg accggggctg tacctgacca	ccagggcaat tggtggctca	gttccgcacg cgcctactac cagcatggca	gcagtgatga ctcaaacacc gtcctgtaca	120 180
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc	ggtctccggg accggggctg tacctgacca ttccttctgg	ccagggcaat tggtggctca agtccagccc	gttccgcacg cgcctactac cagcatggca gggcaaggtg	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc	120 180 240
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg	ggtctccggg accggggctg tacctgacca ttccttctgg gagcaccttc	ccagggcaat tggtggctca agtccagccc gcaaggtgat	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga	120 180 240 300
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt	ggtctccggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca	120 180 240 300 360
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa	ggtctccggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttccact	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg	120 180 240 300 360 420
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc ctcttcttct aacgcagccc	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc	ggtctccggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttccact tggctctttc	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgccgcat	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgttcctcc	120 180 240 300 360 420 480
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc ctcttcttct aacgcagccc tgggcatcct	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc ggacttcctc	ggtctccggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttcact tggctctttc ttcgtcagcc	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgccgcat acgcctatca	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt cagcatcctg	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgtcctcc acccgtgggg	120 180 240 300 360 420 480 540
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc ctcttcttct aacgcagccc tgggcatcct cctctgtgca	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc ggacttcctc gctggtgttt	ggtctccggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttcact tggctctttc ttcgtcagcc ggctttgagt	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgccgcat acgcctatca atgccatcct	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt cagcatcctg gatgacgatg	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgttcctcc acccgtgggg gtgctcacca	120 180 240 300 360 420 480 540 600
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc ctcttcttct aacgcagccc tgggcatcct cctctgtgca tcttcatcaa	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc ggacttcctc gctggtgttt gtatgtgctg	ggtctccggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttccact tggctctttc ttcgtcagcc ggctttgagt cactccgtgg	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgccgcat acgcctatca atgccatcct acctccagag	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt cagcatcctg gatgacgatg tgagaacccc	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgttcctcc acccgtgggg gtgctcacca tgggacaaca	120 180 240 300 360 420 480 540 600 660 720
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc ctcttcttct aacgcagccc tgggcatcct cctctgtgca tcttcatcaa aggctgtgta	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc ggacttcctc gctggtgttt gtatgtgctg catgctctac	ggtctccggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttccact tggctctttc ttcgtcagcc ggctttgagt cactccgtgg acagagctgt	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgccgcat acgcctatca atgccatcct acctccagag ttacaggctt	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt cagcatcctg gatgacgatg tgagaacccc catcaaggtt	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgttcctcc acccgtgggg gtgctcacca tgggacaaca ctgctgtaca	120 180 240 300 360 420 480 540 600 660 720 780
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc ctcttcttct aacgcagccc tgggcatcct cctctgtgca tcttcatcaa aggctgtgta tggccttcat	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc ggacttcctc gctggtgttt gtatgtgctg catgctctac gaccatcatg	ggtctccggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttccact tggctctttc ttcgtcagcc ggctttgagt cactccgtgg acagagctgt atcaaggtgc	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgccgcat acgcctatca atgccatcct acctccagag ttacaggctt acaccttccc	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt cagcatcctg gatgacgatg tgagaacccc catcaaggtt actctttgcc	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgttcctcc acccgtgggg gtgctcacca tgggacaaca ctgctgtaca atccggcca	120 180 240 300 360 420 480 540 600 660 720 780 840
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc ctcttcttct aacgcagccc tgggcatcct cctctgtgca tcttcatcaa aggctgtgta tggccttcat tgtacctggc	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc ggacttcctc gctggtgttt gtatgtgctg catgctctac gaccatcatg catgagacag	ggtctcggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttccact tggctctttc ttcgtcagcc ggctttgagt cactccgtgg acagagctgt atcaaggtgc ttcaagaaag	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgccgcat acgcctatca atgccatcct acctccagag ttacaggctt acaccttccc ctgtgacaga	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt cagcatcctg gatgacgatg tgagaacccc catcaaggtt actctttgcc tgccatcatg	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgtcctcc acccgtgggg gtgctcacca tgggacaaca ctgctgtaca atccggcca tctcgccgag	120 180 240 300 360 420 480 540 600 660 720 780 840 900
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc ctcttcttct aacgcagccc tgggcatcct cctctgtgca tcttcatcaa aggctgtgta tggccttcat tgtacctggc ccatccgcaa	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc ggacttcctc gctggtgttt gtatgtgctg catgctctac gaccatcatg catgagacag catgaacacc	ggtctcggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttccact tggctctttc ttcgtcagcc ggctttgagt cactccgtgg acagagctgt atcaaggtgc ttcaagaaag ctgtatccag	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgccgcat acgcctatca atgccatcct acctccagag ttacaggctt acaccttccc ctgtgacaga atgccaccc	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt cagcatcctg gatgacgatg tgagaacccc catcaaggtt actctttgcc tgccatcatg agaggagctc	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgtcccc acccgtgggg gtgctcacca tgggacaaca ctgctgtaca atccggcca tctcgccgag caggcaatgg	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc ctcttcttct aacgcagccc tgggcatcct cctctgtgca tcttcatcaa aggctgtgta tggccttcat tgtacctggc ccatccgcaa acaatgtctg	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc ggacttcctc gctggtgttt gtatgtgctg catgctctac gaccatcatg catgagacag catgagacag catgaccc catcatctgc	ggtctcggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttccact tggctctttc ttcgtcagcc ggctttgagt cactccgtgg acagagctgt atcaaggtgc ttcaagaaag ctgtatccag cgagaagaga	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgccgcat acgcctatca atgccatcct acctccagag ttacaggctt acaccttccc ctgtgacaga atgccacccc tggtgactgg	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt cagcatcctg gatgacgatg tgagaacccc catcaaggtt actctttgcc tgccatcatg agaggagctc tgccaagaga	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgtcccc acccgtgggg gtgctcacca tgggacaaca ctgctgtaca atccggcca tctcgccgag caggcaatgg ctgccctgca	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc ctcttcttct aacgcagccc tggcatcct cctctgtgca tcttcatcaa aggctgtgta tggccttcat tgtacctggc ccatccgcaa acaatgtctg accacatttt	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc ggacttcctc gctggtgttt gtatgtgctg catgctctac gaccatcatg catgagacag catgagacag catgacacc catcatctgc ccataccagc	ggtctcggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttccact tggctctttc ttcgtcagcc ggctttgagt cactccgtgg acagagctgt atcaagatgc ttcaagaaag ctgtatccag cgagaagaga tgcctgcgct	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgccgcat acgcctatca atgccatcct acctccagag ttacaggctt acaccttccc ctgtgacaga atgccacccc tggtgactgg cctggttcca	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt cagcatcctg gatgacgatg tgagaacccc catcaaggtt actctttgcc tgccatcatg agaggagctc tgccaagaga gcggcagcag	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgttccc acccgtgggg gtgctcacca tgggacaaca ctgctgtaca atccggccca tctcgccgag caggcaatgg ctgccctgca acctgccca	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc ctcttcttct aacgcagccc tggcatcct cctctgtgca tcttcatcaa aggctgtgta tggccttcat tgtacctggc ccatccgcaa acaatgtctg accacatttt	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc ggacttcctc gctggtgttt gtatgtgctg catgctctac gaccatcatg catgagacag catgagacag catgacacc catcatctgc ccataccagc ggatgtctt	ggtctcggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttccact ttggtctttc ttcgtcagcc ggctttgagt cactccgtgg acagagctgt atcaagatgc ttcaagaaag ctgtatccag cgagaagaga tgcctgcgct cgtgcatcgc	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgcccata acgcctatca acgcctatca actccagag ttacaggctt acaccttccc ctgtgacaga atgccacccc tggtgactgg cctggttcca tgccagcgca	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt cagcatcctg gatgacgatg tgagaacccc catcaaggtt actctttgcc tgccatcatg agaggagctc tgccaagaga gcggcagcag gtcaccacca	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgttcctcc accegtgggg gtgctcacca tgggacaaca ctgctgtaca atccggccca tctcgccgag caggcaatgg ctgccctgca acctgccca accccggagc	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc ctcttcttct aacgcagccc tgggcatcct cctctgtgca tcttcatcaa aggctgtgta tggccttcat tgtacctggc ccatccgcaa acaatgtctg accacatttt cctgcggatca	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc ggacttcctc gctggtgttt gtatgtgctg catgctctac gaccatcatg catgagacag catgagacag catgacacc catcatctgc ccataccagc ggatgtcctt ggggccaccc	ggtctccggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttccact tggctcttc ttcgtcagcc ggctttgagt cactccgtgg acagagctgt atcaagacag ttcaagaaag ctgtatccag cgagaagaga tgcctgcgct cgtgcatcgc	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgccgcat acgcctatca atgccatcct acctccagag ttacaggctt acaccttccc ctgtgacaga atgccacccc tggtgactgg cctggttcca tgccagcgca acccccccc	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt cagcatcctg gatgacgatg tgagaacccc catcaaggtt actctttgcc tgccatcatg agaggagctc tgccaagaga gcggcagcag gtcaccacca actcttgcct	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgttcctcc acccgtgggg gtgctcacca ttgggacaaca ctgctgtaca atccggcca tctcgccgag caggcaatgg ctgccctgca acctgccca ccccggagc cagccccca	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc ctcttcttct aacgcagccc tgggcatcct cctctgtgca tcttcatcaa aggctgtgta tggccttcat tgtacctggc ccatccgcaa acaatgtctg accacatttt cctgcggatca acttcccca	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc ggacttcctc gctggtgttt gtatgtgctg catgctctac gaccatcatg catgagacag catgagacag catgacacc catcatctgc ccataccagc ggatgtcctt ggggccaccc gggcctcctg	ggtctccggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttccact tggctcttc ttcgtcagcc ggctttgagt cactccgtgg acagagctgt atcaagaaag ctgtatccag cgagaagaga tgcctgcgct cgtgcatcgc cctgccccc cctcctttc	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgccgcat acgcctatca atgccatcct acctccagag ttacaggctt acaccttccc ctgtgacaga atgccacccc tggtgactgg cctggttcca tgccagcgca acccccacc ctccaggcat	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt cagcatcctg gatgacgatg tgagaacccc catcaaggtt actctttgcc tgccatcatg agaggagctc tgccaagaga gcggcagcag gtcaccacca actcttgcct gttcccactg	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgttcctcc acccgtgggg gtgctcacca ttgggacaaca ctgctgtaca atccggcca tctcgccgag caggcaatgg ctgccctgca acctgccca accccggagc cagccccca tggcccca	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc ctcttcttct aacgcagccc tgggcatcct cctctgtgca tcttcatcaa aggctgtgta tggccttcat tgtacctggc ccatccgcaa acaatgtctg accacatttt cctgcggatca tctgcggatca tctgcggatca acttcccca tgggcccctt	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc ggacttcctc gctggtgttt gtatgtgctg catgctctac gaccatcatg catgagacag catgagacag catgacacc ccataccagc ggatgtctt ggggccaccc gggcctcctg tccacctgtc	ggtctcggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttccact tggctcttc ttcgtcagcc ggctttgagt cactcgtgg acagagctgt atcaagaaag ctgtatccag cgagaagaga tgcctgcgct cgtgcatcgc cctgccccc cctccttttc	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgccgcat acgcctatca atgccatcct acctccagag ttacaggctt acaccttccc ctgtgacaga atgccacccc tggtgactgg cctggttcca tgccagcgca acccccacc ctccaggcat ccagctcagg	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt cagcatcctg gatgacgatg tgagaacccc catcaaggtt actctttgcc tgccatcatg agaggagctc tgccaagaga gcggcagcag gtcaccacca actcttgcct gtcccactg agaggctgtg	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgttcctcc acccgtgggg gtgctcacca ttgggacaaca ctgctgtaca atccggcca tctcgccgag caggcaatgg ctgccctgca acctgccca acctgccca tctcccgagc cagccccca gctcccca	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc ctcttcttct aacgcagccc tgggcatcct cctctgtgca tcttcatcaa aggctgtgta tggccttcat tgtacctggc ccatccgcaa acaatgtctg accacatttt cctgcggatca tctgcggatca tctgcgcatc	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc ggacttcctc gctggtgttt gtatgtgctg catgctctac gaccatcatg catgagacag catgagacag catgacacc catcatctgc ccataccagc ggatgtcctt ggggccaccc gggcctcctg tccacctgtc agcagcctt	ggtctcggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttccact tggctcttc ttcgtcagcc ggctttgagt cactcgtgg acagagctgt atcaagaaag ctgtatccag cgagaagaga tgcctgcgct cgtgcatcgc cctgccccc cctccttttc ccgcctccca	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgcccatca actgccatca actcccagag ttacaggctt acacctccc ctgtgacaga atgccacccc tggtgactgg cctggttcca tgccagcgca accccccc ctgcagcgca acccccacc ctccaggcat ccagctcagg	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt cagcatcctg gatgacgatg tgagaacccc catcaaggtt actctttgcc tgccatcatg agaggagctc tgccaagaga gcggcagcag gtcaccacca actcttgcct gttcccactg agaggctgtg tgagagcaca	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgttcctcc acccgtgggg gtgctcacca ttgggacaaca ctgctgtaca atccggcca tctcgccgag caggcaatgg ctgccctgca acctgccca acctgccca tctcccgagc cagccccca tgccccca tggccccca tggccccca tggccccca tggccccca	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc ctcttcttct aacgcagccc tgggcatcct cctctgtgca tcttcatcaa aggctgtgta tggccttcat tgtacctggc ccatccgcaa acaatgtctg accacatttt cctgcggatca tctgcggatca tctgcgcatc	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc ggacttcctc gctggtgttt gtatgtgctg catgctctac gaccatcatg catgagacag catgagacag catgacacc catcatctgc ccataccagc ggatgtcctt ggggccaccc gggcctcctg tccacctgtc agcagcctt	ggtctcggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttccact tggctcttc ttcgtcagcc ggctttgagt cactcgtgg acagagctgt atcaagaaag ctgtatccag cgagaagaga tgcctgcgct cgtgcatcgc cctgccccc cctccttttc ccgcctccca	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgccgcat acgcctatca atgccatcct acctccagag ttacaggctt acaccttccc ctgtgacaga atgccacccc tggtgactgg cctggttcca tgccagcgca acccccacc ctccaggcat ccagctcagg	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt cagcatcctg gatgacgatg tgagaacccc catcaaggtt actctttgcc tgccatcatg agaggagctc tgccaagaga gcggcagcag gtcaccacca actcttgcct gttcccactg agaggctgtg tgagagcaca	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgttcctcc acccgtgggg gtgctcacca ttgggacaaca ctgctgtaca atccggcca tctcgccgag caggcaatgg ctgccctgca acctgccca acctgccca tctcccgagc cagccccca tgccccca tggccccca tggccccca tggccccca tggccccca	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc cttgtcttct aacgcagccc tgggcatcct cctctgtgca tcttcatcaa aggctgtgta tggccttcat tgtacctggc ccatccgcaa acaatgtctg accacatttt cctgcggatca ctgcggatca tgggcccctt ccaccagtgc	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc ggacttcctc gctggtgttt gtatgtgctg catgctctac gaccatcatg catgaacacg catgaacacg cataccagc ggatgtcctt ggggccaccc gggcctcctg tccacctgtc agcagcctt tgctgcttct	ggtctcggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttcact tggctctttc ttcgtcagcc ggctttgagg acatcgtgg acataggtgc ttcaagaaag ctgtatccag cgagaagaga tgcctgcgct cgtgcatcgc cctgccccc cctccttttc ccgcctccca gccacagcat	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgcccatca actgccatca actcccagag ttacaggctt acacctccc ctgtgacaga atgccacccc tggtgactgg cctggttcca tgccagcgca accccccc ctgcagcgca acccccacc ctccaggcat ccagctcagg	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt cagcatcctg gatgacgatg tgagaacgcc catcaaggtt actctttgcc tgccatcatg agaggagctc tgccaagaga gcggcagcag gtcaccacca actcttgcct gttcccactg agaggctgtg tgagagctct	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgttcctcc acccgtgggg gtgctcacca ttgggacaaca ctgctgtaca atccggccaa cctgccgag cagcactgca acctgccca cccccggagc cagccccca tggccccca tggccccca tggccccca gctcctccat gctgctgca gccccaggg	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc ctcttcttct aacgcagccc tgggcatcct cctctgtgca tcttcatcaa aggctgtgta tggccttcat tgtacctggc ccatccgcaa acaatgtctg accacatttt cctgcggatca tctgcggatca tctgcggatca cctgcgcat cctgcgcat cctgccgtat cctgcggatca tcgggatca tcgggatca tcgggatca tcgggatca tcgggccctt	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc ggacttcctc gctggtgttt gtatgtgctg catgctctac gaccatcatg catgaacacc catcatctgc ccataccagc ggatgtcctt ggggccaccc gggcctcctg tccacctgtc agcagcctt tgctgcttct cctggtttc	ggtctccggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttccact tggctctttc ttcgtcagcc ggctttgagt cactccgtgg acagagctgt atcaaggtgc ttcaagaaag ctgtatccag cgagaagaga tgcctgcgct cgtgcatcgc cctgccccc cctccttttc ccgcctcccc tctcggccca gccacagcat cccttcctc	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgccgcat acgcctatca atgccatcct acctccagag ttacaggctt acaccttccc ctgtgacaga atgccacccc tggtgactgg cctggttcca tgccagcgca acccccacc ctccaggcat ccagctcagg gtggagcagc ctggcccagg ctccctggat	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt cagcatcctg gatgacgatg tgagaacgcc catcaaggtt actctttgcc tgccatcatg agaggagctc tgccaagaga gcggcagcag gtcaccacca actcttgcct gttcccactg agaggctgtg tacaaccaca ctctggctct gggtatgcc	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgttcctcc acccgtgggg gtgctcacca ttgggacaaca ctgctgtaca atccggccaa cctgccgag caggcaatgg ctgcccca acctgccca acctgcccaa gctcctccat gctgctgca gctcctcat gctgctgca gccccagagg ctgcccca	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440
ccacgcgtcc gctcgcggcg tggcggccag agttctaccc tccaggcctt aactgagggc cttgtctggc cttgtcttct aacgcagccc tgggcatcct cctctgtgca tcttcatcaa aggctgtgta tggccttcat tgtacctggc ccatccgcaa acaatgtctg accacatttt cctgcggatca tctgcggatca ctggggccctt ccaccagtgc ccatggccttc	ctgggttcct cctggcgctg cactgtggtg tgtccttgtc agcagagatg cttcaccgtt cttcctcaaa caacatctcc ggacttcctc gctggtgttt gtatgtgctg catgctctac gacatcatg catgaacacc catcatctgc ccataccagc ggatgtcctt ggggccaccc gggcctcctg tccacctgtc agcagcctt tgctgcttct cccccaatg	ggtctceggg accggggctg tacctgacca ttccttctgg gagcaccttc tttcgggatg tgtttccact tggctctttc ttcgtcagcc ggctttgagg acatcegtgg acagagetgt atcaaggtgc ttcaagaaag ctgtatccag cgagaagaga tgcctgcgct cgtgcatcgc cctgccccc cctccttttc ccgcctcccc tctcggccca gccacagcat ccttccctc	ccagggcaat tggtggctca agtccagccc gcaaggtgat tggaacgttc acttcagccc ggctggctga actgccgcat acgcctatca atgccatcct acctccagag ttacaggctt acaccttccc ctgtgacaga atgccacccc tggtgactgg cctggttcca tgccagcgca acccccacc ctccaggcat ccagctcagg gtggagcagc ctggcccagg	gttccgcacg cgcctactac cagcatggca gggcaaggtg ctggtacgcc ccgctttgtt ggaccgtgtg tgtctctctt cagcatcctg gatgacgatg tgagaacgcc catcaaggtt actctttgcc tgccatcatg agaggagctc tgccaagaga gcggcagcag gtcaccacca actcttgcct gttcccactg agaggctgtg tacaaccaca ctctggctct gggtatgcc tgctgggctg	gcagtgatga ctcaaacacc gtcctgtaca ttctttgggc gtcacagaga gcactcttca gactttatgg atgttcctcc acccgtgggg gtgctcacca ttgggacaaca ctgctgtaca atccggccaa ctgccctgca acctgcccac cccccggagc cagccccca tggccccca tggccccca tggccccca tggccccca tgccccca tgccccca gctcctccat gctgctgca acctgcccca	120 180 240 300 360 420 480 540 600 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500

```
gtaacatcca cacactgctg gacgccgcca tgctqcaqat caaccagtac ctcaccgtgc
                                                                  1680
tggcctcctt ggggcccccc cggcctgcca cttcagtcaa ctccactgag gagactgcca
                                                                  1740
ctacagttgt tgctgctgcc tcctccacca gcatccctag ctcagaggcc acgaccccaa
                                                                  1800
ccccaggagc ctccccacca gcccctgaaa tggaaaggcc tccagctcct gagtcagtgg
                                                                  1860
gcacagagga gatgcctgag gatggagagc ccgatgcagc agagctccgc cggcgccgcc
                                                                  1920
1980
ctcttttgag cagccctcgc tggaacatgt cctgccacca agtgccagct ccctctctgt
                                                                  2040
ctgcaccagg gagtagtacc cccagctctg agaaagaggc ggcatcccct aggccaagtg
                                                                  2100
gaaagaggct ggggttccca tttgactcca gtcccaggca gccatgggga tctcgggtca
                                                                  2160
gttccagcct tcctctccaa ctcttcagcc ctgtgttctg ctggggccat gaaggcagaa
                                                                  2220
ggtttagcct ctgagaagcc ctcttcttcc cccacccctt tccaggagaa ggggctgccc
                                                                  2280
ctccaagccc tacttgtatg tgcggagtca cactgcagtg ccgaacagta ttagctcccg
                                                                  2340
ttcccaagtg tggactccag aggggctgga ggcaagctat gaacttgctc gctggcccac
                                                                  2400
ccctaagact ggtacccatt tccttttctt accctgatct ccccagaagc ctcttgtggt
                                                                  2460
ggtggctgtg ccccctatgc cctgtggcat ttctgcgtct tactggcaac cacacaactc
                                                                  2520
agggaaagga atgcctggga gtgggggtgc aggcgggcag cactgaggga ccctgccccg
                                                                  2580
cocctcccc caggecctt tecectgeag ettetcaagt gagactgace tgtetcacce
                                                                  2640
ageagecaet geccageege actecaggea agggecagtg egectgetee tgaccaetge
                                                                  2700
aatcccagcg cccaaggaag gccacttctc aactggcaga acttctgaag tttagaattg
                                                                  2760
gaattacttc cttactagtg tcttttggct taaattttgt cttttgaagt tgaatgctta
                                                                  2820
                                                                  2880
atcccgggaa agaggaacag gagtgccaga ctcctggtct ttccagttta gaaaaggctc
tgtgccaagg agggaccaca ggagctggga cctgcctgcc cctgtctttt ccccttggtt
                                                                  2940
                                                                  3000
ttgtgttaca agagttgttg gagacagttt cagatgatta tttaatttgt aaatattgta
caaattttaa taqcttaaat tgtatataca gccaaataaa aacttgcatt aacaattaaa
                                                                  3060
aaaaaaaaa aaaaaaa
                                                                  3077
```

```
<210> 15
<211> 1082
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (211)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1027)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1041)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1042)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1079)
<223> n equals a,t,g, or c
```

<400> 15

8

gtttccttgg	ggacgtggcg	ccgccgccgg	ccgggccctc	cttccggctg	ggcaaggggc	60
		tgaaccgaga				120
		tgcctgggac				180
		gaccaccgaa				240
		tacttcactg				300
						360
		ttcttcatat				
		tcattaccac				420
gagtagggga	gcttgaagct	actgacactg	aagacccaaa	tctgaattat	ggacttgktg	480
ttgactgtgg	cagcagtggt	tcccggattt	ttgkttattt	ctggccaaga	cataatggga	540
acccccatga	cttgctggac	atcaaacaga	tgagagaccg	caacagccaa	ccagtggtta	600
		tctgcaatgg				660
		gctgctgctc				720
		gcaggcatga				780
						840
		gatttaccac				900
		aagcaggaag				
		gaggatgaat				960
		gggatactgg				1020
atgaagntcc	tacctttccc	nnaaaaaaaa	cccccccct	ttttcccctt	ttggggggna	1080
ta						1082
<210> 16						
<211> 2070						
<212> DNA						
<213> Homo	sapiens					
<400> 16						
ttttggtttt	tttttttt	tttttttc	catctttgaa	gtcctttatt	cccagcagtt	60
		ctggggttcg				120
		cctcatctcc				180
		aggcaagggg				240
						300
		gcaaatatct				
		gccatggttc				360
cacagattcc	cctggagaaa	atacaggcca	ttctcatctt	ctcaacatgc	attttcccac	420
		tatcccctgg				480
gaatacattt	ttattttccc	ttcatgacat	agacttggtt	ccaagtatat	tttattttcc	540
		tccaattttg				600
		agaacaggct				660
		agctcaggtg				720
		tgtccaatac				780
						840
		tgggaagctt				
		tctgggtggg				900
		cagctacact				960
agtaggcctt	cggtaggtat	ctgtggaacc	cacgagtggg	tttcctattt	cattatctgt	1020
tcccctatgc	tctctatttt	tatcagaaat	ctgagcagga	aagagcagag	agaatgagtc	1080
aagagcatcc	tctcaagtga	attcgctgct	gagaaaggaa	ccgtagggct	tgcatttctc	1140
		gctttaacag				1200
		aaagcccttc				1260
						1320
		cttggaagca				1380
		aactttgtca				
		acttatcttt				1440
		acccaacatt				1500
		aatttccagg				1560
		aatgcagtat				1620
		gatgaacaag				1680
		ccccgagatc				1740
		gcatgcttag				1800
		aacactgaag				1860
gegaggeeee	cccggacggg	uacuccyaay	ccgcgccca	Jacocaagge	cccacageca	1000

```
attgcatcac atccacggct gcctccagga cctcaqqqqc cacctgaaac cactgggggt
                                                                       1920
tecceetgge teccetteta accagaaaca ggaaagcaag ceatteceta acetecceae
                                                                       1980
ccaccaggee ttatcaccge etteccagag ttteetetat gatttgeata eccetttgtt
                                                                       2040
                                                                       2070
ccctagtcct gagaacacag cagagctttc
<210> 17
<211> 2055
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (2014)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (2016)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (2038)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (2045)
<223> n equals a,t,g, or c
<400> 17
gacgatgcct gcttgaattt cctggcagct aagggaataa acatccaggg gctgtctgca
                                                                         60
qaaqaqatca qqaatqqaaa cctcaaqqcc attctaggcc tcttcttcag cctctcccga
                                                                        120
tacaagcagc agcagcagca gccccagaag cagcacctct cctcacctct gccgcccgcc
                                                                        180
gtateceagg tggcegggge ecceteceag tgecaggetg geacecetea geageaggtg
                                                                        240
ccagtcactc cccaagcccc gtgccagcct caccagccag caccacatca gcagtcaaaa
                                                                        300
gcacaagctg aaatgcagtc cagagccttt ggcaagttca gcctcctccc accccggaat
                                                                        360
gagtgacaat gcacctgctt ccttggagag cggcagcagc tccaccccta ctaattgcag
                                                                        420
tacctcctcg gccatcccgc agcccggtgc agccaccaag ccttggcgca gcaaatccct
                                                                        480
cagegtgaag cacagtgcca eggtatecat geteteggte aageeteetg ggeetgagge
                                                                        540
ccccaggccc acacctgaag ccatgaagcc ggcccccaac aatcagaagt ccatgctgga
                                                                        600
aaagetgaaa etttteaaca gtaaaggggg etcaaaggca ggtgagggge eggggteeeg
                                                                        660
ggacacaagc tgtgagcggc tggagactct gcccagcttc gaagagagcg aggagctgga
                                                                        720
                                                                        780
ggccgccagt cgcatgctca ccaccgtggg ccctgcttcc agcagcccca agattgcact
caagggcatt gcccagagga cttttagccg ggcactgacc aacaagaaga gttctctgaa
                                                                        840
aggcaatgag aaagagaagg agaaacaaca gcgggagaag gataaggaga aaagcaagga
                                                                        900
                                                                        960
ccttgccaag agagcctctg tgacggagag gctggacctc aaggaggagc caaaagaaga
ccccagtgga gcagctgtgc ccgagatgcc aaaaaagtcc tccaagattg ccagcttcat
                                                                       1020
ccccaaaggg gggaagctca acagtgccaa gaaggagccc atggcccctt cccacagtgg
                                                                       1080
aataccaaaa ccaggaatga agagcatgcc cgggaaatcc ccaagtgccc cagcgccttc
                                                                       1140
caaggaaggg gagcggagcc ggagtgggaa gctgagctca ggactccccc agcagaagcc
                                                                       1200
ccagetggae ggeagaeact ccagtteete ttecageetg gegteeteag aaggaaaagg
                                                                       1260
cccaggaggg accaccctga accacagcat cagcagccag actgtcagtg ggtctgtcgg
                                                                       1320
gaccacccag accacaggaa gcaataccgt cagtgttcag ctacctcagc cccagcagca
                                                                       1380
atacaaccat cocaacactg ccacggttgc acctttcttg tacaggtctc agacggacac
                                                                       1440
tgaagggaat gstacygscg agtcaagctc aacaggtgtg agcgtggagc ccagscactt
                                                                       1500
yccaaqactg gacaqcctgc tctqqaaqaa ctcactgggg aagatcctqa gqctcggcgg
                                                                       1560
```

```
ctgcggacag tgaagaacat cgctgatctg cggcagaatt tggaggaaac catgtccagt
                                                                       1620
ttaaggggaa ctcaggttac acacagcaca ttggaaacca cgtttgacac caatgtcacc
                                                                       1680
acggagatga gtggccgtag catactcagc ttgacaggga ggcccacacc tctgtcctgg
                                                                       1740
agactgggcc agtccagccc tcggctccaa gcaggagacg cccctcaat gggcaatggg
                                                                       1800
tatececete gagecaaege cageaggtte ateaacaetg agteaggteg ctatgtgtae
                                                                       1860
tecgeceete tgagaaggea getggeetee eggggeagta gtgtetgeea tgtggaegte
                                                                       1920
ttagacaagg caggagatga gatggacctg gaaggcatca gcatggacgc ccccggctca
                                                                       1980
tgagcgatgg ggatgtaact gagcaagaac attntngacc gatgacaatt atcaaagncg
                                                                       2040
gggcntacca ttgta
                                                                       2055
<210> 18
<211> 829
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (758)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (767)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (793)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (810)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (814)
<223> n equals a,t,g, or c
<400> 18
gacaggggtg agccaccgcc ccaggcctct ttcggcactg ccctcaacca catgggcctc
                                                                        60
actittette eggegtaeee agaettteee cateteageg cetteeeace ggteetgtgt
                                                                        120
ttccatggcc tttccccggg taggggcctt tcttttccta gcttcgctca gttccctgct
                                                                        180
acattgtege etcetegeag aageegtete tggeegttee gtategetag egeeetetat
                                                                        240
cattegetaq cageteacce ggetetgttt ttetteattg caettetegt tatgtgeegt
                                                                        300
totottataa atgtttttgt otttatooot oocatagaag acacotocat gaaaggooag
                                                                        360
ggctttccga ggttcttttc ctctgtggtt cctagaagag ggcctggcac atagccggcc
                                                                        420
ttggctagct ttttgcgtaa atgtgaaggg atccaccttc ctcccttata agaggtagca
                                                                        480
gtacctcctg ttaccagcag agggcaccac cgtacagcac ttgggggccg cagggatcct
                                                                        540
gctgggatgg gaggtattta aaaagcccac aggcctctcc tcccataatg tgggcgctcc
                                                                        600
cacagetggg aceggaagca ggaagggeee etgegetaat etgeeetgge ageagegare
                                                                        660
tggcaagccc tgggtgcatc atccggtgtg ctctggtgcc caaagtcggg aatacctcam
                                                                        720
tggtggcttg gaaaaaaccc tgagcagtga tgcttctnga caattanaac ctgttccggg
                                                                        780
gtcttaaaat ganggaatga catgagctgn attntcgtta agcgttttg
                                                                        829
```

```
<210> 19
<211> 1056
<212> DNA
<213> Homo sapiens
<400> 19
ggtctaaaca tttyaggaat atctgctaaa gttcctatgt agatcctctt gagctacccc
ttgattaact agttctcctc ggtatctata taataactac ctttgtattt ttattgtgat
                                                                      180
atatcaaaaa ttagcattta ggagcatgga agaagtagca ttcatggttt taaaatatgt
tttgcctttc ttgaagtctc tgtggctcca tgtttactta ctagcagtgc tgtggcctag
actggcttct atgatatcct ttggttccag gttatttcag attgttgatg gtgcttagcc
                                                                      300
tctgagaggt agttttagat attaacctat ttaatgtaat aatgtaatga aaagttttag
                                                                      360
tactaaaata agtgtatgac ccccacatta attccattac aaaattactt tatcaaaaac
                                                                      420
aaattagcta gaaaaaaaat tacatcttat gttttcttat atagataaag agaggcctgt
                                                                      480
ccaqtctttg aaaacatcaa gagatacttc accctcaagt ggttcagcag tttcttcatc
                                                                      540
aaaqqtqtta gacaaaccca gtaggctaac tgaaaaggaa cttgctgagg ctgcaagcaa
                                                                      600
qtqqqctqct qaaaaqctaq aqaaatcaqa tgaaaqtaac ttgcctgaaa tttctgagta
                                                                      660
tgaqqqqqqa tccacaqcac cattqtttac tgaccaqcca gaggaacctg agtcaaacac
                                                                      720
aacacatggg atagaattat ttgaagatag tcagctaacc actcgctcta aagcaatagc
                                                                      780
atcaaaaacc aaagagattg aacaggttta ccgacaagac tgtgaaactt tcgggatggt
                                                                      840
ggtgaaaatg ctgattgaaa aagatccttc attagaaaag tctatacagt ttgcattgag
                                                                      900
gcagaattta catgaaatag gtgagcggtg tgttgaagaa ctcaagcatt tcattgcaga
                                                                      960
qtatqatact tccactcaaq attttqqaqa qcctttttaq atttttctqc tcaqqctaaa
                                                                      1020
aaaaaaaaaa acagtttcta aaaatttttt ttcctg
                                                                      1056
<210> 20
<211> 3143
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (1396)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1442)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (3099)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (3132)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (3143)
<223> n equals a,t,g, or c
<400> 20
geccagtaaa agetactagg tgacactata qaaqgtaege etgeaggtae eggteeggaa
```

60

120

tecceagete gaccaegeg teegetaget cagetgacet tegeacetga accegequete 120 tegeceacete tegeceaget tegegecatt tetgetgatt etgetagtt cagetataa cegatagat 20 tegesgatet tegetaget cagetataa cegatagat 300 getettactt caattett teactett etacatett cataccett acceatgag 300 getettaageagea gacetttegg getgagaagea cegataga 20 getagagaaga gactategg getgagaagat cetagagaag getagagaagagagagagagagagagagagagagagagag							
tgcccagotc tgggcccatt tctgctgttt ctgctagtt caaccctgat gettecttt 240 atgggtgaca ctccagtca tgttcacagcgaa atgtcagotc ttggatggg accasgtagg 360 gtctttactt ccagttctt gttcacagtc ttcactctt cataccctc actcctggg 360 gtcacatcgg ccaccagtaa tgctggttct tagctctgca acaccatgaa cggtgtagta 420 gctaagagaa gagctttcgg gtgtgaagta cctgagtaag gttcctccct tcccctgtgt 480 gtgcctggaa caagagtaaac accaaggaag cgttacccac tgctgccatt cccagagatg 540 acaaaggtga ggctctcctgt ttgccatcta tacaatagaag gttcctccact 660 cttaatgtgt gccagtttet gtcctagcac tttggtggdt agaaaggatg ctaccact 660 cttaatgtgt gccagtttet gtcctaagca tttggtggdt agagagaag gtatccacct 660 cttaatgtgt gccagtttet gtcctaagca tttggtggdt agagagagag gcctaccacg 660 cttaatgtgt gccagtttet gtcctaagca tttggtggdt agagagagag gcgctccacg gcgactccag gcagctct 720 gcctccagg cttaagcaat cctcccacag ctggagatga gggagagag accacagggg 780 tgtaaccacc accatggt aatttttgat tttttattt ttttttt ttttttt tttgtttg	ttcccgggtc	gacccacgcg	tccggtagct	cagctgcatt	tgcacctgga	acccgcgctc	120
atogatgaca etceatgtea eccagagegaa etgteagect ttegagtega acceagtagg 300 gteettatett coagtettett gtteacaget teachecut catacecete actecetggg 360 taacateggg ccaccagtaa tgetggttee tagetetea acceagea eggtgtagta 420 getaagagea gagetteegg tytgagagata ectgagataa gteetgeet teecetgty 480 taacatagaga eggetteegt ttgecateta tacaaatagag dataceacat cecagagatg 540 caaaaaggtga ggeteegtt ttgecateta tacaaatagag dataceacat cecagagatg 540 caaaaaggtga ggeteegtt ttgecateta tacaaatagag dataceacat cecagagatg 540 caaaaaggtga ggeteegtt ttgecateta tacaaatagag dataceacat cecacet 660 teettaatt tattittgaa gatggteeta etttittgatagat ggetgaged ggetgagetga tattittattat tttttattat ttttattatt ttattgeeggetgagetga	tcgcccaccc	tgctctagcc	ctggcctgtg	gctgggacct	ccagcataaa	ccggatgctc	180
gteitlactt coagitiett gtteacagte tieaetect catacocic actocotgg taacateggg cacacagata tgetggtee tagetetga acacatga eggtgtagta 420 getaagaga gagettegg gtgtgaagta ectgagtaea gtteetect teecetgtgt 480 gtgectggaa cagagtaaac acteaggaag egttaccac tgetgecatt cecagagatg saaaagagta ggetetectgt ttgecateta tacaatagaga gtataccact 600 cttaatgtgt gecagtteet gteetagea tittgagat gtgtgagett atttagtget teetattat tattittga gatggteea eggetgtgag tagagagetgeeteeteeteeteeteeteeteeteeteeteeteet	tgcccagctc	tgggcccatt	tctgctgttt	ctgctcagtt	caaccctgat	ggcttccttt	
tacactegg ceaceagtaa tgetggtbc tagetbtga acaccatgca cggtgtagta 420 getaagagca gagettbteg gtgtgaagta cetgagtaca gttcetgett teceetgtgt 480 gtgeetggaa cagagtaaca acteaggaag cgttacecac tgetgeett teceetgtgt 480 gtgeetggaa cagagtaacacac tgetgeett teceetgtgt 540 caaaaaggtga ggtetcegtt ttgeetatet tacaaatagag ataataaaagg ctateceact 600 ttetattgtg gecagttet gteetaggeact tettgagaat gtgtgaget cagagetgeag tgetgaagetgeetgeetgeetgeetgeetgeetgeetge	atgggtgaca	ctccatgtca	cccaggcgaa	ctgtcagcct	ttggagtggc	acccagtagg	300
getcagagaca gagetttegg gtgtgaagta ectgagtaca gttectgect teccetgtg 540 caaaaggtga ggtetcegtt ttgecateta tacaagaag gttaccace tgetgecatt cecagaag 540 cataaaggtga ggtetcegtt ttgecateta tacaaatagag ataataaagg ctateccact 660 cttaatgtgt gecagttett gtectaaggea ttttgtagat gtgtgagett atttagtget 660 cttaatgtgt gecagttett gtectaaggea ttttgtagat gtgtgagett atttagtget 660 gtgtacacec caccatgget ceteccace cageetttea agtagetgag gecagett 720 gecteccagg cttaageaat ceteccacet cageetttea agtagetgag accacaggeg 780 gtgacacect gecteccagg tteaaggat cetegeagea atttttat ttttattt ttattgtt tttgttgtt 840 ttgagacacet gecteccagg tteaagatgat cetegeagea gtgagatga gtggaatgat cttggegea 900 tgeaacette gecageagea tteaaggat tetectgeet cageetteeg agtagetggagggtt 1020 caccatgttg gecaggetgg tetegagete ctaacetag gtgatecace tgeeteagg 960 caccaatgt gecaggetgg tetegagete ctaacetag gtgatecace tgeeteagg 1020 tggatecactg taggettgag cetegagetg ceteccagage cetegageage ggatgagatgag ggatgagggtt 1020 tggeteactg taggetgag ceteccagage cetegageageageageageageageageageageageageag	gtctttactt	ccagtttctt	gttcacagtc	ttcactcctt	catacccctc	actccctggg	360
cacaaggta cagagtaaac acteaggaag cgttaccac tgctgcatt cccaagagatg caaaaggtag ggttccgtt ttgccatcta tacaatagag ataataaagg ctatccact 600 cttaatgtgt gccagtttct tgccagca ttttgtagat gtgtgagctt atttagtgct 660 ttcttattat tattittgag gatggtctac ctgctgcagg ttgagctga tattagtgct 720 gcctcacagg cttaagaat cccaccacct agactttca agaagtagag acaacaggcg 780 ttgagacaga acaccagggt aattittat tattitttga gatggtcaca cagcattgag acacaaggcg 780 ttgagacaga accacagggt aattittat ttattitt ttattgttt ttattgttt ttattgttt ttattgtgt 120 gcaaccaccaccaccaccaccaccaccaccaccaccacca	taacatcggg	ccaccagtaa	tgctggttcc	tagctctgca	acaccatgca	cggtgtagta	420
caaaaggtga ggtetccgtt ttgcctata tacaatagag ataataaagg ctatccact 600 cttaatgtg gccagtttet gtcctaagca ttttgtagat gtgtgagctt atttagtget 660 gttaatgtgt gccagtttttg gatgagtcta ctdgtgggct caggctgag gcagccctt 720 gcctcccagg cttaagcaat ctctccacact cagcctttca agtagctgag gcagccctt 720 gcctcccagg cttaagcaat ctcccacact cagcctttca agtagctgag accacaggcg 780 gtgacacctc gcctccagg ttcaagcag ctgagatgaa gtgagcaga atctcactct gtcaccacag ctgagatgaa gtgagcatga cttggcaca gtgagcaggag attacaggg ctgcacca gtctggagt ctgagatgat cttcactgcc cagctctgag attacaggg ctggagtgaa gtgagcatgat cttggcaca gtaaccaggg 1020 gcacacttttt gagcacaca gtgtggaca attttttgat ttttatttt ttattgttt tttttttt	gctaagagca	gagctttcgg	gtgtgaagta	cctgagtaca	gttcctgcct	tcccctgtgt	480
cttaatagtgt gccagtttot gtectaggca ttttgtagat gegggagct gtectaggca ttattattgg gatggtctoa ctgtgtgggt aggtggagt tgcagctct 720 cctcccagg cttaagcaat cctcccacct cagcctttca agtagctgag tgcaagcctg 780 ttgaaccacc accatggct atttttat tttattttt ttattgttt ttattgtggga gatggatg	gtgcctggaa	cagagtaaac	actcaggaag	cgttacccac	tgctgccatt	cccagagatg	540
tetethatat tattittgga gatggtetea etgtgtgget eaggetgeag tgeageete 720 geeteceagg ethaageaat ecteceacet eageetttea agtagetgaag accaeaggeg 780 tgtaecacce decatgget aattittetat tittitattit tittittittit tittittittit tittigittigit 840 ttgagacaga ateteactet geacaceagg etgagatgea giggeatgat ettggegeac 900 attaeaggtg ectgecacea egtetggeta attittitgat tittitagtaga gacgagggtgg 960 attaeaggtg ectgecacea egtetggeta attittitgat tittitagtaga gacgagggti 1020 caccatgtig gecaggetig teteagatgat etteegece ageageagggti 1020 caccatgtig gecaggetig tetegagete etaaceteag gigatecace tgeeteagee 1080 teceaaagg etgggattae aggeetiggag eactgegee ageageege gegatgatet 1140 tittigittig agacaagag etcacteate egeteaggt gagtgeagt ggeatgatet 1140 tittigittig agacaagag etcaceteate etcaceagi gagtgee ageageaget ggeatgatet 1140 tittigittig agacaagag etcaceate etcaceagi gegagee ageageaget ggeatgatet 1140 tittigittig agacaagag etcaceate etcaceagi gegagetagat gageageage gegatgatet 1140 tittigittig agacagagt etcaceate etcaceagi gegagetagat gygatgeage ggeatgatet 1140 tageteaggat tacgaceaea gegaggata eagageatet tectegete ageeteceag gegaggat 1140 tagetgagagat etcaceaea gegaggata etcaceagi tggaartgeag tggaartgeaga tggaartgeagi tggaartgeaga tggaartgeaga tggaartgeaga tggaagggittig tittigatgagaaga eacaceagagee etcaceagi gegaggata etcaceagaggagagat etcaceagaggagagat tecaceagaggaggagagagagagagagagagagagagaga	caaaaggtga	ggtctccgtt	ttgccatcta	tacaatagag	ataataaagg	ctatcccact	600
gecteceagg ettaageaat ecteceaect eageetttea agtagetgag accaaaggeg 780 tgtaacacce accatagget aattetttat tettatett tatetgettegt 840 tgtaacaacce accatagget teaaceagg etgagatgea gtggaatgat ettggegeae 900 tgcaaacetet gecteceggg teaacgtgat tectectgeet eageeteecg agtagetggg 960 attacaggtg cetggageta tectectgeet eageeteecg agtagetggg 960 attacaggtg ectggageta tectectgeet eageeteecg agtagetggg 960 attacaggtg cetggageta tectggaget ettagageta tetteetgeet eageeteecg agtagetggg 960 attacaggtg gectggageta ettagaget etacageta tettetgat tettagaag gacaggggtt 1020 eaceatgttg gecaggetgg tetegagete etaacteag gtgatecaec egecteagee 1080 teceaaagg etgggatagat etggateae aggeetgage eactgegee ageaggeegg tggggggggggggggggggggg	cttaatgtgt	gccagtttct	gtcctaggca	ttttgtagat	gtgtgagctt	atttagtgct	660
tgtaccacc accatagget attitutat titutatit tatigtity titigity tigaccaccaga atcagaccaga atcaccacta geocaccaga cigagatigos gigagactagat citigagaccac 900 attaccactat geocaccacca cigatigosa tettedect geocaccacca cigactigosa attitutity tititigating accaccatagatigosagagatigosagagatigosagagatigosagagatigosagagatigosagagatigosagagatigosagagatigosagagagatigosagagatigosagagagatigosagagagatigosagagagatigosagagagatigosagagagagagagagatigosagagagagagagagagagagagagagagagagagaga	ttcttattat	tatttttgga	gatggtctca	ctgtgtggct	caggctgcag	tgcagcctct	720
tgaaacaga atctcactct gtcaccagg ctgagtgca gtggcatgat cttggcgcac 900 tgcaactct gcctcccgg ttcaagtgat tctcctgcct cagcctcccg agtagctggg 960 attacaggtg cctgccacca cgtctggcta atttttgtat ttttagtaga gacgaggttt 1020 caccatgttg gccaggctgg tctcgagctc ctaacctcag gtgatccacc tgcctcagcc 1080 tcccaaagtg ctgggattac aggcctgagc cactgcgcc agccagcctg ttgttttgt 1140 ttttgttttg agacaagagt ctcactcatt cactccag gtgatccacc tgcctcagcc 1080 tgcctcactg tagcctccac cttccagatt cacagcacc agccagcctg ttgttttgt 1140 ttttgttttg agacaagagt ctcactcatt cgctcaagcc aggcagccgg gcatgatct 1200 tggctcactg tagcctccac cttccagatt caagcaattc tctctgcctca gcctcccag 1260 tagctgggat tacagacata caccacaacg cccggctaat gktggtttgk ttgkttgktt 1320 gtgaccggagt tttgctcttg ktgcccaggc tggartgcagt ggcaccaatc tyagctyact 1380 cactgtgttg gccaccat gccgggctaa ttttttatat ttttagtaga gatgggggtt 1500 cactgtgttg gccaccat gccggggctaa ttttttatat ttttagtaga gatggggttt 1500 cactgtgttg gccaggctgg tcttgaacc ctgacctcag gtgatccacc cacccttggc 1560 ctccaaagt gctgggatta cacggtgaga cacacgtggt tagcacctcag gtgatggggat tccaaggggata cacagggggata tttcaatgacc ttcaaggtgg atttcaagcc ctagggggata tttcaagtct gagtggagag cctgggtgg actggatgg actggatgg actggatgg accagggggatgagagagagagagagagagagagagagag	gcctcccagg	cttaagcaat	cctcccacct	cagcctttca	agtagctgag	accacaggcg	780
tgcaacctct gcctccggg ttcaagtgat tetcctgcct cagcetceg agtagetggg 960 attacaggttg cctgccacca cgtctggcta attittgtat ttttagtaaga gacgagggtt 1020 caccatgttg gccaggctgg tctcgagctc ctaacctcag gtgatccacc tgctcagcc 1080 tcccaaagtg ctgggattac aggcctgagc cactgcgcc agccagctg ttgttttgt 1140 ttttgtttt agaccaagagt ctcactctat cgctcaagct ggatgacagt ggcatgatct 1200 tggctcactg tagctccac cttccagatt caagcaattc ctcgctcaggc ggctgcagt ggcatgatct 1200 tggctcactg tagctccac cttccagatt caagcaattc ggctcgccag ggctgcagt ggcatgatct 1200 tggctcactg tagctccac cttccagatt caagcaattc tctgctca gcctcccagag 1260 tagctgggat tacagacata caccacaacg cccggctaat gktggtttgk ttgkttgkt 1320 tgagcagagt tttgctcttg ktgcccagac tggartgcag tggcaccacca tcagggt taaagcagta ctcacccagagt ctcacccagagt gccagcacca tctagggt tctagaacca tctagcttca gaccaccac gccgggctaa ttttttatat ttttagtaga gatggggttt 1500 cactgtgtg gccagagctgg tcttgaacc ctaacctcag gtgatccacc caccttggc 1560 ctccaaagt gctggatta caggtgaaga caccatggtg tagcaccatt taaaatgttt 1620 agggagaac accaaggcc agggaagata attacacttt gaacccatt taaaatgttt 1620 agggagaga accaagggcg ctggtgctg gagtgaagata attacacttt gaacccagat tcagatttga 1740 atcagggg cctgctgct gagtgcatgs tttgagtcac tcctgacca caccettcag 1860 ctgttccatc actctgggt attitccac ttgaagttat cagggattga tactactctg 1860 ctgttcacac caggggatt agggggccc ctgcaccac ggcggccac attggggac agggggccc ctgcaccac ggcggcgcc ctgggagac agggggggggg	tgtaccaccc	acccatggct	aatttttat	tttttattt	ttattgtttg	tttgtttgtt	840
attacaggtg cotgocacca cgtctggcta attitutgtat tittagtag gacgaggttt 1020 caccatgttg gocaggctgg totogagctc caacctcag gtgatccacc tgcctcaagcc 1080 toccaaagtg ctgggattac aggcctgagc cactggcgcca gacgacctg ttgtttttgt 1140 tittgtttg agacaagag clcactcat cgctcaggct ggagtgcac tgggtgagt tagaccacc cttccagat caagcaagt totogagat ggagtgggt tagaccaccac cttccagat caagcaattc toctgcctca gcctcccagag 1260 tagctggggt tagacacacac cccagagtcg tggartgcag tgggacgagt ttggttgk ttgkttgkt 1320 gcaacctcca totocoggt toaagcagat toctcgcata gktggtttgk ttgkttgkttgkt 1320 gcaacctcca totocoggt toaagcagat toctctgctca agcctcccaca gagagggggg totogaccacat gcaggagat totttgataga ttttttatat tttagtgag gatgggggg caccggggtagagat cacgggactaa that tagatgag gatgggggg caccgggggg tottgaaccacat gagaggagat tagaccaca gaggagagat cagggagagat cagggagagat cacacggggt tagaccacac gaggagagat cagggagagat cacacggggt tagaccaccacagggagagata tatcacactat gaacccagat tocattttgc 1620 aacaaggaca accaaggacc agggaagata tatcacattt gaacccaggt toctgacacac gaggaagata tatcacattt gaacccaggat toctggggg ctgggggggggggggggggggggggggg	ttgagacaga	atctcactct	gtcacccagg	ctggagtgca	gtggcatgat	cttggcgcac	900
caccatgttg gcaggetgg tetegagete ctaaceteag gtaatecac tgeeteagee 1080 teceaaagtg etgggattae aggeetgage cactgegeee ageageege ttgttttgg 1140 tggeteactg tageeteaa etcactata egeteagget gagatgeagt ggcatgatet 1200 tggeteactg tageeteaa etcactata egeteagget gagatgeaggt ggcatgatet 1200 tggeteactg tageeteaa eccacaacg ceeggetaat tectgeetea geeteegag 1260 tagetgaggat tacaagacata caccacaacg ceeggetaat gtggacaagte tyagetyact 1320 geaaceteca tetecngggt teaaggagt etcetgaget ggcacaact tyagetyact 1320 geaaceteca tetecngggt teaaggegat etcetgaget ggcacaact tyagetyact 1320 geaaceteca tetecngggt teaaggegat etcetgaget ggcacaact tyagetyact 1320 geaacacteca tetecngggt teaaggegat etcetgaget ggcacaact tyagetyact 1320 geaacact getggggtta ettgaacte etgaceteag gtgatecace cacacttggg 1560 etcecaaagt getgggatta caggtgagag ceaceteagg gtgatecace cacacttgge 1560 etcecaaagt getgggatta caggtgagag ceacetegg tagecetttt aaaaaatatt atttagteet teaaggagaga ceacegtget tagecetttt aaaaaatatta atttageteet gagtgeatgg tttgagtea tecetgeec caaggtagg actgttace actggggtg attteetee ttgaagttat ecctgteece caaggttaga actgtteact tecagtteg etgetageagg etggteed attetteete ttgaagttat ecctgteece caagetteet getgteeat atteteece ttgaagttat ecctgteece caaggetteg aaaggegeee etgeaageag geetteace etggettetg ggggaacaa aaceetaggat ttgttgagag ectgtggagaga ectgtgggaata 1980 etggggaaca aggeggeee etgeaageag geetteace etggettetg ggggagaaca gageggeee etgeaageag geetteace etggettetg ggggagaacaag eageaggagagagagagagagagagagagagagaga	tgcaacctct	gcctcccggg	ttcaagtgat	tctcctgcct	cagcctcccg	agtagctggg	960
caccatgttg gccagactg totogagetc ctaacctcag gtgatccacc tgcctcagec 1080 toccaaagtg ctgggatta aggectgage cactgegeec aggeagetg ttgtttttg 1140 ttttgtttttg agacaagaagt ctcactctat cgctcagget ggagtgagetg ggcatgatct 1200 tggctcactg tagcectcac ctccagatt caagcaatt ctcctgctca ggctccccgag 1260 tagctgggat tacagacata caccaacac cccggctaat gktggtttgk ttgkttgktt 1320 gtgacagaggt tttgctcttg ktgcccaggc tggartgcag tggcacaatc tyagctyact 1380 gcaacctcca totocngggt tcaagcgatt ctcctgctc agcctccca gtagctgga 1440 thacaggtgc ctgccaccat gccgggctaa ttttttatat ttttagtaga gatggggtt 1560 cacctgttgt gccaggctgg tcttgaactc ctgacctcag gtgatccacc caccttggc 1560 ctcccaaagt gctgggatta caggtgagag ccaccgtgct tagccctcat gtgatccacc ccaccttggc 1560 ctcccaaagt gctgggatta caggtgagag ccaccgtgct tagcccttt aaaaatttt atttagtcct ttcaatgacc ctaaggtagg aactgttatc tccattttgc 1680 aggtgagaaca cacaaggccc agggagaata tatcacattt gaacccagtt tcagatttga 1620 aaaaaattatt atttagtcct ttcaatgacc ctagagtag aactgttatc tccattttgc 1680 ctgttccatc acttgggtt attttcctc ttgaagttat cacgatttga 1620 aaaccaggt atcctaggtg acttgtgaca ctcctgggct attttcatt gcttgtttag cacctgtctg ctctcaccta gagggatta tactatcctg 1800 ctgttccatc acttgggtt attttcctc ttgaagttat cagggattat tactatcctg 1800 ctgttggagac caggggggt ctgggagac agggcgccc ctgcaagcag gccttcacc ctggcttctt 1800 ctccaggccg agtgtactac ttcaaccaca tcaccaagcc ggcggcacca ggcgggggggggg							1020
tcccaaagtg ctgggattac aggcctagc cactgcgcc agcacgctg ttgttttgt 1140 ttttgttttg agacaagagt ctcactctat cgctcaggct ggagtgcagt ggcatgatct 1200 tggctcatcg tagcctcac cttccagatt caagcaattc tcctgcctca gcctcccag 1260 tagctgggat tacagacata caccacaacg cccggctaat gktggtttgk ttgkttgktt 1320 gtgacaggagt tttgtctttg ktgcccagg tggartgcagt ggcacaatc ctcccggg tcaagcagt ggagtgcagt ggcacaatc ttgctctg gtgacagagt tttgtcttg ktgcccagg tggartgcagt ggcacaatc ttgctcqagg tggacacatc ctaccongggt tcaagcgatt ctcctgctcc agcctcccca gtagctggag 1440 tnacaggtgc ctgcaccat gccgggctaa tttttatat ttttagtaga gatgggggtt 1500 cactgtgttg gccaggctgg tcttgaactc ctgacctcag gtagctccac ccaccttggc 1560 ctccaaagt gccggatta caggtgagag caccgtgct tagcccttt aaaaatattat atttagtcct ttcaatgacc ctaaggtagg aactgttatc tccattttgc 1680 aggtgagaac accaaggccc agggaagaat tatcacattt gaacccagat tcagatttga 1740 atccagggatt acctgggtt aggcatagg tttgaatgac tcctgcccc ccaccttcgc 1800 ctgttcacac accttgggt attttcctcc ttgaagttat caggggattga tactatcctg 1860 ttgtttcatt gcttgttag caccgtgtct ctcacacta ggcggattga tactatcctg 1860 ttgtttcatt gcttgttag caccgtgtcg ctctcaccaca ggcggattga tactatcctg 1860 ttgtttcatt gcttgttag caccgtgctg ctctcaccaca ggcggattga tactatcctg 1860 ttgtttcatt gcttgtaatg aaggcgccc ctgcagcac ggcctcacc ctggcttct 1860 ttgttcatt gcttgtaatg aaggcgccc ctgcaagca ggcctcacac ctggcttct 1860 ttgttggggca attgtgaaaga aaccctagca gaatgtacac ggcgggagaaga accatggg ggcaaaaacg ggcagggga acctgggg agggggcca attgagagaa accatgggg aggggaaca aaccctagct ggaattcac ctggcttctg 2040 gcggcaacag agggagaga ctcgggagaga accaggggg acctggggagaaga accaggggga cagggggaga cagggggaga cagggggaga cagggggaga caggggggagaaga aacccaggag gaaccagggg aggagagaaga accatgagagagaagaagaagaagaagaagaagaagaagaaga							1080
tttgttttg agacaagagt ctcactctat cgctcaggct ggagtgcagt ggcatgatct 1200 tggctcactg tagectccac cttccagatt caagcaatte tcctgctca gcctcccaga 1260 tagctgggat tacagacata cacacaacag cccggctaat gktggtttgk ttgkttgkt 1320 gtgacggagt tttgctcttg ktgcccaggc tggartgcag gktggtttgk ttgkttgkt 1320 gtgacggagt tttgctcttg ktgcccaggc tggartgcag gktggtttgk ttgkttgkt 1320 gtgacggagt tcccagggt tcaagcggt tggartgcag ggcctcccca gtagctyact 1380 gcaacctcca tctccngggt tcaagcggt ctcctgacact ttttatata ttttatgtcct tccaaagtg gccaggctgg tcttgaactc ctgacctcag gtgatccacc ccaccttggc 1560 ctcccaaagt gctgggatta caggtgagag ccaccgtggt tagccctttt aaaaatttat 1620 aaaaattatt atttagtcct ttcaaatgacc ctaaggtagg aacctgatgtg cctgaggggg accaagagtg accacagtgg atttccacc agggaagata tatcacattt gaacccagat tcagatttga 1740 atccaggtgg cctggctgt gagtgcatgg ttttgagtcac tccctgtcc caggttcct tggttcatc acctgggtt atttcctcc ttgaagttat cagggattga tactatcctg 1860 ctgttccatc acttgggtt atttcctcc ttgaagttat cagggattga tactatcctg 1860 cacgggactgt ttgttgaatg aagcggccc ctgcaagcca ggcctcacc ctggcttctg 2040 cacgaggacg caggagtgt ctggaagcac acctaggtg gaattgtagc tctctaaggg 1920 ctccaaggcg aggtgtc ctggaagcac accactagcg ggcctcacc ctggcttctg 2040 ctccaaggcc gaggagtgt cttgaagcac accatagcg gaattgtagc tctctaaggg 1920 ctccaggcc gaggagggg ggcctggagagagagagagagagagagagagagagagaga							1140
tagotcactg tagoctocac ottocagatt caagoaatto toctgoctoa gottocogag 1260 tagotgggat tacagacata caccacacg ocoggotaat gktgyttgk ttgkttgktt 1320 gtgacggagt tttgotottg ktgoccaago toggatgat gtgacacat tyagotyact 1380 gcaacotcoa totocngggt toaagogatt otcotgotto agoctocca gtagotggga 1440 thacaagggat otgocaccat gctggatgaa ttttttatat ttttagtaga gatggggttt 1500 caccataggtg gctgggatta caggtggaga cacacctoca gtgatcacc caccettggc 1560 ctoccaaagt gctgggatta caggtgagaag cacacctoca gtgatcacc caccettggc 1560 ctoccaaagt gctgggatta caggtgagaag cacacgtgct tagocotttt aaaaatgttt 1620 aaaaattatt atttagtoot ttoaatgacc caaggtagg gagtaccacc cacactttgg 1680 aggggaggaga tattoacacttt gaacotttt aaaaatgttt 1620 aacagtgggg ctggctgct gagtgcatgg tttgagtoac toccettgtc cacagtttga 1740 atcoagggagg cacacgggg caccettgagagagagatta tatcacattt gaacotttt accettttga 1740 atcoagggatgg ctggctgct gagtgcatgg tttgagtoac cacagggattga tactacctgg 1860 ctgttoact actotgggt attttoccc ttgaagtta cacgggattga tactacctg 1860 attttocat ttgatttag 1740 aaccetaggagaagaa ttgttgagatga caccatggat ttgttgatag aagocgocc ctgaaagoa accatggat ttgttgaatg aagocgocc ctgaaagoa gaccttgag accettgagaga gaccttagaga gaccttcacc gagggggt ctgggagaaca accatagga gaccttaga gaggagaga accatggggagagaga aggcagaagaa agcaggaga agcaggagaaga gaccatggggagaagaaga gaccatggagagagagagagagagagagagagagagagag	ttttgttttg	agacaagagt	ctcactctat	cgctcaggct	ggagtgcagt	ggcatgatct	1200
tagetgggat tacagacata caccacaacg cceggetaat gktggtttgk ttgkttgktt 1320 gtgacggagat tttgctcttg ktgccaggc tggartgcag tggcacaatc tyagctyact 1380 gcaacctcca tecengggt teaagegate eccetgette agecteccea gtagetggga 1440 tnacaggtgc ctgcaccat geegggtaa tttttatat ttttagtaga gatggggttt 1500 cactggttg gecaggetgg tettgaacte etgacetcag gtgatecace ccaccttggc 1560 ctccaaagt getgggatta aggggaggg ccacctggt tagetcate ccaccttggc 1560 aaaaattatt attragtect ttcaatgace ctaaggtagg aactgttate tecattttge 1680 aggtgagaac accaaggcc gagggaagata tatcacattt gaacccagat teagatttga 1740 atcaggtgg cctggtgt gagtgaagate attteete ttgaagttat eagagtatga tactacceg caccttggt gagtgetggt attteete ttgaagttat eagaggattga tactacceg caccatggt attteete ttgaagttat eagaggattga tactactetg gagggagactg atteete ttgaagttat eagaggattga tactactetg gagggagactg ttgtgtgga cctggagaga ectgtggaga ectggagag ectggggagagagagagagagggagagggagggagggaggg							1260
geaacetcca tetecnggst toaagegatt cleetgette ageetcecea geagegggat 1440 thacaggtge clgcacacat geegggetaa tittitatata tittitagtaga gatgggggtt 1560 cactgtgttg gecaggctgg tettgaacte ctgacetcag gtgatecace cacetttgge 1560 ctccaaaagt getggggtat attgaacet ctgacetcag gtgatecace ccacetttgge 1560 aaaaattatt atttagtect tecatgacet caaggtagga acacegtget tageetitt aaaaatgtit 1620 aggtgagaa cacaaggeeg cacaaggtgg aactgttaat tecattitige 1680 aggtgagaaa accaaggeeg ctgagggggatgadaac accaaggeeg aggggatgadaac accatgggt attteece ttgaaggtaa tatcacattt gaacecaagat tecagattiga 1740 atceaggtgg cetggetget aggggaagata tatcacattt gaacecaagat tecagattiga 1740 atceaggtgg cetggetget attteece ttgaaggtaa cacegggatgadaac accetggggata accetgggat attteece ttgaaggtaa cacegggatga tactatecttg 1860 aggggacetg atcetggeeg cagggggetge caggggeege ctgaceagggagga gacegaagggggggggaagaaca accetgggata agggggeegaa agggggeegaa atggtgggata 1980 acceaggggg agggggeegaa aggggggeegaa aggggggeegaa agggggggg							1320
gcaactccatctccngggttcaagcgattctctgcttcagcctcccagtagctggga1440tnacagtggcctgccaccatgccggctaattttttatattttttatattttttatatgtagagatggggttt1500ctcccaaagtgctgggattacagtgtagagaccaccttaggttgacctcaggtgaccaccccaccttggc1560ctcccaaagtgctgggattacagtgtagagaccacctgtgttagccttttaaaaatttt1620aagatgagaacaccaaggccagggaagattatcacatttgaacccagattcaattttgatccaggtggcttggctgctgatgcatggtttgagtcactccetgtcccccagttcctttgttcattgcttgtttagcacctgtctgtttgagtcacccagggattgatactatcctg1800cagggactgtatcttgccacatttgagccacgattgtagacctctaacctagaatgttagatccttaaaggg1920cagggactgtatcttgccacattggagaacctctaacctagaatgttagacctggtttcg2040caccatggatttttgagacacaccctagctgaattcctgcctgcctccc2100ctccaggccagagtgaaagacgccagtcagggaccgggggagcctgccagggagcggccca2160gcggaacacacacaggagagagcccttggaggcctgccagggacggccccgcctgcagggagcggccca2220ccaactgctgggaagagacgccatgagaggcctgcaggggacatccaga2340cagggagagagcctggaggagagcctggagagagagacctgggggacctgggg2460cggagagagagccagaccggggaatgagagagcctaggggggaccagac2520cacgtcacaca							1380
tnacaggtgc ctgccaccat gccggctaa tttttatat ttttagtaga gatggggttt 1500 cactgtgttg gccaggctgg tcttgaactc ctgcacctag gtgatccacc caccttggc 1560 ctccaaagt gctgggata caggtgagag cacacgtgct tagccctttt aacatgtt 1620 aaaaattatt atttagtcct ttcaatgac ctaaggtagg aactgttatc tccattttgc 1680 aggtgagaac accaaggcc agggaagata tatcacattt gaacccagat tcagatttga 1740 atccaggtgg cctggctgct gagtgcatgg tttgagtcac tccctgtccc caagcttcct 1800 ctgttccatc actttggtt attttcctcc ttgaagttat cagggattga tactatcctg 1860 tgtttcattt gcttgttag cacctgtcg ctctcaccta gaatgtagc tcctaaggg 1920 cagggactgt atcctgcac attggcccac gtctggagaa cctgtggcc caggggtgtc ctggagacac accatggat ttgttgaatg aacctagct gattcacc ctgcaagcca ggccctcacc ctgggtgcc caggggtgtc ctggagacac accactagcc gattcaccac accactagac cagcagtggt ggcaaaaacg ggcagccca ggcagcccc gaccactgct ggtgaagcac agccagtcac ggcggccctc ggcgacctgg ggcgccca 2160 cccaagggagaga gactttgag tcctcagagg ggcggcccc ggcggcgccc ggcgggcgcca ggagagaaga gacctggag gccctggagc ggcggcccc ggcgggcgccc ggcggggggggg							1440
cactgtgttg gccaggctgg tcttgaactc ctgacctcag gtgatccacc ccaccttggc ctcccaaagt gctggatta caggtgagag ccacctgtgct tagcccttt aaaaatgtt 1620 aaaaattatt atttagtcct ttcaatgacc ctaaggtagg aactgttatc tccattttgc 1680 aggtgagaac accaaggcc aggaagata tatcacattt gaacccagat tcagatttga 1740 atccaggtgg cctggctgct gagtgcatgg tttgagtcac tccctgtccc ccagcttcct 1800 ctgttccatc actctgggt attttcctcc ttgaagttat cagggattga tactatcctg 1860 tgtttcattt gcttgttag cacctgtctg ctctcaccta gaatgttga tactatcctg 1860 tgtttcattt gcttgttag cacctgtctg ctctcaccta gaatgttga tactatcctg 1860 tgtttcattt gcttgttag cacctgtctg ctctcaccta gaatgttga tactatcctg 1920 cagggactgt atcctgccac attggccac gtctggagag cctgtgggaca atggtggata 1980 gcctgtgggcc caggggtgtc ctgggagcac aaccctagct gaattcctgc ctgccaccc ctggcttctg 2040 gctgtgggcc aggggtgtc ctgggagcac aaccctagct gaattcctgc ctgccaccc 2100 ctccaggccg agtgtactac ttcaaccaca tcactaaccg cagcagtgg ggcggcaccacg ggcagaacacag ggcaggagagaga							1500
ctcccaaagtgctggattacaggtgagagccaccgtgcttagcccttttaaaaatgtt1620aaaaattattatttagtcctttcaatgaccctaaggtaggaactgttatctccattttgc1680aggtgagaacaccaaggcccaggtgacagattatcacatttgaacccaagttcagatttga1740atccaggtggcctggctgctgagtgcatggtttgagtcaccccctgtcccccaggtttgc1860tgttcattgcttgtttagcacctgtctgctctcacctagaatgttagctcctctaaggg1920caggactgtatcttgccacattggcccacgtctggagagcctgtggcacatggtgtata1980caccatggatttgttgaatgaaggccgcccctgcaagcaggccctcacctggcatteg2040gctgtgggcccaggggtgtcctgggagacacaaccctagctgaattcctgcctggcctccc2100ctccaggccgagtgtaactacttcaaccacatacataacgcgacgagggggacgagggg2220cgcacttgctggtgaaggagcctggcctccgcctggcggctcagcaggggacgagagag2220cgcacttgctggtgaaggaggcctggcctcgcctggcgcttccagtcagggactcaagg2280caggagaggaggactttgagtccttggctcacagttcaagaactcaaggctacatccaga2240cagggagagagcctgggtggcttcagcagaggcccgtgttcacagttcaggcatccac2240cgtttgcgctgcggactggggggtggggagcccgtgttcacagttcaggcatccac2520cattcccgccactgattattgttccaacatggctgggccaggactccaggacttgggaccacccactcctgc <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>1560</td>							1560
aaaaattatt atttagtoot ttoaatgaco ctaaggtagg aactgttato tocattttgo aggtgagaaa accaaggcoc agggagagata tatoacattt gaacccagat toagatttga 1740 atocaggtgg octggotgot gagtgoatgg tttgagtooc tocctgtooc coagettoot 1800 otgttocato actotgggt atttteetoc ttgaagttat cagggattga tactatoctg 1860 tgtttoatt gottgttag cacetgtotg otetoaccta gaatgttaga tactatoctg 1860 otgttoattt gottgttag cacetgtotg otetoaccta gaatgttaga tactatoctg 1920 cagggactgt atcetgooca attggococ otgoaggoa gacetgooca atggtggata 1980 occagggactg ttgtgaatg aaggogococ otgoaggoa gocotcaco otgocococ ocacocococ							1620
aggtgagaac accaaggccc gaggaagata tatcacattt gaacccagat tcagatttga 1740 atcaggtgg cctggctgct gagtgcatgg tttgagtcac tccctgtccc ccagcttcct 1800 ctgttccatc actctgggtt atttcctcc ttgaagttat caggattga tactatcctg 1860 tgtttcatt gctgtttag cacctgtctg ctctcaccta gaatgttage tactatcctg 1920 cagggactgt atcctgcac attggccac gtctgagaag cctgtggaca atggtggatta 1920 gctgtgggcc caggggtgtc ctgggagacc ctgcaagcca ggccctcacc ctggcttctg 2040 gctgtgggcc aggtgatca ttcaaccaca tcactaacgc gaattcctgc ctgcaagcca ggcggccac aggggagagagagagagagag							1680
atccaggtgg cctggctgct gagtgcatgg tttgagtcac tccctgtccc ccagcttcct 1800 ctgttccatc actctgggt atttcctcc ttgaagttat cagggattga tactatcctg 1860 tgtttcattt gcttgtttag cacctgtctg ctctcaccta gaatgttagc tcctcaaggg 1920 cagggactg atcctgccac attggcccac gtctggagag cctgtgggcac atggtggata 1980 gctgtgggcc caggggtgtc ctggaggacc ctggaagcac ggcctcacc ctggcttctg 2040 gctgtgggcc caggggtgtc ctggaggacc aaccctagct gaattcctgc ctgcacccc ctggctccc 2100 ctccaggccg agtgtactac ttcaaccaca tcactaagct gaattcctgc ctgccctccc 2100 gcgcacctgct ggtgaagcac agccagtggt ggcaaaaacg ggcagggga gcctgcaggg gaggggccca gggagagaga ggccttggag caaggaggag gcctggagc caaggagaga ggccttcaggag ctacaccggac caaggagaga gcctggagc tgatcaacgg ctacaccagga caaggagaaga gcctggagc tgatcaacgg ctacatccag aagatcaagt 2340 cggaagagag ggactttgag tcctctggcct cacacgttcag gaagtcacta gaagaccaagg 2400 cacaggagaga cctgggtgcc ttcagccagag gtcagatcac gacaggagaaga gcaggtggag gccgggtgtc cacaggacct gaagacactt gaagacgcct 2460 cgtttgcgct gcgaaccggg gagatgagag ggccgtgtt cacaggatcc gaggagaga cccaggccgg gagatgagag ggccgggtgtc cacaggaccc cactccctgc cacaggaccaca cagtattat tgttccaca atggctgga gggggccct cacacccc cactccctgc 2640 caccgtacac aggatttat tgttccaca atggctggga ggggggccct caaggaccc caggttggga ggggggtgtcc aaagaaaaa tgacttcag gggtggga cccaggtgga ggggggccct caaggttggga ggggggtgtcc aaagaaaaa caaaaaaaa aaaaaaaaa aaaaaaaa							1740
tgttcatt gcttgttag cacctgtctg ctctaccta gaatgtag tactatcctg 1860 tgtttcattt gcttgttag cacctgtctg ctctcaccta gaatgttagc tctctaaggg 1920 cagggactgt atcctgcac attggccac gtctggagag cctgtggaca atggtggata 1980 caccatggat tgttgaatg aaggcccc ctgcaagca ggccctcacc ctggcttctg 2040 ctccaggcag agtgtactac ttcaaccaa tcaccaagct gaattcctgc ctgcccccc 2100 ctccaggcag agtgtactac ttcaaccaca tcactaacgc agcagtggg ggcgaacag cagcagtggt ggcaaaaacg ggcaggggag gcctgcaagg gaggggcca 2160 gcggcaacag cagcagtggt ggcaaaaacg ggcaggggag gcctgcagg gtccgctgct 2220 cgcacctgct ggtgaagcac agccagtcac ggcggcctc gtcctgggg caggagaaga 2280 tcacccggac caaggaggag gccttgagc tgatcaacgg ctacatccag aagatcaagt 2340 cgggagagga cctgggggg gagatggag gcctggagc cacagtgag gaaggagaaga 2400 cagggagaga cctgggggg gagaggagagagagagagagagagagagagag							1800
tgtttcattt gcttgtttag cacetgtetg ctctcaccta gaatgttage tctctaaggg 1920 cagggactgt atcctgecac attggeccac gtctggagag cctgtgggac atggtggata 1980 caccatggat ttgttgaatg aaggegeee ctgcaagea ggeeeteace ctggettetg 2040 getgtgggee caggggtgte ctgggagae aacectaget gaatteetge ctgceeteee 2100 ctccaggeeg gatgtactaa tcactaacge cageeagtgg gagegeeea geggeaacag cageagtggt ggeaacacag ggeagagggg ggeeeteace ggeageegg ggeagaeaggggag cetggeaggg gagegeeea geggeaeacag ggeagagggg ggeeeteace ggeageeggg gagegeeea ggeageeggg ggeagaeaggg ggeagaeacag ggeagagggg aggeagaeagg ggeagagagaga ggeagagagag							1860
cagggactgt atcetgccac attggccac gtetggagag cetgtggcac atggtggata 1980 caccatggat ttgttgaatg aaggegeee etgeaageea ggeeeteace etggettetg 2040 getgtgggee caggggtgte etgggageae aaccetaget gaatteetge etgeeetee 2100 etceaggeeg agtgtactac teaaccaca teactaacge cagcagtgg gageggeeea 2160 geggeaacaag eageagtggt ggeaaaaaeg ggeaggggga geetgeeagg gteegetget 2220 egacetgee ggtgaageae ageeagteee ggeggeeete gteetgggeg eaggagaaga 2280 teaceeggae eaaggaggag geetgggggaggaggaggaggaggaggaggaggaggaggagga							1920
caccatggat ttgttgaatg aaggegeee etgeaageea ggeeeteace etggettetg 2040 getgtgggee eaggggtgte etggggagea aaccetaget gaatteetge etgeeeteee 2100 etceaggeeg agtgtactae tteaaceaea teactaacge eagceagtgg gageggeeea 2160 geggeaceage eageagtggt ggeaaaaaeeg ggeagggga geetgeeagg gteegetget 2220 egeacetget ggtgaageae ageeagteee ggeggeeete gteetggegg eaggagaaga 2280 teaceeggae eaaggaggag geeetgggee eaaggagaaga 2280 eeggggagaggaggaggaggaggaggaggaggaggaggag							1980
getgtgggee cagggtgte etgggageae aaceetaget gaatteetge etgeeeteee 2100 etceaggeeg agtgtactae tteaaceaea teaetaaege cagecagtgg gageggeeea 2160 geggeaaeag cageagtggt ggeaaaaaeg ggeagggga geetgeeagg gteegetget 2220 egaeetget ggtgaageae agecagteae ggeggeeete gteetggegg caggagaaga 2280 teaeceggae caaggaggag geettggage tgateaaegg etaeateeag aagateaagt 2340 egggagagag ggaetttgag tetetggeet eacagtteag egaetgeage teageeaagg 2400 eegggaggaga eetggggee teeageagag ggeeegtgte eacaggagaga eetggggg gagatgagag ggeeegtgte eacaggatee gaagaeeatt gaagaeegee egttgeege teaeteegg ggeeegtgte eacaggatee ggeeegtgte eacaggatee ggeeegtgeeggeeggeegggggggggggggg							2040
ctccaggccg agtgtactac ttcaaccaca tcactaacgc cagccagtgg gagcggccca gegggaacaag cagcagtggt ggcaaaaacg ggcagggga geetgecagg gtccgctget 2220 cgcacctget ggtgaagcac agccagtcac ggcggccctc gtcctggcgg caggagaaga 2280 tcacccggac caaggagag gccctggagc tgatcaacgg ctacatccag aagatcaagt 2340 cgggagagga ggactttgag tctctggcct cacagttcag cgactgcagc tcagccaagg 2400 ccaggggaga cctgggtgcc ttcagccaga gtcagatgca gaagccattt gaagacgcct 2460 cgtttgcgct gcggacgggg gagatgagcg ggcccgtgtt cacggattcc ggcatccaca 2520 tcatcctccg cactgagtga gggtgggag cccaggcctg gcctcggggc agggcagggc							2100
gcggcaacag cagcagtggt ggcaaaaacg ggcagggga gcctgccagg gtccgctgct 2220 cgcacctgct ggtgaagcac agccagtcac ggcggcctc gtcctgggg caggagaga 2280 tcacccggac caaggaggag gccttggagc tgatcaacgg ctacatccag aagatcaagt 2340 cgggagagga ggactttgag tctctggcct cacagttcag cgactgcagc tcagccaagg 2400 ccaggggaga cctgggtgc ttcagcagag gtcagatgca gaagccattt gaagacgcct 2460 cgtttgcgct gcggacgggg ggaatgagcg ggcccgtgtt cacggattcc ggcatccaca 2520 tcatcctccg cactgagtga gggtgggag cccaggcctg gcctcggggc agggcagggc							
cgcacctgct ggtgaagcac agccagtcac ggcggcctc gtcctggcgg caggagaaga 2280 tcacccggac caaggaggag gccctggagc tgatcaacgg ctacatccag aagatcaagt 2340 cgggagagga ggactttgag tctctggcct cacagttcag cgactgcagc tcagccaagg 2400 ccaggggaga cctgggtgc ttcagcagag gtcagatgca gaagccattt gaagacgcct 2460 cgtttgcgct gcggacgggg gagatgageg ggcccgtgtt cacggattcc ggcatccaca 2520 tcatcctccg cactgagtga gggtgggag cccaggcctg gcctcggggc agggcagggc							
tcacceggac caaggaggag gccctggagc tgatcaacgg ctacatccag aagatcaagt 2340 cgggagagga ggactttgag tctctggcct cacagttcag cgactgcagc tcagccaagg 2400 ccaggggaga cctgggtgcc ttcagcagag gtcagatgca gaagccattt gaagacgcct 2460 cgtttgcgct gcggacgggg gagatgagcg ggcccgtgtt cacggattcc ggcatccaca 2520 tcatcctccg cactgagtga gggtgggag cccaggcctg gcctcggggc agggcagggc							
cgggagagga ggactttgag tctctggcct cacagttcag cgactgcagc tcagccaagg 2400 ccagggaga cctgggtcc ttcagcagag gtcagatgca gaagccattt gaagacgcct 2460 cgtttgcgct gcggacggg gagatgagcg ggcccgtgtt cacggattcc ggcatcaca 2520 tcatcctccg cactgagtga gggtgggag cccaggcctg gcctcgggc agggcagggc							
ccaggggaga cctgggtgc ttcagcagag gtcagatgca gaagccattt gaagacgct 2460 cgtttgcgct gcggacggg gagatgagcg ggcccgtgtt cacggattcc ggcatcaca 2520 tcatcctccg cactgagtga gggtgggag cccaggcctg gcctcggggc agggcagggc							
cgtttgcgct gcggacggg gagatgagcg ggcccgtgtt cacggattcc ggcatcaca 2520 tcatcctccg cactgagtga gggtgggag cccaggcctg gcctcggggc agggcagggc							
tcatcctccg cactgagtga gggtggggag cccaggcctg gcctcggggc agggcagggc							
ggctaggceg gccagctece cettgeege cagccagtgg cegaacece cactecetge 2640 cacegteaca cagtattat tgtteecaca atggetgga gggggeett ceagattggg 2700 ggccetgggg teeceacte etgteeatee ceagttgggg etgegacege cagattetee 2760 cttaaggaat tgaetteage aggggtggga ggeteecaga eccagggeag tgtggtggga 2820 gggtgttee aaagagaagg ectggteage agageegee egtgteece eaggtgetgg 2880 aggeagacte gagggeegaa ttgtteetag ttaggeeaeg eteetetgt eagtegeaaa 2940 ggtgaacact catgeggee agccatggge ectetgagea actgtgeage accettteae 3000 ecceaattaa acccagaace actaaaaaaa aaaaaaaaa aaaaaaaaaa aaaaaaaa							
caccgtcaca cagtatttat tgttcccaca atggctggga gggggccctt ccagattggg 2700 ggccctgggg tccccactcc ctgtccatcc ccagttgggg ctgcgaccgc cagattctcc 2760 cttaaggaat tgacttcagc aggggtggga ggctcccaga cccagggcag tgtggtggga 2820 ggggtgttcc aaagagaagg cctggtcagc agagccgccc cgtgtcccc caggtgctgg 2880 aggcagactc gagggccgaa ttgtttctag ttaggccacg ctcctctgtt cagtcgcaaa 2940 ggtgaacact catgcggcc agccatgggc cctctgagca actgtgcagc accctttcac 3000 ccccaattaa acccagaacc actaaaaaaa aaaaaaaaa aaaaaaaaaa							
ggccttgggg tcccactc ctgtccatcc ccagttgggg ctgcgaccgc cagattctcc 2760 cttaaggaat tgacttcagc aggggtggga ggctccaga cccagggcag tgtggtggga 2820 ggggtgttcc aaagagaagg cctggtcagc agagccgcc cgtgtcccc caggtgctgg 2880 aggcagactc gagggccgaa ttgtttctag ttaggccacg ctcctctgtt cagtcgcaaa 2940 ggtgaacact catgcggcc agccatgggc cctctgagca actgtgcagc accctttcac 3000 ccccaattaa acccagaacc actaaaaaaa aaaaaaaaaa							
cttaaggaat tgacttcagc aggggtggga ggctcccaga cccagggcag tgtggtggga 2820 ggggtgttcc aaagagaagg cctggtcagc agagccgcc cgtgtcccc caggtgctgg 2880 aggcagactc gagggccgaa ttgtttctag ttaggccacg ctcctctgtt cagtcgcaaa 2940 ggtgaacact catgcggcc agccatgggc cctctgagca actgtgcagc accctttcac 3000 ccccaattaa acccagaacc actaaaaaaa aaaaaaaaa aaaaaaaaaa							
ggggtgttcc aaagagaagg cctggtcagc agagccgcc cgtgtcccc caggtgctgg 2880 aggcagactc gagggccgaa ttgtttctag ttaggccacg ctcctctgtt cagtcgcaaa 2940 ggtgaacact catgcggcc agccatggg cctctgagca actgtgcagc accctttcac 3000 ccccaattaa acccagaacc actaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaa							
aggcagactc gagggccgaa ttgtttctag ttaggccacg ctcctctgtt cagtcgcaaa 2940 ggtgaacact catgcggcc agccatgggc cctctgagca actgtgcagc accctttcac 3000 ccccaattaa acccagaacc actaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaa							
ggtgaacact catgcggcc agccatgggc cctctgagca actgtgcagc accctttcac 3000 ccccaattaa acccagaacc actaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaa							
ccccaattaa acccagaacc actaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaa							
aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaagggng gccgttttaa aggatccctc 3120							
Jugggggood directaegeg egn J145				aaaaagggiig	geogreeda	aggaccecc	
	gaggggccaa	ancecacycy	-A11				2143

<210> 21

<211> 3878

<212> DNA

<213> Homo sapiens

```
<220>
<221> SITE
<222> (36)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (61)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (210)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (271)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (2410)
<223> n equals a,t,g, or c
<400> 21
                                                                        60
tccctaggtt tgcgcctttt gaataagtat cacttnttag ttgctccatg cctcagtttg
ncatctgaaa atgggggcat ctgtaatgcc tgtgttatga ggagtaaatt acaagcatcc
                                                                        120
                                                                        180
ctgtaagacg tagcacagtg tcgagtacgg aatgttattt ccatccttct cacggagctt
ggttcccctt ccccatgccc tttacttgtn ccagccattg actcatacta cttcccttct
                                                                        240
tgcaggcatt ggtccagtgc tgggcctggt ntgtgtcccg ctcctaggct cagccagtga
                                                                        300
ccactggcgw ggacgctatg gccgccgccg gcccttcatc tgggcactgt ccttgggcat
                                                                        360
cctgctgagc ctctttctca tcccaagggc cggctggcta gcagggctgc tgtgcccgga
                                                                        420
teccaggece etggagetgg caetgeteat cetgggegtg gggetgetgg acttetgtgg
                                                                        480
ccaggtgtgc ttcactccac tggaggccct gctctctgac ctcttccggg acccggacca
                                                                        540
ctgtcgccag gcctactctg tctatgcctt catgatcagt cttgggggct gcctgggcta
                                                                        600
cctcctgcct gccattgact gggacaccag tgccctggcc ccctacctgg gcacccagga
                                                                        660
ggagtgcctc tttggcctgc tcaccctcat cttcctcacc tgcgtagcag ccacactgct
                                                                        720
ggtggctgag gaggcagcgc tgggccccac cgagccagca gaagggctgt cggccccctc
                                                                        780
cttgtcgccc cactgctgtc catgccgggc ccgcttggct ttccggaacc tgggcgccct
                                                                        840
                                                                        900
getteecegg etgeaceage tgtgetgeeg catgeecege accetgegee ggetettegt
qqctgaqctq tqcaqctgga tggcactcat gaccttcacg ctgttttaca cggatttcgt
                                                                        960
gggcgagggg ctgtaccagg gcgtgcccag agctgagccg ggcaccgagg cccggagaca
                                                                       1020
ctatgatgaa ggtaaggcct tggcagccag cagaggctgg tgtgggagcc gcccaccaga
                                                                       1080
gacgacactc ggggctgtgt ctgggctggt gcctctccat cctggccccg acttctctgt
                                                                       1140
caqqaaagtg gggatggacc ccatctgcat acacggcttc tcatgggtgt ggaacatctc
                                                                       1200
tqcttqcqqt ttcaggaagg cctctggctg ctctaggagt ctgatcagag tcgttgcccc
                                                                       1260
                                                                       1320
aqtttqacaq aaqqaaaqqc qqaqcttatt caaaqtctag agggagtgga ggagttaagg
ctggatttca gatctgcctg gttccagccg cagtgtgccc tctgctcccc caacgacttt
                                                                       1380
ccaaataatc tcaccagege ettecagete aggegteeta gaagegtett gaageetatg
                                                                       1440
gccagctgtc tttgtgttcc ctctcacccg cctgtcctca cagctgagac tcccaggaaa
                                                                       1500
ccttcagact accttcctct gccttcagca aggggcgttg cccacattct ctgagggtca
                                                                       1560
gtggaagaac ctagactccc attgctagag gtagaaaggg gaagggtgct ggggagcagg
                                                                       1620
gctggtccac agcaggtctc gtgcagcagg tacctgtggt tccgccttct catctccctg
                                                                       1680
agactgctcc gaccettccc teccaggete tgtetgatgg eccetetece tetgcaggeg
                                                                       1740
ttcggatggg cagcctgggg ctgttcctgc agtgcgccat ctccctggtc ttctctctgg
                                                                       1800
tcatggaccg gctggtgcag cgattcggca ctcgagcagt ctatttggcc agtgtggcag
                                                                       1860
```

ctttccctgt	ggctgccggt	gccacatgcc	tgtcccacag	tgtggccgtg	gtgacagctt	1920
				cctgccctac		1980
ccctctacca	ccgggagaag	caggtgttcc	tgcccaaata	ccgaggggac	actggaggtg	2040
				ccctaagcct		2100
				cccacctcca		2160
				gggtgagccc		2220
				cctggatagt		2280
				ccagctcagc		2340
				catttacttt		2400
				aaacttccag		2460
				ttagccccat		2520
				tctctgctgc		2580
				cctctcctct		2640
				gtctggactt		2700
				ggtggattac		2760
				gggtttttgg		2820
				tgcagcttcg		2880
				ggatttgaac		2940
				ccaggtcccc		3000
				tcaggatgtg		3060
				taacttattt		3120
				taatatttgg		3180
				gggctgatca		3240
				aggaccttgg		3300
				gggtgttgaa		3360
				tettetettg		3420
				gggctgatga		3480
				ttccccacca		3540
				gtttcccaag		3600
				acagaaactc		3660
				ttaagtgccg		3720
				taagtgagca		3780
				taaaaaaaaa		3840
	ggccgctcta					3878
	333	3.33.	3.3333			
<210> 22		,				
<211> 6297						
<212> DNA						
<213> Homo	sapiens					
<400> 22						
ccacgcgtcc	ggtcagcttt	catctcgtcc	tatctttgtt	caggcaaact	tctctagttc	60
tgttttaata	ggcatatttg	ttaggtctgt	tttttgaaat	cctcttttt	acattgttta	120
aagataatgc	cttggctaaa	aagcctgctt	cacttttccc	tgtttttagt	tgttttctcc	180
acattggcag	taaagagcct	tggcgtccca	gtagcagcag	gttctccttt	ttgtattgtg	240
gatgttttgc	atttcatact	gttgtgaaga	gtggctttga	tcatacatgt	tgttggtata	300
tttgcctttt	tgctgggggt	gtgagaagaa	ccagagatga	gcagaggtac	acccagtaga	360
				tcaggtgctt		420
				gtgttcagga		480
				tcttttttt		540
				ttggcacaaa		600
				ccataaaatc		660
				aaaaccttga		720
				gaggtcgcat		780

taagtttggt ggattgctgc ttctcactgg ctgacctttg gaggtcgcat atttcaggat

gtgattccac ttaggctcca tttcacctga cactgcaatt ctgtgccttc agagggattt

gttattgcga atgatgtgga caacaagcgc tgctacctgc tcgtccatca agccaagagg ctgagcagcc cctgcatcat ggtggtcaac catgatgcct ccagcatacc caggctccag

780

840 900

1020 atagatgtgg acggcaggaa agagatcctc ttctatgatc gaattttatg tgatgtccct tgcagtggag acggcactat gagaaaaaac attgatgttt ggaaaaagtg gaccacctta 1080 1140 aatagcttgc agctacatgg cttacagctg cggattgcaa cacgcggggc tgaacagctg 1200 gctgaaggtg gaaggatggt gtattccacg tgttcactaa accctattga ggatgaagca 1260 gtcatagcat ctttactgga aaaaagtgaa ggtgctttgg agcttgctga tgtgtctaat 1320 gaactgccag ggctgaagtg gatgcctgga atcacacagt ggaaggtaac ctttcctcga 1380 gaactttcat tctaaagagt aggtgcagca tcactgaagt agagtcaagt ttcaaagcat 1440 tcacgtgtga gtaacttgaa taaatactac atctggttat gccaattaga atcaatttcg 1500 gagtgttatt tcatgacaca tttcatgaca agtggcatgt ttattcctgg cagtggaaaa 1560 gtttttttt ctccacgtac agaaataaac tcttttactc tcatccctgt aagggtagct ttgctttttt tttttttt taaattgggc cgggattcaa gccttgtttc caatatgaag 1620 taattcatta caattttagg ccagaaacag cctgaggctt gtttaaaaaag aaaaaaacta 1680 1740 gatggaaaat gttattttat aatgcttgtc ctggttttta gaataaatgt atttcatctt 1800 ttgtcttggc aaataatctt cctatctttg gagtgaatga gaatcaccat ttgtcacctt 1860 1920 tgagagaatg gatactcctg ccctgtgatt tttgttggta ttggatagtg ctagtaatct ggaatgtacc ctgtggttct gcaggtaatg acgaaagatg ggcagtggtt tacagactgg 1980 qacqctqttc ctcacaqcaq acacaccaq atccqaccta ccatqttccc tccgaaggac 2040 ccagaaaagc tgcaggccat gcacctggag cgatgcctta ggatattacc ccatcatcag 2100 aatactggag ggttttttgt ggcagtattg gtgaaaaaat cttcaatgcc gtggaataaa 2160 cgtcagccaa aggtgagttt ttcttttcc aaaatgacat aacatttgat cttgtacatt 2220 taagacaaaa actaaccgga gtttagtaga agtacagagg aaagaggagc ttcttgctgt 2280 gggcagcagg agagctgacc ctgaatgagg gggaatttca tttaaatatc aagttttcca 2340 2400 aaaagcagaa atttctcata ggtgataggt aagtggagaa gtcagtgttt gggggaatgt 2460 attcctgcca cactgtaaat ccagttattt aataaaaatt gaaaagacat gaaagattgc tetgtggete teaattggaa geeceaggtt tetgtgetet agtteettgt gagtggttea 2520 2580 tttcaccaat tacagatage agagetetge tgaccccaag ccageceggg ttcacettgg ctgcaaggaa tgatgacggc cttgtccaga cctggctaga aagatgcagc ccggcctgtt 2640 tgctatggat ctaaactgcc tgctggttcc tttccaaggc aggccaggaa acagtggtga 2700 aggagtgttg ccctcatcct aacacgcagt cctttgtaat gcgtgctgtc tcacctgtat 2760 cacgccagca ttatttatta gttcataaat cagccttcca tgatgaaaga acctggcctg 2820 2880 gaatcaaagt ctggaagtct gtatttcttt aagatccatg cttgaaaatt aggacaaaaa acgcttagct ttggaggaac aaaaaggaaa cagttccgca aagagctcca gcctttttct 2940 3000 ggggcacggt ttgtgcagtt taacgttgga acgtacagcc tcagacgggc aaagggggcg actgcacttc tgccgccacc agggtttttc tgtcaggtta gaaagtattt cactttgagg 3060 ctaaaagtct cacaaggtat cttaacgctg atggaatgtt attttcatgg aatcagtata 3120 agaaattata ttgtaaagta ttagatactt tgcattcatt catactaggt ttcagtagct 3180 tgtgttttag actttgcgct tgtcacattt taagtggtca gtgaccacag gcttgtggct 3240 3300 gcccagctgc agagcacagt gcagtcacag aggagcctgt cttagagacg cgtgctttag gttggcctgc attagggctt acattgatgt ttctgacgtg ttaatactta catagaaagg 3360 ttttgacatt ttttcaatta geceettatg tatagtetta etttttagaa caaettattg 3420 tcattttctc gtttaaataa tatgaatact tctctctttc tgttactatg tcagtttctt 3480 3540 attcacttag ttcaacagat ctagtgctag catggcctgt gctgctgttg gtcctactgg 3600 gaacgcaggt agagtctcca tggtcaggat gccgtgttct gttgtggtgc tgaggcctgt 3660 aagcacttgg ctagaagtta ggccagggaa gctcacactg accttggtat ttgaaggtcc 3720 cagaatgagg ttgttgaggt agaacagaga tgggagaaca tgcccttgga gctggactca 3780 acaagaaggc ccctctgggg gaagctgagg ttggacagga agggcgtgtg ccctcactga cttqctcaca qqcttqggqt tcatctgttt tqgtttttgc ttttttacat tatattaaca 3840 tggaaataaa aggtgtteee tgggatgete ceggettete tgeteagtag etttgtgget 3900 ctgagtaaaa tgaacttgcc tgtgttgaaa tatcctaatt tttaaactta cttcataggg 3960 actgaggaat tacgactttt atcaattttg tgacctgtta aaatgttaaa aaggacatgt 4020 attttttaaa gatctttaag taaaacattt tgctcattcc caaagccaaa tttaaattat 4080 accatggccc taattcagaa gttcattctt tggcaggtgt ttccttggtg cctggggcac 4140 tetetette teccagitee tgtggeagit tgtecaggitg cecaagaaca atteatacee 4200 teettteteg ttatttatat aettgtettt ttgeeeetge egggtatttt agaaategtg 4260 4320 cttggtgcac tttgtgtcct tcagtgtgcc ttacccagag cagatgcacg ataagcattt ttacacgaga acaagctggt ggtgtaggcc tctgctaagg aacaggctgt atatgctctt 4380 4440 tgtgggatta aggtagaatc agctttaact ccaaagaaac tgtccatgaa ttttgtttat

aatagcaagt	agatttaaaa	tgacactttg	aaaaaattct	gttgtctttc	tctacatata	4500
atgctgtaga	aaaatataac	tgatggattt	tgtgaacgtg	gtatttttaa	cttttcgtag	4560
cagcacaaag	aatgctcctc	tttgtgtgtc	aatgaaattg	ttctttatga	cagcttcagg	4620
gtaaatctgc	agagaccaga	gaaagcacac	agctgagccc	tgcagatctc	acagaaggga	4680
aacccacaga	tccctctaag	ctggaaagtc	cgtcattcac	aggaactggt	gacacagaaa	4740
tagctcatgc	aactgaggat	ttagagaata	atggcagtaa	gaaagatggc	gtgtgtgggt	4800
	gttatgtctt					4860
	agagccactt					4920
	gtgagggctg					4980
	ttgcacagaa					5040
	cagattgatt					5100
	ttatttggat					5160
	cctattgagt					5220
	tcaaatgtac					5280
	tttttttt					5340
	atcttttaat					5400
	ctggaccggg					5460
	ggagcacgag					5520
	taaaaataca					5580
	ggaggctgag					5640
						5700
	cgcgccgctg					5760
	aaaactggac					5820
	tgagtatata					5880
	cagcatgggt					5940
	gacaagtctg					6000
	ggtcacttac					6060
	aaaataagtc					
	aggttaggag					6120
	caaaaaaaa					6180
	gagaaccgct					6240
ccactgcact	ccagcttgga	agacagagca	agactccata	tcaaaaaaaa	aaaaaaa	6297
210 22						
<210> 23						
<211> 5257						
<212> DNA						
<213> Homo	sapiens					
.400- 22						
<400> 23	~~~++++	-+a+a++	aaaaatatat	attataataa		60
	gcattttaac					120
	gatggcgtgt					180
	ttagatttaa					
	ctgttgtgta					240
	tcattcatca					300
	catttgtggg					360
	tcataaaaca		_			420
	attataaaac					480
	ccatgttgga					540
	aacaaaacag	-		_		600
	gacttattga					660
	ttttaaaagt			_	_	720
	tcattagaaa	_				780
_	aatcacattt					840
	gtttaaaatt	-	_		_	900
	aaataccttt					960
	gagacgaata					1020
	cttttctgaa					1080
gcaatatttc	atacacactt	taaaatttaa	ctttagcttt	ttacaagaaa	cttctaccaa	1140

1200 aaaatgcaat agtcattaac ttgctctctt taattatcaa aatataatct agctagtatt taatttaaca ttttatttat ttttactaag taaattttgt aatagcagga taattttgga 1260 cttcattcta gagtcaattg gctcccagtg aaagacaatg taaaattaca ttgattttgt 1320 tttccaatta cagaagtaat acatagtcat tatagaacat tttggaatat ataaaatgta 1380 tgtaaagaga aggaaaagtc acccaaaact taagcacatt aaaaataatc acaattaaca 1440 tttttgtatt ttcttactat ctttttttct atatgtttat gtataggcat gtatataatc 1500 atatacatgt aaacatcaaa ctatgtatac agtttacatt tcctatcatt agtaagtatt 1560 ttcacatatc attaactatt attcaacatc ttattttttc atgattatat tgcctttatg 1620 gacatgcagt aattcattca atcattcccc aattattgga tatttaagtt gtttcaattt 1680 1740 tttttactat tataaattcc atcaagcata aaactgacac aattgaagta ctactgagag agaggaacac aagcattaga gtaattactg gaggtgccat ggagatgaac atgacagtga 1800 tgtaccaagt ggattggaca gtgaggttca aatcacagag acttcttagt ggagaacaag 1860 gaagaaaggc aaacctggag tcccagccat agaaacagaa aggaaatgat tgatatgaaa 1920 1980 actagtatgt tagaaactta gaaggacttg gcaaatgatg aatattcatg aggtatgagt caaagatcac ttgaaagttt atgtgatggg aagaactgct gccataaaca gaaattgtca 2040 2100 aatttggagg agaaggccat tgaccctaga ggtgaaaccg aagctctgat ggactctcac 2160 agctggagat gaaaatacga gttatacacg gagaatgtaa tggtgaatcc atgggaataa 2220 ttgatatatt tgagggtaat tcagcacaag tggaggaaaa cagggtccag ttgaaatctt 2280 tcagaatgac ccatattttg atgaaaagga gtaagaacca gtgagaaaag agtagtctga aagtggggag gagagggaaa aggagagaat gaattagaac tccagtaata gagattcact 2340 gggagcccag gaaggatgag aactgcaggc tcaaatccac aatggtaagg gccacaggca 2400 2460 actatgccaa gacaggccac tgagaagtta attgtaacct ttaaagaacc acaaaaagac ttcactggtg ttatgaccct aagccagctt gaacaagtag gctatcaaga acaagtaggt 2520 2580 aggcagtcat aggaggtttg gtgagatggt gaaccgcatg ggtgtcctgt tctccataga 2640 2700 atgteteett eeaaccaate eaggeteteg eeatgaaget geetgggaag tagaagaggg 2760 aattcatatg gccaaaccac tttgttgacc taaaaattac tgcttaaaaa ataattttta qaacttttaa aggaatcatt tattcaaggg ggaaaaaaat ctctttttca ggcaaccact 2820 2880 qaqaaaacqq aaccqaataq tcaaqaqqac aaqaatqatq qtggaaaatc aagaaaagqg aatataqaac ttqcctcatc aqqtttqttt cataaqaqac taqttttaaq qcaaatcatg 2940 gtaactgttt aagatgtaat ggaaatagtc aagaattttt cctactgagc cacagaaaag 3000 tagtaattag actccaggag tggtgcggtt gtgctgccac ctagaggctt cctggggaag 3060 ttctqcccgt atggttaatg ttgctgtgaa aataggagcc catgctcttt cttaaagcta 3120 cccaqtttta ttttqttttt taaaatattt atccctataa tcataaaqaa tactqtqttc 3180 ttccatataa atcatgctaa aaattgaggg taggattttg acacacagta acagcaatag 3240 ataagcgaga ggtcaaaaac ataaaaatag acgctgaaat ggtaaagctc acatatagtt 3300 aaaaatgaat atagtgccat gaatctggac agtgagtata atatactgta ttcgttgttt 3360 taggaagaag accetgttcc cgaaagtctt gttcctcaat atttttttgc agcettatca 3420 atatgtttaa cacttttctt cttttgataa acagtaaaac ctctcaccct ctttcaatac 3480 caaattatta ttttttataa qqcctttctc caqtqtttac cacttgagaa acataatttg 3540 tcaattacca aattatttt aggtaacatt tttaaataaa ttaaatatca cttaaaataa 3600 tagcatttac tttttcaaac tagattqtqc cttcacattt tqatatqccc ccttagqtag 3660 tgacttttcc accccttcta aagtgaacct aattcttctt tatgtatcag agaacacttt 3720 attttcattq cattatatac atatacccca caatccqtaa cacattccaa ttaaqaaatt 3780 ctgatgttaa aatggagcat tgaaatacaa aaaaaggaag catcaggttg ctgctcattc 3840 actgggatag aaactacctg tagatgttct cttatctagc ccagctgtca taattatata 3900 tttcgtgtca gcattctgtt ccatgtggtg ttattcagat gtaaaccgtg accettacta 3960 aaaacttaag ttcttcatag tgtggttata ggacgtgatt tgtgttgctt gttgttcaat 4020 accatgaaag agctttggga attccagcat cttaggctct tttatatctc tgagcacact 4080 gtcattcagc ttatattgcc aggacgggat atggactgaa tgtacttcat ggcattgcag 4140 aataaatggt cctatagata tttgattttc ttttccttct gtacgtttct ggatgtaact 4200 ccattgcaga accacagcat tttacaacaa ctgtgactcg atgcagcccg accgtggcct 4260 ttgtggaatt tccctccagc ccccagctga agaatgatgt gtcggaagaa aaagaccaga 4320 agaaaccaga aaatgaaatg agtggaaagg tggagttggt gctgtcacaa aaggtgaagt 4380 4440 gcaqagtgga ggaaagcggt taaacccaca agttaacatg gccccatatt acagctagct gctgctgtgg cagttgtgaa taatgaagat ttatttctct cctcatcttt tttcctatct 4500 4560 agttttgctc ttgttgccca ggctggaatg cagcggtgtg atctctgctc accacaactt 4620

```
ctacctcctg qqttcaagtg attctcctgc cttaggctcc cgagtagctg ggattatagg
                                                                      4680
cqtctqccac cacqcccaqc taatttttat atttttaqta qaqacqgggt ttcaccatgt
                                                                      4740
tggccaggct attctttgtg gaaaagtgta atataagttc taaagccttg cagttaggtt
                                                                      4800
ttagtttgct qtgtgtgttt gcttatttgc tttttaacct gtcagcttac tggctagtct
                                                                      4860
ctctccaata atcatctatt tgttagcaat ggtaattctg atgccactgg atttggataa
                                                                      4920
caagaaacct agaaaattat tattctgata taataggttt taaagtcttg tttttattaa
                                                                      4980
agtttcttcc ttgtttagag tctcatctca ttcacattag tttgatttgt tttcaggtac
                                                                      5040
agagtetaaa aatatteate agttacaeca gttgttegea aeettgatta etettgggaa
                                                                      5100
tttaaaaaat aacaagctag ctgggtgtgg tggctcacaa ctgtaatccc agcactttgg
                                                                      5160
gaggccaggg caggaggatc acttgagccc aggagttcaa gactagcctg ggcaacccag
                                                                      5220
                                                                      5257
aaagtettea tetetaaaaa aaaaaaaaa aaaaaaa
<210> 24
<211> 464
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (404)
<223> n equals a,t,g, or c
<400> 24
ttcctqccqq aattcgggcc ggaattcccg ggtcgaccca cgcgtccgca tctgtcaggt
                                                                        60
                                                                       120
qctcccttqc caatttqaqa catgtqgctc ccagcctqqq ctqccataga aaccttctcc
acttqctcct ctctctctct ctccttccaq ccccqctqqq ctctqqcctc agagggatgt
                                                                       180
qcaqqqtcct atqtcaccac ccacaqqqct ctaqqaqccc acctttqqcc tctctqqtct
                                                                       240
qaccaqttcc tqqqqaaaqq tctqqqqtta aggatccctt tcatcaccca tgcacaccag
                                                                       300
tqatccaqqt tccacaqatq qacctqtqtt ccagcaqcac tqcctqargc atgttctagg
                                                                       360
qatqcaaaac tqaacaqaaa cacaqaqctq qqkttqctct tqancttcct tmaamccagc
                                                                       420
                                                                       464
tttcacccgt gttcttgcgt gaagtgcagt gtgtttgtat acgt
<210> 25
<211> 1116
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (380)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1053)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1062)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1097)
<223> n equals a,t,q, or c
```

```
<220>
<221> SITE
<222> (1098)
<223> n equals a,t,g, or c
<400> 25
gggaagggga gggccagata ttccagctgc ayaccacwct ggcrgagaca cctgctggct
                                                                       60
ccctggacac tctctgctct gcccctggca scactgtcac cacccagctg ggaccttatg
                                                                      120
ccttcaagat cccactgtcc atccgccaga agatatgcaa cagcctagat gcccccaact
                                                                      180
                                                                      240
cacggggcaa tgactggcgg atgttagcac agaagctctc tatggaccgg tacctgaatt
actttgccac caaagcgage cccacgggtg tgatcctgga cctctgggaa gctctgcage
                                                                      300
aggacgatgg ggacctcaac agcctggcga gtgccttgga ggagatgggc aagagtgaga
                                                                      360
tgctggtggc tgtggccacn gacggggact gctgagcctc ctgggacagc gggctggcag
                                                                      420
ggactggcag gaggcaggtg cagggaggcc tggggcagcc tcctgatggg gatgtttggc
                                                                      480
ctctgcttcc tcccagttca cagccagagt tgcctctcct cctcctcttc cccaaccccc
                                                                      540
                                                                      600
agaccatgac cagcettaga aaatecatgt actetgttgt tagagggeec agagtteett
                                                                      660
ctccaccccc gctctctctc tettggcctg agatetetgt gcaggaacca agatggggct
gaageetetg gaggeagttg gttgggggeg ggeaggeagg aggeeeteee tecaceeeee
                                                                      720
cacceteage eeggeaactt etgggtteer tgggttttag tteegttett egttttette
                                                                      780
ctccgttatt gatttctcct ttctccctaa gcccccttct gcttccacgc ccttttcctc
                                                                      840
tttgaagagt caagtacaat tcagacaaac tgctttctcc tgtccaaaag caaaaaggca
                                                                      900
aaggaaagaa agaaagcttc agaccgctag taaggctcaa agaagaagaa aaacaccaaa
                                                                      960
accacaaggg aaaagaaaaa cccagtttct taggaaacgc aaacgattta ttatccagat
                                                                     1020
tatttggata agtccttttt aagaaaaaaa aanaaaaaaa cncgagggg ggcccggtac
                                                                     1080
ccaattcgcc ctatagnnag tcgtattaca attcac
                                                                     1116
<210> 26
<211> 1563
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (1449)
<223> n equals a,t,g, or c
<400> 26
60
ttccagtaca cttaccatgt tacgacttgt ctcctctata taaatgcgta ggggttttag
                                                                      120
ttaaatgtcc tttgaagtat acttgaggag ggtagaatcc tgccccttcc tccacataca
                                                                      180
atgattatga atcagaacca caatttctag gaacgcagct gtatgcccag gaaaaaggaa
                                                                      240
                                                                      300
gagaagaaaa cgaaacccag gaggggcata gtagctccaa caggtaaagg ggtgagagca
                                                                      360
agaaagaagg gttaaaagaa atggtgcagc ggacgtggaa tagatacaat accaagtgtc
aaccetggte tttcattgtg atggcaggag aggaaatgge atgggggca egtetgtgga
                                                                      420
taatgtgtya gttattgttc ttggcagcca gtgagggcat catgccacgc ctgagagcgt
                                                                      480
ctgcttggtg agttacaagt catcttttca taagtcagtt ttgttttgta ttccccaaac
                                                                      540
cctccagcag tttctcagag gaagagttct tccacaaaaa aatatttcat aaatcctaga
                                                                      600
                                                                      660
ctcttccctc attgtttcca gccagcaagc cctggagagc tgctctcagg ctcacttcag
                                                                      720
ttcctgggtg gggttacgtc actgtttttc agtagcgaac tttctcagat gggacacacc
                                                                      780
caacctcaca ggcacccagg agttctcggg tagcatgacc caggctctac tcaagaagtg
eggeceaate ceaeaggete geaacteaga etttetaaga atatgteeca acaaatetea
                                                                      840
gtaaagggtc tgagaattgk ttatactctt ttggctaatt tttctataac tgtgaaatta
                                                                      900
tatcaaaatt aaaaacataa aaacataaca aaatgcccaa ataaacatag tgcaattaag
                                                                      960
agtgactgtt caggctggga geggtggctc acgcccgtaa tcccaacact ttgggaggcc
                                                                     1020
aaggtgggtg gatcacgagg tcaggagttc gagaccaacc tggccaacat ggtgaaaccc
                                                                     1080
catctctaca aaaaatacaa aaattagctt agtgacggcc tgtqqactat gatttagaca
                                                                     1140
```

```
tacttaggtc taaaatcaca cagctetgcc acattetagc tgcgtgacca gaggcaagtt
                                                                     1200
acttaacctc tctqqqcctc agttttctca ttactqtaaa atqtqcaaaa gaatatctac
                                                                     1260
acaaccgtta tgaagatata atataagcca ttattcaaca actatttatt gagtgcctat
                                                                     1320
tggtgccaag cacttaaagc tgtgagagac agttgtggac cccacctttc tgcctttgct
                                                                     1380
tggctgacag cctagtttac cttactcccc accccagccc cacaagaggt ttttgggttt
                                                                     1440
ttgkttggnt ttttttttt tttttttt tttttggtat tacggatctc tttaaaaaat
                                                                     1500
1560
cgc
                                                                     1563
<210> 27
<211> 1528
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (895)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1424)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1502)
<223> n equals a,t,q, or c
<400> 27
tattaggtac gcctgccqqt accqqtccqq aattcccqqq tcqacccacq cqtccqqttt
                                                                       60
atgaattcag aaattctgct cccagcaagc agacctcact atgattctct atatttgcct
                                                                      120
gcttctcaaa atttggggtt gcagtttgcc ctgcaacttc agctttccat tggacttaag
                                                                      180
aaaagtcatg gattttcagt ttgttcagca ttttttctta taaaaacaag agtgatgact
                                                                      240
ctcaagctct ttaaattttg gaactgaaac tagaagcaac aggacattct gacatgaatt
                                                                      300
atttaaaagg gtcattgttg actctagaga cattttaata ttgctgcatc aaaagataaa
                                                                      360
agcattetee tttettettg tgtgatatat geegtgtaca eetetgaget caccactaae
                                                                      420
ctcaactcta ccttatccct aacttcccat ttcaaatgga agggaatggg gatcaaggag
                                                                      480
tagaaggcct gttttaccca ttattgatga ttaaaaagct gaaaataacc catcacaaaa
                                                                      540
tggcctcagt aaagtggctg catcagacat catttagcct ggaaaaccag tatgcataaa
                                                                      600
ggctcawwtt taaatttttg aatccagtgt tttttattta ttattatttt ttttttctg
                                                                      660
agacggagtc tggctctgtc acctaggctg gagtgcagtg gcacgatctt ggctcactgc
                                                                      720
aagetecaee teetgggtte atgecattet cetgeeteag eetecegagt ggetgggaet
                                                                      780
acaggegece gecaecatge ceggetaatt ttttgtattt ttggtagaga cagggtttea
                                                                      840
ccgtgttggc gaggatggtc tcgatctcct aacctcatga tccacccgcc tcggnctccc
                                                                      900
aaagtgctgg gattacaggt atgagccact gcgcccggcc ctgaatccag tattttttaa
                                                                      960
tagaaacatg agttggttga gatactgagt teetgeette teeateetaa teecaaattt
                                                                     1020
ccaatetttg gaaatttgcc cctttaccat ttaatctcct gagcccagct cctctccagc
                                                                     1080
ctgaagagtg tgtctgtcaa gactgtagct gtgaacaaaa cactattact tgagccttat
                                                                     1140
cctggagcaa atgtgtgtgg tctcaccaat gaacatcaga taagtccctt ggcatggatt
                                                                     1200
tcttttcctt tttagtaata caatcataaa ggttattcag acttattgag catttactat
                                                                     1260
ggccagaaat tgtgatactt gctttccata tagkttatct cacttactyc tattaccctt
                                                                     1320
tgaagtcaga attctaacta tgaatcagag aaaataagtg acctgsctaa ggtcatccag
                                                                     1380
ttggkttatg gtgaaggcag gatgcaaact gaaattgctg kganttgagt cggtgctttc
                                                                     1440
cctagtctcc tcctctcaga ggcagaacat aagcatgtaa tagataccac tagggttctt
                                                                     1500
                                                                     1528
gnttctacct tgggaacagc tgtttgca
```

```
<210> 28
<211> 235
<212> DNA
<213> Homo sapiens
<400> 28
gatacaacac cagcatttta aaaatttctt tttgtctgtt cagacatgat aacttttctg
                                                                         60
                                                                        120
cccatcatat tttccattct agtagtggtt acatttgtwa ttggaaattt tgctaatggc
ttcatagcgt tggtaaattc caccgagtgg gtgaagagac aaaagatctc ctttgctgac
                                                                        180
caaattgtca ctgctctggc ggtctccaga gttggtttgc tctgggtgtt attat
                                                                        235
<210> 29
<211> 569
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (196)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (503)
<223> n equals a,t,g, or c
<400> 29
cgctgcccct cccctggtcc ccgcgagctc ggagggcccg gctggtgctg cgggggcccc
                                                                        60
gggaggtacg gacctgggag gcgaggeteg tecggegeta ggateggeet ecgeeteegg
                                                                        120
gccgctttag gtggctggtc tctgcctctc attccctctg ggggctcccc cgtgagaaaa
                                                                        180
totgtggcgg aggcanctct ggcccactct tayggwgtcc yttattgtgg ggctcgctat
                                                                        240
atggagaggg ggtctgtgtc aggagcttcc cctggagagg tttctgttar ggaccgtctt
                                                                        300
tgggagtgat ctatctctgc tctctggggg ggatctttgt ctggagcttt tggggggctt
                                                                        360
gtgtttggaa gtttgccttc ggggagatat ctgtctggga cctcttaggg tttctgtatc
                                                                        420
tgagctttct cttttgtgtc tgtcagtcca agggcagcaa aaagtatgtc ctttctgaag
                                                                        480
cctttttttc cgtaggtttc ttnattcttt tctctcttgt cttatgttca ttttagccat
                                                                        540
                                                                        569
agacttgact ggagtttaga gggaattga
<210> 30
<211> 2767
<212> DNA
<213> Homo sapiens
<400> 30
gegteeggtt ctagategeg ageggeegee ettttttttt ttttttgata tggagtettg
                                                                         60
ctctgtcttc caagctggag tgcagtggcg cagtctcagc tcactgcaac ctctgcctcc
                                                                        120
cgggttgaag cggttctcct gcctcagcct gagtagctgt gattataggt gcacgccacc
                                                                        180
acacctaatt tttttttgta tttttagtaa agacggggtt tcaccacatt ggtcagactg
                                                                        240
gtctcaaact cctaacctca tgatctgcct gcctcagcct ccccaagtgc tgggatgtgc
                                                                        300
ccggctgaga cttattttt aatagacttt tacaaatgta tgcaaaggac cagttattaa
                                                                        360
aaaagacagt aagtgaccgc cctggtaaat agattctaaa attcaatgaa taagaaacag
                                                                        420
atquatgtca gacttgtcct aaaccctttt cctctatatt ctgtctatgt catccctaat
                                                                        480
tagccetcae ceatgetget etteatttet tetacagaaa etgaactaga caacettgge
                                                                        540
tactcgtcta tatactcaat tgagtaattt aggttcagga tcacaactaa tttagattca
                                                                        600
taatcacagt ccagttttet tttgtttttt ttgagacgga gtctcgctct gtcgcccagg
                                                                        660
```

ctggagtgca gcggcgcgat ctcggctcac	tqcaaqctcc	acctcccagg	ttcacgccat	720
tctcctgcct cagcctccag agtagctggg				780
atttttttg tatttttagt agagacgggg				840
ctcctgacct cgtgctccgc ccgtctcggc				900
ccaccgcgcc cggtccagtt ttttttatc				960
ctccttaaat taaaagattg agtaacctct				1020
aaaaggttaa aaaaaaaaaa aagctagaca				1080
atcagttgta catttgatac tctatagtaa				1140
aatccttact caataggtgg aaataatggg				1200
totttaaato caaataactt cattttottt				1260
ttactgccat tattctctaa atcctcagtt				1320
				1380
gtgaatgacg gactttccag cttagaggga				1440
gggetcaget gtgtgettte tetggtetet				1500
ttattccacg gcattgaaga ttttttcacc				1560
tgatgatggg gtaatatcct aaggcatcgc				1620
tccttcggag ggaacatggt aggtcggatc				
cagtetgtaa accaetgeee atetttegte				1680
cacttcagcc ctggcagttc attagacaca				1740
tccagtaaag atgctatgac tgcttcatcc				1800
accatectte cacetteage cagetgttea				1860
ccatgtagct gcaagctatt taaggtggtc				1920
atagtgccgt ctccactgca agggacatca				1980
ttcctgccgt ccacatctat ctggagcctg				2040
atgatgcagg ggctgctcag cctcttggct				2100
tccacatcat tcgcaataac aaatccctct				2160
atttcaatta actgtgtggt ctttgagcca				2220
tgaggccgca cgttgaggag cagtggtggg				2280
tttccagatt ctgtttcact aactagaaac				2340
ctcaagattt ttcgacttaa atttgtgtgc	caggcaagtt	cttcaggata	ccaactcagt	2400
ggctgtggaa cttcaacttt ctgaccgtcc				2460
ttgttcttta agcaatggag aatctctttt	gcgtggcttt	tgtaaccagt	aattcttaaa	2520
gtggccggga gcggctccct gagagcgtcc	atgaactggc	cccactcgcc	ctcgggcacg	2580
atcttgagct cctggtagta gtgctcgaac	agcttgttct	ccttgacgat	ctcggggtag	2640
cctccttccc agcccgcctc gccgcgcttt	ccaccaccct	cggcgccatc	ctccgcgtcc	2700
tccggccgct gctgttgctg gagccgccga	ccccgcgacc	gccgccccat	agcccacgcg	2760
gccgctc				2767
<210> 31				
<211> 1051				
<212> DNA				
<213> Homo sapiens				
<400> 31				
gcgcggccct ccccatgtgc agccggccag				60
accttttcct ggcacgggca ggctgtggga				120
gcagcatece ggeggeggeg eggatecetg	gccccatggg	gcccctatgg	ggggcgcccc	180
tccgggcctg ggcagctgga agcgtcgggt				240
cctctatcag ctcagcgggg gaccccctcg				300
aaattccact tacttggatg accatggacc				360
ccaggtggtg tacaacaggg taggcaagtk				420
aatcttgtcg gagaagcacg gatttaattt				480
gcttactaaa aatgaacaaa tggaactgat	taaaaatata	agtactgccg	aacaacccta	540
tttattcact cgacatgttc atttcctcaa	cttctcaagg	tttggaggag	accagcctgt	600
ctacatcaac atcattagag accccgtcaa	ccggttctta	tccaactatt	ttttccgtcg	660
ctttggagac tggagagggg aacaaaatca	catgatccgc	acccccagca	tgaggcagga	720
ggagcgctac ctggatatca atgagtgtat	tcttgaaaac	tatcccgagt	gctccaaccc	780
caggttattt tacatcattc cgyacttkkg	tggacagcat	cccagatgca	gggagcctgg	840

```
tgaatgggcc cttgagagag caaagctgaa cgtgaatgaa aacttcctgc tcgtggggat
                                                                     900
tcttgaagag ttggaagatg tgctgctgtt actggaaaga tttttacctc attacttcaa
                                                                     960
gggsgtgctc agtactacaa agacccagag cacaggaagc ttggaaacat gactgtgacg
                                                                     1020
                                                                     1051
gtgaagaaga ctgtcccctc tcctgaggct g
<210> 32
<211> 1675
<212> DNA
<213> Homo sapiens
<2205
<221> SITE
<222> (1549)
<223> n equals a,t,g, or c
<400> 32
                                                                        60
gtacgacyca ctatagggwg agagctatga cgtcgcatgc acgcgtaasc ttgggcccct
120
ttttattctt taaaggcatt ctctgattta catgagaatt gagaaactga gatgtatgat
                                                                       180
ttgtctgtta gtcaatttca caccctttca ttctcataag ccccaaattt tgctcagtta
                                                                       240
aggagettge tttaggeeca cetatgtaag tetgttatae tagetaatgt geceatttga
                                                                       300
atagttcaag ggtcagctaa tgctctgagc ttcatggctc cagtataaag aacaaattta
                                                                       360
acaaaattaa gctgttactg tagccgagtt accettctgc tccacacata tgtagtggga
                                                                       420
tottqcaqqa tttccataqt qccaattatc aaaggccttg actacttagc attgctgtat
                                                                       480
tacaqatqtq caaactqaqq cactqaaaaq tcaaatttaa aqtcatattq agggccagaa
                                                                       540
aaggaggett agtttgggge tttggeeatt ttagetaett atctgaaatt getgeagata
                                                                       600
caacqtatqa qcatatcaaa tatttttqac tqtatataat tqatttctaa qqtaaaaaaca
                                                                       660
aataaaaaga aaccaataat ttttaaagga aagatgtagt tcaaaaaaaa aaccaccatt
                                                                       720
aaacatggtg ccattacagg ttaaaacaaa tgctttgtga cttagacctc aaaaacagag
                                                                       780
cttgatgact ttactccaca atttgtgcac ttagtgtata tttaaatgct ctctgttaat
                                                                       840
tagaacaact tcattatgct atcaagattc cagtaatcca taaaacatgt caattatgat
                                                                       900
ttgagtttgt gcgaagccct gtctgtgagc tcatagtctc aatagcctct tctagtaccc
                                                                       960
agaggaagct atagataaaa aataactcta ttggcaaccc atctgtttct gttactggaa
                                                                      1020
atttccacac acctctgctt ttggaaatca cttagaaaac ttgaggggaa ataattcctt
                                                                      1080
ttgctttcag tctggcagca agaaggatcc tgaaggaatt ctgtgggtcc aggatccagt
                                                                      1140
ggggtaattc tgtaaagtgc agtagtgctt gcttaaagcc ataggctcca gaggtgagtc
                                                                      1200
cagatcagtg aaggggcaag tttcatggcc aggtgttggc tagtcttgtt gcaggtttca
                                                                      1260
gattaaagtg ctgggtcatc caaaggcatt tgaaaagtgc aaatggcaag ctctgcaggc
                                                                      1320
caccgaattc ttgttcagag tccagaagct tctttagatg tcatatcagg tcaccctggc
                                                                      1380
teccaagace acaggtteag atageactgt teactteect etttgttgtg gtgacaggte
                                                                      1440
tttttgttgt gtcttttgaa gaatacagct tttgacagag ttgttttctt agggctrtca
                                                                      1500
ckgkgqctat gaaaatgaaa qcaatgatgc aggaggggat gaaaatgtna agcagccaag
                                                                      1560
ttggatgggt cctgggttcc atctgacttt gaaggtcaat gctggccaaa gtaagttccc
                                                                     1620
                                                                      1675
tcacgtgagt attccagaac acacagctga agtttctgcc agggggtggc tttag
<210> 33
<211> 786
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (754)
<223> n equals a,t,g, or c
<220>
```

60

120

180

240

300

360

420

480

540

600 660

720 780

```
<221> SITE
<222> (778)
<223> n equals a,t,g, or c
<400> 33
 ggaatgaaca acttttcttc tcttgaatat atcttaacgc caaattttga gtgctttttt
 gttacccatc ctcatatgtc ccagctggaa agaatcctgg gttggagcta ctgcatgttg
 attgttttgt ttttcctttt ggctgttcat tttggtggct actataagga aatctaacac
 aaacagcaac tgttttttgt tgtttacttt tgcatcttta cttgtggagc tgtggcaagt
 cctcatatca aatacagaac atgatcttcc tcctgctaat gttgagcctg gaattgcagc
 ttcaccagat agcagettta ttcacagtga cagteectaa ggaactgtac ataatagage
 atggcagcaa tgtgaccctg gaatgcaact ttgacactgg aagtcatgtg aaccttggag
 caataacagc cagtttgcaa aaggtggaaa atgatacatc cccacaccgt gaaagagcca
 ctttgctgga ggagcagctg cccctaggga aggcctcgtt cccatmcctc aagtycaagt
 gagggacgaa ggacagtacc aatgcataat catctatggg gtcgcctggg actacaagta
 cctgactctg aaagtcaaag cttcctacag gaaaataaac actcacatcc taaaggttcc
 agaaacagat gaggtagagc tcacctgcca ggctacaggt tatcctctgg cagaagtatc
 ctggccaaac gtcagcgttc ctgccaacac cagncactcc aggacccctg aaggcctnta
ccaggt
<210> 34
<211> 1063
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (23)
<223> n equals a,t,q, or c
<220>
<221> SITE
<222> (27)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1032)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1055)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1056)
<223> n equals a,t,g, or c
<220>
<221> SITE
```

```
<222> (1062)
<223> n equals a,t,g, or c
<400> 34
gttggggggt tatgcccttt cgntccnttn aaatcgagtc actgatsatg taatgatata
                                                                        60
ttttttcatt attatagtag aatattttta tggcaagata tttgtggtct tgatcatacc
                                                                       120
tattaaaata atgccaaaca ccaaatatga attttatgat gtacactttg tgcttggcat
                                                                       180
taaaagaaaa aaacacacat cctggaagtc tgtaagttgt tttttgttac tgtaggtctt
                                                                       240
caaagttaag agtgtaagtg aaaaatctgg aggagaggat aatttccact gtgtggaatg
                                                                       300
tgaatagtta aatgaaaagt tatggttatt taatgtaatt attacttcaa atcctttggt
                                                                       360
cactgtgatt tcaagcatgt tttctttttc tcctttatat gactttctct gagttgggca
                                                                       420
                                                                       480
aagaagaagc tgacacaccg tatgttgtta gagtctttta tctggtcagg ggaaacaaaa
                                                                       540
tottgaccca gotgaacatg tottcotgag toagtgootg aatotttatt ttttaaattg
aatgttcctt aaaggttaac atttctaaag caatattaag aaagacttta aatgttattt
                                                                       600
tggaagactt acgatgcatg tatacaaacg aatagcagat aatgatgact agttcacaca
                                                                       660
taaagtcctt ttaaggagaa aatctaaaat gaaaagtgga taaacagaac atttataagt
                                                                       720
gatcagttaa tgcctaagag tgaaagtagt tctattgaca ttcctcaaga tatttaatat
                                                                       780
caactgcatt atgtattatg tctgcttaaa tcatttaaaa acggcaaaga attatataga
                                                                       840
                                                                       900
ctatgaggta ccttgctgtg taggaggatg aaaggggagt tgatagtctc ataaaactaa
tttggcttca agtttcatga atctgtaact agaatttaat tttcacccca ataatgttct
                                                                       960
1020
                                                                      1063
aggggggcc cnttttaaag gatccaagtt taccnncccc gng
<210> 35
<211> 1178
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (1138)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1176)
<223> n equals a,t,g, or c
geggeegeeg actagtgage tegtegacee gggaattege ggeegegteg actggeettg
                                                                        60
tatttttcta atqqqtqtqq cttttctqaq aacactttct ccttqqtact tqcttccatt
                                                                       120
ctcccctcc aagtccaaga aggccatgac aaaaagagag gtggccaaga ggctttgact
                                                                       180
gaatgettea gatettgggt yeetgatgat geagetataa teteagggtg geettaateg
                                                                       240
ctagatgtga acaatctagt tagatctatt tttagagtgc tgtgttatgt tcttaaaaga
                                                                       300
acaaaccgat aaaagttgct cacagttttg cataatgttt aaggacccag tgccacagta
                                                                       360
agaccatata agttcactgc tttctascag tgataatggt acctacctca ctgagctacc
                                                                       420
gtgaagattg agtgagaaac aattcaaaga aaatccttag cacagtgtct ggtgtaacca
                                                                       480
tcccatacat arctgctggg attttcatta tcatcagagc acccatacct aatagaaatc
                                                                       540
ttgtattata tatctaagta gaaagggacc tcagaaattg acaagttcac aattgcacac
                                                                       600
caagggcagt gacttactct acttcacatc cctattaaat gatatctagc ctgtggttta
                                                                       660
atatttccaa ggacaggagt tcactatctt ttaaaggtac ctcatggtat tgccaatcac
                                                                       720
tettateact aggaagettt teettetaet gageeccaaa tettteteet getttteecc
                                                                       780
tggaacaccc tgaaatgaag ttattatcat ttctgtgtga tggtccttcc atctcagggc
                                                                       840
ctcccttata acactctata gttcttcttt ctagttgtgc tctagggaag aggctggtac
                                                                       900
ttccgattgc agaccagetc tcccttgcca caacctgaag tgtcctacgg aaatcaagca
                                                                       960
gggtctgaaa ggcctaggca aaaggaataa attccaccaa agatcacagg ctatccaatt
                                                                      1020
ctcttttcta cctcccttcc catgataagt gcatccctgc tccacctctg ccctaggaac
                                                                      1080
```

```
actaccaaac acaaacgcac gctcacacac acagaaagaa taggtttaat ttattagntg
                                                                        1140
 ctctttagca aaggctatat agaacattat tggggnga
                                                                        1178
<210> 36
<211> 790
<212> DNA
<213> Homo sapiens
<400> 36
 tgtgtgtgtg tgtgttgtg tgtgttcata taacaggagg acaggaaagg taaggaccca
                                                                          60
 gaacaatgaa gacttattga aatgtggtat gtgtgtgcgt gtgtgtgtgt gtgtgtgtrt
                                                                         120
 gtgtgttcat ataacaggag gacaggaaag gtaaggaccc agaacaatga agacttattg
                                                                         180
 aaatgtgggg ggggtgtgtg tgtgtgtgtg ttcatagaac aggaggacag gaaaggtaat
                                                                         240
 gaccatccat ggaagatgaa ggggtagtac ttagcaccag aatcttttcc agtttttacc
                                                                         300
 catctttcat tactccttgt ctccaaatca ycccttcctt aataacttaa aataacttaa
                                                                         360
 aatattttct gaggacttga tgacaccagt cagaagtcca agagtggtct ggtataaggg
                                                                         420
 agtgttcatc aaggggcagc tggaaaaagt ggaattggca caggcaacat ctttcttttc
                                                                         480
agatgtttga ggtcacccag aggagataac agtctgtcaa catagagccc tcaaagttaa
                                                                         540
 aaagcagtag ccaggcaaga cttgtgtctt ttcagggctc ttccaggctc taagagtgtg
                                                                         600
 aaattcagac agktttttaa aaatcaaaat aaaaggagag tagttcttac aggcagaaac
                                                                         660
 tcttagagct cacaaattgg aaacaactgc aaacttcaga gtaaattcat agcttccaaa
                                                                         720
 tacaaatgtt cacattgtcc ctccgctatt tttacacaaa tgcattcagg tgaagacagc
                                                                         780
                                                                         790
 aacacacatt
<210> 37
<211> 1203
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (10)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (13)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (106)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1160)
<223> n equals a,t,g, or c
<220>
<221> SITE
```

PCT/US00/30654

```
<222> (1188)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1201)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1202)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1203)
<223> n equals a,t,g, or c
<400> 37
 cgggttccnn aanctgccag ttgggaaccc cctggtagat cctgctatat ccagagattt
                                                                          60
 agggcaccgt ctctgaaaaa gtgccccggg ggctttcagc cagcanccag ccctcatcag
                                                                         120
 cgatgatgcc aagtgtccta ttgcgtcaaa tccgggctct tcmcagragg gtccctgccc
                                                                         180
 cctgccaggc tcccaccttt caccggccac ccctcatgag tcaggctgcc accaatactg
                                                                         240
 tcatagtgac caattctgag aatgcgagat cctggattaa agactcccag acccaccagt
                                                                         300
 ggaggctggg agaaccgata gagctgcgga gggccatgaa tgtcatccat ggggatggtg
                                                                         360
 gtggtctgtc aggagggct gcagctgggg tcacagtggg ggtcaccacc attctggctg
                                                                         420
 ttgttatcac cttggccatc tacggcaccc ggaagttcaa gaagaaagca tatcaggcaa
                                                                         480
 ttgaggaaag gcagagtttg gttccaggca ctgcagcaac tggagacacc acttaccaag
                                                                         540
 agcaggggca gagtccagct taaatctctc cccgaaaatg gtttctctca tctccagtgt
                                                                         600
                                                                         660
 ggtcattgct gaccactctg ttttcctaag cattgaaatg gcaagtgcaa ccaaaagtag
 gtatattcgt gacttcttgt ttaggtctct gggccaggaa attcatactg ttacatggat
                                                                         720
 aaggttggga ttggggagag ggaacagttg ggactagaag caaaagtgat tctgggacta
                                                                         780
 aaataggaag cagatgtcct ttcccaatgt gtgttgctgt cttcacctga atgcatttgt
                                                                         840
 gtaaaaatag cggagggaca atgtgaacat ttgtatttgg aagctatgaa tttactctga
                                                                         900
 agtttqcaqt tqtttccaat ttqtqaqctc taaqagtttc tqcctgtaag aactactctc
                                                                         960
 cttttatttt qatttttaaa aamctgtctq aatttcacac tcttagagcc tggaagagcc
                                                                        1020
 ctgaaaagac acaagtettg cctggctact gcttttwaac tttgagggct ctatgttgac
                                                                        1080
 agactqttat ctcctctqqq tqacctcaaa catctraaaa raaagatqtt qcctqtqcca
                                                                        1140
 attecacttt ttecagetgn seetggtett aacceagagg agcataantt cecateceeg
                                                                        1200
                                                                        1203
<210> 38
<211> 804
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (801)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (802)
<223> n equals a,t,g, or c
<400> 38
```

```
geggeegeeg actagtgage tegtegacee gggaattege ggeegegteg aegetggeeg
                                                                         60
 ctgtgtaggq ctqqtgagtg gctggggctg tctgagccat gaacaacttc agggccacca
                                                                         120
 tectettetg ggeageggea geatgggeta aateaggeaa geetteggga gagatggaeg
                                                                         180
 aagttggagt tcaaaaatgc aagaatgcct tgaaactacc tgtcctggaa gtcctacctg
                                                                         240
                                                                         300
 gagggggctg ggacaatctg cggaatgtgg acatgggacg agttatggaa ttgacttact
 ccaactgcag gacaacagag gatggacagt atatcatccc tgatgaaatc ttcaccattc
                                                                         360
 cccagaaaca gagcaacctg gagatgaact cagaaatcct ggaatcctgg gcaaattacc
                                                                         420
 agagtagcac ctcctactcc atcaacacag aactctctct tttttccaaa gtcaatggca
                                                                         480
 agttttccac tgagttccag aggatgaaga ccctccaagt gaaggaccaa gctataacta
                                                                         540
                                                                         600
 cccgagttca ggtaagaaac ctcgkctaca cagtcaaaat caacccaact ttagagctaa
 gctcaggttt taggaaggaa ctccttgaca tctctgaccg tctagagaac aaccagacga
                                                                         660
 ggatggccac ctacctggca gaactcctgg tgctcaacta tggcacccac gtcaccacca
                                                                         720
 gtgtcgacgc tggggctgct cttattcagg aggaccacct caagggctcc ttcctccaag
                                                                         780
                                                                         804
 acagccagag caagtccgta nntg
<210> 39
<211> 1602
<212> DNA
<213 > Homo sapiens
<220>
<221> SITE
<222> (1599)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1602)
<223> n equals a,t,q, or c
<400> 39
 ggggagtgtt gttaaccgga gggcagccgc agtcgcgcgg attgagcggg ctcqcqqcqc
                                                                          60
 tgggttcctg gtctccgggc cagggcaatg ttccgcacgg cagtgatgat ggcggccagc
                                                                         120
 ctggcgctga ccggggctgt ggtggctcac gcctactacc tcaaacacca gttctacccc
                                                                         180
 actgtggtgt acctgaccaa gtccagcccc agcatggcag tcctgtacat ccaggccttt
                                                                         240
                                                                         300
 gtccttgtct tccttctggg caaggtgatg ggcaaggtgt tctttgggca actgagggca
 qcaqagatqq agcaccttct ggaacgttcc tggtacgccg tcacagagac ttgtctggcc
                                                                         360
 ttcaccqttt ttcqqqatqa cttcagcccc cgctttgttg cactcttcac tcttcttctc
                                                                         420
 ttcctcaaat gtttccactg gctggctgag gaccgtgtgg actttatgga acgcagcccc
                                                                         480
                                                                         540
 aacateteet qqetetttea etgeegeatt gtetetetta tgtteeteet gggeateetg
 qactteetet teqteaqeea eqectateae aqeateetqa eeeqtqqqqe etetqtgcag
                                                                         600
                                                                         660
 ctqqtqtttq qctttqaqta tqccatcctq atqacqatqq tqctcaccat cttcatcaag
                                                                         720
 tatgtgctgc actccgtgga cctccagagt gagaacccct gggacaacaa ggctgtgtac
 atgetetaca cagagetgtt tacaggette atcaaggtte tgetgtacat ggeetteatg
                                                                         780
 accatcatqa tcaaqqtqca caccttccca ctctttgcca tccgqcccat gtacctggcc
                                                                         840
 atgagacagt tcaagaaagc tgtgacagat gccatcatgt ctcgccgagc catccgcaac
                                                                         900
 atgaacaccc tgtatccaga tgccacccca gaggagctcc aggcaatgga caatgtctgc
                                                                         960
 atcatctgcc gagaagagat ggtgactggt gccaagagac tgccctgcaa ccacattttc
                                                                        1020
 cataccaget geetgegete etggtteeag eggeageaga cetgeeceae etgeegtatg
                                                                        1080
 gatgteette gtgeateget geeagegeag teaceaceae eeeeggagee tgeggateag
                                                                        1140
 gggccacccc ctgcccssa cccccacca ctcttgcctc agcccccaa cttcccccag
                                                                        1200
 ggcctcctgc ctccttttcc tccaggcatg ttcccactgt ggccccccat gggccccttt
                                                                        1260
 ccacctgtcc cgcctccccc cagctcagga gaggctgtgg ctcctccatc caccagtgca
                                                                        1320
 geagecettt eteggeeeag tggageaget acaaceaeag etgetggeae eagtgetaet
                                                                        1380
                                                                        1440
 getgettetg ceacageate tggeccagge tetggetetg ceccagagge tggecetgee
                                                                        1500
 cetggtttcc cettccetcc tecetggatg ggtatgeecc tgcctccacc etttgcettc
 cccccaatgc ctgtgccccc tgcgggcttt gctgggctga ccccagagga gtacgagctc
                                                                        1560
```

29

tggagggsca tgagcggcag aactggaggc ccggtgcana an

```
<210> 40
<211> 1789
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (1742)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1743)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1781)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1786)
<223> n equals a,t,q, or c
<400> 40
geogeagteg egeggattga gegggetege ggegetgggt teetggtete egggeeaggg
                                                                          60
caatqttccq cacqqcaqtq atqatqqcqq ccaqcatctq qcccaqqctc tqqytctqcc
                                                                         120
ccaraggetg gccctgcccc tggtttcccc ttccctcctc cctggatggg tatqccctq
                                                                         180
cctccaccct ttgccttccc cccaatgcct gtgcccctg cggstttgct gggctgaccc
                                                                         240
cagaggaget acgagetetg gagggecatg ageggeagea cetggaggee eggetgeaga
                                                                         300
qcctqcqtaa catccacaca ctgctggacg ccgccatgct gcagatcaac cagtacctca
                                                                         360
 ccqtqctqqc ctccttqqqq ccccccqqc ctqccacttc agtcaactcc actgaggaga
                                                                         420
ctgccactac agttgttgct gctgcctcct ccaccagcat ccctagctca gaggccacga
                                                                         480
 ceceaacece aqqaqeetee ecaceaqeee etgaaatgga aagqeeteca geteetgagt
                                                                         540
 cagtgggcac agaggagatg cctgaggatg gagagcccga tgcagcagag ctccgccggc
                                                                         600
 qccqcctqca qaaqctqqaq tctcctqttq cccactqaca ctqccccaqc ccagccccag
                                                                         660
                                                                         720
 cetetgetet titgageage cetegetgga acatgicetg ceaceaagig ceageteect
 ctctgtctgc accagggagt agtaccccca gctctgagaa agaggcggca tcccctaggc
                                                                         780
 caagtggaaa gaggctgggg ttcccatttg actccagtcc caggcagcca tggggatctc
                                                                         840
 gggtcagttc cagcettect etecaactet teagecetgt gttetgetgg ggccatgaag
                                                                         900
 qcaqaaqqtt taqcctctga qaaqccctct tcttccccca cccctttcca ggagaagggg
                                                                         960
 ctgcccctcc aagccctact tgtatgtgcg gagtcacact gcagtgccga acagtattag
                                                                        1020
                                                                        1080
 ctcccgttcc caagtgtgga ctccagaggg gctggaggca agctatgaac ttgctcgctg
 geocaecect aagaetggta eccattteet titettaece tgateteece agaageetet
                                                                        1140
 tgtggtggtg gctgtgcccc ctatgccctg tggcatttct gcgtcttact ggcaaccaca
                                                                        1200
                                                                        1260
 caactcaggg aaaggaatgc ctgggagtgg gggtgcaggc gggcagcact gagggaccct
 geologico teccecagg coestitees etgeagette teaagtgaga etgacetgte
                                                                        1320
 teacceagea gecaetgeec ageegeacte caggeaaggg ceagtgegee tgeteetgae
                                                                        1380
 cactgcaatc ccagcgccca aggaaggcca cttctcaact ggcagaactt ctgaagttta
                                                                        1440
 gaattggaat tacttcctta ctagtgtctt ttggcttaaa ttttgtcttt tgaagttgaa
                                                                        1500
 tgcttaatcc cgggaaagag gaacaggagt gccagactcc tggtctttcc agtttagaaa
                                                                        1560
 aggetetgtg ccaaggaggg accacaggag etgggacetg cetgeceetg tetttteece
                                                                        1620
                                                                        1680
 ttggttttgt gttacaagag ttgttggaga cagtttcaga tgattattta atttgtaaat
                                                                        1740
 attgtacaaa ttttaatagc ttaaattgta tatacagcca aataaaaact tgcattaaca
```

30

annaaaaaaa aaaaaagggg ggggcccttt taagaaccag nttaanaac

```
<210> 41
<211> 2102
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (22)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (35)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (83)
<223> n equals a,t,q, or c
<400> 41
ategactegg gagtttgege tntntgeaac etggntatga agtteetace teaacetetg
                                                                       60
teetteetge aaageaggaa gantetgtea agateetget ggetgagtte aaggetggge
                                                                       120
tgtqatqtqc aacacactqa acacqtqtac aqqqtttatq tcacaacttt tctqqqtttc
                                                                       180
ggaggcaact ttgcccggca gcgctacgaa gaccttgttc tgaatgaaac tcttaacaaa
                                                                       240
aacagattgc ttggtcagaa gacaggtctg agtcccgaca atccatttct ggatccctgc
                                                                       300
ctgccagtgg gactcacaga tgtggtggag aggaacagcc aagtcttaca tgtccgagga
                                                                       360
agaggagact gggtgtcttg tggggcaatg ctgagccccc tgctggctcg ctccaacacc
                                                                       420
agccaggcct cactcaatgg catatatcaa tcgcctattg acttcaacaa cagcgagttc
                                                                       480
tacggettet etgagttttt ttattgtaca gaggatgtgt tgegeattgg tggeegetac
                                                                       540
catgggccaa catttgccaa ggctgctcag gattactgtg gcatggcttg gtcggtacta
                                                                       600
actcagagat tcaagaatgg cctcttttca tcacatgcag atgagcatcg actcaaatat
                                                                       660
cagtgtttta aatcggcttg gatgtaccaa gtcttacatg aaggattcca ctttccctat
                                                                       720
gactacccaa acctgcggac agcccagctg gtgtatgacc gagaggttca gtggacgctg
                                                                       780
qqaqccattc tatataaaac acqattctta ccactcaggg atcttcggca ggaaggtgtc
                                                                       840
cgacaagccc atggtagctg gttccgtctc tcctttgtat acaaccacta tctcttcttt
                                                                       900
gcctgtatcc tggtggtgct actggccatc ttcctatacc ttctgcggct acgccgaatt
                                                                       960
caccaccgac aaacacgage ctcageteca ttggacttgc tgtggcttga agaggtggtg
                                                                      1020
cccatgatgg gagtacaggt ggggcgtga ggctggacca ggactagaga agcttgagca
                                                                      1080
cccccgagtt gctgctcatt gaattcctcc actttcttat atagcctcag atgctgtgat
                                                                      1140
gtctgacctt gtggatattt gcccttggaa tttctacttt actttctacc gtaattcctt
                                                                      1200
ctccgtaccc aggtcttctc tgagagaagc tataatttaa tctgtgagga actaaatgac
                                                                      1260
aggagattgg tgctaatacg ggggaccaag ctttgtccaa gtgaagcagg cttcgactcc
                                                                      1320
ttctgagarg tctggtgtt tcctagaatc tcaccttttc ttcccttgct aaagcatgaa
                                                                      1380
1440
gccagrgaca ttctagcaag tgcagcascc ccttctttct ctgtaacaga gatatcattt
                                                                      1500
atgtggagat ccacaacctt taacagggat ccaagatctt tgcagttcaa tcgaccacat
                                                                      1560
aggaatttcc aggcaccaaa atgatataac ttccttgctt ccttgacaaa gaagccatca
                                                                      1620
 tgggtgtgat ccaagatccc tgtcgtagtg ttgatgatgt tagtacatga ttttaaaggt
                                                                      1680
 tagaacccct tctaaatgaa tggtctgtqq aagattttag tatcttatct gatgcctggt
                                                                      1740
```

```
1800
atgatgagga tagaaaattt ttccattttt atgtgcctca caggctgttt gggcattaat
                                                                    1860
tttgcttttt gagccttaag tgtgttagta ggatggagaa actgtgatgg ggactgggaa
cctggatttg tctgatttta ggtcactgtt ccctgggcct gtttttgtga gcccttacac
                                                                    1920
aggaagatat aaagagagtt ctttcatttc actgctaaaa tcagtatgta gtatggggaa
                                                                    1980
                                                                    2040
tgtatttggg ttgtttttaa agaaaagggg aacagaatca ggagagtggg caaaggcaat
                                                                    2100
2102
gc
<210> 42
<211> 1005
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (1004)
<223> n equals a,t,g, or c
<400> 42
atgggaaatg ctcttttgaa ggtacgcccg caggtcccgg tccggaattc ccgggtcgac
                                                                      60
ccacgcgtcc ggccagaagc agccatgaag tgagcctgca ggcaggccag cctgtgacca
                                                                     120
tcctggaggc ccaggacaag aaggggaacc ctgagtggag cctggtggaa gtgaatggac
                                                                     180
                                                                     240
agaggggtta tgtgccttct ggcttcttgg ccagggctcg gagcccagtt ctgtggggct
                                                                     300
ggagtctgcc ctcttagggt accctctttg gagcctacat tgccaaatga tgggggaggc
ttagaggctc tgaccctggg gggaaaagaa gcaaaggaaa ggtggaggtg gaagggaaga
                                                                     360
ccaggccagg gtgggtgaag cacactcagg aggcagccag aagacatggg cgggcctcgc
                                                                     420
agagtgcttg gtgtggtggg ggcacaggag gctccagcca ggactgctca ttatgtctgc
                                                                     480
ataaaqaact cattccqacc tqqqqtcaca atqcacttqq acaqcaggtc acaqctgatt
                                                                     540
ggccaggact ctcgataggt tatggccagt cttagctgtg cctgcatccg ggcctgcctg
                                                                     600
tgggcgtggg tcacacggga taatgttacc tgcgtgctgt gtggttgcag gaagcgggtt
                                                                     660
ctggaggagt ccagaactgc ctggtcagac agttcacttc ctacacatgg tatcaggaga
                                                                     720
catcataacc aatgagtcag cttttatttc tctatgctgg aagctgagtt tatcttgggc
                                                                     780
agtgacccac tgggagccct ctcaagtggg gaagccatgg atttatcggt gtagcagaga
                                                                     840
ggttcccaag actcttgact ggtcctggga gtgggtgtga ccaagtcata gttctggaat
                                                                     900
gtgtgtaggc aaattcagag gctgttccag ggaagagggg attttgatac tgtgttaggt
                                                                     960
                                                                    1005
ggggtgtgtg aggctgytgg cagcaggtga acagctactg ctgng
<210> 43
<211> 2988
<212> DNA
<213> Homo sapiens
<400> 43
                                                                      60
cccacgcgtc cggccagaag cagccatgaa gtgagcctgc aggcaggcca gcctgtgacc
                                                                     120
atcctggagg cccaggacaa gaaggggaac cctgagtgga gcctggtgga agtgaatgga
cagagggtt atgtgcette tggettettg geeagggete ggageceagt tetgtgggge
                                                                     180
 tggagtctgc cctcttaggg taccctcttt ggagcctaca ttgccaaatg atgggggagg
                                                                     240
300
accaggccag ggtgggtgaa gcacactcag gaggcagcca gaagacatgg gcgggcctcg
                                                                     360
cagagtgctt ggtgtggtgg gggcacagga ggctccagcc aggactgctc attatgtctg
                                                                     420
 cataaagaac tcattccgac ctggggtcac aatgcacttg gacagcaggt cacagctgat
                                                                     480
 tggccaggac tctcgatagg ttatggccag tcttagctgt gcctgcatcc gggcctgcct
                                                                     540
gtgggcgtgg gtcacacggg ataatgttac ctgcgtgctg tgtggttgca ggaagcgggt
                                                                     600
 totggaggag tocagaactg cotggtoaga cagttoactt cotacacatg gtatcaggag
                                                                     660
acatcataac caatgagtca gcttttattt ctctatgctg gaagctgagt ttatcttggg
                                                                     720
cagtgaccca ctgggagccc tctcaagtgg ggaagccatg gatttatcgg tgtagcagag
                                                                     780
```

32

	aggttcccaa	qactcttgac	tggtcctggg	agtgggtgtg	accaagtcat	agttctggaa	840
			ggctgttcca				900
			gcagcaggtg				960
			catagaggaa				1020
			gcttgctttc				1080
			ggcccctgag				1140
			gtaggacaca				1200
			atgacatggg				1260
			atgacagcag				1320
			tggcagcaaa				1380
			ggggcttctc				1440
			ccattctaga				1500
			cctgctgggg				1560
			ttgctctggg				1620
			atcttaacaa				1680
			tagtttagat				1740
							1800
			ctctggtttt ctcctctggg				1860
			gttcctttct				1920
							1980
			ttcctgctca acccactcgt				2040
							2100
			caggagttct				2160
			ccaggctccg				2220
			aggaattcag				
			ctagacacaa				2280
			aggacgtgcc				2340
			tgaaagggga				2400
			agggacctga				2460
			gaaccaagtc				2520
			tttctcatag				2580
			gaagatgaga				2640
			ccaaatgcct				2700
			taaacttgca				2760
			tcacaagggt				2820
			aactcagttg				2880
			ggttaatatg			taactgatgt	2940
	gaactgctgg	gaataaagga	cttcaaagat	ggaaaaaaaa	aaaaaaa		2988
<	210> 44						
	211> 2052						
	:212> DNA						
	213> Homo s	sapiens					
<	400> 44						
			aagtccttta				60
			accaagaatt				120
			gttggggcct				180
			tgaaccagac				240
	aggcaaatat	ctttgcaagt	ttagtatgag	acagcccaac	ggttaaataa	ataagacaca	300
			tggagaggga				360
	aaatacaggc	cattctcatc	ttctcaacat	gcattttccc	actcttcagt	gacttttaat	420
	cttatcccct	ggtctatgag	aaaccataac	ccacqtqcta	ctgaatacat	ttttattttc	480

cttatcccct ggtctatgag aaaccataac ccacgtgcta ctgaatacat ttttattttc

catccaattt tgttcaggtc ccttttaatg gcacttaata aatatacatt ctgagacctg

agageteagg tggggeaegt cetagettae agetewtgge catetetgge accaggteta

tctgtccaat actttgtgtc tagggtagag gtccctaacc ctggctgcac attggaagca

gcagaacagg ctgtcccctt tcacactgcc tttaaagcgc ctgtttgaac tagctagtgc

480

540

600

660

```
cctgggaagc tttctgaatt cctgaggccc gagccacacc ctaaaccaat ttcatcagaa
                                                                         840
 tototgggtg ggacggagcc tggattctgc cagttgaaac ctgccatggt aacttcagtg
                                                                         900
agcagctaca ctgagaactc ctgagctaca attctagcac acagtaggcc ttcggtaggt
                                                                         960
atotgtggaa cocacgagtg ggtttcctat ttcattatct gttcccctat gctctctatt
                                                                        1020
 ttkatcagaa atctgagcar gaaagagcag agaqaatgag tcaagagcat cctctcaagt
                                                                        1080
 qaattcqctq ctqaqaaaqq aaccgtaqqq cttqcatttc tcttqtqtca tqcaqtcttc
                                                                        1140
atgetttaac aggeecagag gaggeaagtt atagaetgac acagacatgt atatatttet
                                                                        1200
 taaaagccct tcaaaaacca gagctcactg cttaggcact atggttataa cacagacatg
                                                                        1260
ttcttqqaaq catatctaaa ctacctcctg tttgacacac attctaactt gggttggtta
                                                                        1320
caaacttigt cagtigttaa gatcacactt ggtcacattt tcccattict gtgaatcttg
                                                                        1380
caacttatct ttgcccagag caacagccta gacatgacca ccccaagcag ggactgcact
                                                                        1440
gcacccaaca ttgccccagc aggtcagtcc tccttgaaca ggaactgttt ttgaggggct
                                                                        1500
ccaatttcca ggttctagaa tggggtggct cacttaccaa gttaaagagg ctggctacat
                                                                        1560
agaatgcagt attgagaagc cccccaaggt agatcctggg ttacaggaaa gaaagctata
                                                                        1620
ctgatgaaca aggtttgctg ccacaggcat gggcgtgggg gagggcagca tgccgggggc
                                                                        1680
cacccgaga tcactgctgt catttacatt tgtatcacac ttcacagttt acagggagct
                                                                        1740
ctgcatgctt agccccatgt cattctcagc acaaccctgt gagtgaggtc tttctggatg
                                                                        1800
ggaacactga agttgtgtcc tacatctaag gtcccacagc caattgcatc acatccacgg
                                                                        1860
ctgcctccag gacctcaggg gccacctgaa accactgggg gttccccctg gctccccttc
                                                                        1920
taaccagaaa caggaaagca agccattccc taacctcccc acccaccagg ccttatcacc
                                                                        1980
gccttcccag agtttcctct atgatttgca tacccctttg ttccctagtc ctgagaacac
                                                                        2040
agcagagett te
                                                                        2052
<210> 45
<211> 617
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (600)
<223> n equals a,t,g, or c
<400> 45
qtaccqqtcc qqattcqcqq ccqcgtcqac gatqcctqct tgaatttcct gqcaqctaaq
                                                                          60
qqaataaaca tccaqqqqct qtctqcaqaa qaqatcaqqa atqqaaacct caaqqccatt
                                                                         120
ctaqqcctct tcttcaqcct ctcccqatac aaqcaqcaqc aqcaqcaqcc ccaqaaqcaq
                                                                         180
caceteteet cacetetgee geoegeegta teccaggtgg ceggggeece eteccagtge
                                                                         240
caggetggea ceceteagea geaggtgeea gteacteece aageeeegtg ceageeteac
                                                                         300
caqccaqcac cacatcaqca qtcaaaaqca caaqctqaaa tqcaqtccaq aqcctttqqc
                                                                         360
aagktcagec tyeteecace eeggaatgag tgacaatgea eetgetteet tggagagegg
                                                                         420
cagcagetye acceptacta awtgcagtae ctycteggge atycegeare ceggtgcaag
                                                                         480
caccaaqcct tqqcqcaasa aatcctyarc qkqqaacaca aqtqqccacq qtatccakct
                                                                         540
yttcgggyaa gcttctgggg ctkaaggccc caaggcccaa accttgaaag ccattgaaan
                                                                         600
                                                                         617
ccgggcccca acaatta
<210> 46
<211> 558
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (390)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (391)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (434)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (485)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (541)
<223> n equals a,t,g, or c
<400> 46
 gaccctgcaa cgaaatacct ccctgggcct cggagacgct gacagctggg acgacagcag
                                                                          60
 ctccgtcagc agcggcatca gcgacaccat agacaacctc agcactgatg acatcaacac
                                                                         120
 cageteetee ateagetett atgecaacae acetgeetye tetegaaaaa acetggatgt
                                                                         180
 gcagactgat gctgagaagc actcacaggt ggagaggaat tcctgtggtc tggtgatgat
                                                                         240
 gtcaagaaat cagacggagg ctcagacagc ggcataaaaa tggagccagg ttycaagtgg
                                                                         300
                                                                         360
 aggeggaate ettetgatgt gtetgaegag teegacaaaa geaegteggg caagaagaat
 cctqqcatct ccaqacaqqc tcatqqcqqn naqqcatqac aqctcaaqtq qqcatcacca
                                                                         420
 tqccaaqqac qaanqcttca qccqqcaqq cqcactqaaq accccaqqaa ctqqaaaaaac
                                                                         480
 agacnacgca aaggtgtctg agaaaggaaa gggttttttc taaaggcttc caagtgaaag
                                                                         540
 nggttcccat caaatgca
                                                                         558
<210> 47
<211> 1454
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (10)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (15)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (38)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1427)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1429)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1445)
<223> n equals a,t,g, or c
<400> 47
nacatttggn attentaage taatettttt atttttgnaa gggtgtettt etnagaaagg
                                                                         60
cagccagagg cacagcacca acctttctga cagtgtggtc ttcacactgt tagttctgac
                                                                         120
aaagggagtc aaggagtcgt ccttggagga ggcgatgagg ccagtggaag aattgtggct
                                                                        180
qqqqacccct ccactgctga qqqaqatqtc qatqqactca cagctqqtqt qqaqqctqct
                                                                        240
qacaqactqa aaqcccaqqc catccttgct aactqcqqaq qaqctqctqq cgttqqtqcc
                                                                        300
ccaqqtqaqq ctqttqqaaq qqqccqaqtq qqctqaqctq qqqctqqaqq ctaqcqqaqa
                                                                        360
ctgqttqaqq tccacattct tqctqtaqaq aqqactqctq ctcccactqc tcaqqacqcc
                                                                        420
actgcctqac qqqqaqtcta qqttaccttq ctqaqtcatq qtqqcatqaq qattqqaqat
                                                                        480
gaccaccgaa tttttcatgt tttcagctgt ggcgatgggc acttgcttgg taggcttccc
                                                                        540
accaaagagt ctgcggagtg tgggagaggc cacatctggg tacttggctc caggctggag
                                                                         600
actqqtctqa qccqqactqq acacaqqctq qqctqccqqa ttcactttca ccqaqttaca
                                                                        660
ggaagccaca ctctcgtkgt ctgatgagat gcctttctcc ttgtctgttt ggttgaccag
                                                                        720
acctggtaga gagctgccta gggctgtttt ggaaggctcc ctcagtttgg gcactggcag
                                                                        780
gcctgcggac ttgctgctaa tgttggaatc tatgctgctg gtgctagacc tgttcccagc
                                                                        840
cccgttccgg ctgttggact tactgggcct cggcaaactc cggtactgaa ggtttgtccg
                                                                        900
ggagettagg getagatace egteateetg attetgagee ecatecatae ttgaetteeg
                                                                        960
accagcagac cgactgacga gtgcagatga ctttgggatt ttgcccagtg tggctgacct
                                                                       1020
gctggtgaca gtcaccccgc tggctgtgat catggccagg ccggcggcgg aaccactctg
                                                                       1080
cttcttgaac ccaaagctgt tggcattggc agtaggtgtc ctagagctgc tggggagggg
                                                                       1140
ctttttggat tcgtcaccac tgctccggcc tgcatctgat ggggagcgct tcacctggga
                                                                       1200
ggctttagga gaaagccttc ctttctcaga cacctttgcg tcgtctgttt ttccagttcc
                                                                       1260
tggggtcttc agtgcgcctg ccggggctga agccttcgtc cttggcatgg tgatgcccac
                                                                       1320
ctgagctgtc atgcctcgcc gccatgagcc tgtaaggaaa atgacaggat tcttcttgcc
                                                                       1380
                                                                       1440
cgacgtgctt ttgtcggact cgtcaggcrg gyagytgaaa ctaaacntng gaagtgtacc
acconctcac caac
                                                                        1454
<210> 48
<211> 835
<212> DNA
<213> Homo sapiens
```

```
<211> 835
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (204)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (781)
<223> n equals a,t,g, or c
<400> 48
ccgctcagag gaagagtggg tatgtctgct gctgccctcc gagagaacct gtgcacattc
                                                                         60
ctgaagcccc tcctagctcc tgcaggccta gtttggtggg tggttaagct gggctcaaat
                                                                        120
acacatattc ccagtgtggc tttaggcggg ctttgtacat ctgctaagcc tcagttgctt
                                                                        180
gtttgggaaa tggaatgata atancaatat ctcccttttg gtgtggctgt gactgtgggg
                                                                        240
ctttaagagc acattccagg aggcagattg cccagccctg tctatctatg tggccttggg
                                                                        300
ccagtcactt aagctgtccg ggcctcagtt tccttgtgta gaacgggaca gcgatatgac
                                                                        360
ctmcctccct ragttgttgt raggatccag tgagttttta tgcataaagc acttaaagag
                                                                        420
 ttcctggcat raggtcagca ccatgtaagt gttggctatt rgccaatgtt tggagatcac
                                                                        480
 tttcctctgc cttggctcct aataagctct tggtgaaagg tagttgttat ttttaacttc
                                                                        540
 ttcgttctcc ttcactgtct taattcccac cttcatttag ccttgcaatt tcctttaaat
                                                                        600
accttatctt ctcccctcgt ttgttgtcaa tctgctgcac taccaataaa ggcgtgcata
                                                                        660
aattatattt gtcccatgtt tacattcata aaacatttcc catgcactcc tgtcccaacc
                                                                        720
                                                                        780
tcacagcaaa cgcgtgagcg agcagtgcag ctcatgtcat tgccctcatt ttgagagccc
nggacagggt gtgatctgtc cagaagcatc acctgctcag gggtgtctcc aagcc
                                                                        835
<210> 49
<211> 516
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (435)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (510)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (515)
<223> n equals a,t,g, or c
<400> 49
ttttttttt ttttttttt ggagacaggg tctcactttg tcacccagac tggagtgtag
                                                                          60
tggcacaatc ttggctcaag ccattctccc acctcagcct catgagtagc tgggattaca
                                                                         120
ggtgtgagcc accgcacctg accaacataa taataattct taacatatga tcaccatatg
                                                                        180
ctgggagaac geeeteetae acteetgage ctagecaegt tacteteaga agtaagggtg
                                                                        240
tatgtgccta gtccctggag gggtgtgtgg ctctgccctc tgcagtgggc atcagagtgt
                                                                        300
gtgggtgccc ccctgtgccc agggccacca gttcagtaac agagtgggcc gtgaaacagg
                                                                        360
aggcatgggg atgtgggtgg agtgcagccc tggaatgaca cctgcagccc ccacgtgcac
                                                                        420
cccgatttct cargntcctc ttcctcttcc ttgcgggccc tagcacagga ttcaagcagc
                                                                         480
agagttttaa gccctcccag tgtgaatgtn ttcana
                                                                         516
<210> 50
<211> 534
```

<212> DNA

<213> Homo sapiens

```
<220>
<221> SITE
<222> (6)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (516)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (519)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (525)
<223> n equals a,t,g, or c
<400> 50
 ggggtncctc ngaggcaggc agatccttga ggccaggagt tagagactag cctggccaac
                                                                          60
 atggtgaacc ccatctctac aaaaaataca aaaatttgaa tcaaacattt taaacagact
                                                                         120
 attttagatg tttatttaat actgaaatgt tgtcaactat cataaagtat ttctctgcat
                                                                         180
 cmcaaaaatt ccatatatta aggatttacm caatccagga aaaaaaattt ttagaaactg
                                                                         240
 tttttttttt ttttaqcctq aqcaqaaaaa tctaaaaaaqq ctctccaaaa tcttqaqtqq
                                                                         300
 aagtatcata ctctgcaatg aaatgcttga gttcttcaac acaccgctca cctatttcat
 gtaaattetg ceteaatgea aactgtatag aettttetaa tgaaggatet tttteaatea
                                                                         420
 gcattttcac caccatcccg aaagtttcac agtcttgtcg gtaaacctgt tcaatctctt
                                                                         480
 tggtttttga tgctattgct ttagagccgg aaaggnttng ggggnttttt ttaa
                                                                         534
<210> 51
<211> 503
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (422)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (474)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (493)
<223> n equals a,t,g, or c
```

```
<400> 51
ttttctctaa gataccaaag tattcagttt attaggatag tacactttaa catattacaa
                                                                          60
gttacaaagc ctaagaaaaa gcaagcaaca agtcaataaa atcacaactc agaattctaa
                                                                         120
 cattttcaga tggtatatgt gttgggcagg gagcggtggt cacgcctgta atctcaacac
                                                                         180
 tttgagaggc tgaggcaggc agatcacttg aggccaggag ttagagacta gcctggccaa
                                                                         240
 catggtgaac cccatctcta caaaaaatac aaaaatttga atcaaacatt ttaaacagac
                                                                         300
 tattttagat gtttatttaa tactgaaatg ttgtcaacta tcataaagta tttctctgca
                                                                         360
 tcacaaaaat tccatatatt aaggatttac acaatccagg aaaaaaaatt tttagaaact
                                                                         420
 gntttttttt ttttttagcc tgagcagaaa aatctaaaaa ggctcccccc gtgnccgaat
                                                                         480
                                                                         503
 tccttggccc cgngggccca att
<210> 52
<211> 607
<212> DNA
<213> Homo sapiens
<400> 52
                                                                          60
gcccagtaaa agctactagg tgacactata gaaggtacgc ctgcaggtac cggtccggaa
 ttcccgggtc gacccacgcg tccggtagct cagctgcatt tgcacctgga acccgcgctc
                                                                         120
 tegeceaece tgetetagee etggeetgtg getgggaeet ecageataaa eeggatgete
                                                                         180
 tgcccagctc tgggcccatt tctgctgttt ctgctcagtt caaccctgat ggcttccttt
                                                                         240
 atgggtgaca ctccatgtca cccaggcgaa ctgtcagcct ttggagtggc acccagtagg
                                                                         300
 gtotttactt ccagtttctt gttcacagtc ttcactcctt catacccctc actccctggg
                                                                         360
 taacatcggg ccaccagtaa tgctggttcc tagctctgca acaccatgca cggtgtagta
                                                                         420
gctaagagca gagctttcgg gtgtgaagta cctgagtaca gttcctgcct tcccctgtgt
                                                                         480
gtgcctggaa cagagtaaac actcaggaag cgttacccac tgctgccatt cccagagatg
                                                                         540
 caaaaaggtga ggtctccgtt ttgccatcta tacaatagag ataataaagg ctatcccact
                                                                         600
 cttaatg
                                                                         607
<210> 53
<211> 432
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (420)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (422)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (428)
<223> n equals a,t,g, or c
<400> 53
gggcggaacc agyctgcacg cgctggctcc gggtgacagc cgcgcgcctc ggccaggatc
                                                                          60
 tgagtgatga gacgtgtccc cactgaggtg ccccacagca gcaggtgttg agcatgggct
                                                                         120
 gagaagctgg accggcacca aagggctggc agaaatgggc gcctggctga ttcctaggca
                                                                         180
                                                                         240
gttggcggca gcaaggagga gaggccgcag cttctggagc agagccgaga cgaagcagtt
 ctggagtgcc tgaacggccc cctgagccct acccgcctgg cccactatgg tccagaggct
                                                                         300
 gtgggtgage egeetgetge ggeaeeggaa ageeeagete ttgetggtea acetgetaae
                                                                         360
```

```
ctttggcctg gargtgtgtt tggccgcagg attcacctat gtgccgctct gctgtggaan
                                                                        420
 tngggtanaa ga
                                                                        432
<210> 54
<211> 794
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (760)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (769)
<223> n equals a,t,g, or c
<400> 54
 ttccngaccc yggsctgmgg gggcacacca agagaaagaa gagaatacca mggacatacc
                                                                         60
 yeagteacet etggateeet ggkeetgeac agageetgge teataggaga caetggagaa
                                                                        120
 atgctcctaa cctttggcta gcccttttat aatttatagc gattatctca tttaatgctt
                                                                        180
 acaaccacca tttqaqqtqa tccattttac aqaqaaqqaa qcaqaqqctt ttaaqaqqtt
                                                                        240
 aggtaagtct tagccaaagc caaatagcag ctgaacagta gagctgggac tccatcaagg
                                                                        300
 totoccagoo ggagottgot cotaccoota ggacaagggg tggactootg actotgoaga
                                                                        360
 taaattctac aaaagccaca gaaggcaagt agtaaccatt gtgtgacaac ccctcacccc
                                                                        420
 caggaagagg ggcccctgtg aggattgcag gctctggagt cacactgctt gttgaaacgc
                                                                        480
 tgcctcttac cctccctagg tctgcgcctt tgaataagta tcacktctta gttgctccat
                                                                        540
 gcctcagttt gyccatctga aaatgggggc atctgtaatg cctgtgktat gaggagtaaa
                                                                        600
 ttacagcaty cctgtgaaga cgtarcacag tgycgagtac ggaatggtat ttccatcctt
                                                                        660
 ctacggagct tggtccctty cccttgcctt tacttgccca gccattgayt catactactt
                                                                        720
 ccttcttgca ggcattggtc cagtgctggc ctggctgggn ccgttctang ctcagcagtg
                                                                        780
 accatgcgtg gacg
                                                                        794
<210> 55
<211> 1019
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (962)
<223> n equals a,t,g, or c
 gcccctcgag ggatcctcta gagcggccgc cctttttttt ttttttttt tttttttaac
                                                                         60
 atataaraaa gootttaatt ttgtcaccat aaacattata ctctgattgc tcacttacag
                                                                        120
 tataaaatat tcaccccgct aaataaataa gacgacatta ttgcaaacgg cacttaaacc
                                                                        180
 ccccctgaga gataagacct cccttagctc aggcaggggg tgctcctgag tttctgtgtg
                                                                        240
 agattcccca agcacagata tactctgggg gctgagatgg acaaaggctt gggaaaccgc
                                                                        300
 actttgtgct tctggtcctg cagtagctcc aaacagggtt gtggagctgg tggggaaagt
                                                                        360
```

```
tgggggtagg ggaaagttgg gggtagggga aattttgggc agtgccttca tcagcccagt
                                                                       420
 cctagagaga gtagaggga gtggaagtgg ggggaaccag gctgggccaa gagaagaggg
                                                                       480
 gtggttaggg aagccgttga gacctgaagc cccaccctct accttccttc aacaccctaa
                                                                       540
 ccttgggtaa cagcatttgg aattatcatt tgggatgagt agaatttcca aggtcctggg
                                                                       600
 ttaggcattt tggggggcca gaccccagga gaagaagatt ctggcaatga tcagcccaat
                                                                       660
 gaccagetat etcaggggae etgattgttg gggateeeee accetaceea aatattagae
                                                                       720
 accaacacag aaaagctagc aatggattcc cttctacttt gytaaataaa taagttaaat
                                                                       780
 atttaaatgc ctgtgtctct gtgatggcaa cagaaggacc aacaggccac atcctgataa
                                                                       840
 aaggtaagag gggggtggat cagcaaaaag acagtgctgt gggctsaggg gacctggttc
                                                                       900
 ttgtgtgttg cccctcagga ctcttcccta caaataactt tatatgttca aatcccatgg
                                                                       960
angagteget teatectaga aacteeeatt geaagaacet accattaaac egaagetge
                                                                      1019
<210> 56
<211> 2042
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (2001)
<223> n equals a,t,g, or c
<400> 56
ggtcagcttt catctcgtcc tatctttgtt caggcaaact tctctagttc tgttttaata
                                                                        60
ggcatatttg ttaggtctgt tttttgaaat cctctttttt acattgttta aagataatgc
                                                                       120
cttggctaaa aagcctgctt cacttttccc tgtttttagt tgttttctcc acattggcag
                                                                       180
taaagageet tggegteeca gtageageag gtteteettt ttgtattgtg gatgttttge
                                                                       240
atttcatact qttqtqaaqa qtqqctttqa tcatacatqt tqttqqtata tttqccyttt
                                                                       300
 tgctgggggt gtgagaagaa ccagagatga gcagaggtac acccagtaga cttcccagcc
                                                                       360
 tgcagagcct cccgggaaga gcttccgtgt tcaggtgctt ggggccccwc cctaggagcc
                                                                       420
 tgwctcwcag tcagagcwgg gtcccggctt gygttcagga ttttgaaaca tttgtawggt
                                                                       480
gattttgttg tttctacacc tttctcctca tctttttttt tttgtagtta atcgttacta
                                                                       540
ataacagaaa agacattttt ggcatggtaa ttggcacaaa gtgaataatt gttgaataga
                                                                       600
 tgacttttga ggctttcaaa attcgagtgt ccataaaatc catccagagc cacctggttc
                                                                       660
ctttttttga accacttaac gtaattctgg aaaaccttga ctgtgggtct taagtttggt
                                                                       720
ggattgctgc ttctcactgg ctgacctttg gaggtcgcat atttcaggat gtgattccac
                                                                       780
 ttaggeteca ttteacetga eactgeaatt etgtgeette agagggattt gttattgega
                                                                       840
atgatgtgga caacaagege tgctacctge tegtecatea agecaagagg etgageagee
                                                                       900
cctgcatcat ggtggtcaac catgatgcct ccaqcatacc caggctccag atagatgtgg
                                                                       960
 acqqcaqqaa aqaqatcctc ttctatqatc qaattttatq tqatqtccct tqcaqtqqaq
                                                                      1020
acggcactat gagaaaaaac attgatgttt ggaaaaagtg gaccacctta aatagcttgc
                                                                      1080
 agctacatgg cttacagetg eggattgeaa caegegggge tgaacagetg getgaaggtg
                                                                      1140
gaaggatggt gtattccacg tgttcactaa accetattga ggatgaagca gtcatagcat
                                                                      1200
ctttactgga aaaaagtgaa ggtgctttgg agcttgctga tgtgtctaat gaactgccag
                                                                      1260
ggctgaagtg gatgcctgga atcacacagt ggaaggtaat gacgaaagat gggcagtggt
                                                                      1320
ttacagactg ggacgctgtt cctcacagca gacacccca gatccgacct accatgttcc
                                                                      1380
ctccgaagga cccagaaaag ctgcaggcca tgcacctgga gcgatgcctt aggatattac
                                                                      1440
cccatcatca gaatactgga gggttttttg tggcagtatt ggtgaaaaaa tcttcaatgc
                                                                      1500
cgtggaataa acgtcagcca aagcttcagg gtaaatctgc agagaccaga gaaagcacac
                                                                      1560
agctgagccc tgcagatctc acagaaggga aacccacaga tccctctaag ctggaaagtc
                                                                      1620
cgtcattcac aggaactggt gacacagaaa tagctcatgc aactgaggat ttagagaata
                                                                      1680
atggcagtaa gaaagatggc gtgtgtggtc ctcctccatc aaagaaaatg aagttatttg
                                                                      1740
gatttaaaga agatccattt gtatttattc ctgaagatga cccattattt ccacctattg
                                                                      1800
agtaaggatt cagccttttt aattattcat ttaaagaaat ttactataga gtatcaaatg
                                                                      1860
 1920
ttaacctttt taactgcata ttagagcagg atgaaacttt agaggttact caatctttta
                                                                      1980
atttaaggag aaagtaaaca nttactttgt gaacatgata gataaaaaaa aactggaccg
                                                                      2040
```

```
2042
 gg
<210> 57
<211> 584
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (469)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (509)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (519)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (531)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (536)
<223> n equals a,t,g, or c
<400> 57
 gtaccggtcc ggaattcccg ggtcgaccca cgcgtccgca ttttaacatc tctaaatcag
                                                                         60
 gatctgtctt ataatcaaaa gtgcatcata tttaacagat ggcgtgtttt ctttcttagt
                                                                         120
 agtacctaaa gtaatacaac ttaaaattga tggcatttta gatttaataa aatatgttca
                                                                         180
 tttctttgtt catttttggt ctggtgaggc tttggccctg ttgtgtagtt atttattttg
                                                                         240
 tttatagtat ttgtaaacac cagtgttctc aagaggctca ttcatcaata tttaactgca
                                                                         300
 aatttgtttc ccagtctcag ttttctataa tgtaatccat tgtggggaag gggaagctaa
                                                                         360
 aaatcagtat tcygccagta tttyctatat agawgtcata aaaccaaaaa taccatcatg
                                                                        420
 tattaatatt cctacawggt ggcaagacag cactttggaa ttataaaanc caacttaatt
                                                                         480
 cctttgccaa tgccaaaact gggttgganc ttccaaaanc ccactaccca nggttnggag
                                                                         540
 ggttcaataa taggccaaac caaatggtaa aaccaccacc acaa
                                                                         584
<210> 58
<211> 684
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (173)
<223> n equals a,t,g, or c
<220>
<221> SITE
```

```
<222> (243)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (663)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (668)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (681)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (683)
<223> n equals a,t,g, or c
<400> 58
aaaaccccat acgggcagaa cttccccagg aagcctctag gtggcagcac aaccgcacca
                                                                          60
                                                                         120
ctcctggagt ctaattacta cttttctgtg gctcagtagg aaaaattctt gactatttcc
attacatctt aaacagttac catgatttgc cttaaaacta gtctcttatg aancaaacct
                                                                         180
gatgaggcaa gttctatatt cccttttctt gattttccac catcattctt gtcctcttga
                                                                         240
ctnttcggtt ccgttttctc agtggttgcc tgaaaaagag attttttcc cccttgaata
                                                                         300
aatgattcct ttaaaagttc taaaaattat tttttaagca gtaattttta ggtcaacaaa
                                                                         360
gtggtttggc catatgaatt ccctcttcta cttcccaggc agcttcatgg cgagagcctg
                                                                         420
                                                                         480
gattggttgg aaggagacat totatggaga acaggacaco catgoggttc accatotomo
caaacctcct atgactgcct tggacgcaca tcccmcattt tcttttcttt caccaccaaa
                                                                         540
ageteaaaat catggetate acetaettgt tettgatage etaettgtte aagetggett
                                                                         600
aaggtaataa caccagtgaa gtctttttgt ggttctttaa aggttacaat taggttcgga
                                                                         660
ggncaaantc aaggcagaag ngna
                                                                         684
<210> 59
<211> 2070
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (108)
<223> n equals a,t,g, or c
<400> 59
cateccacet ttttcctttt cctttcacca ccaaaagete aaaattcatg getatcacet
                                                                          60
acttggttct tgatagcctt acttgttcaa gctggcttag ggtcatanca ccagtgaagt
                                                                         120
ctttttgtgg ttctttaaag gttacaatta ccttctcagt ggcctgtctt ggcatagttg
                                                                         180
cctgtggccc ttaccattgt ggatttgagc ctgcagttct catccttcct gggctcccag
                                                                         240
tgaatctcta ttactggagt tctaattcat tctctcttt tccctctcct ccccactttc
                                                                         300
agactactct tttctcactg gttcttactc cttttcatca aaatatgggt cattctgaaa
                                                                         360
gatttcaact ggaccctgtt ttcctccact tgtgctgaat taccctcaaa tatatcaatt
                                                                         420
attcccatgg attcaccatt acattctccg tgtataactc gtattttcat ctccagctgt
                                                                         480
qaqaqtccat cagagetteg gtttemeete taqqqtcaat ggeettetee tecaaatttg
                                                                         540
```

```
acaatttctq tttatqqcaq caqttcttcc catcacataa actttcaagt gatctttgac
                                                                       600
 tcatacctca tqaatattca tcatttgcca agtccttcta agtttctaac atactagttt
                                                                       660
 toatateaat cattteettt etgtttetat ggetgggaet eeaggtttge etttetteet
                                                                       720
tgttctccac taagaagtct ctgtgatttg aacctcactg tccaatccac ttggtacatc
                                                                       780
actgtcatgt tcatctccat ggcacctcca gtaattactc taatgcttgt gttcctctct
                                                                       840
                                                                       900
 ctcagtagta cttcaattgt gtcagtttta tgcttgatgg aatttataat agtaaaaaaa
 attgaaacaa cttaaatatc caataattgg ggaatgattg aatgaattac tgcatgtcca
                                                                      960
 taaaggcaat ataatcatga aaaaataaga tgttgaataa tagttaatga tatgtgaaaa
                                                                      1020
 tacttactaa tgataggaaa tgtaaactgt atacatagww tgatgtttac atgtatatga
                                                                      1080
 ttatatacat gcctatacat aaacatatag aaaaaaagat agtaagaaaa tacaaaaatg
                                                                      1140
 ttaattgtga ttatttttaa tgtgcttaag ttttgggtga cttttccttc tctttacata
                                                                     1200
 cattttatat attccaaaat gttctataat gactatgtat tacttctgta attggaaaac
                                                                     1260
                                                                     1320
 aaaatcaatg taattttaca ttgtctttca ctgggagcca attgactcta gaatgaagtc
                                                                     1380
 1440
 tactagctag attatatttt gataattaaa gagagcaagt taatgactat tgcatttttt
 ggtagaagtt tottgtaaaa agotaaagtt aaattytara gtgtgtatga aatattgcat
                                                                      1500
 aaattttaaa aggttttaag ataaaggcta aagttggttt cagaaaaggc attattaact
                                                                      1560
 cataaaatat ccccatgggt tctcgagaac tatgaattta ttcgtctctc ataagtatat
                                                                      1620
 atattttatc cataaatcaa attttgcctc tcaaaatgaa aggtatttaa agttaatgca
                                                                      1680
 ttggtggaaa ccatcactga attctttaaa aacaaagaaa ttttaaacaa caaaactttc
                                                                      1740
 aagtttctaa aaggttttac aatagcatct agtggcaaaa atgtgatttt tctttggagg
                                                                      1800
 atggagtagt tttgaaatcc tcataattag atgggcattt tctaatgaca gatagtcatg
                                                                      1860
                                                                      1920
 tatcaattct qaaaqaacat aatattaagt taaaacacac ttttaaaacc ctaggcagga
 aatatqcatc accttqqatt ttqtaatatt ttaatatatc aataagtctg acttgamycc
                                                                      1980
 ctqcaaqaqa cttaaatqaq tqaqaataqt taactqqtct qttttqttat atttaggtta
                                                                      2040
 tggtacatgt gtgtgtttac attgtgggct
                                                                      2070
<210> 60
<211> 427
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (384)
<223> n equals a,t,g, or c
<400> 60
 ggccgccctt ttttttttt ttttttttt agagatgaag actttctggg ttgcccaggc
                                                                        60
 tagtettgaa eteetggget caagtgatee teetgeeetg geeteecaaa gtgetgggat
                                                                       120
 tacagttgtg agccaccaca cccagctagc ttgttatttt ttaaattccc aagagtaatc
                                                                       180
 aaggttgcga acaactggtg taactgatga atatttttag actctgtacc tgaaaacaaa
                                                                       240
tcaaactaat gtgaatgaga tgagactcta aacaaggaag aaactttaat aaaaacaaga
                                                                       300
 ctttaaaacc tattatatca ggaataataa ttttctaggg ttcctgttat ccaaatccag
                                                                       360
 tqqcatcaqa attaccaatt qccnaacaaa taggatgatt atqqaqaqaq actagccagt
                                                                       420
 aaqctqa
                                                                       427
<210> 61
<211> 341
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (51)
<223> n equals a,t,g, or c
```

44

•

```
<220>
<221> SITE
<222> (54)
<223> n equals a,t,g, or c
<400> 61
cctgatatct cccagtatca tgactcaaca gtgccccaaa gcaactcagc nccnccgaaa
                                                                         60
cctcacacat ggatgtgact cgccacccac agtgacaggc acagccaagt ctgatttagg
                                                                         120
aagatgtttt caaagcagag taactcgcaa ctttcctgga tcatctctaa accaaaaaca
                                                                         180
                                                                         240
aattagggaa tcagttttgc cacctgctga aggtgaactc gcaggtgaag ccactctgaa
                                                                         300
accttctcag gtctgagagg ctccagtgcc ccaggagggc atcccatctg ccaggaggtg
                                                                         341
cccagaagat gctaagttgt ctcaaagcca agggcaaaag g
<210> 62
<211> 804
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (74)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (795)
<223> n equals a,t,g, or c
<400> 62
 ctgattggcc acasscagtn tggcgcctct cagtgtcagc aggcccaggt ttctaagtat
                                                                          60
 agaccccatg cagnoccgtg gctsctagta aatccctgga taccatttga tacctaactg
                                                                         120
 geoctgaget geoggettae ceageatgge etgtgaegee ageetetgee agetgetggg
                                                                         180
 ggaggggta gcacgttgcc caaacccatc ctcaccctcc actggagaga atggagacca
                                                                         240
 gcagtctcct gctaatgaca tgactggatt gtcacagact gggagtgacc tcagcactca
                                                                         300
 actggccctg ctctccaatt attatcagaa agaataactt aatcccacct actggagaac
                                                                         360
 atateteetg gtttgagaga gacaggcaga ggcagggage caatgatete tgatgetgte
                                                                         420
 actetgetce teatteetge atececacet gtgtgcacee atgetaacee tgagaettgt
                                                                         480
                                                                         540
 cggagctggg actgggcatc tctcaagatg gattgggcat ctcctatgat ggtctgggca
 tccatgtctt ccgtttttgg tttgtagttc catattttgk tctttagaca gaagctgggg
                                                                         600
 tgggcagtaa ttccttggag gcagtacgga ctyccagccg ggttcttcag aactttgggg
                                                                         660
                                                                         720
 tatgggcaga gagaggggcc ytttgccctt ggctttgaga caacttaaca tcttctgggc
                                                                         780
 accttctqqs agatqqqatq ccttctgggg cactggarcc tttagacctg araaggtttc
                                                                         804
 aaarggcttw actgnagtta cctt
<210> 63
<211> 1081
<212> DNA
<213> Homo sapiens
<220>
```

```
<221> SITE
<222> (500)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (993)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1018)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1036)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1068)
<223> n equals a,t,g, or c
<400> 63
geggeegeee ttttttttt tttttattea teteeteete acceatacea agttteaagt
                                                                         60
totcaaagta actacattta ttattacaaa ctatttgcca gaacaatatg cotagggett
                                                                         120
tgtatacatt attttatctt taatcaactc cgcaagtaga tggagttaag tccatcttac
                                                                         180
tgaggctcag agacttcaca gcttaacaag tggctgagca gaattgaaac ccacgtgcgc
                                                                         240
acquitccaa acctecteca aatatteeat getqteeact tqttaacctq qcaaaqeett
                                                                         300
gggatacagc agctaccttt caggggaaat tattttttc gaagtaaatt aatttctacc
                                                                         360
tactttcaga aaatagaagt gaggtacaga aacagctgga ttggttacag ctcctttgcc
                                                                         420
ttatttgaac aagattcgaa cagttggcta catttgattg gcacaagtgc agtctacagt
                                                                         480
gtttttatac ctccacttgn tatagttcat gatatacaga aaaaccttta ggctgaactt
                                                                         540
aaaatatcta aggaggtagc tctaggctaa acttgattta acacacttct ctgccttttt
                                                                         600
actgaacaag aaacccaacg gcagcaatgg caatgctaaa cagaaaaccc ccgctttcct
                                                                         660
cccttggtgt tggggaaagg ggcaggcaat ggaggggcac cagaacttct ggttttaaag
                                                                         720
aaatctgaat ttttattttt aaatggctgg cttttacatg gtgataacta attcaaatct
                                                                         780
gtgcaaacaa aacaaattat gtccatgagg aacatggggc ttccaggcct aagcgcggag
                                                                         840
accccatggg aagaatctga tgccttccaa ggttaatctg atcagtgagt gacatctaaa
                                                                         900
actttatttc tgtaggcaaa cgggggagga tgcaggcccc agtagcaagt acttcagggg
                                                                        960
accapacttt ctcaqtqaqq qqcccaccct qqnaacaaaq qqcccaactt tccaactnta
                                                                       1020
caactqqctc tqaqanccaa tqqtaactta atcaaqaaaq qaaaqctncc caqqaccqqt
                                                                       1080
                                                                        1081
<210> 64
<211> 2211
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (44)
<223> n equals a,t,g, or c
<220>
```

<221> SITE

```
<222> (60)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (78)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (81)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (113)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (126)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (199)
<223> n equals a,t,g, or c
<400> 64
tctaagttcc aaaaagctta agctttcccg gtgtcaagtc aagntttgca acggtggaan
                                                                         60
 cctttgaaag ccgggtgncc ntggcttgtg ctttcataat gcccaggaag tgnagaagga
                                                                         120
 aggetnagaa agettggttt eccaagette tgatteteea cagggeaett etaataacee
                                                                         180
 ttetteteae ceaeceegnt aeggtytkaa ragatytgaa awacmeettt eecagtggea
                                                                         240
 agggttgcca gggttgaggg gacagcacat accaccccca cccaacctgt tcgaggggcc
                                                                         300
 ctgcatggca cgggatgagt ccctgccctg tgcagctgcc tggcagtggc tgggacaagg
                                                                         360
 atottgcago cagcacagag gootottcaa aggoototoo otottggcac tocaggcaag
                                                                         420
 gcaggtgccc gcttccccaa cacctccagg cagtgaccct agggcatgcc ccagcaggtc
                                                                         480
 tccgagcagc cactgggacc cgtctcagca catcctggcc tttgaaagtc tgatatcctg
                                                                         540
 agaggagggc aggttttagg gccgcagttc cagccagcgt ccccagcctg gcttccctgc
                                                                         600
 catggactca gtagctcgtg gggcttctta ccacccacca gccccgctgg ggtgcggcct
                                                                         660
 ggctgtgggc aaaggaggac ttgcctggag atttgagaga agattccttc taccagggct
                                                                         720
 gctgaggggc caggcctgca tcaggggcta ggctctggct gggcccggag gctgagacta
                                                                         780
 aggetttega eeetggtgee teeatgtgga tgetgeetea gacaaaggea gtgageette
                                                                         840
 cctgccaaag tgcccatccc atgggctcgg cctcactggt cactgttagc ccatgaacac
                                                                         900
 gtgtgggcct cggtcacgtg gctttgaggg cagtctgacc aggctagacc acacgtgccg
                                                                         960
 tgacaggggg tgccattccc ctcgcaggct ctaatgtgcc cacatgtagc ctggcagtcc
                                                                        1020
 aaagaccaag aatcaacttg caaatctgcc attaaactgc tgtgcgactt caggcatatc
                                                                        1080
 actgeettet etgggettea gtgteetttt catacetaga agtetgeggt etgaggetet
                                                                        1140
 ttgggttcag acacactgtt ctaggettct gtagrggacc ttgtgatctg ccgtgcccct
                                                                        1200
 cottectigtt cttttctgtc ctccccaccc caccctcaga agctgcttgc tctgccccca
                                                                        1260
 ggacaggagc ttgacggatg argtgcagcc agccacccag gtgccatttc cagtctgact
                                                                        1320
 tccagaaatg tgcaccatgt cctagagcac agacccattg gctggagcct cctgggaggg
                                                                        1380
 ttcaaaccat cagctctatg agaaatgccc agaaaggctt tgccgactcc atccgtctgt
                                                                        1440
 ggaggetgee tgeeteeggg gtgggatggg tggtttetee tecaatteag acceaagagg
                                                                        1500
                                                                        1560
 tagcccccga gggcatgtac ctggtgggaa gcagctcagg tacccttggg ggttgcargg
 cccttacgca gtatttctct ctctcccc tctggggtgc gtgtgtgcgt gcgcgtgtgc
                                                                        1620
 ttgcctatgc ttttctctgt gggcacatca ggatgcccct cggagagcat gtgcacgtgt
                                                                        1680
                                                                        1740
 coccacetga gegagegtgt gtgtgtgete etetgegtee caggtttgga egtetagggt
```

```
ttqqtqtqcc tqtcttctqc cctccctgag cccacaqqqt caqtcaatgt atcttctacg
                                                                      1800
 tgcctctccc tctgccttct ctcacagtgc ccccggctcc agagctcagg ggtaggggtt
                                                                      1860
ctcctgaggg tgcaggggat ccttctcatc tcctggaccc tccagggcac tctggtccct
                                                                      1920
                                                                      1980
attccccage tectaggeag etgageeggg tecettaggg gaggtgacca ggagetttgg
                                                                      2040
tgcagggagc tcttggtggg gcaaagggct ggacccctgc caggtctgtg gacatggtta
                                                                     2100
 tatgcccggg agagggggt gcagggcccc agggatggcc cccaatccca cctctgttta
ttctgtaaac tgcaacctat aaataacctt tagcattcct attgtaacaa aattaatttt
                                                                     2160
2211
<210> 65
<211> 1236
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (69)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (71)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (843)
<223> n equals a,t,g, or c
<400> 65
                                                                        60
 aactncntta agatactctc cccttcggag gtgagaataa cgaaagtgtc agtgagtaat
ccaatgtcnt ncatttgctc accagacaga aagaccaaga gttcacctct cctgcctatt
                                                                       120
 agtccagtgc tcgggtggcc catgagttca tgttggccct gtcagaccaa agacagtaat
                                                                       180
 qaatattaaa cccagaatgc accatattat caggcctttt ttgtttttgt tttctattag
                                                                       240
 taacacaqqt aqaaqaqqaa acaactaaaa ccccaacatt agaggctcac catccccacc
                                                                       300
 ttctqqcca ccactqqcaa tqaacccaaq cacaqqtcac tqtqqtctca tqaaaqaaaa
                                                                       360
                                                                       420
 ctgatgtggg ggttgggtgg gcttcagggt gttgactgcc atcttcccct ccagcacctg
                                                                       480
 aaaaqctaaq ttatqqtqtq aaqtcagaaa atgtgqaatc tgcaagcctg tctttaaaaa
                                                                       540
 acaaaaaac tcatagaact tggactttaa tcataaagat cattttacca aagcatattt
                                                                       600
 tttaaaggct gtgaaatatt atgcaacgtt tgcatggttt aattatgagt ttagaaaasc
 ctagcacgac tttttcacta cagtaaaaca tgacggagca tgaatcatgg catagtactt
                                                                       660
                                                                       720
 tatgettagt gtggetttag acatggggtt agaggtgtga ggetgtetae acaacaagge
                                                                       780
 gtgaattact gtactgcagt tcacaccccg gggggcttta tgacagttct gaaacctctt
 tkgtttgctt ttaaaatgat taaagtattg gagtactata tattcactta gtaaatgtgt
                                                                       840
 qtntctagta tatacgcatg tcttatacaa aatatctaag tatatgattt ttttttcact
                                                                       900
                                                                       960
 tqqaqcaaaa tacttqcaqt aqcatqqqqa tattqaaccg tctqctattt ctgtttgcct
                                                                      1020
 ttagtcattg gaaacactgt tagctgtaag attacacagg agcttcagcc aaggttgaac
```

atttattttc tqctgagttt aaaatggacc agctcctttt gttccttgcc agctctttaa

atcctctaaa atttqqaata aaatgaagac ctttctttaa tattagattt caaagattcc

48

1080

1140

```
aagttaaact atttgcctgg gaactaccag gttttttaaa cttaaaaaat cagttatttt
                                                                        1200
cactcacaca caaaaaaaaa aaaaaagggc ggccgc
                                                                        1236
<210> 66
<211> 797
<212> DNA
<213 > Homo sapiens
<220>
<221> SITE
<222> (16)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (26)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (751)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (763)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (781)
<223> n equals a,t,g, or c
<400> 66
 gggcaaatta ggcagntaat ctagcngtta gcccagatac agcccttggg caccctagta
                                                                          60
 gctgtaactt ccagaaggca ggaaccttcc attcactagt gagtccccaa aacagtggcc
                                                                         120
 caagtgaagc aaaaatgttt gttgggaaat akgagygaat gammaagtaa tttcatgaac
                                                                         180
 atatgaatga ataaatgaat gaagcaacac ccagtatgat gattaatgcc acaggaagat
                                                                         240
 geettteeaa geateacaag ateetgggat etteactgae tgtaagtgee tgtggggeag
                                                                         300
 qqaccatgtt gqtcttattc atcactctcc tgccaggtaa attagcacat tcctggcaca
                                                                         360
 ctgtaaatgt tcaataagct tttgttcttt tagatggatt gacttatcag aggcaactct
                                                                         420
 ttcaagaaca agtagccctg tgctctggag aatgatttac agtggttctc ttcctcagcc
                                                                         480
 tggggccttt tctggataac tcccatcgta ctctyctcta cttcctcttc ctagaataca
                                                                         540
 caaatttatt attacaggca ccactcttca ccccacatct gattcttccc tgactctgct
                                                                         600
                                                                         660
 taatgtacaa gtaaagcaaa gaaatactgt gtaggaccta ttggaattag aatcctgctc
                                                                         720
 tgtcaccatt ggaaaggatt tagggatcac ctyccttcgg aggtgagaat waagaaagtg
 gcargtgagt aatccaatgg cacccagttg nttaaccaag acngaaagac ccaagaggtt
                                                                         780
                                                                         797
 nccttttctg gctaata
```

<210> 67 <211> 534 <212> DNA <213> Homo sapiens

```
<220>
<221> SITE
<222> (77)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (471)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (475)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (499)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (510)
<223> n equals a,t,g, or c
<400> 67
cettegtagg gacagageta tgacgtegea tgcaegegta agettgggee eetegaggga
                                                                        60
tectetagag eggeegneet ttttttttt tttttetete tetttetete tetetete
                                                                        120
 acteteacce aggetgeagt gecaeagtta cageteactg catacttgaa etecteagtt
                                                                        180
 caagaaatcc tcccacctca gcctcccaag tagctgggac tatagtgcat gacaccacac
                                                                       240
 gtggctaatt tttaaaattt tttttggtaa aggcctgaac gaccacaccc ggcaaaaaaa
                                                                       300
taggttttat tacatagctc ataaatgacc attcaaaagt gctttgaaca atggcaatga
                                                                       360
 cgtcattctc atggtggtaa ctcagaaggg cgggccaact tcattcacat gtacagtttg
                                                                       420
agttctatgg gttgtcaaag ttcatgtcac tatgttaggg ctggctttta nagtngtact
                                                                       480
tctcttaagt gtgggtgtnc caaagatatn tggaaaaaat actttgctag gatg
                                                                        534
<210> 68
<211> 1096
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (57)
<223> n equals a,t,g, or c
<220>
```

```
<221> SITE
<222> (253)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (887)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (969)
<223> n equals a,t,g, or c
<400> 68
 aggttttaaa aattcccatg gaaattgaaa ttnccaccat gggcttncaa taatttnttg
                                                                         60
 aggaattttt ggccatattt tgaataatct gccagttcca tatgaaaaac caaagaagag
                                                                        120
                                                                        180
 tatgttattg gccaatgttc ttaagttttt caccacaca atacacaca atacatacat
 tttttagact aggttaaaga tttatctagg tatatgtttg gaaattattc atacacatac
                                                                        240
 attacagaaa acncagtaag aaatataaaa tgtttcatac accaccagtt tgttttctgc
                                                                        300
 tagaagacac acaatgcccc tcttctgaat ctatggagat gaaggcttct ctcctttcac
                                                                        360
 ccagtacgtc atttgccaca aaactgaaag ataagtctgc tttagcttct tgtttcccca
                                                                        420
 aatcaggatg aacgggtggg ctgaagaaca gctgaatcca atagcttggc agaacatgaa
                                                                        480
                                                                        540
 gacaggtttg ttttccagat tcttaaaact ccaaactgat attattacag acacaaagta
 aatggcacat aacaagagga aggagatcac agtttgcaaa acttttatgt ggaccttggt
                                                                        600
 actgggatct tgagatcctt tgccatggag gtgcatcttc ttgagatgtt tacacagaga
                                                                        660
                                                                        720
 acagactaac agcagaaaag atatcagggt tacagtaaag ggtactaagt ttgctagcat
 qqttacaqtc qtatctgaaa ggtacattgc acgcctcaat ttgatcttcc aagtcatgtt
                                                                        780
                                                                        840
 tccttcatat tcttttqtcc atacaatstq attcatqttt accacaaaaa qataacaaqc
 caaaratagc aaaggcccca acagcatcac cagaatgaca ctcttancts tcctctttaa
                                                                        900
 ggcgaagaaa artaaggktg gagaaattgg caatcttgag caaataaaat atgctgaggc
                                                                        960
 tagtagcang ccagttgctg aaatggcccg gttactgccc agwtattata agcagtagtt
                                                                       1020
 cttaattcta cactacaaaa agctggattc aacacagttg aatmcaattt aataataccc
                                                                       1080
 ccagagcaaa ccaact
                                                                       1096
<210> 69
<211> 1288
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (404)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1261)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (1263)
<223> n equals a,t,g, or c
<220>
```

<221> SITE

```
<222> (1266)
<223> n equals a,t,g, or c
<400> 69
atcatggtct tgattgctat tatcggtttc catacgcagt tagaaacatc atttcttcca
                                                                       60
gcttttgaat taaagaaaag ctgtttttga agttgagatc tgatgtaaat tattttagta
                                                                      120
 tttttttcta aggcacttct aagcccctga attgctaatt ataycctcwt ctyccwttta
                                                                      180
caaaattcct tctaaacttc agwtaagaga actcaawtct tctcttttct aaaaaaaaaa
                                                                      240
amctatcmat gtaaaaatag atagaaatta tggaaaataa ttccagtgaa mctttktggt
                                                                      300
aaatgttaaa atagtatcta tgaaatctat gtattaatta tgggatgtgc cttaccattg
                                                                      360
 taattttgtt gtcagtgatg aaagtgtttt gacatattca ttancaggaa gttctattat
                                                                      420
aagaaagaaa tgtacagtct tgttcacagc taaattctat atgactacat taattcttgg
                                                                      480
 tgttatgaag ttttaacaat gttatttaat gttatttaaa ccttaagata aatcatcccc
                                                                      540
 acacctgatt tatqtaattt tttaatcata tatcttcctc agtacaatgt aagaactgta
                                                                      600
                                                                      660
 aagaaagaga teatgtetga ettgetttet gttgaeteee aggaeetaga acceageace
 aagaatagat ggccaaaaat gatactttaa tgaacaaata aatgggtggc taaaatggat
                                                                      720
                                                                      780
 aagttgatgt ggtaaatcaa tgaaaaggaa actcatcaca aaatctgcag ttgcatgaat
 tcccctgttc tggtctcagg ttgaggttkc aggcttatcc aagcagaatc cttcctcaga
                                                                      840
                                                                      900
ggaaaagttt ggctattcca caattttagg ggaaatatca cactagtgat atatatagtg
 atatatagtc acactatata tatatatagt gatatatagt cttgatgcag ctgtgtcagg
                                                                      960
                                                                     1020
 tgtctgaatt ggagacaagg taaaacatca aaattagatg gcaccttgga aggctgaggc
ggkcggatca cgaggtcagg atatcgagac catcccggct actatggtga aaccccgtct
                                                                     1080
 ccactaaaaa tacaaaaaa ttagctggga gtggtggtgg gcacctgtat tcccagctac
                                                                     1140
 tcqqaaqqct qtqqccaqaq aatggcqtga acgtgqgtqq cagagcttgc agtgagccga
                                                                     1200
1260
ntntanagga tccctcgagg ggcccaag
                                                                     1288
<210> 70
<211> 3319
<212> DNA
<213> Homo sapiens
<400> 70
gtgacgccgg ggcagggccg gaaggagtgc agcggctgcc acggagctcg tagctgcagc
                                                                       60
 tttggaggag taagcggcgt ggtagcgaag gtcgccgaac ccgcctggct agccggcgag
                                                                      120
 ttgagtggcg actcttttga aacagatggt caccatgttt agatattagc agtcccgtat
                                                                      180
gtgcatgtct gcatttgaaa atggaagagg gaaacaacaa tgaagaggta attcacttga
                                                                      240
acaactttca ctgccatcgg ggacaagact ttgtaatttt cttctggaaa acccagatta
                                                                      300
 tccaaagaga gaagacagaa tcattataaa tcccagtagc agtctgctgg ccagccaaga
                                                                      360
tgagacaaag ttgcctaaaa taagactttt ttgactattc taaattgact cctcttgacc
                                                                      420
 agcactgctt catccaagct gctgacctcc tcatggccga cttcaaagtg ctcagtagtc
                                                                      480
aggacatcaw gtgggccctg cacgagctca aaggacacta tgcaatcacc cgaaaggcct
                                                                      540
 tktctgatgc cattaaaaaa tggcaggagc trtcaccaga aaccagtgga aaaaggaaga
                                                                      600
 agagaaaaca aatgaaccag tattettaca ttgattteaa gtttgaacaa ggtgacataa
                                                                      660
 aaatagaaaa gaggatgttc tttcttgaaa ataagcgacg acattgtagg tcctatgacc
                                                                      720
 qacqtqctct ccttccaqct qtqcaacaag agcaqqaqtt ctatqaqcaq aaaatcaaag
                                                                      780
                                                                      840
 agatggcaga gcatgaagac tttttgcttg ccctacagat gaatgaagaa cagtatcaaa
 aggatggcca gctgattgag tgtcgctgct gctatgggga atttccattc gaggagctga
                                                                      900
 cgcatgcgca gatgctcact tgttctgcaa agagtgtctc atcagatatg cccaagaggc
                                                                      960
                                                                     1020
 agtetttggw tetggaaagt tggageteag etgeatggaa ggeagetgea egtgttegtt
 cccaaccagt gagetggaga aggtgetece ccagaccate etgtataagt actatgageg
                                                                     1080
 aaaagccgag gaggaggttg cggcagccta cgccgacgag cttgtcaggt gcccgtcctg
                                                                     1140
 tagettteeg getetgttgg acagtgatgt gaagaggtte agetgteeta atceteactg
                                                                     1200
 ccgaaaggaa acctgtagga agtgtcaggg actctggaaa gaacataatg gcctcacctg
                                                                     1260
 1320
 tgctgcccgc attagaaaat gccacaagtg tgggactggc ctcatcaaat ctgaaggctg
                                                                     1380
 caaccqcatg tottqccqct qtqqtqccca qatgtgctac ctctgtcqaq tttctattaa
                                                                     1440
```

```
tggatatgac catttctgcc aacatccccg ctcaccagga gccccttgcc aggagtgttc
                                                                        1500
 aaqatgctct ctctggaccg atcccactga agatgatgag aagcttattg aggaaatcca
                                                                        1560
 gaaggaggot gaagaggaac agaaaagaaa gaatggagag aacaccttca aacgcattgg
                                                                        1620
 accecegetg gagaageetg tggagaaggt geagagggtg gaggeeetee egaggeeegt
                                                                        1680
 tecqcaqaac etgecacage cacagatgee accetatgee ttegegeace caccetteee
                                                                        1740
                                                                        1800
 cctgcctccc gtgcggcctg tgttcaacaa cttcccactc aacatggggc ctatcccagc
 cccgtacgtg ccccctctgc ccaacgtgcg ggtcaactat gacttcggtc ccatccacat
                                                                        1860
 gcccctggag cacaacctgc ccatgcactt tggcccccag ccgcggcatc gcttctgatg
                                                                        1920
 gccccgaatc cccattgagc agcacaaagc ccgtttgggg taggagtgtg gatggagaac
                                                                        1980
 cctccccaa ggctggtgtc tgtaccattg catcctaagt cagcttgaag ggtaggctgg
                                                                        2040
 ttttcttccc acccctttcc tagaagggct actgctcctg gaagagtgga cggatccata
                                                                        2100
 ataaagacgt cccaaatggt ggagttcgga gagagctgcg atgtgaactg cccctcscct
                                                                        2160
 cgcatccccc aggccaccaa cggcagtcct tctgccttgt ccatggcata ggccatagac
                                                                       2220
 caggiccotg cigcicacac cigggectot cologgagec gaccociggg tagcaaggea
                                                                       2280
 gccgagagca tctccctgga ggggcccacg gttgggccaa gggcagaggg ggctgcacct
                                                                       2340
 gcgggcctgg gaagcattgc tcagggtggg gggctgggac catggcccgc agaggcactg
                                                                       2400
 ccacagctgt gagggccaag atgctgtccc cccatccaaa acccgtgcgc cactgcagtg
                                                                       2460
 agtgttgagg gcacctctcc tcccctctta cacctactca gatgaggcag cagcagaccc
                                                                       2520
 atctegegge gggggttttg ttetgttgee gectaaettt eteateeteg gtetetggaa
                                                                        2580
 agtcaggctg agaaatcctt tcccaggcca ggccgctgcg gtacactgga tggttctgaa
                                                                       2640
 getggeecat tgaaagagee tettaaggea getgggaeag aggeetggtg geeetgetgg
                                                                        2700
                                                                       2760
 gcagcccaac tgctggggga gacgtttcts ccaccctggg tgatgagcag cttttccccc
 ctggctttct gggggaggag tgggcctcct tagggagaca ggtgaccctg ggtgccaccc
                                                                       2820
 ctgccccgtg tgtgccccgg gtgttctcag tggttgctga aggcaggtag agggtgctgt
                                                                       2880
 ccagtatece ccatgtgaag gtcacttece tteteatgga gtcagetgag cateagetea
                                                                       2940
                                                                       3000
 geoetgecat greeceacte accetecteg cerectgree ggecergggt tretageggt
 gcctgaggca tcactctggc ccattgacag atgagaggtc tgaagccttc ctggccacag
                                                                       3060
 gcatcacttt ctcctcctcc tcatqccctg ccttqtcctt gtcqtgttgc catqgggttc
                                                                        3120
 tqaqaqqctq qqaqttcaca qacctcaqac acaqctqaqt ccqacaacca ttqqqqtqqq
                                                                        3180
 gctgcatcag tctccggagt ggcccgccac ctcctgaagc agggcctggc ccacccaagg
                                                                        3240
 tgcctggggc aggcgggcac cgtcattcgc tgccattggc ttctcagatg tatttcaagg
                                                                        3300
                                                                        3319
 actaaagtgg gctctaaga
<210> 71
<211> 372
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (309)
<223> n equals a,t,q, or c
```

```
ggcacgagaa gactggagcc tttgcggcgg cgctgccct cccctggtcc ccgcgagctc 60 ggagggcccg gctggtgctg cgggggcccc gggaggtacg gacctgggag gcgaggctcg 120 tccggcgcta ggatcggcct ccgcctccgg gccgctttag gttgaaacta agcatggga 180 agagctgcaa ggtggtcgtg tgtggccagg cgtctgtggg caaaacttca atcctggagc 240 agcttctgta tgggaaccat gtagtgggt cggagatgat cgagacgcag gaggacatta 300 cgtgggctnc attgagacag accgggggt gcgagagcag gtgcgtttta tgacaaccgg 360 gggctccgag at 372
```

<210> 72 <211> 337 <212> DNA <213> Homo sapiens

<400> 71

```
<220>
<221> SITE
<222> (326)
<223> n equals a,t,g, or c
 gtgcccggct gaagacttat ttttaataga cttttacaaa gtatgcaaag gaccagttat
                                                                         60
 taaaaaagac agtaagtgac cgccctggta aatagattct aaaattcaat gaataagaaa
                                                                         120
 cagatgaatg tcagacttgt cctaaaccct tttcctctat attctgtcta tgtcatccct
                                                                         180
 aattageeet cacceatget getetteatt tettetacag aaactgaact agacaacett
                                                                         240
 ggctactcgt ctatatactc aattgagtaa tttaggttca ggatcacaac taatttagat
                                                                        300
 tcataatcac agtccagttt tctttngttt ttttgtg
                                                                         337
<210> 73
<211> 1415
<212> DNA
<213> Homo sapiens
<220>
<221> SITE
<222> (64)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (117)
<223> n equals a,t,g, or c
<220>
<221> SITE
<222> (119)
<223> n equals a,t,g, or c
<400> 73
 ggttttttta aagcaagtaa acceteteea attgtggtat ggetgattat gateatgace
                                                                          60
 cagnetgtga ggaetgaggg geetgaaatg aageettggg aetgtgaate taaaatnene
                                                                         120
 aaccaattaq aatcactaqc tcctqtqtat aatattttca taaatcatac tcaqtaaqca
                                                                         180
 aaactctcaa qcaqcaaqca tatqcaqcta qtttaacaca ttatacactt aaaaatttta
                                                                         240
 tatttacctt agagetttaa atetetgtag gtagtttgte caattatgte acaccacaga
                                                                         300
 aqtaaqqttc cttcacaaaq atcccaaqct aqcaqatctc ccaqtcacqa cqttqtaaaa
                                                                         360
 cgacggccag tgcctagctt ataatacgac tcactatagg gagagagcta tgacgtcgca
                                                                         420
 tgcacgcgta agettgggcc cetegaggga teetetagag eggcegegtg ggctatgggg
                                                                         480
 cggcggtcgc ggggtcggcg gctccagcaa cagcagcggc cggaggacgc ggaggatggc
                                                                         540
 gccgagggtg gtggaaagcg cggcgaggcg ggctgggaag gaggctaccc cgagatcgtc
                                                                         600
 aaggagaaca agctgttcga gcactactac caggagctca agatcgtgcc cgagggcgag
                                                                         660
 tggggccagt tcatggacgc tctcagggag ccgctcccgg ccactttaag aattactggt
                                                                         720
 tacaaaagcc acgcaaaaga gattctccat tgcttaaaga acaaatattt taaggaattg
                                                                         780
 gaggacetgg aggtggacgg teagaaagtt gaagtteeae ageeaetgag ttggtateet
                                                                         840
 gaagaacttg cctggcacac aaatttaagt cgaaaaatct tgagaaaatc gccacacttg
                                                                         900
 gaaaagtttc atcagtttct agttagtgaa acagaatctg gaaatattag tcgtcaagaa
                                                                         960
 gctgttagca tgatcccacc actgctcctc aacgtgcggc ctcatcataa gatcttagat
                                                                        1020
 atgtgtgcag cacctggctc aaagaccaca cagttaattg aaatgctaca tgccgacatg
                                                                        1080
 aatgtcccct ttccagaggg atttgttatt gcgaatgatg tggacaacaa gcgctgctac
                                                                        1140
 ctgctcgtcc atcaagccaa gaggctgagc agccctgca tcatggtggt caaccatgat
                                                                        1200
 gcctccagca tacccaggct ccagatagat gtggacggca ggaaagagat cctcttctat
                                                                        1260
 gatsgatttt atgtgatgtc ccttqcaqtq qaacqgcact atgagaaara acatgatgtt
                                                                        1320
```

-	-	_					gatto	_		cggg	999	caaga	attc	ctat	gagtgg
<211 <212	2210> 74 2211> 283 2212> PRT 2213> Homo sapiens														
<400> 74															
Met 1	Ile	Phe	Leu	Leu 5	Leu	Met	Leu	Ser	Leu 10	Glu	Leu	Gln	Leu	His 15	Gln
Ile	Ala	Ala	Leu 20	Phe	Thr	Val	Thr	Val 25	Pro	Lys	Glu	Leu	Tyr 30	Ile	Ile
Glu	His	Gly 35	Ser	Asn	Val	Thr	Leu 40	Glu	Cys	Asn	Phe	Asp 45	Thr	Gly	Ser
His	Val 50	Asn	Leu	Gly	Ala	Ile 55	Thr	Ala	Ser	Leu	Gln 60	Lys	Val	Glu	Asn
Asp 65	Thr	Ser	Pro	His	Arg 70	Glu	Arg	Ala	Thr	Leu 75	Leu	Glu	Glu	Gln	Leu 80
Pro	Leu	Gly	Lys	Ala 85	Ser	Phe	His	Ile	Pro 90	Gln	Val	Gln	Val	Arg 95	Asp
Glu	Gly	Gln	Tyr 100	Gln	Cys	Ile	Ile	Ile 105	Tyr	Gly	Val	Ala	Trp 110	Asp	Tyr
Lys	Tyr	Leu 115	Thr	Leu	Lys	Val	Lys 120	Ala	Ser	Tyr	Arg	Lys 125	Ile	Asn	Thr
His	Ile 130	Leu	Lys	Val	Pro	Glu 135	Thr	Asp	Glu	Val	Glu 140	Leu	Thr	Cys	Gln
Ala 145	Thr	Gly	Tyr	Pro	Leu 150	Ala	Glu	Val	Ser	Trp 155	Pro	Asn	Val	Ser	Val 160
Pro	Ala	Asn	Thr	Ser 165	His	Ser	Arg	Thr	Pro 170	Glu	Gly	Leu	Tyr	Gln 175	Val
Thr	Ser	Val	Leu 180	Arg	Leu	Lys	Pro	Pro 185	Pro	Gly	Arg	Asn	Phe 190	Ser	Cys
Val	Phe	Trp 195	Asn	Thr	His	Val	Arg 200	Glu	Leu	Thr	Leu	Ala 205	Ser	Ile	Asp
Leu	Gln 210	Ser	Gln	Met	Glu	Pro 215	Arg	Thr	His	Pro	Thr 220	Trp	Leu	Leu	His
Ile 225	Phe	Ile	Pro	Ser	Cys 230	Ile	Ile	Ala	Phe	Ile 235	Phe	Ile	Ala	Thr	Val 240
Ile	Ala	Leu	Arg	Lys 245	Gln	Leu	Cys	Gln	Lys 250	Leu	Tyr	Ser	Ser	Lys 255	Asp

55

Thr Thr Lys Arg Pro Val Thr Thr Thr Lys Arg Glu Val Asn Ser Ala 260 265 270

Val Asn Leu Asn Leu Trp Ser Trp Glu Pro Gly 275 280

<210> 75

<211> 184

<212> PRT

<213> Homo sapiens

<400> 75

Met Ser Arg Thr Ala Tyr Thr Val Gly Ala Leu Leu Leu Leu Gly
1 5 10 15

Thr Leu Leu Pro Ala Ala Glu Gly Lys Lys Gly Ser Gln Gly Ala 20 25 30

Ile Pro Pro Pro Asp Lys Ala Gln His Asn Asp Ser Glu Gln Thr Gln
35 40 45

Ser Pro Gln Gln Pro Gly Ser Arg Asn Arg Gly Arg Gly Gln Gly Arg
50 55 60

Gly Thr Ala Met Pro Gly Glu Glu Val Leu Glu Ser Ser Gln Glu Ala 65 70 75 80

Leu His Val Thr Glu Arg Lys Tyr Leu Lys Arg Asp Trp Cys Lys Thr 85 90 95

Gln Pro Leu Lys Gln Thr Ile His Glu Glu Gly Cys Asn Ser Arg Thr 100 105 110

Ile Ile Asn Arg Phe Cys Tyr Gly Gln Cys Asn Ser Phe Tyr Ile Pro 115 120 125

Arg His Ile Arg Lys Glu Glu Gly Ser Phe Gln Ser Cys Ser Phe Cys 130 135 140

Lys Pro Lys Lys Phe Thr Thr Met Met Val Thr Leu Asn Cys Pro Glu
145 150 155 160

Leu Gln Pro Pro Thr Lys Lys Lys Arg Val Thr Arg Val Lys Gln Cys
165 170 175

Arg Cys Ile Ser Ile Asp Leu Asp
180

<210> 76

<211> 716

<212> PRT

<213> Homo sapiens

<400> 76

Met Asn Asn Phe Arg Ala Thr Ile Leu Phe Trp Ala Ala Ala Arp
1 5 10 15

Ala	Lys	Ser	Gly 20	Lys	Pro	Ser	Gly	Glu 25	Met	Asp	Glu	Val	Gly 30	Val	Glr
Lys	Cys	Lys 35	Asn	Ala	Leu	Lys	Leu 40	Pro	Val	Leu	Glu	Val 45	Leu	Pro	GlΣ
Gly	Gly 50	Trp	Asp	Asn	Leu	Arg 55	Asn	Val	Asp	Met	Gly 60	Arg	Val	Met	Glu
Leu 65	Thr	Tyr	Ser	Asn	Cys 70	Arg	Thr	Thr	Glu	Asp 75	Gly	Gln	Tyr	Ile	Ile 80
Pro	Asp	Glu	Ile	Phe 85	Thr	Ile	Pro	Gln	Lys 90	Gln	Ser	Asn	Leu	Glu 95	Met
Asn	Ser	Glu	Ile 100	Leu	Glu	Ser	Trp	Ala 105	Asn	Tyr	Gln	Ser	Ser 110	Thr	Sei
Tyr	Ser	Ile 115	Asn	Thr	Glu	Leu	Ser 120	Leu	Phe	Ser	Lys	Val 125	Asn	Gly	Lys
Phe	Ser 130	Thr	Glu	Phe	Gln	Arg 135	Met	Lys	Thr	Leu	Gln 140	Val	Lys	Asp	Glr
Ala 145	Ile	Thr	Thr	Arg	Val 150	Gln	Val	Arg	Asn	Leu 155	Val	Tyr	Thr	Val	Lys 160
Ile	Asn	Pro	Thr	Leu 165	Glu	Leu	Ser	Ser	Gly 170	Phe	Arg	Lys	Glu	Leu 175	Leı
Asp	Ile	Ser	Asp 180	Arg	Leu	Glu	Asn	Asn 185	Gln	Thr	Arg	Met	Ala 190	Thr	Туз
Leu	Ala	Glu 195	Leu	Leu	Val	Leu	Asn 200	Tyr	Gly	Thr	His	Val 205	Thr	Thr	Sei
Val	Asp 210	Ala	Gly	Ala	Ala	Leu 215	Ile	Gln	Glu	Asp	His 220	Leu	Arg	Ala	Sei
Phe 225	Leu	Gln	Asp	Ser	Gln 230	Ser	Ser	Arg	Ser	Ala 235	Val	Thr	Ala	Ser	Ala 240
Gly	Leu	Ala	Phe	Gln 245	Asn	Thr	Val	Asn	Phe 250	Lys	Phe	Glu	Glu	Asn 255	Туз
Thr	Ser	Gln	Asn 260	Val	Leu	Thr	Lys	Ser 265	Tyr	Leu	Ser	Asn	Arg 270	Thr	Ası
Ser	Arg	Val 275	Gln	Ser	Ile	Gly	Gly 280	Val	Pro	Phe	Tyr	Pro 285	Gly	Ile	Thi
Leu	Gln 290	Ala	Trp	Gln	Gln	Gly 295	Ile	Thr	Asn	His	Leu 300	Val	Ala	Ile	Asp
Arg 305	Ser	Gly	Leu	Pro	Leu 310	His	Phe	Phe	Ile	Asn 315	Pro	Asn	Met	Leu	Pro 320

Asp	Leu	Pro	Gly	Pro 325	Leu	Val	Lys	Lys	Val 330	Ser	Lys	Thr	Val	Glu 335	Thr
Ala	Val	Lys	Arg 340	Tyr	Tyr	Thr	Phe	Asn 345	Thr	Tyr	Pro	Gly	Cys 350	Thr	Asp
Leu	Asn	Ser 355	Pro	Asn	Phe	Asn	Phe 360	Gln	Ala	Asn	Thr	Asp 365	Asp	Gly	Ser
Cys	Glu 370	Gly	Lys	Met	Thr	Asn 375	Phe	Ser	Phe	Gly	Gly 380	Val	Tyr	Gln	Glu
Cys 385	Thr	Gln	Leu	Ser	Gly 390	Asn	Arg	Asp	Val	Leu 395	Leu	Cys	Gln	Lys	Leu 400
Glu	Gln	Lys	Asn	Pro 405	Leu	Thr	Gly	Asp	Phe 410	Ser	Cys	Pro	Ser	Gly 415	Tyr
Ser	Pro	Val	His 420	Leu	Leu	Ser	Gln	Ile 425	His	Glu	Glu	Gly	Tyr 430	Asn	His
Leu	Glu	Cys 435	His	Arg	Lys	Cys	Thr 440	Leu	Leu	Val	Phe	Cys 445	Lys	Thr	Val
Cys	Glu 450	Asp	Val	Phe	Gln	Val 455	Ala	Lys	Ala	Glu	Phe 460	Arg	Ala	Phe	Trp
Cys 465	Val	Ala	Ser	Ser	Gln 470	Val	Pro	Glu	Asn	Ser 475	Gly	Leu	Leu	Phe	Gly 480
Gly	Leu	Phe	Ser	Ser 485	Lys	Ser	Ile	Asn	Pro 490	Met	Thr	Asn	Ala	Gln 495	Ser
Cys	Pro	Ala	Gly 500	Tyr	Phe	Pro	Leu	Arg 505	Leu	Phe	Glu	Asn	Leu 510	Lys	Val
Cys	Val	Ser 515	Gln	Asp	Tyr	Glu	Leu 520	Gly	Ser	Arg	Phe	Ala 525	Val	Pro	Phe
Gly	Gly 530	Phe	Phe	Ser	Cys	Thr 535	Val	Gly	Asn	Pro	Leu 540	Val	Asp	Pro	Alā
Ile 545	Ser	Arg	Asp	Leu	Gly 550	Ala	Pro	Ser	Leu	Lys 555	Lys	Cys	Pro	Gly	Gly 560
Phe	Ser	Gln	His	Pro 565	Ala	Leu	Ile	Ser	Asp 570	Gly	Cys	Gln	Val	Ser 575	Tyr
Cys	Val	Lys	Ser 580	Gly	Leu	Phe	Thr	Gly 585	Gly	Ser	Leu	Pro	Pro 590	Ala	Arg
Leu	Pro	Pro 595	Phe	Thr	Arg	Pro	Pro 600	Leu	Met	Ser	Gln	Ala 605	Ala	Thr	Asn
Thr	Val 610	Ile	Val	Thr	Asn	Ser 615	Glu	Asn	Ala	Arg	Ser 620	Trp	Ile	Lys	Asp
Ser	Gln	Thr	His	G] n	Trp	Ara	Leu	Glv	G] 11	Pro	Ile	Glu	Leu	Ara	Arc

WO 01/34629

PCT/US00/30654

630 640 625 635 Ala Met Asn Val Ile His Gly Asp Gly Gly Leu Ser Gly Gly Ala 650 Ala Ala Gly Val Thr Val Gly Val Thr Thr Ile Leu Ala Val Val Ile 665 Thr Leu Ala Ile Tyr Gly Thr Arg Lys Phe Lys Lys Lys Ala Tyr Gln 680 Ala Ile Glu Glu Arg Gln Ser Leu Val Pro Gly Thr Ala Ala Thr Gly Asp Thr Thr Tyr Gln Glu Gln Gly Gln Ser Pro Ala 710 <210> 77 <211> 617 <212> PRT <213> Homo sapiens <400> 77 Met Phe Arg Thr Ala Val Met Met Ala Ala Ser Leu Ala Leu Thr Gly 10 Ala Val Val Ala His Ala Tyr Tyr Leu Lys His Gln Phe Tyr Pro Thr Val Val Tyr Leu Thr Lys Ser Ser Pro Ser Met Ala Val Leu Tyr Ile Gln Ala Phe Val Leu Val Phe Leu Leu Gly Lys Val Met Gly Lys Val Phe Phe Gly Gln Leu Arg Ala Ala Glu Met Glu His Leu Leu Glu Arg Ser Trp Tyr Ala Val Thr Glu Thr Cys Leu Ala Phe Thr Val Phe Arg Asp Asp Phe Ser Pro Arg Phe Val Ala Leu Phe Thr Leu Leu Leu Phe 105 Leu Lys Cys Phe His Trp Leu Ala Glu Asp Arg Val Asp Phe Met Glu 115 Arg Ser Pro Asn Ile Ser Trp Leu Phe His Cys Arg Ile Val Ser Leu 135 Met Phe Leu Leu Gly Ile Leu Asp Phe Leu Phe Val Ser His Ala Tyr 150 155 His Ser Ile Leu Thr Arg Gly Ala Ser Val Gln Leu Val Phe Gly Phe 170 Glu Tyr Ala Ile Leu Met Thr Met Val Leu Thr Ile Phe Ile Lys Tyr

			180					185					190		
Val	Leu	His 195	Ser	Val	Asp	Leu	Gln 200	Ser	Glu	Asn	Pro	Trp 205	Asp	Asn	Lys
Ala	Val 210	Tyr	Met	Leu	Tyr	Thr 215	Glu	Leu	Phe	Thr	Gly 220	Phe	Ile	Lys	Val
Leu 225	Leu	Tyr	Met	Ala	Phe 230	Met	Thr	Ile	Met	Ile 235	Lys	Val	His	Thr	Phe 240
Pro	Leu	Phe	Ala	Ile 245	Arg	Pro	Met	Tyr	Leu 250	Ala	Met	Arg	Gln	Phe 255	Lys
Lys	Ala	Val	Thr 260	Asp	Ala	Ile	Met	Ser 265	Arg	Arg	Ala	Ile	Arg 270	Asn	Met
Asn	Thr	Leu 275	Tyr	Pro	Asp	Ala	Thr 280	Pro	Glu	Glu	Leu	Gln 285	Ala	Met	Asp
Asn	Val 290	Cys	Ile	Ile	Cys	Arg 295	Glu	Glu	Met	Val	Thr 300	Gly	Ala	Lys	Arg
Leu 305	Pro	Cys	Asn	His	Ile 310	Phe	His	Thr	Ser	Cys 315	Leu	Arg	Ser	Trp	Phe 320
Gln	Arg	Gln	Gln	Thr 325	Cys	Pro	Thr	Cys	Arg 330	Met	Asp	Val	Leu	Arg 335	Ala
Ser	Leu	Pro	Ala 340	Gln	Ser	Pro	Pro	Pro 345	Pro	Glu	Pro	Ala	Asp 350	Gln	Gly
Pro	Pro	Pro 355	Ala	Pro	His	Pro	Pro 360	Pro	Leu	Leu	Pro	Gln 365	Pro	Pro	Asn
Phe	Pro 370	Gln	Gly	Leu	Leu	Pro 375	Pro	Phe	Pro	Pro	Gly 380	Met	Phe	Pro	Leu
Trp 385	Pro	Pro	Met	Gly	Pro 390	Phe	Pro	Pro	Val	Pro 395	Pro	Pro	Pro	Ser	Ser 400
Gly	Glu	Ala	Val	Ala 405	Pro	Pro	Ser	Thr	Ser 410	Ala	Ala	Ala	Leu	Ser 415	Arg
Pro	Ser	Gly	Ala 420	Ala	Thr	Thr	Thr	Ala 425	Ala	Gly	Thr	Ser	Ala 430	Thr	Ala
Ala	Ser	Ala 435	Thr	Ala	Ser	Gly	Pro 440	Gly	Ser	Gly	Ser	Ala 445	Pro	Glu	Ala
Gly	Pro 450	Ala	Pro	Gly	Phe	Pro 455	Phe	Pro	Pro	Pro	Trp 460	Met	Gly	Met	Pro
Leu 465	Pro	Pro	Pro	Phe	Ala 470	Phe	Pro	Pro	Met	Pro 475	Val	Pro	Pro	Ala	Gly 480
Phe	Ala	Gly	Leu	Thr 485	Pro	Glu	Glu	Leu	Arg 490	Ala	Leu	Glu	Gly	His 495	Ğlu

60

Arg Gln His Leu Glu Ala Arg Leu Gln Ser Leu Arg Asn Ile His Thr 505 Leu Leu Asp Ala Ala Met Leu Gln Ile Asn Gln Tyr Leu Thr Val Leu 520 Ala Ser Leu Gly Pro Pro Arg Pro Ala Thr Ser Val Asn Ser Thr Glu 535 Glu Thr Ala Thr Thr Val Val Ala Ala Ser Ser Thr Ser Ile Pro 550 555 Ser Ser Glu Ala Thr Thr Pro Thr Pro Gly Ala Ser Pro Pro Ala Pro 565 570 Glu Met Glu Arq Pro Pro Ala Pro Glu Ser Val Gly Thr Glu Glu Met 585 Pro Glu Asp Gly Glu Pro Asp Ala Ala Glu Leu Arg Arg Arg Leu 600 Gln Lys Leu Glu Ser Pro Val Ala His <210> 78 <211> 288 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (87) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (99) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (230) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (263) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (264) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE

Asn Leu Asn Tyr Gly Leu Xaa Val Asp Cys Gly Ser Ser Gly Ser Arg 85 90 95

Ile Phe Xaa Tyr Phe Trp Pro Arg His Asn Gly Asn Pro His Asp Leu 100 105 110

Leu Asp Ile Lys Gln Met Arg Asp Arg Asn Ser Gln Pro Val Val Lys
115 120 125

Lys Ile Lys Pro Gly Ile Ser Ala Met Ala Asp Thr Pro Glu His Ala 130 135 140

Ser Asp Tyr Leu Arg Pro Leu Leu Ser Phe Ala Ala His Val Pro 145 150 155 160

Val Lys Lys His Lys Glu Thr Pro Leu Tyr Ile Leu Cys Thr Ala Gly
165 170 175

Met Arg Leu Pro Glu Arg Lys Gln Leu Ala Ile Leu Ala Asp Leu 180 185 190

Val Lys Asp Leu Pro Leu Glu Phe Asp Phe Leu Phe Ser Gln Ser Gln 195 200 205

Ala Glu Val Ile Ser Gly Lys Gln Glu Gly Val Tyr Ala Trp Ile Gly
210 215 220

Ile Asn Phe Val Leu Xaa Arg Phe Asp His Glu Asp Glu Ser Asp Ala 225 230 235 240

Glu Ala Thr Gln Glu Leu Ala Ala Gly Arg Arg Thr Val Gly Ile
, 245 250 255

Leu Asp Met Gly Gly Ala Xaa Xaa Gln Ile Ala Tyr Glu Xaa Pro Thr

62

260 265 270

Phe Pro Xaa Lys Lys Thr Pro Pro Leu Phe Pro Leu Leu Gly Gly Ile 275 280 285

<210> 79

<211> 83

<212> PRT

<213> Homo sapiens

<400> 79

Gly His Val Leu Ala Tyr Ser Ser Trp Pro Ser Leu Ala Pro Gly Leu 1 5 10 15

Ser Val Gln Tyr Phe Val Ser Arg Val Glu Val Pro Asn Pro Gly Cys 20 25 30

Thr Leu Glu Ala Pro Gly Lys Leu Ser Glu Phe Leu Arg Pro Glu Pro 35 40 45

His Pro Lys Pro Ile Ser Ser Glu Ser Leu Gly Gly Thr Glu Pro Gly 50 55 60

Phe Cys Gln Leu Lys Pro Ala Met Val Thr Ser Val Ser Ser Tyr Thr 65 70 75 80

Glu Asn Ser

<210> 80

<211> 39

<212> PRT

<213> Homo sapiens

<400> 80

Met His Leu Leu Pro Trp Arg Ala Ala Ala Ala Pro Pro Leu Leu Ile 1 5 10 15

Ala Val Pro Pro Arg Pro Ser Arg Ser Pro Val Gln Pro Pro Ser Leu 20 25 30

Gly Ala Ala Asn Pro Ser Ala 35

<210> 81

<211> 41

<212> PRT

<213> Homo sapiens

<400> 81

Met Ala Phe Pro Arg Val Gly Ala Phe Leu Phe Leu Ala Ser Leu Ser 1 10 15

63

Ser Leu Leu His Cys Arg Leu Leu Ala Glu Ala Val Ser Gly Arg Ser 20 25 30

Val Ser Leu Ala Pro Ser Ile Ile Arg 35 40

<210> 82

<211> 50

<212> PRT

<213> Homo sapiens

<400> 82

Met Glu Glu Val Ala Phe Met Val Leu Lys Tyr Val Leu Pro Phe Leu 1 5 10 15

Lys Ser Leu Trp Leu His Val Tyr Leu Leu Ala Val Leu Trp Pro Arg
20 25 30

Leu Ala Ser Met Ile Ser Phe Gly Ser Arg Leu Phe Gln Ile Val Asp 35 40 45

Gly Ala 50

<210> 83

<211> 62

<212> PRT

<213> Homo sapiens

-400× 83

Met Leu Cys Pro Ala Leu Gly Pro Phe Leu Leu Phe Leu Leu Ser Ser 1 5 10 15

Thr Leu Met Ala Ser Phe Met Gly Asp Thr Pro Cys His Pro Gly Glu 20 25 30

Leu Ser Ala Phe Gly Val Ala Pro Ser Arg Val Phe Thr Ser Ser Phe 35 40 45

Leu Phe Thr Val Phe Thr Pro Ser Tyr Pro Ser Leu Pro Gly
50 55 60

<210> 84

<211> 371

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (20)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 84

Met Leu Phe Pro Ser Phe Ser Arg Ser Leu Val Pro Leu Pro His Ala

1				5					10					15	
Leu	Tyr	Leu	Xaa 20	Gln	Pro	Leu	Thr	His 25	Thr	Thr	Ser	Leu	Leu 30	Ala	Gly
Ile	Gly	Pro 35	Val	Leu	Gly	Leu	Val 40	Cys	Val	Pro	Leu	Leu 45	Gly	Ser	Ala
Ser	Asp 50	His	Trp	Arg	Gly	Arg 55	Tyr	Gly	Arg	Arg	Arg 60	Pro	Phe	Ile	Trp
Ala 65	Leu	Ser	Leu	Gly	Ile 70	Leu	Leu	Ser	Leu	Phe 75	Leu	Ile	Pro	Arg	Ala 80
Gly	Trp	Leu	Ala	Gly 85	Leu	Leu	Cys	Pro	Asp 90	Pro	Arg	Pro	Leu	Glu 95	Leu
Ala	Leu	Leu	Ile 100	Leu	Gly	Val	Gly	Leu 105	Leu	Asp	Phe	Cys	Gly 110	Gln	Val
Cys	Phe	Thr 115	Pro	Leu	Glu	Ala	Leu 120	Leu	Ser	Asp	Leu	Phe 125	Arg	Asp	Pro
Asp	His 130	Cys	Arg	Gln	Ala	Tyr 135	Ser	Val	Tyr	Ala	Phe 140	Met	Ile	Ser	Leu
Gly 145	Gly	Cys	Leu	Gly	Tyr 150	Leu	Leu	Pro	Ala	Ile 155	Asp	Trp	Asp	Thr	Ser 160
Ala	Leu	Ala	Pro	Tyr 165	Leu	Gly	Thr	Gln	Glu 170	Glu	Cys	Leu	Phe	Gly 175	Leu
Leu	Thr	Leu	Ile 180	Phe	Leu	Thr	Cys	Val 185	Ala	Ala	Thr	Leu	Leu 190	Val	Ala
Glu	Glu	Ala 195	Ala	Leu	Gly	Pro	Thr 200	Glu	Pro	Ala	Glu	Gly 205	Leu	Ser	Ala
Pro	Ser 210	Leu	Ser	Pro	His	Cys 215	Cys	Pro	Cys	Arg	Ala 220	Arg	Leu	Ala	Phe
Arg 225	Asn	Leu	Gly	Ala	Leu 230	Leu	Pro	Arg	Leu	His 235	Gln	Leu	Cys	Cys	Arg 240
Met	Pro	Arg	Thr	Leu 245	Arg	Arg	Leu	Phe	Val 250	Ala	Glu	Leu	Cys	Ser 255	Trp
Met	Ala	Leu	Met 260	Thr	Phe	Thr	Leu	Phe 265	Tyr	Thr	Asp	Phe	Val 270	Gly	Glu
Gly	Leu	Tyr 275	Gln	Gly	Val	Pro	Arg 280	Ala	Glu	Pro	Gly	Thr 285	Glu	Ala	Arg
Arg	His 290	Tyr	Asp	Glu	Gly	Lys 295	Ala	Leu	Ala	Ala	Ser 300	Arg	Gly	Trp	Cys
Gly 305	Ser	Arg	Pro	Pro	Glu 310	Thr	Thr	Leu	Gly	Ala 315	Val	Ser	Gly	Leu	Val 320

65

Pro Leu His Pro Gly Pro Asp Phe Ser Val Arg Lys Val Gly Met Asp 325 330 335

Pro Ile Cys Ile His Gly Phe Ser Trp Val Trp Asn Ile Ser Ala Cys 340 345 350

Gly Phe Arg Lys Ala Ser Gly Cys Ser Arg Ser Leu Ile Arg Val Val 355 360 365

Ala Pro Val 370

<210> 85

<211> 46

<212> PRT

<213> Homo sapiens

<400> 85

Met Pro Trp Leu Lys Ser Leu Leu His Phe Ser Leu Phe Leu Val Val 1 5 10 15

Phe Ser Thr Leu Ala Val Lys Ser Leu Gly Val Pro Val Ala Ala Gly
20 25 30

Ser Pro Phe Cys Ile Val Asp Val Leu His Phe Ile Leu Leu 35 40 45

<210> 86

<211> 53

<212> PRT

<213> Homo sapiens

<400> 86

Met Phe Ile Ser Leu Phe Ile Phe Gly Leu Val Arg Leu Trp Pro Cys 1 5 10 15

Cys Val Val Ile Tyr Phe Val Tyr Ser Ile Cys Lys His Gln Cys Ser 20 25 30

Gln Glu Ala His Ser Ser Ile Phe Asn Cys Lys Phe Val Ser Gln Ser 35 40 45

Gln Phe Ser Ile Met 50

<210> 87

<211> 73

<212> PRT

<213> Homo sapiens

<400> 87

Met Trp Leu Pro Ala Trp Ala Ala Ile Glu Thr Phe Ser Thr Cys Ser

1 5 10 15

66

Ser Leu Ser Leu Ser Phe Gln Pro Arg Trp Ala Leu Ala Ser Glu Gly 20 25 30

Cys Ala Gly Ser Tyr Val Thr Thr His Arg Ala Leu Gly Ala His Leu
35 40 45

Trp Pro Leu Trp Ser Asp Gln Phe Leu Gly Lys Gly Leu Gly Leu Arg
50 55 60

Ile Pro Phe Ile Thr His Ala His Gln 65 70

<210> 88

<211> 80

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (25)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 88

Met Gly Thr Ser Thr Ala Trp Arg Val Pro Trp Arg Arg Trp Ala Arg

1 10 15

Val Arg Cys Trp Trp Leu Trp Pro Xaa Thr Gly Thr Ala Glu Pro Pro

Gly Thr Ala Gly Trp Gln Gly Leu Ala Gly Gly Arg Cys Arg Glu Ala 35 40 45

Trp Gly Ser Leu Leu Met Gly Met Phe Gly Leu Cys Phe Leu Pro Val 50 60

His Ser Gln Ser Cys Leu Ser Ser Ser Ser Pro Thr Pro Arg Pro 65 70 75 80

<210> 89

<211> 36

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (17)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 89

Met Ala Gly Glu Glu Met Ala Trp Gly Ala Arg Leu Trp Ile Met Cys

1 10 15

Xaa Leu Leu Phe Leu Ala Ala Ser Glu Gly Ile Met Pro Arg Leu Arg

67 25 30 20 Ala Ser Ala Trp 35 <210> 90 <211> 40 <212> PRT <213> Homo sapiens <400> 90 Met Ile Leu Tyr Ile Cys Leu Leu Lys Ile Trp Gly Cys Ser Leu Pro Cys Asn Phe Ser Phe Pro Leu Asp Leu Arg Lys Val Met Asp Phe Gln Phe Val Gln His Phe Phe Leu <210> 91 <211> 63 <212> PRT <213> Homo sapiens <400> 91 Met Ile Thr Phe Leu Pro Ile Ile Phe Ser Ile Leu Val Val Val Thr 10 Phe Val Ile Gly Asn Phe Ala Asn Gly Phe Ile Ala Leu Val Asn Ser 20 25 Thr Glu Trp Val Lys Arg Gln Lys Ile Ser Phe Ala Asp Gln Ile Val Thr Ala Leu Ala Val Ser Arg Val Gly Leu Leu Trp Val Leu Leu 50 55 <210> 92 <211> 86 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (2) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (25) <223> Xaa equals any of the naturally occurring L-amino acids

Ser Xaa Ile Val Gly Leu Ala Ile Trp Arg Gly Gly Leu Cys Gln Glu

<400> 92

68

10 Leu Pro Leu Glu Arg Phe Leu Leu Xaa Thr Val Phe Gly Ser Asp Leu 25 Ser Leu Leu Ser Gly Gly Asp Leu Cys Leu Glu Leu Leu Gly Gly Leu Cys Leu Glu Val Cys Leu Arg Gly Asp Ile Cys Leu Gly Pro Leu Arg Val Ser Val Ser Glu Leu Ser Leu Leu Cys Leu Ser Val Gln Gly Gln Gln Lys Val Cys Pro Phe <210> 93 <211> 20 <212> PRT <213> Homo sapiens <400> 93 Met Asn Val Arg Leu Val Leu Asn Pro Phe Pro Leu Tyr Ser Val Tyr Val Ile Pro Asn 20 <210> 94 <211> 75 <212> PRT <213> Homo sapiens <400> 94 Met Gly Pro Leu Trp Gly Ala Pro Leu Arg Ala Trp Ala Ala Gly Ser Val Gly Cys Pro Cys Cys Leu Ser Cys Ala Ser Pro Ser Ser Ile Ser Ser Ala Gly Asp Pro Leu Ala Ser Cys Ser Thr Cys Gly Ser Thr Trp 35 40 45 Glu Ile Pro Leu Thr Trp Met Thr Met Asp His Leu Leu Val Arg Tyr Tyr Leu Ser Gln Ala Arg Trp Cys Thr Thr Gly 70 <210> 95 <211> 23 <212> PRT

<213> Homo sapiens

```
<400> 95
Leu Phe Leu Leu Glu Ile Ser Thr His Leu Cys Phe Trp Lys Ser
Leu Arg Lys Leu Glu Gly Lys
             20
<210> 96
<211> 93
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (89)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (92)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 96
Met Ile Phe Leu Leu Met Leu Ser Leu Glu Leu Gln Leu His Gln
Ile Ala Ala Leu Phe Thr Val Thr Val Pro Lys Glu Leu Tyr Ile Ile
Glu His Gly Ser Asn Val Thr Leu Glu Cys Asn Phe Asp Thr Gly Ser
His Val Asn Leu Gly Ala Ile Thr Ala Ser Leu Gln Lys Val Glu Asn
Asp Thr Ser Pro His Arg Glu Arg Ala Thr Leu Leu Glu Glu Gln Leu
Pro Leu Gly Lys Ala Ser Phe Pro Xaa Leu Lys Xaa Lys
<210> 97
<211> 77
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
```

70

<220>
<221> SITE
<222> (10)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (16)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 97

Leu Gly Gly Tyr Ala Leu Ser Xaa Xaa Xaa Asn Arg Val Thr Asp Xaa 1 5 10 15

Val Met Ile Tyr Phe Phe Ile Ile Ile Val Glu Tyr Phe Tyr Gly Lys 20 25 30

Ile Phe Val Val Leu Ile Ile Pro Ile Lys Ile Met Pro Asn Thr Lys
35 40 45

Tyr Glu Phe Tyr Asp Val His Phe Val Leu Gly Ile Lys Arg Lys Lys 50 55 60

His Thr Ser Trp Lys Ser Val Ser Cys Phe Leu Leu Leu 65 70 75

<210> 98

<211> 84

<212> PRT

<213> Homo sapiens

<400> 98

Thr Tyr Ser Phe Cys Val Cys Glu Arg Ala Phe Val Phe Gly Ser Val
1 5 10 15

Pro Arg Ala Glu Val Glu Gln Gly Cys Thr Tyr His Gly Lys Gly Gly 20 25 30

Arg Lys Glu Asn Trp Ile Ala Cys Asp Leu Trp Trp Asn Leu Phe Leu 35 40 45

Leu Pro Arg Pro Phe Arg Pro Cys Leu Ile Ser Val Gly His Phe Arg 50 55 60

Leu Trp Gln Gly Arg Ala Gly Leu Gln Ser Glu Val Pro Ala Ser Ser 65 70 75 80

Leu Glu His Asn

<210> 99

<211> 61

<212> PRT

<213> Homo sapiens

<220>

```
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
Met Trp Tyr Val Cys Ala Cys Val Cys Val Cys Val Xaa Val Cys Ser
                                     10
Tyr Asn Arg Arg Thr Gly Lys Val Arg Thr Gln Asn Asn Glu Asp Leu
Leu Lys Cys Gly Gly Val Cys Val Cys Val Phe Ile Glu Gln Glu
Asp Arg Lys Gly Asn Asp His Pro Trp Lys Met Lys Gly
                         55
<210> 100
<211> 11
<212> PRT
<213> Homo sapiens
<400> 100
Val Cys Cys Cys Leu His Leu Asn Ala Phe Val
<210> 101
<211> 66
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
Ser Trp Val Asp Phe Asp Cys Val Xaa Glu Val Ser Tyr Leu Asn Ser
Gly Ser Tyr Ser Leu Val Leu His Leu Glu Gly Leu His Pro Leu Glu
Leu Ser Gly Lys Leu Ala Ile Asp Phe Gly Lys Lys Arg Glu Phe Cys
Val Asp Gly Val Gly Gly Ala Thr Leu Val Ile Cys Pro Gly Phe Gln
                                             60
Asp Phe
65
<210> 102
<211> 505
<212> PRT
```

72

```
<213> Homo sapiens
<220>
<221> SITE
<222> (358)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (494)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (504)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (505)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 102
Met Phe Arg Thr Ala Val Met Met Ala Ala Ser Leu Ala Leu Thr Gly
Ala Val Val Ala His Ala Tyr Tyr Leu Lys His Gln Phe Tyr Pro Thr
                                 25
Val Val Tyr Leu Thr Lys Ser Ser Pro Ser Met Ala Val Leu Tyr Ile
Gln Ala Phe Val Leu Val Phe Leu Leu Gly Lys Val Met Gly Lys Val
                         55
Phe Phe Gly Gln Leu Arg Ala Ala Glu Met Glu His Leu Leu Glu Arg
                                         75
Ser Trp Tyr Ala Val Thr Glu Thr Cys Leu Ala Phe Thr Val Phe Arg
Asp Asp Phe Ser Pro Arg Phe Val Ala Leu Phe Thr Leu Leu Leu Phe
Leu Lys Cys Phe His Trp Leu Ala Glu Asp Arg Val Asp Phe Met Glu
Arg Ser Pro Asn Ile Ser Trp Leu Phe His Cys Arg Ile Val Ser Leu
                        135
Met Phe Leu Leu Gly Ile Leu Asp Phe Leu Phe Val Ser His Ala Tyr
                                        155
His Ser Ile Leu Thr Arg Gly Ala Ser Val Gln Leu Val Phe Gly Phe
                                    170
Glu Tyr Ala Ile Leu Met Thr Met Val Leu Thr Ile Phe Ile Lys Tyr
```

185

190

73

PCT/US00/30654

Val	Leu	His 195	Ser	Val	Asp	Leu	Gln 200	Ser	Glu	Asn	Pro	Trp 205	Asp	Asn	Lys
Ala	Val 210	Tyr	Met	Leu	Tyr	Thr 215	Glu	Leu	Phe	Thr	Gly 220	Phe	Ile	Lys	Val
Leu 225	Leu	Tyr	Met	Ala	Phe 230	Met	Thr	Ile	Met	Ile 235	Lys	Val	His	Thr	Ph∈ 240
Pro	Leu	Phe	Ala	Ile 245	Arg	Pro	Met	Tyr	Leu 250	Ala	Met	Arg	Gln	Phe 255	Lys
Lys	Ala	Val	Thr 260	Asp	Ala	Ile	Met	Ser 265	Arg	Arg	Ala	Ile	Arg 270	Asn	Met
Asn	Thr	Leu 275	Tyr	Pro	Asp	Ala	Thr 280	Pro	Glu	Glu	Leu	Gln 285	Ala	Met	Asp
Asn	Val 290	Cys	Ile	Ile	Cys	Arg 295	Glu	Glu	Met	Val	Thr 300	Gly	Ala	Lys	Arg
Leu 305	Pro	Cys	Asn	His	Ile 310	Phe	His	Thr	Ser	Cys 315	Leu	Arg	Ser	Trp	Phe 320
Gln	Arg	Gln	Gln	Thr 325	Cys	Pro	Thr	Cys	Arg 330	Met	Asp	Val	Leu	Arg 335	Ala
Ser	Leu	Pro	Ala 340	Gln	Ser	Pro	Pro	Pro 345	Pro	Glu	Pro	Ala	Asp 350	Gln	Gly
Pro	Pro	Pro 355	Ala	Pro	Xaa	Pro	Pro 360	Pro	Leu	Leu	Pro	Gln 365	Pro	Pro	Asn
Phe	Pro 370	Gln	Gly	Leu	Leu	Pro 375	Pro	Phe	Pro	Pro	Gly 380	Met	Phe	Pro	Leu
Trp 385	Pro	Pro	Met	Gly	Pro 390	Phe	Pro	Pro	Val	Pro 395	Pro	Pro	Pro	Ser	Ser 400
Gly	Glu	Ala	Val	Ala 405	Pro	Pro	Ser	Thr	Ser 410	Ala	Ala	Ala	Leu	Ser 415	Arg
Pro	Ser	Gly	Ala 420	Ala	Thr	Thr	Thr	Ala 425	Ala	Gly	Thr	Ser	Ala 430	Thr	Ala
Ala	Ser	Ala 435	Thr	Ala	Ser	Gly	Pro 440	Gly	Ser	Gly	Ser	Ala 445	Pro	Glu	Ala
Gly	Pro 450	Ala	Pro	Gly	Phe	Pro 455	Phe	Pro	Pro	Pro	Trp 460	Met	Gly	Met	Pro
Leu 465	Pro	Pro	Pro	Phe	Ala 470	Phe	Pro	Pro	Met	Pro 475	Val	Pro	Pro	Ala	Gl _y 480
Phe	Ala	Gly	Leu	Thr	Pro	Glu	Glu	Tyr	Glu 490	Leu	Trp	Arg	Xaa	Met	Ser

74

Gly Arg Thr Gly Gly Pro Val Xaa Xaa 500 505

<210> 103

<211> 191

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (18)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (21)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 103

Met Phe Arg Thr Ala Val Met Met Ala Ala Ser Ile Trp Pro Arg Leu

1 5 10 15

Trp Xaa Cys Pro Xaa Gly Trp Pro Cys Pro Trp Phe Pro Leu Pro Ser 20 25 30

Ser Leu Asp Gly Tyr Ala Pro Ala Ser Thr Leu Cys Leu Pro Pro Asn 35 40 45

Ala Cys Ala Pro Cys Gly Phe Ala Gly Leu Thr Pro Glu Glu Leu Arg 50 55 60

Ala Leu Glu Gly His Glu Arg Gln His Leu Glu Ala Arg Leu Gln Ser 65 70 75 80

Leu Arg Asn Ile His Thr Leu Leu Asp Ala Ala Met Leu Gln Ile Asn 85 90 95

Gln Tyr Leu Thr Val Leu Ala Ser Leu Gly Pro Pro Arg Pro Ala Thr 100 105 110

Ser Val Asn Ser Thr Glu Glu Thr Ala Thr Thr Val Val Ala Ala Ala 115 120 125

Ser Ser Thr Ser Ile Pro Ser Ser Glu Ala Thr Thr Pro Thr Pro Gly 130 135 140

Ala Ser Pro Pro Ala Pro Glu Met Glu Arg Pro Pro Ala Pro Glu Ser 145 150 155 160

Val Gly Thr Glu Glu Met Pro Glu Asp Gly Glu Pro Asp Ala Ala Glu
165 170 175

Leu Arg Arg Arg Leu Gln Lys Leu Glu Ser Pro Val Ala His 180 185 190

75

<211> 33

<212> PRT

<213> Homo sapiens

<400> 104

Lys Ile Leu Val Ser Tyr Leu Met Pro Gly Met Met Arg Ile Glu Asn
1 5 10 15

Phe Ser Ile Phe Met Cys Leu Thr Gly Cys Leu Gly Ile Asn Phe Ala 20 25 30

Phe

<210> 105

<211> 67

<212> PRT

<213> Homo sapiens

<400> 105

Met Asp Arg Gly Val Met Cys Leu Leu Ala Ser Trp Pro Gly Leu Gly
1 5 10 15

Ala Gln Phe Cys Gly Ala Gly Val Cys Pro Leu Arg Val Pro Ser Leu 20 25 30

Glu Pro Thr Leu Pro Asn Asp Gly Gly Gly Leu Glu Ala Leu Thr Leu
35 40 45

Gly Gly Lys Glu Ala Lys Glu Arg Trp Arg Trp Lys Gly Arg Pro Gly
50 60

Gln Gly Gly 65

<210> 106

<211> 67

<212> PRT

<213> Homo sapiens

<400> 106

Met Asp Arg Gly Val Met Cys Leu Leu Ala Ser Trp Pro Gly Leu Gly
1 10 15

Ala Gln Phe Cys Gly Ala Gly Val Cys Pro Leu Arg Val Pro Ser Leu 20 25 30

Glu Pro Thr Leu Pro Asn Asp Gly Gly Gly Leu Glu Ala Leu Thr Leu 35 40 45

Gly Gly Lys Glu Ala Lys Glu Arg Trp Arg Trp Lys Gly Arg Pro Gly 50 60

Gln Gly Gly

```
<210> 107
<211> 83
<212> PRT
<213> Homo sapiens
<400> 107
Gly His Val Leu Ala Tyr Ser Ser Trp Pro Ser Leu Ala Pro Gly Leu
Ser Val Gln Tyr Phe Val Ser Arg Val Glu Val Pro Asn Pro Gly Cys
                                 25
Thr Leu Glu Ala Pro Gly Lys Leu Ser Glu Phe Leu Arg Pro Glu Pro
His Pro Lys Pro Ile Ser Ser Glu Ser Leu Gly Gly Thr Glu Pro Gly
Phe Cys Gln Leu Lys Pro Ala Met Val Thr Ser Val Ser Ser Tyr Thr
Glu Asn Ser
<210> 108
<211> 63
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 108
Met His Leu Pro Trp Arg Ala Ala Ala Xaa Pro Leu Leu Xaa
Ala Val Pro Xaa Arg Ala Xaa Arg Xaa Pro Val Gln Ala Pro Ser Leu
                                 25
Gly Ala Xaa Asn Pro Xaa Arg Gly Thr Gln Val Ala Thr Val Ser Xaa
         35
Xaa Ser Gly Lys Leu Leu Gly Leu Lys Ala Pro Arg Pro Lys Pro
<210> 109
<211> 9
<212> PRT
<213> Homo sapiens
<400> 109
Pro Ser Ala Ala Ala Ser Ala Thr Pro
<210> 110
<211> 94
<212> PRT
<213> Homo sapiens
<400> 110
Leu Ala Val Ile Met Ala Arg Pro Ala Ala Glu Pro Leu Cys Phe Leu
Asn Pro Lys Leu Leu Ala Leu Ala Val Gly Val Leu Glu Leu Gly
             20
                                 25
Arg Gly Phe Leu Asp Ser Ser Pro Leu Leu Arg Pro Ala Ser Asp Gly
Glu Arg Phe Thr Trp Glu Ala Leu Gly Glu Ser Leu Pro Phe Ser Asp
```

78

75

50 55 60

Thr Phe Ala Ser Ser Val Phe Pro Val Pro Gly Val Phe Ser Ala Pro

70

Ala Gly Ala Glu Ala Phe Val Leu Gly Met Val Met Pro Thr

<210> 111

<211> 77

<212> PRT

<213> Homo sapiens

<400> 111

Phe Val Leu Leu His Cys Leu Asn Ser His Leu His Leu Ala Leu Gln
1 10 15

Phe Pro Leu Asn Thr Leu Ser Ser Pro Leu Val Cys Cys Gln Ser Ala 20 25 30

Ala Leu Pro Ile Lys Ala Cys Ile Asn Tyr Ile Cys Pro Met Phe Thr
35 40 45

Phe Ile Lys His Phe Pro Cys Thr Pro Val Pro Thr Ser Gln Gln Thr 50 55 60

Arg Glu Arg Ala Val Gln Leu Met Ser Leu Pro Ser Phe 65 70 75

<210> 112

<211> 87

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (26)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 112

Xaa His Ser His Trp Glu Gly Leu Lys Leu Cys Cys Leu Asn Pro Val 1 5 10 15

Leu Gly Pro Ala Arg Lys Arg Lys Arg Xaa Leu Arg Asn Arg Gly Ala
20 25 30

Arg Gly Cys Arg Cys His Ser Arg Ala Ala Leu His Pro His Pro 35 40 45

His Ala Ser Cys Phe Thr Ala His Ser Val Thr Glu Leu Val Ala Leu 50 55 60

```
Gly Thr Gly Gly His Pro His Thr Leu Met Pro Thr Ala Glu Gly Arg
                     70
                                         75
Ala Thr His Pro Ser Arg Asp
                 85
<210> 113
<211> 86
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 113
Lys Lys Xaa Pro Xaa Xaa Leu Ser Gly Ser Lys Ala Ile Ala Ser Lys
                5
Thr Lys Glu Ile Glu Gln Val Tyr Arg Gln Asp Cys Glu Thr Phe Gly
Met Val Val Lys Met Leu Ile Glu Lys Asp Pro Ser Leu Glu Lys Ser
Ile Gln Phe Ala Leu Arg Gln Asn Leu His Glu Ile Gly Glu Arg Cys
Val Glu Glu Leu Lys His Phe Ile Ala Glu Tyr Asp Thr Ser Thr Gln
                                         75
Asp Phe Gly Glu Pro Phe
<210> 114
<211> 53
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (10)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 114
Ile Gly Pro Xaa Gly Pro Arg Asn Ser Xaa Thr Gly Gly Ala Phe Leu
Asp Phe Ser Ala Gln Ala Lys Lys Lys Xaa Gln Phe Leu Lys Ile
Phe Phe Pro Gly Leu Cys Lys Ser Leu Ile Tyr Gly Ile Phe Val Met
Gln Arg Asn Thr Leu
     50
<210> 115
<211> 62
<212> PRT
<213> Homo sapiens
<400> 115
Met Leu Cys Pro Ala Leu Gly Pro Phe Leu Leu Phe Leu Leu Ser Ser
Thr Leu Met Ala Ser Phe Met Gly Asp Thr Pro Cys His Pro Gly Glu
Leu Ser Ala Phe Gly Val Ala Pro Ser Arg Val Phe Thr Ser Ser Phe
Leu Phe Thr Val Phe Thr Pro Ser Tyr Pro Ser Leu Pro Gly
                         55
<210> 116
<211> 48
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (45)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
```

81

<220> <221> SITE <222> (48) <223> Xaa equals any of the naturally occurring L-amino acids <400> 116 Met Val Gln Arg Leu Trp Val Ser Arg Leu Leu Arg His Arg Lys Ala Gln Leu Leu Val Asn Leu Leu Thr Phe Gly Leu Glu Val Cys Leu Ala Ala Gly Phe Thr Tyr Val Pro Leu Cys Cys Gly Xaa Xaa Val Xaa 40 <210> 117 <211> 12 <212> PRT <213> Homo sapiens <400> 117 Ile Leu Gln Arg Arg Lys Gln Arg Leu Leu Arg Gly <210> 118 <211> 129 <212> PRT <213> Homo sapiens Arg Lys Val Glu Gly Gly Ala Ser Gly Leu Asn Gly Phe Pro Asn His Pro Ser Ser Leu Gly Pro Ala Trp Phe Pro Pro Leu Pro Leu Pro Ser Thr Leu Ser Arg Thr Gly Leu Met Lys Ala Leu Pro Lys Ile Ser Pro Thr Pro Asn Phe Pro Leu Pro Pro Thr Phe Pro Thr Ser Ser Thr Thr Leu Phe Gly Ala Thr Ala Gly Pro Glu Ala Gln Ser Ala Val Ser Gln Ala Phe Val His Leu Ser Pro Gln Ser Ile Ser Val Leu Gly Glu Ser His Thr Glu Thr Gln Glu His Pro Leu Pro Glu Leu Arg Glu Val Leu 105

Ser Leu Arg Gly Gly Leu Ser Ala Val Cys Asn Asn Val Val Leu Phe

125

120

82

Ile

<210> 119

<211> 46

<212> PRT

<213> Homo sapiens

<400> 119

Met Pro Trp Leu Lys Ser Leu Leu His Phe Ser Leu Phe Leu Val Val 1 5 10 15

Phe Ser Thr Leu Ala Val Lys Ser Leu Gly Val Pro Val Ala Ala Gly 20 25 30

Ser Pro Phe Cys Ile Val Asp Val Leu His Phe Ile Leu Leu 35 40 45

<210> 120

<211> 53

<212> PRT

<213> Homo sapiens

<400> 120

Met Phe Ile Ser Leu Phe Ile Phe Gly Leu Val Arg Leu Trp Pro Cys
1 5 10 15

Cys Val Val Ile Tyr Phe Val Tyr Ser Ile Cys Lys His Gln Cys Ser 20 25 30

Gln Glu Ala His Ser Ser Ile Phe Asn Cys Lys Phe Val Ser Gln Ser 35 40 45

Gln Phe Ser Ile Met 50

<210> 121

<211> 4

<212> PRT

<213> Homo sapiens

<400> 121

Phe Leu Ser Ser

<210> 122

<211> 19

<212> PRT

<213> Homo sapiens

<400> 122

Leu Val Cys Phe Val Ile Phe Arg Leu Trp Tyr Met Cys Val Phe Thr 1 5 10 . 15

83

Leu Trp Ala <210> 123 <211> 51 <212> PRT <213> Homo sapiens <400> 123 Gln Ala Ser Trp Val Trp Trp Leu Thr Thr Val Ile Pro Ala Leu Trp Glu Ala Arg Ala Gly Gly Ser Leu Glu Pro Arg Ser Ser Arg Leu Ala 25 Trp Ala Thr Gln Lys Val Phe Ile Ser Lys Lys Lys Lys Lys Lys Arg Ala Ala 50 <210> 124 <211> 5 <212> PRT <213> Homo sapiens <400> 124 Ser Phe Ala Thr Cys <210> 125 <211> 10 <212> PRT <213> Homo sapiens <400> 125 Trp Ala Ser Met Ser Ser Val Phe Gly Leu 1 5 <210> 126 <211> 57 <212> PRT <213> Homo sapiens <400> 126 Ile Ser Tyr His His Val Lys Ala Ser His Leu Lys Ile Lys Ile Gln 10 Ile Ser Leu Lys Pro Glu Val Leu Val Pro Leu His Cys Leu Pro Leu 20 25

Ser Pro Thr Pro Arg Glu Glu Ser Gly Gly Phe Leu Phe Ser Ile Ala

40

84

Ile Ala Ala Val Gly Phe Leu Val Gln 50 55

<210> 127

<211> 164

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (95)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 127

Arg Met Xaa Cys Ser Gln Pro Pro Arg Cys His Phe Gln Ser Asp Phe 1 5 10 . 15

Gln Lys Cys Ala Pro Cys Pro Arg Ala Gln Thr His Trp Leu Glu Pro
20 25 30

Pro Gly Arg Val Gln Thr Ile Ser Ser Met Arg Asn Ala Gln Lys Gly 35 40 45

Phe Ala Asp Ser Ile Arg Leu Trp Arg Leu Pro Ala Ser Gly Val Gly 50 55 60

Trp Val Val Ser Pro Pro Ile Gln Thr Gln Glu Val Ala Pro Glu Gly 65 70 75 80

Met Tyr Leu Val Gly Ser Ser Ser Gly Thr Leu Gly Gly Cys Xaa Ala 85 90 95

Leu Thr Gln Tyr Phe Ser Leu Ser Pro Leu Trp Gly Ala Cys Val Arg 100 105 110

Ala Arg Val Leu Ala Tyr Ala Phe Leu Cys Gly His Ile Arg Met Pro 115 120 125

Leu Gly Glu His Val His Val Ser Pro Pro Glu Arg Ala Cys Val Cys 130 135 140

Ala Pro Leu Arg Pro Arg Phe Gly Arg Leu Gly Phe Gly Val Pro Val
145 150 155 160

Phe Cys Pro Pro

<210> 128

<211> 2

<212> PRT

```
<213> Homo sapiens
<400> 128
Gly Cys
 1
<210> 129
<211> 22
<212> PRT
<213> Homo sapiens
<400> 129
Leu Val Leu Phe Ile Thr Leu Leu Pro Gly Lys Leu Ala His Ser Trp
His Thr Val Asn Val Gln
<210> 130
<211> 53
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 130
Thr Glu Glu Phe Lys Tyr Ala Val Ser Cys Asn Cys Gly Thr Ala Ala
Trp Val Arg Val Arg Glu Arg Glu Arg Lys Arg Glu Lys Lys Lys
Lys Arg Xaa Ala Ala Leu Glu Asp Pro Ser Arg Gly Pro Ser Leu Arg
Val His Ala Thr Ser
     50
<210> 131
<211> 7
<212> PRT
<213> Homo sapiens
<400> 131
Thr Tyr Ile His Phe Leu Asp
<210> 132
<211> 8
<212> PRT
<213> Homo sapiens
```

86

PCT/US00/30654

<400> 132 Leu Thr Met Leu Phe Asn Val Ile 1 5

<210> 133

WO 01/34629

<211> 352

<212> PRT

<213> Homo sapiens

<400> 133

Val Ser Leu Leu Trp Gly Ile Ser Ile Arg Gly Ala Asp Ala Cys
1 5 10 15

Ala Asp Ala His Leu Phe Cys Lys Glu Cys Leu Ile Arg Tyr Ala Gln
20 25 30

Glu Ala Val Phe Gly Ser Gly Lys Leu Glu Leu Ser Cys Met Glu Gly

Ser Cys Thr Cys Ser Phe Pro Thr Ser Glu Leu Glu Lys Val Leu Pro 50 55 60

Gln Thr Ile Leu Tyr Lys Tyr Tyr Glu Arg Lys Ala Glu Glu Val 65 70 75 80

Ala Ala Ala Tyr Ala Asp Glu Leu Val Arg Cys Pro Ser Cys Ser Phe
85 90 95

Pro Ala Leu Leu Asp Ser Asp Val Lys Arg Phe Ser Cys Pro Asn Pro 100 105 110

His Cys Arg Lys Glu Thr Cys Arg Lys Cys Gln Gly Leu Trp Lys Glu 115 120 125

His Asn Gly Leu Thr Cys Glu Glu Leu Ala Glu Lys Asp Asp Ile Lys
130 140

Tyr Arg Thr Ser Ile Glu Glu Lys Met Thr Ala Ala Arg Ile Arg Lys 145 150 155 160

Cys His Lys Cys Gly Thr Gly Leu Ile Lys Ser Glu Gly Cys Asn Arg 165 170 175

Met Ser Cys Arg Cys Gly Ala Gln Met Cys Tyr Leu Cys Arg Val Ser 180 185 190

Ile Asn Gly Tyr Asp His Phe Cys Gln His Pro Arg Ser Pro Gly Ala 195 200 205

Pro Cys Gln Glu Cys Ser Arg Cys Ser Leu Trp Thr Asp Pro Thr Glu 210 215 220

Asp Asp Glu Lys Leu Ile Glu Glu Ile Gln Lys Glu Ala Glu Glu 225 230 235 240

Gln Lys Arg Lys Asn Gly Glu Asn Thr Phe Lys Arg Ile Gly Pro Pro

87

 Leu
 Glu
 Lys
 Pro
260
 Val
 Glu
 Lys
 Val
 Gln
 Arg
265
 Val
 Glu
 Arg
265
 Val
 Glu
 Arg
265
 Val
 Leu
 Pro
285
 Pro
 Arg
280
 Pro
 Gln
 Arg
265
 Val
 Glu
 Arg
 Pro
285
 Tyr
 Ala
 Phe
320

 Ala
 His
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Ala
 Pro
 Tyr
 Pro
 Pro
 Pro
 Pro
 Ala
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro
 Pro</

<210> 134

<211> 7

<212> PRT

<213> Homo sapiens

<400> 134

Ser Phe Cys Met Gly Thr Met

<210> 135

<211> 20

<212> PRT

<213> Homo sapiens

<400> 135

Met Asn Val Arg Leu Val Leu Asn Pro Phe Pro Leu Tyr Ser Val Tyr 1 5 10 15

Val Ile Pro Asn 20

<210> 136

<211> 11

<212> PRT

<213> Homo sapiens

<400> 136

Leu Glu Ile Leu Val Val Lys Lys Leu Leu Ala 1 5 10

<210> 137

88

<211> 233

<212> PRT

<213> Homo sapiens

<400> 137

His Pro Val Ala Ala Leu Phe Thr Val Thr Ala Pro Lys Glu Val Tyr
1 5 10 15

Thr Val Asp Val Gly Ser Ser Val Ser Leu Glu Cys Asp Phe Asp Arg
20 25 30

Arg Glu Cys Thr Glu Leu Glu Gly Ile Arg Ala Ser Leu Gln Lys Val ${\tt 35} {\tt 40} {\tt 45}$

Glu Asn Asp Thr Ser Leu Gln Ser Glu Arg Ala Thr Leu Leu Glu Glu 50 55 60

Gln Leu Pro Leu Gly Lys Ala Leu Phe His Ile Pro Ser Val Gln Val 65 70 75 80

Arg Asp Ser Gly Gln Tyr Arg Cys Leu Val Ile Cys Gly Ala Ala Trp 85 90 95

Asp Tyr Lys Tyr Leu Thr Val Lys Val Lys Ala Ser Tyr Met Arg Ile 100 105 110

Asp Thr Arg Ile Leu Glu Val Pro Gly Thr Gly Glu Val Gln Leu Thr 115 120 125

Cys Gln Ala Arg Gly Tyr Pro Leu Ala Glu Val Ser Trp Gln Asn Val 130 135 140

Ser Val Pro Ala Asn Thr Ser His Ile Arg Thr Pro Glu Gly Leu Tyr 145 150 155 160

Gln Val Thr Ser Val Leu Arg Leu Lys Pro Gln Pro Ser Arg Asn Phe 165 170 175

Ser Cys Met Phe Trp Asn Ala His Met Lys Glu Leu Thr Ser Ala Ile 180 185 190

Ile Asp Pro Leu Ser Arg Met Glu Pro Lys Val Pro Arg Thr Trp Pro 195 200 205

Leu His Val Phe Ile Pro Ala Cys Thr Ile Ala Leu Ile Phe Leu Ala 210 215 220

Ile Val Ile Ile Gln Arg Lys Arg Ile 225 230

<210> 138

<211> 233

<212> PRT

<213> Homo sapiens

<400> 138

His Gln Ile Ala Ala Leu Phe Thr Val Thr Val Pro Lys Glu Leu Tyr

89

10 15 Ile Ile Glu His Gly Ser Asn Val Thr Leu Glu Cys Asn Phe Asp Thr Gly Ser His Val Asn Leu Gly Ala Ile Thr Ala Ser Leu Gln Lys Val Glu Asn Asp Thr Ser Pro His Arg Glu Arg Ala Thr Leu Leu Glu Glu Gln Leu Pro Leu Gly Lys Ala Ser Phe His Ile Pro Gln Val Gln Val Arg Asp Glu Gly Gln Tyr Gln Cys Ile Ile Tyr Gly Val Ala Trp Asp Tyr Lys Tyr Leu Thr Leu Lys Val Lys Ala Ser Tyr Arg Lys Ile Asn Thr His Ile Leu Lys Val Pro Glu Thr Asp Glu Val Glu Leu Thr 120 Cys Gln Ala Thr Gly Tyr Pro Leu Ala Glu Val Ser Trp Pro Asn Val 135 Ser Val Pro Ala Asn Thr Ser His Ser Arg Thr Pro Glu Gly Leu Tyr Gln Val Thr Ser Val Leu Arg Leu Lys Pro Pro Pro Gly Arg Asn Phe Ser Cys Val Phe Trp Asn Thr His Val Arg Glu Leu Thr Leu Ala Ser Ile Asp Leu Gln Ser Gln Met Glu Pro Arg Thr His Pro Thr Trp Leu Leu His Ile Phe Ile Pro Ser Cys Ile Ile Ala Phe Ile Phe Ile Ala Thr Val Ile Ala Leu Arg Lys Gln Leu <210> 139 <211> 184 <212> PRT <213> Homo sapiens <400> 139 Met Ser Arg Thr Ala Tyr Thr Val Gly Ala Leu Leu Leu Leu Gly 5

Thr Leu Leu Pro Ala Ala Glu Gly Lys Lys Lys Gly Ser Gln Gly Ala 20 25 30

Ile Pro Pro Pro Asp Lys Ala Gln His Asn Asp Ser Glu Gln Thr Gln

,

WO 01/34629 PCT/US00/30654

90 40 45 35 Ser Pro Gln Gln Pro Gly Ser Arg Asn Arg Gly Arg Gly Gln Gly Arg 55 Gly Thr Ala Met Pro Gly Glu Glu Val Leu Glu Ser Ser Gln Glu Ala Leu His Val Thr Glu Arg Lys Tyr Leu Lys Arg Asp Trp Cys Lys Thr Gln Pro Leu Lys Gln Thr Ile His Glu Glu Gly Cys Asn Ser Arg Thr Ile Ile Asn Arg Phe Cys Tyr Gly Gln Cys Asn Ser Phe Tyr Ile Pro 120 Arg His Ile Arg Lys Glu Glu Gly Ser Phe Gln Ser Cys Ser Phe Cys 135 Lys Pro Lys Lys Phe Thr Thr Met Met Val Thr Leu Asn Cys Pro Glu 150 155 Leu Gln Pro Pro Thr Lys Lys Lys Arg Val Thr Arg Val Lys Gln Cys 170 Arg Cys Ile Ser Ile Asp Leu Asp 180 <210> 140 <211> 330 <212> PRT <213> Homo sapiens <400> 140 Leu Met Ile Gly Gly Ser Cys Val Ala Thr Ala Ala Thr Ile Leu Asn Ala Phe Leu Ile Asn Lys Gln Phe Tyr Pro Ser Ile Val Tyr Leu Ser Lys Ser Asn Ala Ser Met Ala Val Ile Tyr Val Gln Gly Ile Val Leu

91

120 125 115 Thr Leu Arg Phe His Leu Arg Met Met Thr Val Leu Ala Ala Leu Gly 135 Phe Ala Asp Ser Tyr Phe Val Ser Ser Ala Tyr Phe Thr Thr Ile Thr Arg Gly Ala Ser Ala Gln Ile Val Phe Gly Phe Glu Tyr Ala Ile Leu 170 Leu Ala Leu Val Leu His Val Thr Ile Lys Tyr Leu Leu His Met His Asp Leu Arg Asn Pro Gln Ser Trp Asp Asn Lys Ala Val Tyr Leu Leu 200 Tyr Ala Glu Leu Phe Ile Asn Leu Ile Arg Cys Leu Leu Tyr Gly Phe Phe Ala Val Val Met Leu Arg Val His Thr Phe Pro Leu Phe Ser Val 230 235 Arg Pro Phe Tyr Gln Ser Val Arg Ala Leu His Lys Ala Phe Leu Asp Val Ile Leu Ser Arg Arg Ala Ile Asn Ala Met Asn Ser Gln Phe Pro 265 Val Val Ser Ala Glu Asp Leu Ala Ala Met Asp Ala Thr Cys Ile Ile Cys Arg Glu Glu Met Thr Val Asp Ala Ser Pro Lys Arg Leu Pro Cys Ser His Val Phe His Ala His Cys Leu Arg Ser Trp Phe Gln Arg Gln Gln Thr Cys Pro Thr Cys Arg Thr Asp Ile 325 <210> 141 <211> 328 <212> PRT <213> Homo sapiens <400> 141 Val Met Met Ala Ala Ser Leu Ala Leu Thr Gly Ala Val Val Ala His 10 Ala Tyr Tyr Leu Lys His Gln Phe Tyr Pro Thr Val Val Tyr Leu Thr 2.0 25

Lys Ser Ser Pro Ser Met Ala Val Leu Tyr Ile Gln Ala Phe Val Leu

Val Phe Leu Leu Gly Lys Val Met Gly Lys Val Phe Phe Gly Gln Leu

	50					55					60				
Arg 65	Ala	Ala	Glu	Met	Glu 70	His	Leu	Leu	Glu	Arg 75	Ser	Trp	Tyr	Ala	Val 80
Thr	Glu	Thr	Cys	Leu 85	Ala	Phe	Thr	Val	Phe 90	Arg	Asp	Asp	Phe	Ser 95	Pro
Arg	Phe	Val	Ala 100	Leu	Phe	Thr	Leu	Leu 105	Leu	Phe	Leu	Lys	Cys 110	Phe	His
Trp	Leu	Ala 115	Glu	Asp	Arg	Val	Asp 120	Phe	Met	Glu	Arg	Ser 125	Pro	Asn	Ile
Ser	Trp 130	Leu	Phe	His	Cys	Arg 135	Ile	Val	Ser	Leu	Met 140	Phe	Leu	Leu	Gly
Ile 145	Leu	Asp	Phe	Leu	Phe 150	Val	Ser	His	Ala	Tyr 155	His	Ser	Ile	Leu	Thr 160
Arg	Gly	Ala	Ser	Val 165	Gln	Leu	Val	Phe	Gly 170	Phe	Glu	Tyr	Ala	Ile 175	Leu
Met	Thr	Met	Val 180	Leu	Thr	Ile	Phe	Ile 185	Lys	Tyr	Val	Leu	His 190	Ser	Val
Asp	Leu	Gln 195	Ser	Glu	Asn	Pro	Trp 200	Asp	Asn	Lys	Ala	Val 205	Tyr	Met	Leu
Tyr	Thr 210	Glu	Leu	Phe	Thr	Gly 215	Phe	Ile	Lys	Val	Leu 220	Leu	Tyr	Met	Ala
Phe 225	Met	Thr	Ile	Met	Ile 230	Lys	Val	His	Thr	Phe 235	Pro	Leu	Phe	Ala	Ile 240
Arg	Pro	Met	Tyr	Leu 245	Ala	Met	Arg	Gln	Phe 250	Lys	Lys	Ala	Val	Thr 255	Asp
Ala	Ile	Met	Ser 260	Arg	Arg	Ala	Ile	Arg 265	Asn	Met	Asn	Thr	Leu 270	Tyr	Pro
Asp	Ala	Thr 275	Pro	Glu	Glu	Leu	Gln 280	Ala	Met	Asp	Asn	Val 285	Cys	Ile	Ile
Cys	Arg 290	Glu	Glu	Met	Val	Thr 295	Gly	Ala	Lys	Arg	Leu 300	Pro	Cys	Asn	His
Ile 305	Phe	His	Thr	Ser	Cys 310	Leu	Arg	Ser	Trp	Phe 315	Gln	Arg	Gln	Gln	Thr 320
Cys	Pro	Thr	Cys	Arg 325	Met	Asp	Val								

<210> 142 <211> 283

<212> PRT

<213> Homo sapiens

93

<400> 142 Met Gly Arg Ile Gly Ile Ser Cys Leu Phe Pro Ala Ser Trp His Phe Ser Ile Ser Pro Val Gly Cys Pro Arg Ile Leu Asn Thr Asn Leu Arg Gln Ile Met Val Ile Ser Val Leu Ala Ala Ala Val Ser Leu Leu Tyr Phe Ser Val Val Ile Ile Arg Asn Lys Tyr Gly Arg Leu Thr Arg Asp Lys Lys Phe Gln Arg Tyr Leu Ala Arg Val Thr Asp Ile Glu Ala Thr Asp Thr Asn Asn Pro Asn Val Asn Tyr Gly Ile Val Val Asp Cys Gly Ser Ser Gly Ser Arg Val Phe Val Tyr Cys Trp Pro Arg His Asn 105 Gly Asn Pro His Asp Leu Leu Asp Ile Arg Gln Met Arg Asp Lys Asn Arg Lys Pro Val Val Met Lys Ile Lys Pro Gly Ile Ser Glu Phe Ala Thr Ser Pro Glu Lys Val Ser Asp Tyr Ile Ser Pro Leu Leu Asn Phe Ala Ala Glu His Val Pro Arg Ala Lys His Lys Glu Thr Pro Leu Tyr Ile Leu Cys Thr Ala Gly Met Arg Ile Leu Pro Glu Ser Gln Gln Lys Ala Ile Leu Glu Asp Leu Leu Thr Asp Ile Pro Val His Phe Asp Phe Leu Phe Ser Asp Ser His Ala Glu Val Ile Ser Gly Lys Gln Glu Gly Val Tyr Ala Trp Ile Gly Ile Asn Phe Val Leu Gly Arg Phe Glu His 235 Ile Glu Asp Asp Glu Ala Val Val Glu Val Asn Ile Pro Gly Ser 250 Glu Ser Ser Glu Ala Ile Val Arg Lys Arg Thr Ala Gly Ile Leu Asp 265 Met Gly Gly Val Ser Thr Gln Ile Ala Tyr Glu

280

<210> 143

WO 01/34629 PCT/US00/30654

```
<211> 269
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (87)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (99)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (230)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (263)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (264)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 143
Met Ala Arg Ile Ser Phe Ser Tyr Leu Cys Pro Ala Ser Trp Tyr Phe
Thr Val Pro Thr Val Ser Pro Phe Leu Arg Gln Arg Val Ala Phe Leu
Gly Leu Phe Phe Ile Ser Cys Leu Leu Leu Met Leu Ile Ile Asp
Phe Arg His Trp Ser Ala Ser Leu Pro Arg Asp Arg Gln Tyr Glu Arg
Tyr Leu Ala Arg Val Gly Glu Leu Glu Ala Thr Asp Thr Glu Asp Pro
Asn Leu Asn Tyr Gly Leu Xaa Val Asp Cys Gly Ser Ser Gly Ser Arg
                                     90
Ile Phe Xaa Tyr Phe Trp Pro Arg His Asn Gly Asn Pro His Asp Leu
                                105
Leu Asp Ile Lys Gln Met Arg Asp Arg Asn Ser Gln Pro Val Val Lys
                            120
Lys Ile Lys Pro Gly Ile Ser Ala Met Ala Asp Thr Pro Glu His Ala
    130
                        135
Ser Asp Tyr Leu Arg Pro Leu Leu Ser Phe Ala Ala Ala His Val Pro
```

95

145 150 155 160 Val Lys Lys His Lys Glu Thr Pro Leu Tyr Ile Leu Cys Thr Ala Gly 170 Met Arg Leu Leu Pro Glu Arg Lys Gln Leu Ala Ile Leu Ala Asp Leu Val Lys Asp Leu Pro Leu Glu Phe Asp Phe Leu Phe Ser Gln Ser Gln 200 Ala Glu Val Ile Ser Gly Lys Gln Glu Gly Val Tyr Ala Trp Ile Gly Ile Asn Phe Val Leu Xaa Arg Phe Asp His Glu Asp Glu Ser Asp Ala 235 Glu Ala Thr Gln Glu Leu Ala Ala Gly Arg Arg Thr Val Gly Ile Leu Asp Met Gly Gly Ala Xaa Xaa Gln Ile Ala Tyr Glu 265 <210> 144 <211> 112 <212> PRT <213> Homo sapiens <400> 144 Met Ser Ser Gly Cys Leu Leu Ser Val Leu His Pro Pro Trp Pro Gly Leu Pro Phe His Leu His Leu Ser Phe Ala Ser Phe Pro Pro Arg Val Arg Ala Ser Lys Pro Pro Pro Ser Phe Gly Asn Val Gly Ser Lys Glu Gly Thr Leu Arg Gly Gln Thr Pro Ala Pro Gln Asn Trp Ala Pro Ser Pro Gly Gln Glu Ala Arg Arg His Ile Thr Pro Leu Ser Ile His Phe His Gln Ala Pro Leu Arg Val Pro Leu Leu Val Leu Gly Leu Gln Asp Gly His Arg Leu Ala Cys Leu Gln Ala His Phe Met Ala Ala Ser Gly

105

110

<210> 145

<211> 404

<212> PRT

```
<213> Homo sapiens
<220>
<221> SITE
<222> (365)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (367)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (379)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 145
Met Ser Asp Asn Ala Pro Ala Ser Leu Glu Ser Gly Ser Ser Ser Thr
Pro Thr Asn Cys Ser Thr Ser Ser Ala Ile Pro Gln Pro Gly Ala Ala
             20
Thr Lys Pro Trp Arg Ser Lys Ser Leu Ser Val Lys His Ser Ala Thr
Val Ser Met Leu Ser Val Lys Pro Pro Gly Pro Glu Ala Pro Arg Pro
Thr Pro Glu Ala Met Lys Pro Ala Pro Asn Asn Gln Lys Ser Met Leu
Glu Lys Leu Lys Leu Phe Asn Ser Lys Gly Gly Ser Lys Ala Gly Glu
Gly Pro Gly Ser Arg Asp Thr Ser Cys Glu Arg Leu Glu Thr Leu Pro
Ser Phe Glu Glu Ser Glu Glu Leu Glu Ala Ala Ser Arg Met Leu Thr
Thr Val Gly Pro Ala Ser Ser Pro Lys Ile Ala Leu Lys Gly Ile
                        135
Ala Gln Arg Thr Phe Ser Arg Ala Leu Thr Asn Lys Lys Ser Ser Leu
145
                    150
                                        155
Lys Gly Asn Glu Lys Glu Lys Gln Gln Arg Glu Lys Asp Lys
                                    170
Glu Lys Ser Lys Asp Leu Ala Lys Arg Ala Ser Val Thr Glu Arg Leu
            180
                                185
Asp Leu Lys Glu Glu Pro Lys Glu Asp Pro Ser Gly Ala Ala Val Pro
                            200
Glu Met Pro Lys Lys Ser Ser Lys Ile Ala Ser Phe Ile Pro Lys Gly
```

WO 01/34629 PCT/US00/30654

215 220 210 Gly Lys Leu Asn Ser Ala Lys Lys Glu Pro Met Ala Pro Ser His Ser 230 235 Gly Ile Pro Lys Pro Gly Met Lys Ser Met Pro Gly Lys Ser Pro Ser 250 Ala Pro Ala Pro Ser Lys Glu Gly Glu Arg Ser Arg Ser Gly Lys Leu Ser Ser Gly Leu Pro Gln Gln Lys Pro Gln Leu Asp Gly Arg His Ser Ser Ser Ser Ser Leu Ala Ser Ser Glu Gly Lys Gly Pro Gly Gly Thr Thr Leu Asn His Ser Ile Ser Ser Gln Thr Val Ser Gly Ser Val Gly Thr Thr Gln Thr Thr Gly Ser Asn Thr Val Ser Val Gln Leu Pro 330 Gln Pro Gln Gln Gln Tyr Asn His Pro Asn Thr Ala Thr Val Ala Pro Phe Leu Tyr Arg Ser Gln Thr Asp Thr Glu Gly Asn Xaa Thr Xaa Glu 360 Ser Ser Ser Thr Gly Val Ser Val Glu Pro Xaa His Phe Pro Arg Leu Asp Ser Leu Leu Trp Lys Asn Ser Leu Gly Lys Ile Leu Arg Leu Gly 390 395 Gly Cys Gly Gln <210> 146

<211> 1020

<212> PRT

<213> Homo sapiens

<400> 146

Met Ser Asp Asn Ala Pro Ala Ser Leu Glu Ser Gly Ser Ser Ser Thr
1 5 10 15

Pro Thr Asn Cys Ser Thr Ser Ser Ala Ile Pro Gln Pro Gly Ala Ala

Thr Lys Pro Trp Arg Ser Lys Ser Leu Ser Val Lys His Ser Ala Thr 35 40 45

Val Ser Met Leu Ser Val Lys Pro Pro Gly Pro Glu Ala Pro Arg Pro 50 60

Thr Pro Glu Ala Met Lys Pro Ala Pro Asn Asn Gln Lys Ser Met Leu

65					70					75					80
Glu	Lys	Leu	Lys	Leu 85	Phe	Asn	Ser	Lys	Gly 90	Gly	Ser	Lys	Ala	Gly 95	Glu
Gly	Pro	Gly	Ser 100	Arg	Asp	Thr	Ser	Cys 105	Glu	Arg	Leu	Glu	Thr 110	Leu	Pro
Ser	Phe	Glu 115	Glu	Ser	Glu	Glu	Leu 120	Glu	Ala	Ala	Ser	Arg 125	Met	Leu	Thr
Thr	Val 130	Gly	Pro	Ala	Ser	Ser 135	Ser	Pro	Lys	Ile	Ala 140	Leu	Lys	Gly	Ile
Ala 145	Gln	Arg	Thr	Phe	Ser 150	Arg	Ala	Leu	Thr	Asn 155	Lys	Lys	Ser	Ser	Leu 160
Lys	Gly	Asn	Glu	Lys 165	Glu	Lys	Glu	Lys	Gln 170	Gln	Arg	Glu	Lys	Asp 175	Lys
Glu	Lys	Ser	Lys 180	Asp	Leu	Ala	Lys	Arg 185	Ala	Ser	Val	Thr	Glu 190	Arg	Leu
Asp	Leu	Lys 195	Glu	Glu	Pro	Lys	Glu 200	Asp	Pro	Ser	Gly	Ala 205	Ala	Val	Pro
Glu	Met 210	Pro	Lys	Lys	Ser	Ser 215	Lys	Ile	Ala	Ser	Phe 220	Ile	Pro	Lys	Gly
Gly 225	Lys	Leu	Asn	Ser	Ala 230	Lys	Lys	Glu	Pro	Met 235	Ala	Pro	Ser	His	Ser 240
Gly	Ile	Pro	Lys	Pro 245	Gly	Met	Lys	Ser	Met 250	Pro	Gly	Lys	Ser	Pro 255	Ser
Ala	Pro	Ala	Pro 260	Ser	Lys	Glu	Gly	Glu 265	Arg	Ser	Arg	Ser	Gly 270	Lys	Leu
Ser	Ser	Gly 275	Leu	Pro	Gln	Gln	Lys 280	Pro	Gln	Leu	Asp	Gly 285	Arg	His	Ser
Ser	Ser 290	Ser	Ser	Ser	Leu	Ala 295	Ser	Ser	Glu	Gly	Lys	Gly	Pro	Gly	Gly
Thr 305	Thr	Leu	Asn	His	Ser 310	Ile	Ser	Ser	Gln	Thr 315	Val	Ser	Gly	Ser	Val 320
Gly	Thr	Thr	Gln	Thr 325	Thr	Gly	Ser	Asn	Thr 330	Val	Ser	Val	Gln	Leu 335	Pro
Gln	Pro	Gln	Gln 340	Gln	Tyr	Asn	His	Pro 345	Asn	Thr	Ala	Thr	Val 350	Ala	Pro
Phe	Leu	Tyr 355	Arg	Ser	Gln	Thr	Asp 360	Thr	Glu	Gly	Asn	Val 365	Thr	Ala	Glu
Ser	Ser 370	Ser	Thr	Gly	Val	Ser 375	Val	Glu	Pro	Ser	His 380	Phe	Thr	Lys	Thr

385	GIII	FIO	AIQ	Бей	390	Giu	ЦСИ	1111	Gly	395	Asp	FLO	J1 u	AIG	400
Arg	Leu	Arg	Thr	Val 405	Lys	Asn	Ile	Ala	Asp 410	Leu	Arg	Gln	Asn	Leu 415	Glu
Glu	Thr	Met	Ser 420	Ser	Leu	Arg	Gly	Thr 425	Gln	Val	Thr	His	Ser 430	Thr	Leu
Glu	Thr	Thr 435	Phe	Asp	Thr	Asn	Val 440	Thr	Thr	Glu	Met	Ser 445	Gly	Arg	Ser
Ile	Leu 450	Ser	Leu	Thr	Gly	Arg 455	Pro	Thr	Pro	Leu	Ser 460	Trp	Arg	Leu	Gly
Gln 465	Ser	Ser	Pro	Arg	Leu 470	Gln	Ala	Gly	Asp	Ala 475	Pro	Ser	Met	Gly	Asn 480
Gly	Tyr	Pro	Pro	Arg 485	Ala	Asn	Ala	Ser	Arg 490	Phe	Ile	Asn	Thr	Glu 495	Ser
Gly	Arg	Tyr	Val 500	Tyr	Ser	Ala	Pro	Leu 505	Arg	Arg	Gln	Leu	Ala 510	Ser	Arg
Gly	Ser	Ser 515	Val	Cys	His	Val	Asp 520	Val	Leu	Asp	Lys	Ala 525	Gly	Asp	Glu
Met	Asp 530	Leu	Glu	Gly	Ile	Ser 535	Met	Asp	Ala	Pro	Gly 540	Tyr	Met	Ser	Asp
Gly 545	Asp	Val	Leu	Ser	Lys 550	Asn	Ile	Arg	Thr	Asp 555	Asp	Ile	Thr	Ser	Gly 560
Tyr	Met	Thr	Asp	Gly 565	Gly	Leu	Gly	Leu	Tyr 570	Thr	Arg	Arg	Leu	Asn 575	Arg
Leu	Pro	Asp	Gly 580	Met	Ala	Val	Val	Arg 585	Glu	Thr	Leu	Gln	Arg 590	Asn	Thr
Ser	Leu	Gly 595	Leu	Gly	Asp	Ala	Asp 600	Ser	Trp	Asp	Asp	Ser 605	Ser	Ser	Val
Ser	Ser 610	Gly	Ile	Ser	Asp	Thr 615	Ile	Asp	Asn	Leu	Ser 620	Thr	Asp	Asp	Ile
Asn 625	Thr	Ser	Ser	Ser	Ile 630	Ser	Ser	Tyr	Ala	Asn 635	Thr	Pro	Ala	Ser	Ser 640
Arg	Lys	Asn	Leu	Asp 645	Val	Gln	Thr	Asp	Ala 650	Glu	Lys	His	Ser	Gln 655	Val
Glu	Arg	Asn	Ser 660	Leu	Trp	Ser	Gly	Asp 665	Asp	Val	Lys	Lys	Ser 670	Asp	Gly
Gly	Ser	Asp 675	Ser	Gly	Ile	Lys	Met 680	Glu	Pro	Gly	Ser	Lys 685	Trp	Arg	Arg

WO 01/34629

100

PCT/US00/30654

Asn Pro Ser Asp Val Ser Asp Glu Ser Asp Lys Ser Thr Ser Gly Lys 695 Lys Asn Pro Val Ile Ser Gln Thr Gly Ser Trp Arg Arg Gly Met Thr 710 715 Ala Gln Val Gly Ile Thr Met Pro Arg Thr Lys Ala Ser Ala Pro Ala 730 Gly Ala Leu Lys Thr Pro Gly Thr Gly Lys Thr Asp Asp Ala Lys Val Ser Glu Lys Gly Arg Leu Ser Pro Lys Ala Ser Gln Val Lys Arg Ser Pro Ser Asp Ala Gly Arg Ser Ser Gly Asp Glu Ser Lys Lys Pro Leu Pro Ser Ser Arg Thr Pro Thr Ala Asn Ala Asn Ser Phe Gly Phe 795 Lys Lys Gln Ser Gly Ser Ala Ala Gly Leu Ala Met Ile Thr Ala Ser Gly Val Thr Val Thr Ser Arg Ser Ala Thr Leu Gly Lys Ile Pro Lys 825 Ser Ser Ala Leu Val Ser Arg Ser Ala Gly Arg Lys Ser Ser Met Asp Gly Ala His Asn Gln Asp Asp Gly Tyr Leu Ala Leu Ser Ser Arg Thr 855 Asn Leu Gln Tyr Arg Ser Leu Pro Arg Pro Ser Lys Ser Asn Ser Arg Asn Gly Ala Gly Asn Arg Ser Ser Thr Ser Ser Ile Asp Ser Asn Ile 890 Ser Ser Lys Ser Ala Gly Leu Pro Val Pro Lys Leu Arg Glu Pro Ser Lys Thr Ala Leu Gly Ser Ser Leu Pro Gly Leu Val Asn Gln Thr Asp Lys Glu Lys Gly Ile Ser Ser Asp Asn Glu Ser Val Ala Ser Cys Asn Ser Val Lys Val Asn Pro Ala Ala Gln Pro Val Ser Ser Pro Ala Gln 955 Thr Ser Leu Gln Pro Gly Ala Lys Tyr Pro Asp Val Ala Ser Pro Thr 970 Leu Arg Arg Leu Phe Gly Gly Lys Pro Thr Lys Gln Val Pro Ile Ala 985 Thr Ala Glu Asn Met Lys Asn Ser Val Val Ile Ser Asn Pro His Ala

101

1000 995 1005 Thr Met Thr Gln Gln Gly Arg Arg Gly Arg Glu Phe 1010 1015 <210> 147 <211> 252 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (162) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (222) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (236) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (240) <223> Xaa equals any of the naturally occurring L-amino acids <400> 147 Met Gly Ser Leu Gly Leu Phe Leu Gln Cys Ala Ile Ser Leu Val Phe Ser Leu Val Met Asp Arg Leu Val Gln Arg Phe Gly Thr Arg Ala Val Tyr Leu Ala Ser Val Ala Ala Phe Pro Val Ala Ala Gly Ala Thr Cys Leu Ser His Ser Val Ala Val Val Thr Ala Ser Ala Ala Leu Thr Gly Phe Thr Phe Ser Ala Leu Gln Ile Leu Pro Tyr Thr Leu Ala Ser Leu Tyr His Arg Glu Lys Gln Val Phe Leu Pro Lys Tyr Arg Gly Asp Thr Gly Gly Ala Ser Ser Glu Asp Ser Leu Met Thr Ser Phe Leu Pro Gly 105 Pro Lys Pro Gly Ala Pro Phe Pro Asn Gly His Val Gly Ala Gly Gly 120 Ser Gly Leu Leu Pro Pro Pro Pro Ala Leu Cys Gly Ala Ser Ala Cys 130 135 140

PCT/US00/30654

WO 01/34629

Asp Val Ser Val Arg Val Val Gly Glu Pro Thr Glu Ala Arg Val 150 155 Val Xaa Gly Arg Gly Ile Cys Leu Asp Leu Ala Ile Leu Asp Ser Ala 170 Phe Leu Leu Ser Gln Val Ala Pro Ser Leu Phe Met Gly Ser Ile Val Gln Leu Ser Gln Ser Val Thr Ala Tyr Met Val Ser Ala Ala Gly Leu 200 Gly Leu Val Ala Ile Tyr Phe Ala Thr Gln Val Val Phe Xaa Lys Ser Asp Leu Ala Asn Thr Gln Arg Asp Phe Gln Xaa Ile Gly Val Xaa 235 Gly Leu Pro His Trp Val Pro Ala Pro Cys Ser Cys 245 <210> 148 <211> 272 <212> PRT <213> Homo sapiens <400> 148 Leu His Ala Ala Pro Glu Glu His Lys Ile Pro Pro Gly Phe Val Leu Ala Asn Asp Val Asp Asn Asn Arg Cys Tyr Met Leu Val His Gln Ala Lys Arg Leu Asn Ser Pro Cys Leu Leu Val Thr Asn His Asp Ser Ser Val Phe Pro Asn Leu Val Thr Thr Lys Pro Asp Gly Ser Lys Ala Ile Leu Lys Phe Asp Lys Ile Leu Cys Asp Val Pro Cys Ser Gly Asp Gly Thr Leu Arg Lys Asn Pro Asp Ile Trp Leu Lys Trp Asn Leu Ala Gln Ala Tyr Asn Leu His Gly Ile Gln Tyr Arg Ile Val Arg Arg Gly Ala Glu Met Leu Glu Val Gly Gly Arg Leu Val Tyr Ser Thr Cys Ser Leu 120 Asn Pro Ile Glu Asn Glu Ala Val Leu Gln Arg Ile Ile Lys Asp Ala 135 Asp Gly Ala Leu Glu Leu Val Asp Ala Gly His Leu Val Pro Gly Leu 145 150 155

103

LysTyrLysProGly 165MetThrAspTrpLysLeuAlaThrLysGlu 175Val 175AspGlnIlePhe 180ThrArgPhe 180Phe 180Phe 185Phe 185Val 185ProGlu ProGlu ProGlu ProGlu ProGlu ProHis 190Phe 190P

<210> 149

<211> 272

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (5)

<223> Xaa equals stop translation

<400> 149

Leu His Phe Thr Xaa His Cys Asn Ser Val Pro Ser Glu Gly Phe Val

1 5 10 15

Ile Ala Asn Asp Val Asp Asn Lys Arg Cys Tyr Leu Leu Val His Gln
20 25 30

Ala Lys Arg Leu Ser Ser Pro Cys Ile Met Val Val Asn His Asp Ala 35 40 45

Ser Ser Ile Pro Arg Leu Gln Ile Asp Val Asp Gly Arg Lys Glu Ile 50 55 60

Leu Phe Tyr Asp Arg Ile Leu Cys Asp Val Pro Cys Ser Gly Asp Gly 65 70 75 80

Thr Met Arg Lys Asn Ile Asp Val Trp Lys Lys Trp Thr Thr Leu Asn 85 90 95

Ser Leu Gln Leu His Gly Leu Gln Leu Arg Ile Ala Thr Arg Gly Ala 100 105 110

104

Glu	Gln	Leu 115	Ala	Glu	Gly	Gly	Arg 120	Met	Val	Tyr	Ser	Thr 125	Cys	Ser	Leu
Asn	Pro 130	Ile	Glu	Asp	Glu	Ala 135	Val	Ile	Ala	Ser	Leu 140	Leu	Glu	Lys	Ser

Lys Trp Met Pro Gly Ile Thr Gln Trp Lys Val Met Thr Lys Asp Gly
165 170 175

Gln Trp Phe Thr Asp Trp Asp Ala Val Pro His Ser Arg His Thr Gln 180 185 190

Ile Arg Pro Thr Met Phe Pro Pro Lys Asp Pro Glu Lys Leu Gln Ala 195 200 205

Met His Leu Glu Arg Cys Leu Arg Ile Leu Pro His His Gln Asn Thr 210 220

Gly Gly Phe Phe Val Ala Val Leu Val Lys Lys Ser Ser Met Pro Trp 225 230 235 240

Asn Lys Arg Gln Pro Lys Leu Gln Gly Lys Ser Ala Glu Thr Arg Glu 245 250 255

Ser Thr Gln Leu Ser Pro Ala Asp Leu Thr Glu Gly Lys Pro Thr Asp 260 265 270

<210> 150

<211> 130

<212> PRT

<213> Homo sapiens

<400> 150

Glu Gly Glu Gly Gln Ile Phe Gln Leu His Thr Thr Leu Ala Glu Thr
1 5 10 15

Pro Ala Gly Ser Leu Asp Ala Leu Cys Ser Ala Pro Gly Asn Ala Ala 20 25 30

Thr Thr Gln Leu Gly Pro Tyr Ala Phe Lys Ile Pro Leu Ser Ile Arg
35 40 45

Gln Lys Ile Cys Asn Ser Leu Asp Ala Pro Asn Ser Arg Gly Asn Asp 50 60

Trp Arg Leu Leu Ala Gln Lys Leu Ser Met Asp Arg Tyr Leu Asn Tyr 65 70 75 80

Phe Ala Thr Lys Ala Ser Pro Thr Gly Val Ile Leu Asp Leu Trp Glu 85 90 95

105

Ala Arg Gln Gln Asp Asp Gly Asp Leu Asn Ser Leu Ala Ser Ala Leu 100 105 110

Glu Glu Met Gly Lys Ser Glu Met Leu Val Ala Met Thr Thr Asp Gly
115 120 125

Asp Cys 130

<210> 151

<211> 130

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (30)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 151

Glu Gly Glu Gly Gln Ile Phe Gln Leu His Thr Thr Leu Ala Glu Thr

1 5 10 15

Pro Ala Gly Ser Leu Asp Thr Leu Cys Ser Ala Pro Gly Xaa Thr Val 20 25 30

Thr Thr Gln Leu Gly Pro Tyr Ala Phe Lys Ile Pro Leu Ser Ile Arg 35 40 45

Gln Lys Ile Cys Asn Ser Leu Asp Ala Pro Asn Ser Arg Gly Asn Asp 50 55 60

Trp Arg Met Leu Ala Gln Lys Leu Ser Met Asp Arg Tyr Leu Asn Tyr 65 70 75 80

Phe Ala Thr Lys Ala Ser Pro Thr Gly Val Ile Leu Asp Leu Trp Glu 85 90 95

Ala Leu Gln Gln Asp Asp Gly Asp Leu Asn Ser Leu Ala Ser Ala Leu 100 105 110

Glu Glu Met Gly Lys Ser Glu Met Leu Val Ala Val Ala Thr Asp Gly
115 120 125

Asp Cys 130

<210> 152

<211> 130

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (30)

<223> Xaa equals any of the naturally occurring L-amino acids

```
<400> 152
Glu Gly Glu Gly Gln Ile Phe Gln Leu His Thr Thr Leu Ala Glu Thr
                            10
Pro Ala Gly Ser Leu Asp Thr Leu Cys Ser Ala Pro Gly Xaa Thr Val
                                 25
Thr Thr Gln Leu Gly Pro Tyr Ala Phe Lys Ile Pro Leu Ser Ile Arg
Gln Lys Ile Cys Asn Ser Leu Asp Ala Pro Asn Ser Arg Gly Asn Asp
Trp Arg Met Leu Ala Gln Lys Leu Ser Met Asp Arg Tyr Leu Asn Tyr
Phe Ala Thr Lys Ala Ser Pro Thr Gly Val Ile Leu Asp Leu Trp Glu
Ala Leu Gln Gln Asp Asp Gly Asp Leu Asn Ser Leu Ala Ser Ala Leu
                                105
Glu Glu Met Gly Lys Ser Glu Met Leu Val Ala Val Ala Thr Asp Gly
                            120
Asp Cys
   130
<210> 153
<211> 113
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (20)
<223> Xaa equals stop translation
<220>
<221> SITE
<222> (67)
<223> Xaa equals stop translation
<220>
<221> SITE
<222> (82)
<223> Xaa equals stop translation
<220>
<221> SITE
<222> (90)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (106)
```

107

<223> Xaa equals stop translation Val Phe Phe Ile Tyr Tyr Phe Phe Phe Ser Glu Thr Glu Ser Gly Ser Val Thr Xaa Ala Gly Val Gln Trp His Asp Leu Gly Ser Leu Gln 25 Ala Pro Pro Pro Gly Phe Met Pro Phe Ser Cys Leu Ser Leu Pro Ser Gly Trp Asp Tyr Arg Arg Pro Pro Pro Cys Pro Ala Asn Phe Leu Tyr Phe Trp Xaa Arg Gln Gly Phe Thr Val Leu Ala Arg Met Val Ser Ile Ser Xaa Pro His Asp Pro Pro Ala Ser Xaa Ser Gln Ser Ala Gly Ile 90 Thr Gly Met Ser His Cys Ala Arg Pro Xaa Ile Gln Tyr Phe Leu Ile 100 105 Glu <210> 154 <211> 256 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (59) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (197) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (198) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (199) <223> Xaa equals any of the naturally occurring L-amino acids Leu Leu Pro Phe Leu Arg Phe Ser Leu Leu Tyr Gln Leu Ser Gly Gly 10 Pro Pro Arg Phe Leu Leu Asp Leu Arg Gln Tyr Leu Gly Asn Ser Thr

108

25 30 20 Tyr Leu Asp Asp His Gly Pro Pro Pro Ser Lys Val Leu Pro Phe Pro 40 Ser Gln Val Val Tyr Asn Arg Val Gly Lys Xaa Gly Ser Arg Thr Val Val Leu Leu Leu Arg Ile Leu Ser Glu Lys His Gly Phe Asn Leu Val Thr Ser Asp Ile His Asn Lys Thr Arg Leu Thr Lys Asn Glu Gln Met Glu Leu Ile Lys Asn Ile Ser Thr Ala Glu Gln Pro Tyr Leu Phe Thr 105 Arg His Val His Phe Leu Asn Phe Ser Arg Phe Gly Gly Asp Gln Pro Val Tyr Ile Asn Ile Ile Arg Asp Pro Val Asn Arg Phe Leu Ser Asn Tyr Phe Phe Arg Arg Phe Gly Asp Trp Arg Gly Glu Gln Asn His Met Ile Arg Thr Pro Ser Met Arg Gln Glu Glu Arg Tyr Leu Asp Ile Asn Glu Cys Ile Leu Glu Asn Tyr Pro Glu Cys Ser Asn Pro Arg Leu Phe 180 Tyr Ile Ile Pro Xaa Xaa Gly Gln His Pro Arg Cys Arg Glu Pro 200 Gly Glu Trp Ala Leu Glu Arg Ala Lys Leu Asn Val Asn Glu Asn Phe 210 Leu Leu Val Gly Ile Leu Glu Glu Leu Glu Asp Val Leu Leu Leu Leu 230 235 Glu Arg Phe Leu Pro His Tyr Phe Lys Gly Val Leu Ser Thr Thr Lys 250

<210> 155

<211> 45

<212> PRT

<213> Homo sapiens

<400> 155

Met Lys Lys Gln Gln His Pro Gly Gly Gly Ala Asp Pro Trp Pro 1 5 10 15

His Gly Ala Pro Met Gly Gly Ala Pro Pro Gly Leu Gly Ser Trp Lys

109

20 25 30 Arg Arg Val Pro Leu Leu Pro Phe Leu Arg Phe Ser Leu 40 <210> 156 <211> 31 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (3) <223> Xaa equals any of the naturally occurring L-amino acids <400> 156 Gln Gly Xaa Ala Gln Tyr Tyr Lys Asp Pro Glu His Arg Lys Leu Gly Asn Met Thr Val Thr Val Lys Lys Thr Val Pro Ser Pro Glu Ala 25 <210> 157 <211> 301 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (95) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (233) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (234) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (235) <223> Xaa equals any of the naturally occurring L-amino acids <400> 157 Met Lys Lys Gln Gln His Pro Gly Gly Gly Ala Asp Pro Trp Pro His Gly Ala Pro Met Gly Gly Ala Pro Pro Gly Leu Gly Ser Trp Lys 20 Arg Arg Val Pro Leu Leu Pro Phe Leu Arg Phe Ser Leu Leu Tyr Gln

40

45

Leu	Ser 50	Gly	Gly	Pro	Pro	Arg 55	Phe	Leu	Leu	Asp	Leu 60	Arg	Gln	Tyr	Leu
Gly 65	Asn	Ser	Thr	Tyr	Leu 70	Asp	Asp	His	Gly	Pro 75	Pro	Pro	Ser	Lys	Val 80
Leu	Pro	Phe	Pro	Ser 85	Gln	Val	Val	Tyr	Asn 90	Arg	Val	Gly	Lys	Xaa 95	Gly
Ser	Arg	Thr	Val 100	Val	Leu	Leu	Leu	Arg 105	Ile	Leu	Ser	Glu	Lys 110	His	Gly
Phe	Asn	Leu 115	Val	Thr	Ser	Asp	Ile 120	His	Asn	Lys	Thr	Arg 125	Leu	Thr	·Lys
Asn	Glu 130	Gln	Met	Glu	Leu	Ile 135	Lys	Asn	Ile	Ser	Thr 140	Ala	Glu	Gln	Pro
Tyr 145	Leu	Phe	Thr	Arg	His 150	Val	His	Phe	Leu	Asn 155	Phe	Ser	Arg	Phe	Gly 16.0
Gly	Asp	Gln	Pro	Val 165	Tyr	Ile	Asn	Ile	Ile 170	Arg	Asp	Pro	Val	Asn 175	Arg
Phe	Leu	Ser	Asn 180	Tyr	Phe	Phe	Arg	Arg 185	Phe	Gly	Asp	Trp	Arg 190	Gly	Glu
Gln	Asn	His 195	Met	Ile	Arg	Thr	Pro 200	Ser	Met	Arg	Gln	Glu 205	Glu	Arg	Tyr
Leu	Asp 210	Ile	Asn	Glu	Cys	Ile 215	Leu	Glu	Asn	Tyr	Pro 220	Glu	Cys	Ser	Asn
Pro 225	Arg	Leu	Phe	Tyr	Ile 230	Ile	Pro	Xaa	Xaa	Xaa 235	Gly	Gln	His	Pro	Arg 240
Cys	Arg	Glu	Pro	Gly 245	Glu	Trp	Ala	Leu	Glu 250	Arg	Ala	Lys	Leu	Asn 255	Val [.]
Asn	Glu	Asn	Phe 260	Leu	Leu	Val	Gly	Ile 265	Leu	Glu	Glu	Leu	Glu 270	Asp	Val
Leu	Leu	Leu 275	Leu	Glu	Arg	Phe	Leu 280	Pro	His	Tyr	Phe	Lys 285	Gly	Val	Leu
Ser	Thr	Thr	Lys	Thr	Gln	Ser		Gly	Ser	Leu	Glu 300				

INTERNATIONAL SEARCH REPORT

International application No. PCT/US00/30654

	SSIFICATION OF SUBJECT MATTER								
IPC(7) :Please See Extra Sheet. US CL :Please See Extra Sheet.									
According to International Patent Classification (IPC) or to both national classification and IPC									
	B. FIELDS SEARCHED								
Minimum d	ocumentation searched (classification system followed	l by classification symbols)							
U.S. : 1	Please See Extra Sheet.								
Documentat	tion searched other than minimum documentation to the	extent that such documents are included in the fields searched							
		me of data base and, where practicable, search terms used)							
Please Sec	e Extra Sheet.								
C. DOC	UMENTS CONSIDERED TO BE RELEVANT								
Category*	Citation of document, with indication, where ap	propriate, of the relevant passages Relevant to claim No.							
x	US 5,831,056 (JACOBS et al.) 03 N	November 1998, see entire 1-10, 21							
	document.								
•	D. J. G. D. J. (EGT). A	TO ANYLOSOOS NOT COAD 1 10 21							
X	Database GenBank (EST); Accession N tumor gene index; 20 October 1999; have	1							
	with SEQ ID NO: 11; vector: pT7T3D	· · · · · · · · · · · · · · · · · · ·							
	alignment result 5).	Tue, nost cent. Diffod, (see							
	, ,								
X	US 5,807,709 (JACOBS et al.), 15								
	proteins and polynucleotides encoding	them"							
		·							
	ner documents are listed in the continuation of Box C								
-	ecial categories of cited documents: cument defining the general state of the art which is not considered	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the priority or theory underlying the invention.							
to	to be of particular relevance "X" document of particular relevance: the claimed invention cannot be								
	rlier document published on or after the international filing date cument which may throw doubts on priority claim(s) or which is	considered novel or cannot be considered to involve an inventive step when the document is taken alone							
cite	cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be								
	document referring to an oral disclosure, use, exhibition or other means considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art								
"P" do	cument published prior to the international filing date but later than e priority date claimed	"&" document member of the same patent family							
	actual completion of the international search	Date of mailing of the international search report							
0 8 JAN U	ARY 2001	26 FEB 2001							
Name and r	mailing address of the ISA/US	Authorized officer DELIA MAE COLUMN MP							
Commissio Box PCT	oner of Patents and Trademarks	PARALEGAI STECIAL							
•	n, D.C. 20231 No. (703) 305-3230	Telephone No. (703) 308-0196 CENTER 1800							

INTERNATIONAL SEARCH REPORT

International application No. PCT/US00/30654

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
Please See Extra Sheet.
1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
·
4. X No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-10,14,15 and 21, all in part.
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

International application No. PCT/US00/30654

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

C07H 21/04; C07H 21/02; C07K 5/00; C07K 14/00; C12Q 1/68; C12N 1/21; C12N 15/63; C12N 15/85, 15/86

A. CLASSIFICATION OF SUBJECT MATTER:

US CL:

536/23.1, 23.5, 24.31; 530/300, 350; 435/6, 69.1, 252.3, 320.1, 325

B. FIELDS SEARCHED

Minimum documentation searched Classification System: U.S.

536/23.1, 23.5, 24.31; 530/300, 350; 435/6, 69.1, 252.3, 320.1, 325 514/2, 12

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

WEST, STN (Database: Biosis, Embase, Medline, Scisearch, Lifesci, Caplus).

Search terms: secreted protein or peptide, butyrophilin_like protein, polynucleotide, DNA, RNA, nucleic acid, oligonucleotide, dendritic cell, uterus, spleen, thymus, aorta, T-cell lymphoma, testis.

GenBank (Databases: GenEmbl, N_Genseq_36, Issued_Patents, EST, A_Genseq_36, PIR_65, SwissProt_39, Sptrembl 14)

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Groups 1-63, claim(s)1-10, 14, 15 and 21, all in part, drawn to an isolated nucleic acid of SEQ ID NO X or a peptide of SEQ ID NO NO: Y, wherein X and Y are values that correlate to those listed in Table 1, and correspond to one of the cDNA Clone IDs, respectively. For example,

If group I is elected, this correlates to Gene NO 1, cDNA clone ID HDPPA04 of Table 1, wherein X is 11 and Y is 74.

If group 2 is elected, this correlates to Gene NO 2, cDNA clone ID HOHBY44, wherein X is 12 and Y is 75.

Groups 64-126, claim(s) 11, 12, 16 and 23, all in part, each group directed to a peptide of SEQ ID NO; Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 64 is elected, this correlates to Gene NO 1, cDNA clone ID HDPPAO4 of Table 1, wherein Y is 74.

INTERNATIONAL SEARCH REPORT

If group 65 is elected, this correlates to Gene NO 2, cDNA clone ID HOHBY44, wherein Y is 75.

Groups 127-189, claim 13, in part, drawn to an isolated antibody which binds to a protein with SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 127 is elected, this correlates to Gene NO 1, cDNA clone ID HDPPA04 of Table 1, wherein Y is 74.

If group 128 is elected, this correlates to Gene NO 2, cDNA clone ID ${\tt HOHBY44}$, wherein Y is 75.

Groups 190-252, claim 17, in part, drawn to a method for preventing, treating or ameliorating an undefined medical condition by administering a polypeptide of SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 190 is elected, this correlates to Gene NO 1, cDNA clone ID $\frac{1}{2}$ HDPPA04 of Table 1, wherein Y is 74.

If group 191 is elected, this correlates to Gene NO 2, cDNA clone ID HOHBY44, wherein Y is 75.

Groups 253-315, claim 17, in part, drawn to a method for preventing, treating or ameliorating an undefined medical condition by administering a polynucleotide of SEQ ID NO X encoding a protein of SEQ ID NO Y, wherein X and Y correlate to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 253 is elected, this correlates to Gene NO 1, cDNA clone ID HDPPA04 of Table 1, wherein Y is 74.

If group 254 is elected, this correlates to Gene NO 2, cDNA clone ID HOHBY44, wherein Y is 75.

Groups 316-378, claims 18 and 19, in part, drawn to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO X, wherein X correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 316 is elected, this correlates to Gene NO 1, cDNA clone ID ${\tt HDPPA04}$ of Table 1, wherein X is 11.

If group 317 is elected, this correlates to Gene NO 2, cDNA clone ID ${\tt HOHBY44}$, wherein X is 12.

Groups 379-441, claim 20, in part, drawn to a method of identifying a binding partner to a polypeptide defined by SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

INTERNATIONAL SEARCH REPORT

International application No. PCT/US00/30654

If group 379 is elected, this correlates to Gene NO 1, cDNA clone ID HDPPA04 of Table 1, wherein Y is 74.

If group 380 is elected, this correlates to Gene NO 2, cDNA clone ID ${\tt HOHBY44}$, wherein Y is 75.

Groups 442-504, claim 22, in part, drawn to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polypeptide encoded by SEQ ID NO X, wherein X correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 442 is elected, this correlates to Gene NO 1, cDNA clone ID HDPPAO4 of Table 1, wherein X is 11.

If group 443 is elected, this correlates to Gene NO 2, cDNA clone ID HOHBY44, wherein X is 12.

The inventions listed as Groups 1-504 do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The polynucleotides and polypeptides of each invention are unrelated, each to each other. The polynucleotide sequences encode structurally distinct polypeptides. Additionally the claimed methods produce different products and/or different results which are not coextensive and which do not share the same technical feature.